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Interleukin-1 (IL-1) is a key mediator of infection, inflammation and immunity and two different IL-1
proteins are known to exist, IL-la andIL-lJ3. Each is synthesised as a proprotein, Mr = 31kD,
which is subsequent cleaved to yield the mature protein, Mr = 17.5kD. Whereas both forms of IL-la
show equivalent biological activities, IL-1 (3 requires cleavage with resultant conformational change
for optimal activity. IL-1 has been extensively studied in human and murine systems but at the time
this project was initiated, nothing was known about its actions in the sheep and no reagents were
available with which to study ovine IL-1. This thesis describes the successful cloning and expression
of biologically active ovine IL-la and IL-1 (3 and their use in determining IL-1 receptor (IL-1R)
expression by ovine alveolar macrophages (M<t>) and afferent lymph dendritic cells (DC).
Lipopolysaccharide (LPS) stimulated Mp were used as the source of IL-1 mRNA. The specific IL-1
cDNAs were amplified by polymerase chain reaction, cloned into pTZ18R/19R vectors and
sequenced. Ovine IL-la and IL-1 (3 were found to be 97% and 96% identical to their bovine
counterparts and 81% and 78% identical, respectively, to the human sequences. Translation of the
nucleotide sequences shows that ovine IL-la has 97% and 72% identity with bovine and human IL-
la respectively and ovine IL-1{3 has 95% and 62% identity with bovine and human IL- lp
respectively. Use of the cloned IL-lcDNAs for northern blot analysis of IL-1 mRNA production by
Mp, showed IL-la mRNA to reach maximal levels at around 6h and IL-1 (3 mRNA at around 4h after
LPS stimulation.
The proprotein (p) and mature protein (m) forms of ovine IL-la and IL-1 (3 have been expressed as
fusion proteins with yeast pi, using the Ty-vlp system of British Biotechnology Ltd. The fusion
protein self-assembles in the form of a virus-like particle (vlp), from which the rIL-1 is cleaved by
the action of Factor Xa restriction protease (FXa). FXa cleavage of IL- lap:pl vlps revealed a relaxed
FXa recognition site within EL-lap which yielded a putative N-terminus at Ser-120, equivalent to the
N-terminus of human EL-lam. It is proposed that FXa may be one of the natural processing enzymes
for IL-la. The activities of purified IL-1 mature proteins on ovine thymocytes were ~2.5xl07 U/mg
EL-la and >1.25xl06 U/mg IL-1 p. Activities on ovine xiphoid cartilage were ten times less. Ovine
rIL-1 shows a species preference for homologous thymocytes and cross-species sequence analysis
highlights 5 amino acid residues which may be of relevance in this context. Ovine rIL-l(3p is
biologically active, but about 5 times less so than EL-lj3m.
By using ovine 125I-rIL-l, -16500 IL-lR/cell (Kd ~4.6pM) for IL-1|3 and -2600 IL-lR/cell (Kd
~56pM) for IL-la were detected on Mp. <24% of Mp expressed IL-1R. DC, isolated from lymph
from cannulated sheep pseudoafferent lymph ducts, expressed -510 IL-lR/cell (Kd ~30pM) for IL-
la and -350 IL-lR/cell (Kd ~160pM) for IL-1|3. Quantitation of IL-1R expressed by fresh DC has
not previously been reported for any species, as far as I am aware. Following secondary ovalbumin
challenge of primed sheep, DC expression of receptors for IL-la, but not for IL-1 (3, is greatly
upregulated. Two peaks of increased expression were detected, a transient increase at around 4h
followed by an increase to maximal expression of >21700 IL-la sites/cell (Kd ~181pM) between
43-72h. Only a very small proportion of individual DC were seen to bind IL-1 even after secondary
antigen challenge.
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GM-CSF granulocyte-macrophage-colony stimulating factor
GTC guanidinium iso thiocyanate
HBSS Hanks balanced salt solution
HPLC high pressure liquid chromatography
hu human
ICAM-1 intercellular adhesion molecule-1
ICE interleukin-1 converting enzyme
IDDM insulin-dependent diabetes mellitus
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IL-1RI IL-1 receptor type I
IL-1RII IL-1 receptor type II
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LC Langerhans' cell (epithelial)
LFA-1 leucocyte function antigen
LIF leukemia inhibitory factor
LPS gram-negative bacterial lipopolysaccharide
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Mcj) macrophage
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MNL mononuclear leukocytes - refers to monocytes within the context
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pi yeast pi protein constitutively expressed from pMA5620 plasmid
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PCR polymerase chain reaction
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TNF tumour necrosis factor
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vlp virus-like particle
x-gal 5-bromo-4-chloro-3-indolyl-p-D-galactoside
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C cysteine (Cys)
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Interleukin-1 was originally isolated from neutrophils by Menkin and Beeson in
the 1940s as a fever-inducing substance called granulocyte pyrogen (GP).
Subsequently other factors were isolated, endogenous pyrogen (EP) from blood
of rabbits made fibrile by injection of bacteria, leukocyte endogenous mediator
(LEM) which was thought to induce acute phase responses, and lymphocyte
activating factor (LAF) which described a factor derived from mononuclear
phagocytes which enhanced mitogen-driven thymocyte proliferation. It was not
until 1972 that lipopolysaccharide (LPS) stimulated monocytes rather than
neutrophils were found to be the major source of EP. Around the same time it
was beginning to be realised that agents stimulating EP release also stimulated
LAF production, the kinetics of release being similar (Atkins et al., 1960; Gery
et ah, 1971,1972; Gery and Waksman, 1972; Wolff, 1973; Kampschmidt, 1981).
On purification, LPS stimulated monocyte supernatants yielded active protein
products of heterogeneous molecular weight (12000 - 17000) with a broad
spectrum of isoelectric points (pi 5 - 7). Two forms of human IL-1 of differing
pi were subsequently resolved, IL-la (pi 5) and EL-1(3 (pi 7) (Auron et al., 1984;
Lomedico et ah, 1984; Furutani et ah, 1985; March et ah, 1985), and equivalent
proteins have now been identified in a number of species.
The term "Interleukin" was coined in 1979 at the Second International
Lymphokine Workshop in Ermatingen, Switzerland and was primarily devised
to describe the soluble mediators produced by activated T-lymphocytes which
acted at short range on responder lymphocytes. It was decided that the
'monokine' variously referred to as GP, EP, LEM, and LAF should henceforth be
known as Interleukin-1 (IL-1) (Mizel and Farrar, 1979). Other activities now
attributed to IL-1 are those previously known as mononuclear cell factor (Krane
et ah, 1985), catabolin (Saklatvala et ah, 1983), osteoclast-activating factor
(Dewhirst et ah, 1985) and hemopoetin-1 (Moore and Warren, 1987; Mochizuki
et ah, 1987).
1
Is is now clear that although the actions of IL-1 are extremely diverse, the main
aspects of its function are immunostimulation, mediation of shock and
inflammation, stimulation of hematopoesis and tissue moulding.
1.2 Sources of IL-1
IL-1 is now known to be produced by the majority of mammalian cell types,
with the production of IL-1 a and IL-1 (3 being differentially regulated,
presumably a consequence of functional requirements. Certain cells appear to
produce either IL-1 a or IL-13 virtually exclusively. With the exception of a few
cell types, notably keratinocytes and certain central nervous system cells, IL-1
mRNA only becomes detectable in response to various stimuli. High levels of
IL-1 expression are seen in the spleen, liver and kidney of normal individuals
(Tovey et al., 1988). Proteins with IL-l-like activities have been detected in
invertebrates (Beck and Habicht, 1986) but these will not be addressed further.
Both forms of IL-1 are initially produced as a proprotein of about Mr=31K
which is subsequently cleaved to a mature Mr=17-18K form (Sect 1.4). The
proprotein and mature forms are equally active. DL-la is predominantly cell
associated with small quantities only of the mature form being secreted (Conlon
et al., 1987; Fuhlbrigge et al., 1988). Pro-IL-la is glycosylated and about 10% is
known to be membrane bound via a lectin-like interaction which is specifically
dissociated with D-mannose (Brody and Durum, 1989). On the other hand IL-1 (3
in all species studied so far is secreted and appears to require cleavage and
consequent conformational change for both receptor binding and activity
(Mosley et al., 1987a; Schmidt and Bomford, 1991). Certain recombinant pro-
IL-l(3s are reportedly active as will be detailed in Sect. 1.9. A small proportion
of IL-1 (3 may also be membrane bound (Folks et al., 1987; Hawrylowicz et al.,
1989a).
Epithelial cells, fibroblasts and polymorphonuclear leucocytes all produce IL-1,
the latter very inefficiently, (Wagner et al., 1985; Bandari et al., 1989; Canning
and Neill, 1989). Endothelial and smooth muscle cells express biologically
active IL-1 on their surface but do not release it in any quantity and activated
platelets produce IL-1a and IL-1 (3 which are both entirely membrane bound
(Hawrylowicz et al., 1989a). IL-ip but no IL-1a has been detected from
synovial fibroblasts and in the stromal areas of ovarian cancer cells (Bandari et
al., 1989; Naylor et al., 1990). Only IL-1 a is synthesised by human mesangial
cells (Abbott et al., 1992).
2
Keratinocytes and sweat gland epithelium (Luger et al., 1991; Reitamo et al.,
1990) constitutively produce IL-1 thus creating a major reservoir of IL-1 in the
skin. Unlike cultured keratinocytes which produce active IL-1 a precursor
molecule and accumulate large amounts of inactive, unprocessed IL-1 (3
precursor (Bigler et al., 1992), both normal and psoriatic keratinocytes do
process IL-1 (3 to a mature form, although somewhat ineffectively (Cooper et al.,
1990a; Hammerberg et al., 1990). This epidermal form of IL-lp has been shown
to be incapable of stimulating cells possessing the type I IL-1 receptor (Cooper
et al., 1990b). U937, a human histiocyte derived cell line, produces proteins
analogous to the inactive precursors of both IL-1 [3 and TNFa but the active
forms of either have not yet been detected (Demeter et al., 1991).
Of the inducible IL-1 producers, stimulated monocytes, tissue macrophages and
glial cells are the major sources of IL-1, with generally more IL-1 [3 than IL-1a
being produced. B cell production of IL-1 differs significantly from that of
macrophages both in kinetics and in the signals which induce it. TNF and LPS,
which are both potent stimulators of M(|) IL-1, have no effect on B cells, whereas
IL-2 and IL-4 both stimulate B-cell but not M(|) IL-1 production. B cell IL-1
expression is several orders of magnitude less than that of M(j) and is
significantly slower, peaking at about 48h compared to less than 6h after M(j)
stimulation (Hawrylowicz et al., 1989b; Weaver and Unanue, 1986).
Constitutive IL-1 production from normal cultured human B lymphocytes
(Pistoia et al., 1986), can be increased by stimulatory agents.
Blood dendritic cells do not produce detectable IL-1 (Bhardwaj et al., 1989;
Vakkila et al., 1990). Dendritic cells and their relationship to IL-1 will be dealt
with in Sect. 1.15.2.
There is much evidence for disconnected synthesis and secretion of IL-1 a and p.
Studies on connective tissue diseases show increased concentrations of
extracellular IL-1 a and P but intracellular concentrations remain normal and do
not correlate with their respective extracellular concentrations (Aotsuka et al.,
1991). Whilst cultured bone marrow-derived macrophages remain able to
produce IL-1, IL-6 and TNFa over a 3-week period, their ability to release IL-1
is lost although the intracellular accumulation is unchanged (Aznar et al., 1990).
Sheep red blood cells and carbonyl-iron, but not the compounds hemoglobin,
globin and ferric citrate, enhance IL-ip production from phagocytic, but not
non-phagocytic, human blood monocytes indicating that phagocytosis must be
an important trigger for this mechanism of IL-1 release (Okamoto et al., 1991).
Studies on inflammatory sites have yielded much information on the production
and involvement of cytokines in tissue function, see Sect. 1.5. LPS induced
3
release of IL-1 from peritoneal macrophages during the exudative response to
Freund's complete adjuvant, over 30days, shows that EL-1 is produced at high
levels much earlier than TNF and is associated with the recruitment phase of the
reaction (Chensue et al., 1989). TNF seems to be associated more with the
established exudate stage. Immunohistochemically, EL-la and (3 show
comparable expression at 6h post LPS but whereas IL-1a persists in the
cytoplasm for at least 18h, IL-1 (3 rapidly disappears from the adjuvant recruited
cells.
1.3 Induction of IL-1 - Transcriptional and Translational Control
The term 'Cytokine Network' refers to the overlapping functions of two or more
cytokines which can have synergistic effects or may antagonise each other. In
addition, the production and release of cytokines are influenced by positive and
negative feedback loops from the same or other cytokines. External agents can
also initiate cytokine synthesis and interactions. As an example, bacterial
endotoxin (LPS) induces primarily IL-1 (3 and TNF synthesis from macrophages.
In response to these two cytokines, IL-6 and IL-8 are produced which, in turn,
inhibit the production of IL-1 and TNF.
The most commonly used stimulus for IL-1 transcription is LPS but other agents
which induce factors required for IL-1 gene transcription include complement
components, clotting components, bile salts and the cytokines TNFa, CSF-1,
GM-CSF and IL-1 itself. Inhibitory agents include corticosteroids, prostacyclin,
prostaglandins and cytokines EL-4, IL-6, IL-8, IL-10 and TGFJ3. The precise
pattern of IL-1 gene response, ie. enhanced and suppressed transcription, mRNA
stability and translational control is dependent on the stimulus. IL-1a and IL-1 (3
are under separate transcriptional control and transcription and translation of IL-
1 are distinct and dissociated processes in macrophages (M<j>), peripheral blood
monocytes (PBMC) and polymorphonuclear leukocytes (PMN) (Marucha et al.,
1991; Ohmori et al., 1990; Turner etal., 1989; Yamoto et al., 1989).
Macrophages are thought of as being the prime controllers of cytokine
influences in normal and diseased tissues. The response to endotoxin
(lipopolysaccharide, LPS) stimulation is dramatic. LPS and CSF-1 induce early
genes encoding functional proteins eg. IL-1 and TNF as well as immediate early
genes (c-fos, c-myc, c-fms, c-fgr) which initiate both positively and negatively
interacting transduction cascades. Production of IL-1 a, IL-1 (3, IL-6, TNFa and
M-CSF from LPS stimulated monocytes and macrophages is differentially
modulated by numerous factors. IL-4 is thought to be one of the major factors
involved in regulation of EL-1 production (Wong et al., 1993). It inhibits
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production of IL-1 (3 and TNFa from LPS, IFNy or IL-la stimulated
macrophages whilst acting synergistically to stimulate IL-1 receptor antagonist
(IL-lra, see Sect. 1.13.1) production (Vannier et al., 1992; Hart et al., 1991).
Different IL-4 actions have been detected in different species (Hart et al., 1991).
Production of IL-1 from human monocytes in culture is affected by serum
concentrations in the medium. Cells in medium with 1% heat-inactivated serum
produced about 3-fold more IL-la than IL-ip by 18h whereas 1 % non-
inactivated serum or 5% fresh plasma induced similar amounts of IL-la and IL-
lp. In all cases 80-90% of IL-la remained cell associated for 24h with
increasing amounts being found extracellularly subsequently (Lonnemann et al.,
1989).
Cytokine release varies with the state of maturation of the monocytes. In tissue
culture monocyte to macrophage differentiation shows M-CSF to be the only
cytokine secreted constitutively up to 7 days and becomes inhibited by LPS. Of
the LPS dependent cytokines, IL-lp and IL-6 are down regulated and TNFa
increases greatly (Scheibenbogen and Andreesen, 1991). After LPS stimulation,
more than 81% of monocytes but only about 43% of macrophages express EL-1
mRNA transcripts (Bernaudin et al., 1988).
Although LPS induces similar increases in mRNA levels in monocytes (MNL)
and polymorphonuclear leukocytes (PMN), with IL-lp transcription
predominating over IL-la, mRNA translation in PMN is far less efficient. PNM
must be subject to specific control because rabbit reticulocyte lysates will
translate MNL and PMN IL-1 mRNAs equally efficiently (Lord et al., 1991).
Complement, P-glucan polymers and adherence of monocytes/macrophages to
surfaces all induce transcription without translation and in each case the steady
state levels for IL-ip mRNA are comparable to those detected after lOng/ml
endotoxin (Schindler et al., 1990b,c,d; Yamoto et al., 1989). C5a, which is
produced during activation of the complement cascade and is a potent mediator
of various inflammatory events, stimulates IL-1 release from monocytes and
there is significant synergism with LPS or IFNy (Okusawa et al., 1987). The
signal provided by C5a is primarily transcriptional, the translational signal being
provided by LPS or IL-1 itself (Schindler et al., 1990b,c; Geiger et al., 1992).
IL-6 production can not be triggered by C5a alone but C5a significantly
increases IL-6 production from LPS or IL-1 stimulated monocytes, indicating a
potentially important differential regulation of IL-1 and IL-6 by C5a (Montz et
al., 1991). IFNy has no effect on either IL-1 or TNF mRNA in macrophages but
does enhance cytokine synthesis from GM-CSF, TNFa or LPS stimulated cells.
IFNy increases and sustains LPS induction of IL-la and J3 dramatically as
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opposed to inducing only a transient TNFa response. On the other hand, IFNy
suppresses IL-1 transcription from IL-1 stimulated cells (Chantry et al., 1990;
Schindler et al., 1990a; Ucla et al., 1990). IL-4, IL-6 and TGF(3 suppress IL-1
transcription and IL-10 inhibits IL-1 expression from LPS stimulated monocytes
(Hart et al., 1991; Schindler et al., 1990b; Chantry et al., 1990; de Waal Malefyt
et al., 1991).
Cycloheximide, a translation inhibitor, added together with TNF superinduces
IL-1 (3 mRNA and stabilises both IL-1 mRNAs, indicating posttranscriptional
control in monocytes (Turner et al., 1989). In PMN the effect is different and
cycloheximide abrogates TNF, or IL-1 plus TNF, induced accumulation of IL-ip
mRNA, an effect not caused by inhibition of IL-ip mRNA transcripton. During
experimental endotoxemia, in vivo treatment with dexamethasone (DEX), an
immuno-suppressive and anti-inflammatory agent, prevents LPS induction of IL-
la mRNA and suppresses but does not completely inhibit IL-ip mRNA
transcription (Ulich et al., 1990). Glucocorticoids also selectively decrease both
transcription and stability of IL-ip mRNA (Nishida et al., 1988b; Lee et al.,
1988) Nonsteroidal anti-inflammatory drugs do not stimulate IL-1 production
but relieve the inhibition caused by the presence of prostaglandins (Otterness et
al., 1988). In vivo evidence supports the importance of lipoxygenase products in
the reduction of IL-1 synthesis and the 13-lipoxygenase products are thought to
be involved in the early events of transcription (Endres et al., 1989; Schade et
al., 1991).
Because of the differences in ability of stimuli to affect transcription and mRNA
stabilisation, it has been concluded that the effects may be directed, in part,
through second messenger pathways. IL-1 gene expression in monocyte lineage
cells is regulated by calmodulin dependent-kinase while TNF is not affected.
Hurme (1987) has shown from studies using phorbol myristate acetate (PMA),
an activator of PKC, that PKC activation alone is sufficient for IL-1 [3 gene
induction but additional signals, provided by LPS, are required for the activation
of the IL-1a gene. In the presence of PMA and cycloheximide, transcription is
not induced indicating that induction of transcription with PMA requires de novo
protein synthesis. IL-1 production by activators of PKC is suppressed by IFNy
(Schindler et al., 1990a) and DEX decreases PMA induction of IL-1 (3 mRNA in
U937 cells. Recently tyrosine kinase activity was shown to be required for the
PMA induced IL-lp expression and that this activity is independent of PMA
induced AP-1 activity (Palkama et al., 1993).
The effects of cAMP on IL-1 synthesis seem to be dependent on the stimulus.
PGE-induced suppression of EL-1 could be via the induction of cAMP, raised
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levels of which inhibit LPS induced translation but not transcription of IL-1
mRNA (Knudsen et al., 1986; Hurme and Serkkola, 1991). However, conflicting
studies (Cavaillon and Haeffner-Cavaillon, 1990) have shown that LPS induced
PGE2 is not involved in elevation of intracellular cAMP and the cAMP
suppression may be independent of PGE2 effects. IL-1 (5 production has also been
shown to be increased by oral cyclo-oxygenase inhibitors such as indomethacin,
which blocks IL-1 induced PGE2 in vitro (Endres et al., 1989; Takii et al., 1992).
Human immunoglobulin (IgG-IV), suppresses IL-1 and TNFa production from
rabbit peritoneal exudate cells stimulated with LPS, possibly as a result of Ig
binding to the cells via Fc gamma receptors which in turn increases intracellular
cAMP levels (Shimozato et al., 1990). Histamine, which also reduces LPS-
induced IL-1 via a cAMP pathway, enhances IL-1 induced IL-1 synthesis and
gene transcription (Vannier and Dinarello, 1991).
Early reports claimed no central role for calcium in the induction and release of
human IL-1 (Newton, 1987; Schindler et al., 1990a) but calcium ionophore has
now been found to stimulate a transient increase in IL-1 mRNA from mast cells
and to have some positive effect on IL-1 at both transcriptional and
posttranscriptional levels in monocytes and macrophages (Labadia et al., 1990;
Suttles et al., 1990; Mahe et al., 1991).
IL-1 and TNFa are very similar mediators and IL-6 mediates many of the effects
of both IL-1 and TNFa, eg. in fever induction and there are several examples of
discoordinate expression of these cytokines. Increased levels of PGE2/cAMP can
downregulate TNF expression by reducing its transcription rate, whereas IL-1
mRNA is not affected and IL-6 mRNA can be elevated by cAMP (Bailly et al.,
1990; Endres et al., 1991; Kunkel et al., 1988; Scales et al., 1989). Raised
soluble cGMP levels suppress LPS stimulated IL-1 production while having no
effect on TNFa (Endres et al., 1991).
A general principle appears to be that only those cells which possess high
numbers of LPS receptors are efficient inducible producers of IL-1.
1.4 Processing and Secretion of IL-1
The primary IL-1 translation products are 3IK precursors which are largely
found intracellularly in the cytosol and can be associated with lysosomes and
microtubules but not golgi apparatus (Baldari and Telford, 1989; Bakouche et
al., 1987). Myristyl groups have been detected on both proproteins and are
thought to be added posttranslationally. These groups may be utilised for IL-
1 /membrane associations (Bursten et al., 1988).
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Most IL-la remains in the cytosol but some of the precursor form becomes
membrane associated (Beuscher et al., 1987; Brody and Durum, 1989). A
calcium activated neutral protease, calpain, processes IL-la to the mature form
with amino terminal Ser-113 (Kobayashi et al., 1990; Carruth et al., 1991) but
numerous active IL-la sub-fragments are routinely detected in biological fluids
and appear to be generated by digestion at trypsin-sensitive sites or by serine
proteases (Cannon and Dinarello, 1985). Monocyte IL-la remains cell-
associated for the first 20 hours and has a half-life of 15 hours (Hazuda et al.,
1988).
Unlike IL-la, the IL-lp precursor must be cleaved for optimal activity.
Processing and secretion of IL-1 P are closely linked. Although monocytes and
macrophage secrete IL-ip efficiently, contrary to endothelial cells, smooth
muscle cells and fibroblasts, there is controversy about IL-ip release and
processing by monocytes/macrophages. Intact pro-IL-ip has been observed as
the predominant released form and thought to be processed in the extracellular
space (Hazuda et al., 1988, 1990; Beuscher et al., 1990; Suttles et al., 1990), but
there is also evidence that the proprotein is processed within the cell and that
processing may be concurrent with secretion (Hogquist et al., 1991a,b;
Thornberry et al., 1992; Rubartelli et al., 1993). Still other data suggests that
cultured monocytes release more of the unprocessed form than do fresh
monocytes and that release in culture is pH and temperature dependent (Arend et
al., 1989; Rubartelli et al., 1993). Cell injury releases predominantly the
proprotein (Hogquist et al., 1991a,b). Although processed IL-ip is only
observed extracellularly, both the processing enzymes and the IL-1 proprotein
are present in the cytosol. The amount of IL-1 released and processed also
depends on the stimulatory agent, eg. LPS induced IL-lp is rapidly released and
processed but IL-1 P induced by IL-la or IL-2 remains cell-associated (Dinarello
et al., 1987; Numerof et al., 1990). The effects of IL-1 as the inducer may
depend on its concentration (Manson et al., 1989). Interaction of immune
complexes with Fc receptors may drive monocytes to release pre-existing
intracellular IL-lp (Rubartelli et al., 1993).
IL-1 has no conventional secretory signal sequence and various routes of release
have been proposed, such as exocytosis from vesicles, active transport by carrier
proteins or cell death (Bakouche et al., 1987; Rubartelli et al., 1990; Hogquist et
al., 1991a,b). Data from expression of recombinant IL-ip suggests that fusion to
a heterologous leader sequence allows IL-ip to be translocated across the
membrane of the endoplasmic reticulum and to be transported and secreted via
the endocytic pathway (Baldani et al., 1987; Pecceu et al., 1991). There is a
growing number of extracellular proteins which, like IL-1, lack N-terminal
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hydrophobic signal peptides, have glycosylation sites which do not appear to be
utilised and are secreted with slow kinetics from producer cells (see Sect. 1.7.2
re glycosylation of IL-lp). Transporter proteins exist, such as the prokaryotic
HlyB and CyaB, yeast Ste6 and murine Mdr, whose expression appears to be
restricted to specific tissues and substrates (Kuchler and Thorner, 1990). Very
recently members of the ATP-driven transporter family of proteins, which
resemble HlyB and CyaB and have been detected in mammalian cells, have been
proposed as candidate IL-1 transporters (Kuchler and Thorner, 1990; Howard et
al., 1991; Rubartelli et al., 1993).
The amino terminus of mature IL-1(3 is Ala-117 but other naturally occuring N-
termini have been reported. In particular, a 22K partially cleaved product is
found in monocyte supernatants. Processing of IL-1 (3 after secretion is by any of
several proteases released at inflammatory sites. Proteinase K has been shown to
transform IL-lp to the active form which is proteinase K insensitive, as is IL-1 a.
Elastase, cathepsin G, collagenase, all of which are found in bronchoalveolar
lavage fluid, as well as serine proteases and plasmin have been shown to release
active mature protein through cleavage at sites other than Ala-117 (Auron et al.,
1984; Black et al., 1988; Hazuda et al 1988, 1990; Mizutani et al., 1991a). Cells
such as keratinocytes do not produce enzymes which process IL-ip and the
serine protease, mast cell chymase, is thought to process the released IL-lp
locally (Mizutani et al., 1991b). The significance of these small peptides is not
yet understood.
The highly specific monocyte processing enzyme, IL-1 converting enzyme
(ICE), cleaves at Asprhydrophobic motifs to yield active protein (Howard et al.,
199; Mosley et al., 1987a; Sleath et al., 1990). This convertase enzyme has been
cloned and is a member of the cysteine protease family (Ceretti et al., 1992;
Thornberry et al., 1992). The mRNA is detectable in a variety of cells and it has
been suggested that the enzyme may have other substrates as well as IL-ip
precursor (Cerretti et al., 1992). Mapping of the enzyme to chromosome llq23,
which is frequently involved in rearrangement in human cancer, raises the
possibility that altered production of the protease contributes to some of these
disease states. The murine form of the enzyme, located on murine chromosome
9, has been detected in mononuclear phagocyte and T lymphocyte cell lines as
well as in spleen, heart, brain and adrenal glands (Nett et al., 1992). The critical
function of this protease is indicated by the finding that cowpox virus encodes a
highly specific ICE inhibitor which is necessary for the virus to suppress the host
inflammatory response (Ray et al., 1992).
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1.5 Actions of IL-1
Interleukin-1 is a key mediator in the cytokine network, affecting many
pathophysiological cell and tissue functions. The effects of systemic injection of
IL-1 include increases sodium excretion, hypotension, depressed myocardial
function, leukopenia, thrombocytopenia, pulmonary congestion and tissue
neutrophilic infiltration. IL-1 belongs to a group of cytokines, IL-1, TNFa and
IL-6, which have multiple overlapping actions. The pleiotropic nature of IL-1
actions has been well documented and although the majority of biological effects
attributable to IL-1 are associated interchangeably with IL-1 a and IL-1 (3, there
are notable exceptions to this.
T-cell proliferation is dependent on the secretion of autocrine growth factors.
The involvement of IL-1 is now becoming clarified. IL-1 induces IL-2 in T cells
to a small extent but acts synergistically with IL-6 leading to an IL-2 dependent
pathway of proliferation (Kuhweide et al., 1990). Blocking the IL-2R eliminates
IL-1 induced effects but does not affect IL-6/PHA induced proliferation.
IL-1 is involved in B cell maturation and proliferation in response to antigenic
stimulation. Activated B cells participate in the immune response as accessory
cells for T cell activation, not only by physically presenting antigen but also by
releasing IL-1 (Pistoia et al., 1986). However, unlike macrophages, B-cell
antigen presenting potential is not enhanced by IL-1 (Krieger et al., 1986).
Synergism with IL-6 is equally important for B and T cell activation. IL-1 can
also act indirectly via stimulation of T cell secretion of various colony
stimulating factors and IFNs which can act synergistically with IL-1 to promote
B cell proliferation (Caussy and Sauder, 1989). Cell surface expression of CD5,
expressed by the majority of T cells and some B cells, has also been cited as
regulating the binding of and responsiveness to IL-1 of these cells (Nishimura et
al., 1988).
Whilst GM-CSF and EL-3 are the most important mediators of stem cell
differentiation, IL-1 plays a supplementary role (Takaue et al., 1990; Shieh et
al., 1991; Zucali et al., 1991; Santiago-Schwarz et al., 1992)
IL-2 is the most effective stimulator of natural killer (NK) cells. EL-1 can trigger
modest activation of these cells and evidence from human and porcine studies
shows NK activity to be augmented by EL-la and IL-2 in a non-synergistic
fashion. It is thought that IL-1 may act by influencing IL-2R expression. The
actions of both IL-1 and IL-2 are inhibited by IL-4 (Ostensen et al., 1989;
Knoblock and Canning, 1992). It has also been shown, however, that EL-4
induces NK activity activity in human lymphocytes pre-activated by IL-2
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(Higuchi et al., 1989). IL-lra strongly potentiates the stimulatory action of IL-2
on NK activity in the same way as IL-1 but as IL-4 stimulates production of IL-
lra, inhibition of an intermediate pathway by the latter, may be involved (Conti
et al., 1991). IL-1 may also act by increasing binding of NK cells to tumour cells
(Herman et al., 1985).
IL-1 is involved in the recruitment of cells to sites of inflammation or injury via
various mechanisms. Intrapulmonary IL-1 mediates acute IgG immune complex
induced alveolitis in the rat, the dramatic increases in IL-1 concentrations
showing positive correlation with recruitment of neutrophils to the lung (Warren,
1991). Potentially fundamental differences in the requirements for cytokines in
lung and dermal vascular injury after deposition of IgG immune complexes have
now become apparent. TNFa and IL-1 are both found in the lung but only IL-1
in the dermis (Mulligan and Ward, 1992). IL-1 exerts its influence on PMN by
initiating PMN migration during an acute inflammatory response and is the
dominant signal for movement of PMN from bone marrow to local sites of
accumulation (Mclntyre et al., 1991; Cybulski et al., 1986) and induced
neutrophil migration across IL-1-activated endothelium is abolished by GM-CSF
(Yong and Linch, 1993). IL-1, TNF and C5a have all been shown to be actively
involved in vivo in the mobilisation of PMN to inflammatory sites (Mason and
Van Epps, 1989) but TNF, and not IL-1, appears to induce PMN migration
through fibroblast layers by an alternative fibroblast-dependent mechanism
(Morzycki and Issekutz, 1991). Normal bovine neutrophils are known to be
responsive to recombinant bovine IL-1 (3. It appears to augment phagocyte
oxidative metabolic responses to subsequent stimulation by microbial antigens
(Canning and Baker, 1990).
Synovial cells stimulated by IL-1 produce factors selectively chemotactic for
neutrophils, lymphocytes and monocytes which could potentially facilitate
inflammatory arthritis (DeMarco et al., 1991). In addition, synovial fibroblasts
secrete IL-1 a, which activates chondrocytes directly and bFGF, which
potentiates the activity of IL-1. The IL-1 induced release of another, as yet
unclassified, factor acting on chondrocytes has elicited the idea of a new
cytokine (Bandara et al., 1992).
Chondrocytes are responsive to IL-1 which triggers the expression of
collagenase, caseinase, phospholipase and cyclooxygenase genes, increases
release of proteoglycans (the basis of one biological assay for IL-1 and TNF),
induces large amounts of IL-6 and inhibits plasminogen activator. The
metalloproteinase production is not affected by any factor such as LPS, PMA,
Con A or indomethacin which affect T-cell proliferation. TNF, on the other
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hand, only decreases plasminogen activator and does not elicit production of
either the metalloproteases or PGE2 (Schnyder et al., 1987; Shinmei et al., 1989).
IL-1 directly increases transcription of Types I, III and IV collagen (Kahn et al.,
19*) but inhibits Type II collagen synthesis by a mechanism involving DNA
regulatory sequences on the collagen gene (Chandrasekhar et al., 1990).
Heckman et al. (1993) have demonstrated that that the effects of IL-1 on dermal
fibroblasts may be concentration dependent. At low IL-1 concentrations,
chemotactic responsiveness was enhanced whereas higher concentrations were
required to stimulated collagenase mRNA synthesis. Fibroblasts and endothelial
cells are a potent sources of hematopoetic growth factors such as GM-CSF and
G-CSF when stimulated by IL-1 or TNFa (Pober et al., 1987; Broudy et al.,
1987) but are not themselves targets for these factors (Yong et al., 1991). TGFJ3
production is also stimulated (Phan et al., 1992). In vitro senescent endothelial
cells no longer respond to exogenous growth factors and contain large amounts
of IL-1a transcript which is not found to any extent in transformed endothelial
cells. The proliferative lifespan of the cells can be extended by treatment with an
IL-1 a mRNA antisense oligodeoxynucleotide, indicating that IL-1a can regulate
the dynamics of endothelial cell senescence (Maier et al., 1990).
Endothelial and smooth muscle cells express biologically active IL-1 on then-
surface and do not release it in any quantity. The resultant requirement for
intercellular contact between vascular cells and infiltrating leukocytes could
conceivably permit costimulation while limiting undue propagation of
inflammatory effects under normal conditions (Loppnow and Libby, 1992). Both
IL-6 and TNF are released from these cell types on stimulation with IL-1 which
is obviously acting as a controlling signal. IL-1 and TNF inhibit endothelial cell
growth but stimulate smooth muscle cell growth and IL-6, acting alone, has also
been proposed as being important for smooth muscle cell proliferation. The
mechanism may involve differential regulation of the heparin-binding
(fibroblast) growth factor receptors, the expression of which correlates inversely
with mitogenic effects (Sawada et al., 1990; Morimoto et al., 1991).
The effects of IL-1, TNF and other cytokines on leukocyte-endothelial adhesion
has led to the discovery of several endothelial adhesion molecules (Cotran and
Pober, 1990). Platelet-derived IL-1, which is entirely cell associated, stimulates
cytokine production from endothelial cells as well as inducing selective adhesion
molecule expression which is dependent on the source of the cells eg. vascular
expression of ELAM-1 occurs on cells from cutaneous rather than noncutaneous
sites sites. Although other cytokines probably play an enhancing role, platelet-
delivered IL-1 appears to be the essential component for stimulation of
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endothelial cells by platelets, as antisera to IL-la and P completely block
platelet induced responses. In conjunction with an increasing volume of data on
platelet-endothelial cell interactions, this delivery of IL-1 to vascular endothelial
cells following injury, implicates platelets as providers of an initiating signal for
the inflammatory response (Hawrylowicz et al., 1991).
ICAM-1 (CD54) is upregulated by IL-la but LFA-3 (CD2) is not (Swerlick et
al., 1991). A further adhesion molecule, ELAM-1 is only very transiently
expressed upon stimulation by IL-la (Beekhuizen et al., 1991). IL-1, TNFa and
IFNy also induce expression of the adhesion molecule ICAM-1 on synovial
fibroblasts and increase the number of cells expressing it. Of the three cytokines
IL-1 has the least effect. Removal of the cytokines causes a rapid decrease in
ICAM-1 expression. At the same time HLA class I antigen expression is slightly
increased by all three cytokines but only IFNy increases class II expression
(Chin et al., 1990).
Two recent reports have also indicated a role for cell-associated IL-1 (3. Data
from patients on continuous ambulatory peritoneal dialysis which show that
inflammatory peritoneal monocytes have reduced ability to secrete IL-1,
compared to autologous blood monocytes but are still inflammatory, have raised
the possibility that an intracellular location may be important for utilisation of
IL-lp in vivo (Hart et al., 1993). Both LPS and IL-ip stimulated human fetal
microglial cells produce abundant levels of potent IL-lp which remains
primarily cell associated (Lee et al. 1993).
Monocyte MHC Class I expression is not upregulated by IL-1 (Swerlick et al.,
1991; Migita et al., 1991). EL-la has been shown to be a potent inducer of the
extremely unstable prostaglandin H sythetase enzyme (PGHs) in macrophages. It
is thought that CSF-1 is the main regulator during differentiation of pro¬
monocyte to monocyte and monocyte to macrophage and that IL-la, IL-ip,
IFNa, IFNP and perhaps IL-2 regulate the differentiation of macrophages
(Bartolini et al., 1990; Peters et al., 1992). Monocytes/macrophages are the main
controllers of the cytokine network and the role of IL-1 is to stimulate the
release of numerous cytokines and growth factors (see Appendix 2 for examples
of cytokine networking). EL-1 has been strongly implicated as an hematopoetic
factor, synergising with IL-3 in particular, but also with GM-CSF, in stimulating
growth and differentiation of hematopoetic stem cells from bone marrow
(Mochizuki et al., 1987; Kobayashi et al., 1991).
Bone metabolism is dependent on differential cytokine release by the various
cells involved, eg. Macrophages are known to be involved in the early stages of
laying down of osteoblasts which are derived from stromal cell progenitors, as
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are chondrocytes. They produce IL-lp but also present membrane-bound IL-1
directly to bone calvaria. Mast cells are present in excessive amounts in
conditions like RA and osteoporosis where there is bone loss (Nishihara et al.,
1989). Mast cells and basophils are induced by IL-1 to produce histamine
(Subramanian and Bray, 1987), which can in turn enhance IL-1 induced IL-1
synthesis and gene transcription in macrophages (Vannier and Dinarello, 1991).
IL-1 [3 is the most active cytokine to be involved in bone resorption and
inhibition of bone formation. TGFj3 acts most strongly in opposition but IFNy
and calcitonin also inhibit the resorptive effects of IL-1 and TNF (Boyce et al.,
1989; Gowen et al., 1990). The actions of DL-1 are inhibited by IL-lra (Rosen et
al, 1990). IL-6 can be produced from bone cultures and may prove to be
important in the regulation of osteoclast development and stimulation of
resorption at an early stage of osteoclast recruitment. Glucocorticoids predispose
to osteoporosis, an action effected by IL-ip, and have a positive effect on
osteoclasts.
A mutual antagonism exists between IL-1 as pro-inflammatory and
glucocorticoids as anti-inflammatory mediators. Examples of this phenomenon
are DEX induced alkaline phosphatase production from endothelial cells which
can be completely inhibited by simultaneous incubation with IL-1, and IL-1
induced neutral metalloproteinase synthesis from endothelial cells or fibroblasts
which is inhibited by DEX and glucocorticoids via involvement of the
glucocorticoid receptor (DiBattista et al., 1991; Mulkins and Allison, 1987).
Stromelysin is a tissue-degrading proteinase important in tissue-moulding
processes such as in wound healing, inflammatory reactions, rheumatoid arthritis
and tumour invasion. Frisch and Ruley (1987) have demonstrated that DEX can
suppress IL-1 and phorbol ester induction of transcription from the stromelysin
promoter.
IL-1 acting in the brain (Dinarello 1984; Tobler et al., 1984; Besedovsky et al.,
1986; Brown et al., 1991) has a variety of biological effects including induction
of fever, slow wave sleep and potent stimulation of the pituitary-adrenal (P-A)
axis via release of corticotropin-releasing factor (CRF). Intravenous injection of
of IL-1a and IL-1 (5 appear to result in distinct responses with only DL-1J3
significantly increasing plasma levels of adrenocorticotropic hormone (Uehara et
al., 1987). Induction of IL-1 in the brain rapidly suppresses peripheral immune
responses via the CRF-mediated activation of both the pituitary-adrenal axis and
the sympathetic nervous system (Sundar et al., 1991). In cultured hepatocytes,
IL-6 has also been implicated as the mediator of IL-1 and TNF induced synthesis
of the acute phase proteins, C-reactive protein and serum amyloid A (Yap et al.,
1991). In the gut, a possible interaction between the immune and gastrointestinal
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systems has been suggested. The involvement of IL-1 includes stimulation of
PGE2 synthesis by the stomach, retardation of gastric emptying and actions as a
cryoprotective and antisecretory agent (Saperas et al., 1990; Robert et al., 1991).
IL-1 has numerous endocrinologic effects, including inhibition of thyrocyte
function and prolactin release and induction of ACTH with resultant increases in
steroid synthesis (Krogh- et al., 1991, Migita et al., 1991). A number of reports
indicate IL-1 induced increase in phosphorylation of serine residues of the small
heat shock protein hsp 27. (see IL-1 signal transduction in Sect 1.12.2).
Threonine and tyrosine residues are not phoshorylated in either control or
stimulated cells (Kaur et al., 1989).




Mobilisation to inflammatory sites Neutrophil
Degranulation and histamine release Mast cell/Basophil/Eosinophil
Immunologic T lymphocyte
TABLE 1.1




















1.6 IL-1 involvement in disease states
As traumatic, infectious and inflammatory diseases may result in near
simultaneous appearance of IL-1, IL-4, IL-6, TNFa, IFNy and C5a, synergistic
and/or inhibitory actions are obviously clinically relevant.
1.6.1 Septic shock syndrome
The clinical syndrome of Gram-negative bacterial septicemia appears to be the
result of excessive stimulation of the host system by LPS leading to, amongst
other effects, fever, intravascular coagulation and circulatory shock.
The septic shock syndrome is characterised by multiple cytokine release (TNFa,
IL-la and IL-1 (3, IL-6, IL-8, CSFs, TGF(3) from macrophages and monocytes,
as well as release of numerous tissue factors and of antagonists such as IL-lra.
TNFa is thought of as being the central mediator and the mechanism of IL-1
involvement is associated with its ability to increase plasma concentrations of
small mediator molecules such as platelet-activating factor, prostaglandins and
nitric oxide, all of which are potent vasodilators (Dal Nogare et al., 1991;
Dofferhof et al., 1991).
There appears to be differential regulation of IL-1 and TNF during endotoxin
tolerance. Injection of LPS into mice elicits transient increase in both factors.
TNF appears rapidly followed by IL-1 at 3-4h. Early IL-1 production may be
partially controlled by TNF but a second LPS injection at 20h results in a
significant increase in serum IL-1 but no further response by TNF (Zuckerman et
al., 1991).
IL-6 may again be an important effector of IL-1 (3 and TNFa actions in vivo.
Fever attributed to LPS induction of IL-1 and TNFa is thought to be mediated
by IL-6 (LeMay et al.,1990; Shalaby et al., 1989).
The sepsis syndrome in humans is consistently associated with marked increases
in the number of IL-1 R expressed on circulating PMN without there being any
concommitant increase in complement receptor 3 (Fasano et al., 1991). The
mechanism and functional significance is at present unknown but presumably
the increase occurs as a result of the increased production of circulating IL-1.
The multiple actions triggered by LPS are detailed in a comprehensive review by
Lynn and Golenbock (1992).
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1.6.2 Autoimmune related diseases
1.6.2.1 Rheumatic diseases
Several distinct cytokine patterns have been noted in synovial fluid from
rheumatic patients. Immune activation pathways appear to be different in
rheumatoid (RA) and osteoarthritis (Westacott et al., 1990; Kirkham, 1991).
Cells with dendritic morphology and bright IL-la staining circulate in the blood
of RA patients but are not seen in OA or normal subjects. IL-1 (3 is not detected
in these cells (Barkley et al., 1990). Serum IL-1 (3 concentrations are higher in
RA than in other arthritic conditions, whereas IL-2, TNFa, IFNa, and IFNy are
all lower. No correlation has been found between IL-1 [3 and any other cytokine
in synovial fluid. Strong evidence for the involvement of IL-1 in RA is given by
an assessment of RA patients with symmetric and asymmetric knee joint
inflammation which shows that IL-1J3 levels in all inflamed joints are
significantly higher than in contralateral uninflamed joints (Rooney et al., 1990).
Relatively high numbers of dendritic cells are found in RA effusions during
acute flares of the disease but it is only macrophages which make the real
contribution to the IL-1 detected. IL-6 has been detected in these exudates and
implicated in the pathogenesis of RA (Bhardwaj et al., 1988, 1989). IL-1 (3 has
been shown to correlate with disease progression and in situ work has shown
macrophages to be the major source of IL-1 (3 within the rheumatoid synovium
(Eastgate et al., 1988; Wood et al., 1992). There is some evidence that B cell
derived IL-la and (3, both of which are greatly increased in RA, may be
involved in the B cell clonal expansion of RA (Yamamura et al., 1990). The
involvement of EL-la in RA has been difficult to determine (Eastgate et al.,
1991) but circulating cells of dendritic morphology which contain IL-la (but not
IL-1 (3), do appear to correlate with RA but not OA disease activity (Barkley et
al., 1990).
Rheumatoid synovial fibroblasts have the ability to secrete large amounts of the
matrix-degrading metalloproteinases, collagenase and stromelysin. Two
metalloproteinases, the 92K (type V collagenase) and 68K (type IV Collagenase)
gelatinases, appear to be differentially and independently regulated by cytokines.
Although a large range of cytokines can stimulate collagenase synthesis, only
IL-1, TNFa and lymphotoxin can induce the 92K gelatinase. which is
constitutively expressed in rheumatoid but not normal cells. These three
mediators are involved in potentiating the matrix-degradative phenotype in
rheumatoid synovial fibroblasts (Unemori et al., 1991). In a canine model of
osteoarthritis, stromelysin, IL-la and IL-1 (3 were found to be localised in
superficial synovial lining cells, infiltrating mononuclear cells, endothelial cells
and smooth muscle cells of blood vessles whereas the oncogenes, c-fos, c-jun
and c-myc, were detected predominantly in the synovial lining cells (Pelletier et
17
al., 1993). The latter are thought to be the mediators through which IL-1 induces
metalloproteinase expression.
1.6.2.2 Insulin-dependent (type I) Diabetes Mellitus
Activated mononuclear cells appear to be important effector cells in autoimmune
pancreatic beta-cell loss leading to insulin-dependent (type 1) diabetes mellitus
and there is evidence that systemic IL-1 (3, but not IL-1a, is directly involved in
the specific cell destruction (Bendtzen et al., 1986; Reimers et al., 1991). Recent
evidence indicates that IL-1 induced nitric oxide and subsequent inhibition of
mitochondrial enzymes could contribute to this destruction (Dimmeler et al.,
1993). In mice, type I diabetes has been found to be linked to the IL-1 type I
receptor (see Sect. 1.11 for IL-1 receptors) on chromosome 1 (Cornall et al.,
1991).
1.6.3 Bacterial meningitis
There is controversy over the involvement of IL-1 (3 in bacterial meningitis and
damage to the blood-brain barrier. TNFa appears to be the main culprit, but
whether IL-1 synergises with TNF or acts by inducing it has not been clarified.
IL-1 does not, however, seem to correlate with any cerebro-spinal fluid indices
so far measured (Quagliarello et al., 1991; Sharief et al., 1992).
1.6.4 Renal function
Monocytes produce increased amounts of IL-1 (3 in long term dialysis and end-
stage renal failure patients (Schiller et al., 1991). Local production of IL-1, TNF
and platelet activating factor in glomeruli by infiltrating or resident
inflammatory cells may alter the growth pattern of of glomerular cells and the
composition of the secreted matrix leading eventually to glomerulosclerosis
(Camussi et al., 1990). IL-1 induces mesangial cell proliferation (Zoja et al.,
1991) and has been proposed to play a role in the development of lupus nephritis
and immune complex nephritis.
1.6.5 Inflammatory Bowel Disease
Ulcerative colitis and Crohn's disease are characterised by infiltrating activated
neutrophils and macrophages which spontaneously release IL-1 (Satsangi et al.,
1987). Clinical trials with EL-lra have been initiated on patients with ulcerative
colitis (Dinarello and Wolff, 1993). IL-1 and IL-8, a cytokine with neutrophil-
chemoattractant and neutrophil-stimulating properties and which is induced by
IL-1, are both high in inflammatory bowel disease but there is also evidence for
the presence of regulators of IL-1a and IL-1 (3 induced T-cell activation in
Crohn's disease. These regulators, which correlate with disease activity, are not
autoantibodies and do not inhibit fibroblast production of PGE2 (Brynskov et al.,
1991).
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Paratuberculosis (Johne's disease) is a chronic enteric infection caused by
Mycobacterium paratuberculosis, most often affecting ruminants. Monocytes
from cattle naturally infected with Mycobacterium tuberculosis spontaneously
release high levels of IL-1. Although the role of cytokines has been examined in
related human diseases such as Crohn's disease, only very recently has data on
cattle appeared, which suggests that blood monocytes in infected cattle are either
non-specifically activated with respect to IL-1 production or possess a defective
regulatory mechanism (Kreeger et al., 1991).
1.6.6 Other Disease Implications
Spontaneous release of IL-1 from monocytes and macrophages has been noted in
patients with diseases such as sarcoidosis (Hunninghake et al., 1984),
tuberculosis (Chensue et al., 1986), scleroderma (Alocer-Varela et al., 1985),
and tuberculoid leprosy (Watson et al., 1984). Macrophages and dermal
dendritic cells are known to play a central role in the lesions of all these
diseases. In lepromatous leprosy, which is characterised by a lack of
responsiveness to Mycobacterium leprae (Kaplan et al., 1987), blood monocyte-
derived macrophages do not produce IL-1 on initial stimulation with M. leprae,
but can be induced to do so by addition of cyclo-oxygenase inhibitors like
indomethacin. This restoration of activity is M. leprae specific (Ridel et al.,
1986). Reversal reactions, which constitute the type I lepra state and represent
naturally occuring delayed-type hypersensitivity reactions favouring macrophage
activation and protective immunity, appear to be characterised by increased
production of IL-1 (Sarno et al., 1991; Uyemura et al., 1992).
In connective tissue diseases such as systemic lupus erythematosus, Sjogren's
syndrome and progressive systemic sclerosis, secretion of both IL-1 a and IL-1 (3
is significantly upregulated in monocytes from patients with active disease. The
intracellular levels remain normal, there being no correlation between the intra-
and extracellular concentrations (Aotsuka et al., 1991).
IL-1 functional activity in psoriatic lesions is reduced, relative to normal skin,
this reduction being attributed to increased IL-lra, reduced IL-1a levels and an
IL-1 (3 which lacks activity in T-cell and thymocyte assays. It has been postulated
that IL-1 (3 is processed to a novel form which is important in skin homeostasis
(Cooper et al., 1990a,b).
IL-1 has been suggested as an autocrine growth factor in myeloid leukemia
although some cells do not appear to process IL-1 (3 to its mature form. An
inhibitor, probably EL-Ira, is also released by monocytic leukemic cells
(Cozzolino et al., 1989). Carcinoma lines elaborating colony-stimulating factors
19
have shown frequent co-production of IL-la and IL-6 but not necessarily of IL-
1 p (Okuno etal., 1991).
1.6.7 IL-1 and Virus Infection
Macrophage infiltration is a constant feature of human viral infections and virus
induced production of cytokines would be expected but data on the interaction of
IL-1 and viruses is frequently contradictory.
Viruses such as CMV have been reported to reduce or abrogate the ability of
thymic epithelial cells and macrophages to produce IL-1 (Wainberg et al., 1988;
van Bruggen et al., 1989). The immediate early genes of HCMV are capable of
regulating IL-ip expression which may have some influence on the inflamatory
processes associated with the infection (Iwamoto et al., 1990). However, a 95K
inhibitor, which is not IL-lra, is also produced from virus-infected monocytes
and could contribute to lack of detectable IL-1 activity (Roberts et al., 1985;
Rodgers et al., 1986)
Under endotoxin-free conditions HIV has been reported not to induce IL-1, IL-6
or TNF from peripheral blood mononuclear cells. IL-1 may activate HIV via
induction of the cellular DNA binding protein NF-kB which activates the HIV
LTR by binding to cis -acting sequences although TNF reportedly activates HIV
more efficiently than IL-1 (Clouse et al., 1989; Kobayashi et al., 1989). Further
data shows IL-1 to be capable of inhibiting the anti-viral action of IFN(3,
whereas TNF seems rather to exhibit an additive effect with IFNp (Kohase et al.,
1988).
Interestingly, two vaccinia virus surface proteins show homology to human and
murine IL-1 and IL-6 receptors. A method of immune evasion by the virus has
been postulated in which these virus proteins may bind IL-1 and IL-6 hence
preventing interaction of the cytokines and their receptors, consequently
decreasing the inflammatory response and increasing virus replication, a
mechanism utilised by several pox viruses (Smith et al., 1993).
Infection of monocytes with bovine viral diarrhoea virus results in the
production and/or activation of an as yet uncharacterised soluble inhibitor of IL-
1 activity which primarily affects thymocytes or immature T cells. IL-1 levels
are not affected by the virus (Jensen and Schultz, 1991).
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1.7 Cloning and Expression of IL-1
1.7.1 IL-1 Cloning
Initially, cDNAs were isolated by differential screening of a cDNA library from
LPS stimulated monocyte polyA+ RNA using probes from unstimulated and
stimulated monocyte polyA4" RNA. Use of a goat anti-IL-1 raised against
purified murine IL-1 (Mizel et al., 1983) subsequently identified the proteins
expressed by in vitro translation from the rabbit reticulocyte system (Lomedico
et al., 1984; Giri et al., 1985). At the start of the study described in this thesis,
IL-1 from human (Auron et al., 1984; Furutani et al., 1985; March et al., 1985;
Cameron et al., 1986; Gubler et al., 1986; Tocci et al., 1987), murine (Lomedico
et al., 1984; Gray et al., 1986; Huang et al., 1988), rat (Nishida et al., 1988a)
rabbit (Furutani et al., 1985; Mori et al., 1988) and bovine (Malisewski et al.,
1988) sources had all been cloned and sequenced and the majority expressed as
recombinant proteins. The porcine IL-1 a sequence was subsequently published
(Malisewski et al., 1990). Equine IL-1(3 has been characterised but not yet
cloned (May et al., 1990). IL-la and IL-1 (3 display marked cross species
conservation but are themselves about 40% similar at the nucleic acid level and
only about 25% similar at the amino acid level.
The complete IL-1 genomic sequences of the human IL-la and IL-1 (3 and
murine IL-1 (3 genes are known and the organisation of each is very similar
(Furutani et al., 1989; Clark et al., 1986; Bensi et al., 1987), see Sect 1.8.
1.7.2 Expression of Recombinant IL-1
E. coli, rabbit reticulocyte lysates, Xenopus laevis oocytes, COS-7 monkey cells,
hamster ovarian cells, Saccharomyces cerevisiae, have all been used for
expression of human, murine and rabbit recombinant IL-1 (Auron et al., 1984;
Lomedico et al., 1984; March et al., 1985; Furutani et al., 1985, 1986; Gray et
al., 1986; Gubler et al., 1986; Rosenwasser et al., 1986; Jobling et al., 1988;
Baldani et al., 1987). Bovine IL-1 has been expressed in E. coli (Malisewski et
al., 1988). Cloning showed that the C-terminal portions of each IL-1,
corresponding to the mature proteins, were sufficient to generate biological
activity and that the primary IL-la translation product is also active. In addition
none of the recombinant proteins contain a stretch of hydrophobic amino acids
which would normally comprise a secretory signal.
Fuhlbrigge et al (1988) showed that mouse L cells transfected with murine pro-
IL-la c-DNA expressed biologically active pro-IL-la, which was neither
processed to the 17kD mature form nor secreted. The transfected cells also
expressed membrane associated biological activity indicating that the pro-IL-la
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can direct expression of membrane associated IL-1 and that cleavage of the pro-
molecule is not required for membrane presentation. In contrast, transfected pro-
EL-lp c-DNA did not generate biologically active material.
Initial data on the functionally active sites of IL-1 {3 was published in 1987 by
Mosley et al. who showed that deletion of the N-terminal beyond position 133
resulted in a complete loss of receptor binding and biological activity. It has
been postulated that processing to the mature form, which induces a
conformational change, is required for maximal IL-ip activity (Mosley et al.,
1987; Black et al., 1988). Whether the recombinant IL-ip proprotein is active
may be dependent on the expression system. If expressed in E. coli, the IL-ip
primary transcript is not active but if expressed in other systems such as COS-7
cells or by in vitro translation, it does show some activity (Rosenwasser et al.,
1986; Jobling et al., 1988).
Human IL-lp is the only IL-lp to possess a glycosylation site in the mature
protein, all other species have sites in the proprotein N-terminal sequence.
Glycosylated recombinant human IL-lp mature protein has been produced from
chinsese hamster ovary cells but only by use of fused hybrid secretory
sequences. This protein is inactive until deglycosylated (Baldani et al., 1987;
Pecceu et al., 1991).
1.8 Genomic organisation
Both human (Todd and Naylor, 1991; Lafage et al., 1989) and murine
(D'Eustachio et al., 1987) IL-1 a and IL-1 P genes have been located on
chromosome 2, the two loci being very closely linked. The human IL-1 genes
have been mapped to the 2ql3->2q21 region and the murine genes are located in
the F region of chromosome 2, approximately 4.7 centimorgans distal to beta-2
microglobulin (D'Eustachio et al., 1987; Boultwood et al., 1989).
The genomic structure of human and murine IL-1 genes are known. (Clark et al.,
1986; Furutani et al., 1986; Bensi et al., 1987). Human and murine IL-ip genes
are almost identical except for the human exon 7 which has an additional 200bp
in the 3' untranslated region. The conservation of gene structure suggests a
common ancestor ie. both EL-la and IL-ip genes consist of seven exons and six
introns with similar positioning of intron/exon boundaries. Restriction digests of
genomic DNA suggest that IL-1 a and IL-ip exist as single copies in the bovine
(Malisewski et al., 1988), as well as the human genome. The genes differ in
regions known to control transcription (Angel et al., 1987; Hurme et al., 1991;
Hunninghake et al., 1992). The IL-1a promoter, in contrast to the IL-ip
promoter, lacks a CAT box and has a very poor TATA box. Although both
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genes contain the consensus sequence found in PMA inducible genes, IL-la
requires an additional signal for activation. NF(3A is known to play a selective
role in expression of IL-18 but not IL-la. IL-1, like many other cytokines which
control cell growth, contains AU-rich sequences within the 3' untranslated RNA
regions which confer extremely short half-lives on the mRNAs and are also
important with respect to imposition of translational blockade (Turner et al.,
1989; Kruys et al., 1989).
Polymorphisms have been found in all regions of the human IL-1 genes
including the promoter regions which may have disease implications (Clark et
al., 1986; Bensi et al., 1987; di Giovine et al., 1992; McDowell et al., 1993;
Bailly et al., 1993). Data from unrelated individuals has revealed 6 IL-la alleles
within genomic DNA (Todd and Naylor, 1991; Bailly et al., 1993). Three
control regions of the IL-1(3 gene have been shown to be important in
transcriptional regulation; -395bp to -132bp enhances expression; -736bp to -
395bp is inhibitory and +387bp to +550bp is the first intron-l/exon-2 region
reported to mediate positive IL-ip gene expression (Zhang et al., 1991).
1.9 Physical Properties of IL-1
1.9.1 Crystallographic Structure
Crystallographic and nuclear magnetic resonance studies have shown that both
mature IL-la (Graves et al., 1990) and IL-lp (Priestle et al., 1989; Clore et al.,
1990, 1991a,b; Veerapandian et al., 1992) are in the form of a trigonal pyramid
or tetrahedron with the interior being strongly hydrophobic. 12 antiparallel P
strands form a complex of hydrogen bonds with approximate threefold internal
symmetry. Mutational data suggests the presence of three distinct binding sites
for the IL-1 receptor on the surface of the molecule. It is postulated that each of
the three immunological domains which comprise the extracellular portion of the
IL-1 receptor recognises one of these sites.
Amino acids known to form the binding site of IL-lp are all situated on the
outside of the molecule (Labriola-Tompkins et al., 1991). The putative nuclear
location sequence is away from the residues involved in receptor binding and is
situated on one of the exterior folds of the IL-lp molecule (Grenfell et al.,
1991). Comparison of sequence aligments shows interior residues to be well
conserved and exterior residues markedly less so (Priestle et al., 1989). IL-la
shows similar folding patterns (Eriksson et al., 1991; Zhu et al., 1991).
Topologically equivalent folds have also been found in human basic fibroblast
growth factor, bFGF, and bovine acidic FGF. These latter two proteins are
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members of the FGF family which stimulate proliferation and differentiation of a
variety of cell types through receptor-mediated pathways. Although IL-ip and
bFGF possess only 10% sequence identity, they represent a family of structurally
related mitogenic factors (Zhu et al., 1991; Zhang et al., 1991; Eriksson et al.,
1991).
1.9.2 Glycosylation and Phosphorylation of IL-1
Pro-IL-la is glycosylated and is phosphorylated at Ser-90 which is in the amino
terminal third of the precursor. Phosphorylation presumably increases resistance
to proteolytic cleavage. (Beuscher et al., 1988; Kobayashi et al., 1990). There is
no evidence that natural IL-1 (3 is either glycosylated or phosphorylated.
1.10 Systemic clearance of IL-1
From studies on mice (EL-1J3: Newton et al., 1988) and rats (IL-la: Poole et al.,
1990) it has been shown that the major route of clearance is the kidney.
Intravenous injection of IL-1 (3 shows a rapid initial loss of IL-1 from the
circulation followed by a slower loss over the next hour. Intraperitoneal or
subcutaneous injection gives an initial peak in circulating IL-1 after lOmin
which is sustained over at least the next 7h. Circulating IL-1 is associated with
the plasma fraction and is not cell associated. Two hours after injection most
tissues contain an equal amount of IL-1 on a weight basis, with the exception of
bone which contains half the amount, and kidney which contains 4-8 fold more.
10-20% of the label is found in the urine within hours of injection of IL-1 (3. The
IL-1 found in the urine is intact 17kD IL-1.
EL-la in rats has a plasma half-life of 2.5min. Unlike IL-1 (3, 5kD and 9kD
fragments of EL-la are detectable in the urine and intact IL-la is only found in
the plasma. In vitro studies on kidney homogenates show that EL-la is
endocytosed and hydrolysed by lysosomal proteinases.
1.11 IL-1 receptors
Two IL-1 receptors, Type I (IL-1RI) and Type II (IL-1RII) have so far been
identified on human, murine and porcine cells (Savage et al., 1989; Sims et al.,
1988; Chizzonite et al., 1989a,b). EL-1RI and IL-1RII represent different gene
products but map to the same chromosomal location (Copeland et al., 1991).
Human IL-1RI maps to chromosome 2ql2 and EL-1RII to 2ql2->2q22, the same
region as the human IL-1 genes. In contrast, murine IL-1R genes map to the
centromere-proximal region of chromosome 1, a different location to the murine
IL-1 genes on chromosome 2. A specific soluble receptor from human
monocytes and RAJI B cells has also been characterised (Symons et al.,
1991a,b).
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1.11.1 Cellular IL-1 Receptors
1.11.1.1 Structure
The molecular weight of IL-1RI is 80-85kD and of IL-1RII, 60-68kD. Both
receptors are members of the Ig super family and consist of three segments
(Sims et al., 1988; Dower et al., 1990; McMahan et al., 1991); i) the
extracellular segments of approximately 300 residues, which are 28%
homologous, each consisting of three Ig-like domains and possessing several
potential glycosylation sites; 2) the highly homologous transmembrane segments
of roughly 21 residues; 3) non-homologous cytoplasmic domains of about 213
(IL-1RI) and 29 (IL-1RII) residues. The cytoplasmic segment of IL-1RII posses
no significant similarity with any sequence in either the GenBank or EMBL
databases.
Although there is evidence that N- and O-linked patterns of IL-1RI glycosylation
differ with cell lineage, which may affect relative binding of IL-1 a and IL-1 (3
(Mancilla et al., 1989) there is also evidence that glycosylation is not essential
for binding but may be a prerequisite for subsequent function (Sect. 1.12).
Removal of N-linked oligosaccharides leaves a receptor protein core of 50-60K
which shows some loss of activity but retains the expected Kd (Urdal et al.,
1988).
1.11.1.2 IL-1R Distribution
It was originally thought that IL-1RI was expressed by T lymphocytes,
fibroblasts, chondrocytes, hepatocytes, synovial lining cells and epithelial cells
and IL-1RII by bone marrow cells, B cell lineages and polymorphonuclear
leucocytes but there is accumulating evidence that the segregated distribution to
different cell lineages may not be so straightforward.
In addition to the predominant 80K type I receptor, 40K, 60K, 75K, 100K and
220K molecular weight receptors have also been detected on murine T cell lines
by cross-linking of IL-1 (Bird et al., 1987; Chizzonite et al., 1989; Savage et al.,
1989). It has been suggested by some that the Type I receptor on EL4 cells is a
heterodimer consisting of the 40/80K proteins (Kroggel et al., 1988) and by
others eg. EL4 and NOB-1 and Balb/C 3T3, is an 80/102K doublet (Solari et al.,
1990a,b). Deglycosylation reduces the smaller receptor by a further 12K.
Glycosylation patterns may again be affecting signal transduction from the
different receptor molecules.
Human B cells only express the 60K form and murine B cells a 75K form of
receptor (Solari et al., 1990a,b). Some B cell lines, however, exhibit a
heterogeneous population of receptors, expressing 68K and 80K or 11 OK forms,
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the two larger of which bind IL-la with a greater affinity than IL-lj3 (Benjamin
et al., 1990; Cronkhite et al., 1993). It has been suggested that the 110K receptor
is a dimer. Some EBV B cell lines express an 80K receptor (Benjamin et al.,
1990) and one report suggests that monocytes may also express an 80K receptor
(Uhl et al., 1989).
These differences are becoming resolved by data such as that of McMahan et al
(1991) who have shown that several different cell lines, including B
lymphoblastoid lines, HepG2 cells and peripheral blood T cells, can be induced
to express mRNA and protein for both receptor types, presumably in order to
utilise different signal transduction pathways. They have also indicated
preliminary, and as yet unpublished, evidence that the two receptors cannot bind
IL-1 simultaneously.
I.11.1.3 Binding Properties of the IL-1 Receptors
Bird and Saklatvala, in 1986, detailed initial studies which showed that natural
porcine IL-la and IL-1 (3 both bound to IL-1 receptors on porcine, human and
murine connective tissue cells in a specific fashion and with similar affinities.
Chondrocytes displayed 7,000 sites per cell with Kd 2.5 x 1010, fibroblasts and
osteoblasts had 3-5,000 sites with Kd 1.5 xlO10. In numerous subsequent studies
in various species, recombinant IL-la and IL-1 (3 have been found to bind to
both receptors but with affinities dependent on receptor type (eg. Dower et al.,
1986; Horuk et al., 1987; Ghiara et al., 1989; Savage et al., 1989). The only
exception so far described, is the central nervous system in which specific IL-1 {3
receptors which do not bind IL-la are heterogeneously distributed in the brain
(Katsura et al., 1988).
Scapigliati et al first demonstrated differential binding of IL-la and IL-1 (3 to
receptors on T and B cells. Murine thymoma EL4-6.1 cells, predominant
receptor 80K Type I, express more receptors per cell for IL-la (22656, Kd 3.6 x
10"10) than for IL-1 (3 (2988, Kd 1 x lO9) but IL-la and IL-1 (3 are mutually
competitive. Human B lymphoma RAJI cells, predominant receptor 68K Type
II, were shown to have a higher number of binding sites for IL-1 (3 (2400, Kd 1.3
x 10-10) than for IL-la (316, Kd 2.2 x 10"9). IL-la could effectively be displaced
by both IL-la and IL-1 (3 while only IL-1 (3 could displace bound IL-1 (3. IL-1
binding to the Type I receptor is rapid and followed by internalisation of the
complex whereas type II receptor binding is slower and the complex does not
appear to be internalised efficiently (Chizzonite et al., 1989; Benjamin et al.,
1990; Bomsztyk et al., 1989; Ghiara et al., 1989; Horuk et al., 1987; Scapigliati
et al., 1989). One documented exception is of rapid rhIL-la binding to a PMN
receptor of 60-70K, with subsequent rapid internalisation at 37°C (Rhyne et al.,
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1988). These IL-1RI and IL-1RII binding patterns hold true in general for human
and murine cells. IL-1 receptor binding data for numerous cells types is given in
detail in Appendix A.l. In general, untransformed cells or cells isolated from
tissues or blood express few IL-1 receptors, ie. 100-500 per cell, but some cell
lines express extremely high receptor numbers, ie. MO4.
High and low affinity classes of receptor have been detected on a large number
of cell types. The functional significance of the measured affinities is unclear as
cells with the type I receptor can respond to femtomolar concentrations of IL-1,
far below reported dissociation constants for even the high affinity class. It has
also been suggested that some T cells can respond to subpicomolar
concentrations of IL-1 without demonstrable binding (Rosoff, 1990). This may
be consistent with the observation that less than 5% receptor occupancy can
trigger phopshorylation of the remaining receptors (Gallis et al., 1989). It has
been proposed that as few as 1-10 molecules per cell can elicit biological
responses and that these responses are mediated through the lower rather than
the higher affinity IL-1R (Dower et al., 1986; Qwarnstrom et al., 1988).
From the small number of studies which report binding of IL-1 at a single cell
level, it appears that only a proportion of either resting cells, <16%, or activated
cells, <30%, bind IL-1 (Tanaka et al., 1989; Stoppaciaro et al., 1991; Chin et al.,
1987).
1.11.1.4 Internalisation of IL-1
IL-1 bound to the IL-1RII is poorly internalised, remains bound to the surface
for up to 60 minutes and is found in the extracellular fluid in a degraded form
(Horuk and McCubrey, 1989; Horuk, 1991; Shelly et al., 1992) whereas IL-1
bound to the IL-1RI is internalised within minutes via an azide sensitive
mechanism and can remain inside the cell for 12 hours (Matsushima et al., 1986;
Uhl et al., 1989; Horuk et al., 1987; Horuk, 1991). Most of the internalised IL-1
is undegraded, retains binding activity and accumulates both on the nuclei in a
receptor specific fashion and in lysosomes. The putative IL-1 (3 nuclear
localisation sequence is a seven amino acid sequence (-PKKKMEK-; h(3-208-
214) which shows some identity with the nuclear localisation sequence of SV40
large T-antigen (Roberts, 1989). The structurally similar bFGF, contains the
same peptide sequence in a similar position and also accumulates at the nucleus
after internalisation (Grenfell et al., 1989).
This sequence is well conserved across all EL-lps so far cloned, including
bovine giving reason to believe that it will also be conserved in ovine IL-1 (3.
Such conservation strongly indicates functional significance. Grenfell et al
(1989) demonstrated that IL-1 binding to EL4 nuclei is specific and saturable
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and shows similar kinetics to the plasma membrane receptor. Several lines of
evidence from IL-1 internalisation profiles using fibroblasts and EL4 cells, also
suggest that receptor-mediated endocytosis of IL-1 and transport to the nucleus
may be required for generation of a biological response and that nuclear
translocation may occur with IL-1 still complexed to its receptor (Mizel et al.,
1987; Qwarnstrom et al., 1988; Falk et al., 1989; Curtis et al., 1990). On the
other hand it has also been claimed that biological potency of IL-1J3 is not
necessarily related to its internalisation and nuclear accumulation (Grenfell et al.,
1991; Heguy et al., 1991). The suggestion that nuclear transport may not play a
significant role in IL-1 signal transduction is consistent with the fact that EL-1
bound to truncated mutants of the IL-1RI extracellular domains can be
internalised without initiating a full signal transduction cascade (Dower et al.,
1989). Hisactophilin, a unique actin binding protein of similar 3-D structure to
IL-1 (3 and bFGF but with an unrelated primary amino acid sequence, triggers
signal transduction but only at pH values below seven (Habazetti et al., 1992)
which may have some relevance to IL-1 elicited signals. Signalling through IL-
1/IL-1R binding is discussed further below (Sect. 1.12).
The IL-la proprotein contains a polybasic sequence (-LKKRRL-; ha-81-86)
which might serve as a nuclear localisation signal but the mature IL-la has no
obvious signal.. Nuclear accumulation of mature IL-la has been detected in
murine thymoma EL4 6.1 cells and specific saturable binding to isolated nuclei
has been demonstrated (Grenfell et al., 1989). The IL-1 type I receptor has a
potential nuclear localisation signal in its cytoplasmic tail (-VKKSRR-) (Sims et
al., 1988) which may serve to target membrane-receptor-bound IL-la. More
recently, Weitzman and Savage (1992) have reported nuclear intemalisation of
IL-la in numerous cell lines and demonstrated DNA binding by both IL-1R and
the IL-la/IL-lR complex, but not by IL-la alone.
1.11.1.5 Regulation of IL-1R Expression
Specific and different stimuli appear to be required for upregulation of each
receptor. IL-1RI expression can be upregulated by other cytokines eg. IL-3, IL-4
and GM-CSF (Dubois et al., 1989; Lacey and Erdmann, 1990), growth factors
eg. fgf and PDGF (Chandrasekhar et al., 1989; Bonin and Singh, 1988;) and
PGE2 or cAMP generating agents eg. forskolin (Akahoshi et al., 1988a; Takii et
al., 1992). IL-1RII is upregulated by DEX and glucocorticoids (Scapigliati et al.,
1989; Stoppciaro et al., 1991; Akahoshi et al., 1988a). DEX can induce IL-1RI
as well as IL-1RII mRNA in monocytes but only the latter appears to be
translated (Spiggs et al., 1990). IL-1 can upregulate both IL-1RI and IL-1RII
(Akahoshi et al., 1988b; Takii et al., 1992; Shieh et al., 1990; McMahan et al.,
1991; Dubois et al., 1991). PMA drastically reduces IL-1RII expression but has
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very little effect on IL-1RI expression (Bomstzyk et al., 1989; Lowenthal and
MacDonald, 1986) despite having an equally potent effect in activating PKC.
Upregulation increases both the number of cells expressing receptors and the
number of receptors expressed per cell. Binding affinity is not generally altered
by upregulation but some human B lymphoblastoid lines do exhibit decreased
affinity with increased receptor expression (Stoppacciaro et al., 1991). Induction
of IL-1 receptors seems to require synthesis of both new RNA and protein,
actinomycin D and cycloheximide both inhibit the induction of type II receptors
by GC (Akahoshi et al., 1988a,b). DEX can induce IL-1RI mRNA without
inducing surface expression of the receptor.
The half-life of the type II receptor on B cells is 2 hours, shorter than that of the
type I receptor on T cells, 5-12 hours (Horuk et al., 1989).
1.11.1.6 The IL-1/IL-1R Interaction
Antibody studies indicate that the binding domains of the IL-1RI for the two IL-
1 species are distinct (Ikejima et al., 1990), contributing to the different
biological responses to IL-1 a or IL-1 (5 which can be effected from the type I
receptor. It is postulated that all three immunological domains which comprise
the extracellular portion of the IL-1 receptor are involved in generating an active
IL-1 binding-site (Dower et al., 1989, Bomstzyk et al., 1989b, Clore et al.,
1991b). Minimal data is available on IL-1RII binding.
The structure/function relationships of IL-1 receptor binding still require much
clarification but various IL-1 residues have so far been implicated as being
essential either for receptor binding or for generation of biological responses.
Structural specifications appear to be less rigid than those determining biological
activity. The residues detailed below are numbered with respect to the human
sequences unless otherwise indicated.
The N-terminal regions of the IL-1 mature proteins show greatest conservation
and several reports have indicated that alteration of amino acids in this region
affects IL-1 activity without altering binding affinities ie. residues a-134-155
and p-126-144.
For IL-la activity (Yanofsky et al., 1990; Nanduri et al., 1991; Poindexter et al.,
1991; Kawashima et al., 1992), there appears to be an absolute requirement for a
basic a-128 residue. Other important residues are a-Leu-136, a-Asp-138, a-
Glu-142, a-Ile-144, a-Leu-152. Apart from two conservative differences in the
murine sequence, residues 136-143 are conserved across all IL-las and 141-143
constitute a potential receptor binding site. Although some of these residues are
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conserved in IL-ip, P-Asp-128 is the only equivalent residue so far to have been
implicated in activity. a-Asp-263 and its equivalent J3-Asp-261 are the only
important C-terminal residues to have been noted. a-Asp-138 and a-Asp-263
which appear to be essential for lymphocyte activation, cytostatic activity
against human melanoma cells and PGE2 induction are fully conserved across
IL-la and IL-ip of all species and are spatially situated very close to one
another. They may therefore constitute one of the active sites for IL-1/IL-1R
binding (Kawashima et al., 1992). Further evidence for this comes from
mutation of Lys to Arg at the equivalent position in the IL-1 receptor antagonist
(see Sect 1.13.II), which results in the antagonist displaying minimal IL-1-like
activity (Ju et al., 1991).
Seven residues, Arg-120, Leu-122, Phe-162, Ile-172, Lys-209, Lys-219 and Glu-
221, have been proposed to be the major contributors to a discontinuous IL-
1P/IL-1RI binding site (Chang et al., 1992; Nanduri et al., 1991; Veerapandian
et al., 1992; Yem et al., 1992). There is absolute conservation of all seven
residues apart from bovine P-Gln-117, P-Ile-119, P-Arg-206, which align with
the human [3-Arg-120, P-Leu-122, P-Lys-209 respectively and represent
conservative changes. The 3-D structure of IL-ip shows that these essential
residues are all clustered in one region (Labriola-Tompkins et al., 1991). P-Asn-
224 which has only a minor effect on binding is on one edge of the site and five
residues found to be non-essential for binding lie on the periphery.
Several pieces of evidence indicate that IL-ip activities can be dissociated, for
example, anti-IL-lp studies have shown that residues P-148-192 are not
implicated in the binding to IL-1RI, despite containing two of the residues
supposedly involved in the discontinuous binding site, but are important for T
cell activation (Boraschi et al., 1991b; Herzbeck et al., 1989). The peptide 161-
173, which lies in the hinge region between p-strands 4 and 5 (Priestle et al.,
1989) is immunostimulatory but does not induce the majority of inflammation-
related IL-ip activities (Tagliabue et al., 1991). (See Sect 1.14 for adjuvant
activity of this peptide). The epitope for immunostimulation may be different to
that for stimulation of bone resorption (Lemer et al., 1991) and some peptide
sequences have been shown to reproduce only a limited range of IL-1 activities,
eg. hyperalgesia (Ferreira et al., 1988) and somnogenesis (Obal et al., 1990).
Point mutations at different sites can uncouple IL-1 activities, for example,
mutation of p-Arg-120 results in markedly reduced pyrogenic potency while
retaining normal immunostimulatory activity and ability to induce hematopoetic
growth factors (Nanduri et al., 1991; Nakai et al., 1990). Mutation of Gly for P-
Arg-127 in the human or murine sequence has no effect on receptor binding but
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causes failure of T cell proliferation (Gehrke et al., 1990; Conca et al., 1991).
Residues in the bovine sequence equivalent to human P-Asp-120 and P-Arg-127
are both Glu, indicating possible species differences in binding requirements, an
idea highlighted by the lack of reactivity of bovine IL-ip on murine cells
(Malisewski et al., 1988). Similarly deamidation of the unique murine P-Asn-
149 causes loss of receptor binding and co-mitogenic activity (Daumy et al.,
1991) but the equivalent human and bovine residues, Glu and Lys respectively,
which may indicate a degree of species specificity.
The putative nuclear location sequence is away from the residues involved in
receptor binding and is situated on one of the exterior folds of the IL-ip
molecule, thus making it accessible for nuclear membrane binding, whether or
not IL-1 is bound to its receptor at this stage. According to Mosley et al.
(1978b), the IL-1RI does not bind proIL-lp but this data has not been
corroborated by any other groups.
Data on IL-1RII requirements is lacking but residues (3-166-169 and (3-177-186
have been implicated as binding peptides (Boraschi et al., 1991a). pPhe-162 is
the only one of the residues of the IL-1RI discontinuous binding site which has
any effect on IL-1RII binding. PAsp-261 is essential for IL-1RII binding (Ju et
al., 1991).
Substitution of either Met-160 or Val-174, results in the loss of binding to both
types of receptor. These residues are fully conserved across EL-la and IL-1 {3 and
the side chains containing them are both buried, confirming their probable
importance for the structural stability of IL-1.
Patterns of IL-1 a and IL-1 (3 cross-linking to the doublet receptor found on EL4
cells are not identical (Solari et al., 1990a,b). Murine Thl cells (MTgl2B),
which are involved in delayed type hypersensitivity reactions, express the 60K
form of receptor but do not respond to IL-1 even though it does bind to the cells.
Th2 cells express both 80K and 60K forms but only selected functions are
affected ie. IL-1 promotes cell growth, but does not enhance the constitutive IL-
4 production by these cells (Solari et al., 1990b, Williams and Unanue, 1991).]
IL-1 a does not compete efficiently with IL-ip for type II binding which
indicates different binding requirements whereas competition for type I binding
indicates similar IL-1 a and IL-ip requirements. The mutational and antibody
data described above indicates that the contact points in each receptor/ligand
complex are probably different and determined by the 3-D structures and
different residues may be involved in the binding to the two different types of
receptor.
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1.11.2 Soluble IL-ip Receptor (sIL-lR)
A soluble 47K receptor from the human B cell line, RAJI, specifically binds
human or murine IL-1 (3, both proprotein and mature protein, which is not
displaceable by either DL-la or by IL-1 receptor antagonist (Symons et al.,
1991a,b). This soluble receptor demonstrates a similar affinity to that of the
RAJI cell surface receptor, ie. 2200pM, and appears to be a proteolytically
cleaved form of this Type II receptor. Cells possessing a Type II receptor which
binds IL-la and IL-lfJ equally eg. U937, do not release the sIL-lR suggesting
either structural heterogeneity within IL-1RII, lack of a specific protease or a
third type of receptor. The same authors have also reported a specific IL-1 (J
binding protein from PHA stimulated human monocytes which has the same
properties. LPS or IL-la stimulation does not consistently induce synthesis of
this binding protein.
1.12 IL-1 receptor signalling (IL-1 signal transduction)
Elucidating the events which occur once IL-1 has bound to cells has been a
controversial area and there is still no consensus of opinion. Cytokines such as
IL-1 bind to cells and induce various reactions including ultimately, the
transcriptional activation of target genes and a cascade of biological reactions.
At the different levels of activation the signals are known as first messengers
(extracellular signals), second messengers (initial intracellular signals such as
cAMP and kinases) and third messengers (transcription factors). Transcription
factors mediate transcriptional induction by interacting with specific elements in
the regulatory regions of genes hence influencing their expression. Cytokines are
thus in turn themselves regulated by transcription factors.
1.12.1 IL-1 as a First Messenger
The two IL-1 receptors appear to employ different signal transduction pathways.
From studies on the human IL-1 receptor antagonist, signaling through the type I
receptor is the dominant pathway for IL-1 induction of transient neutrophilia,
elevation of hepatic acute phase proteins and movement of PMN from bone
marrow to local sites of accumulation (Mclntyre et al., 1991) but may not be
required for antigen-specific cell-mediated or humoral responses (Faherty et al.,
1992). It has been postulated by Stoppacciaro (1991) that the type II receptor is
involved in initiation of the cell cycle because of the responsiveness of cells in
Go-Gi phase to IL-1. There is also evidence that IL-1 can drive the cycling of
bone marrow cells (Neta et al., 1987) as well as initiate their differentiation
(Mochizuki et al., 1987), presumably by stimulation of specific growth and
differentiation factors.
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The cytosolic region of IL-1RI has no homology with any known protein kinase
but the serine/threonine residues are phosphorylated soon after IL-1 has bound to
the extracellular domains (Gallis et al., 1989). The complex is internalised
(Qwarnstrom et al., 1988; Curtis et al., 1990) and the cells are triggered to
respond. Heguy et al (1991) have presented evidence that IL-1 internalisation
and nuclear localisation are not sufficient to trigger IL-1 activation of gene
expression in T-cells. The cytoplasmic domain of the receptor is not involved in
the internalisation process but a 50-amino acid segment in the cytoplasmic
domain of the fibroblast IL-1R has been shown to be critical for signal
transduction. This region is strikingly conserved across human, murine and
chicken IL-lRs. A functional homology between IL-1R and the Drosophila toll
protein has been suggested (Heguy et al., 1992). The fate of IL-1 bound to the
Type II receptor is less clearly defined although the shortened IL-1RII
cytoplasmic domain may explain some of the differences in signal transduction
from the two receptors.
A number of mechanisms possibly involved in IL-1 signal transducion have so
far been elucidated but there is still much debate as to exactly how IL-1 exerts its
influence and it appears that no single signal transduction pathway is sufficient
to explain all the effects of IL-1 on its many target cells.
1.12.2 Second Messengers and Protein Kinases
Most cell activators lead to a change in the levels of specific second messengers
such as diacylglycerol (DAG) or cAMP, activators of protein kinases C and A
(PKC, PKA) respectively. Subsequent phosphorylation of discrete substrates
ultimately leads to the cellular response.
Reports from several laboratories indicate that IL-1 can activate serine/threonine
kinases. Tyrosine-specific phosphorylation does not seem to be common (Lovett
et al., 1988) but tyrosine kinases are rapidly recruited in the early stages of
signalling (Guy et al., 1991). Data on PKC and/or PKA involvement in IL-1
induced protein phosphorylation is contradictory but the evidence does not point
to either being obligatory.
Effects of EL-1 can certainly be mimicked by activators of PKC such as phorbol
myristyl acetate (PMA) eg. stimulation of collagenase and PGE2 production
(Postlethwaite et al., 1983; Taylor et al., 1988) but many DL-1 induced
phosphorylations such as of serine residues in the cytosolic P65 protein and the
EGF receptor as well as serine and threonine residues of a triad of small heat
shock protein hsp 27 isoforms, are PKC independent (Shiroo et al., 1990; Kaur
et al., 1989; Bird and Saklatvala, 1990). P65 phosphorylation is also not
attributable to PKA or calmodulin-dependent kinases.
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Changes in DAG or cAMP levels have not been consistently detected although
both classes of receptor have been shown to be capable of inducing increases.
The phospholipid source for increased DAG seems to vary with cell type ie.
hydrolysis of phosphatidylethanolamine in mesangial cells, phosphatidylinositol
in macrophages and phosphatidylcholine in T cells. The latter at least, appears to
be PKC independent (Mills et al., 1989). Murine macrophage IL-1R is possibly
activated by rapid, 5s, hydrolysis of phosphoinositides and generation of the
second messenger, inositol trisphosphate (IP3) (Wijelath et al., 1988). Although
activation of adenyl cyclase does not seem to be an obligatory feature of IL-1
signalling, occupancy of Type I EL-1R has been shown to activate a tyrosine
kinase and generate the accumulation of intracellular cAMP but in amounts
considered not great enough to stimulate phosphorylation. Neither IL-1 nor TNF
increase cAMP levels in monocytes, Type IIR (Shiroo and Matsushima, 1990)
and lack of significant effects of IL-1 on cAMP metabolism in cells expressing
either type of receptor has also been demonstrated by RayK et al. (1992).
Further evidence for lack of PKC/PKA involvement is given by IL-1 being able
to stimulate rapid phosphorylation of its own receptor on serine/threonine
residues despite the absence of demonstrable protein kinase activity intrinsic to,
or associated with the receptor (Gallis et al., 1989). In addition there are
indications that PKC is not translocated from the cytosol to the membrane
(Shiroo and Matsushima, 1990). On the other hand, IL-1 appears to be capable
of activating PKC and PKA through independent EL-1R in the same T cell line
(Munoz et al., 1991,1992b). Whether this variability arises from different types
of receptor expression or plasiticity in response coupling of IL-1R, as suggested
by Farrar et al. (1990) has not been determined although Chedid et al. (1991)
have proposed that the level of AP-1 activity in T cells may be determined by
the balance between several serine/threonine protein kinases and phosphatases.
Two proposals with respect to elevation of cAMP have been put forward, i) that
it may be secondary to induction of prostaglandins ie. via increased arachidonic
acid and cyclooxygenase (Bomsztyk et al., 1990; Oppenheim et al., 1980) and ii)
that the IL-1R is coupled to a Gl-like guanine nucleotide binding protein, G
protein which activates adenyl cyclase (Chedid et al., 1989; O'Neill et al., 1990).
Studies involving the bacterial pertussis toxin, have indicated a role for G
protein, in IL-1 signal transduction, in fibroblasts and in the membrane of the IL-
1 receptor-rich strain (NOB-1) of the murine EL4 thymoma line (O'Neill et al.,
1990;; Rollins et al., 1991; Chedid et al., 1989). IL-la is ten-fold more potent
than IL-ip and acts by increasing the affinity but not the number of GTP binding
sites. GTPase activity in the membrane in also increased in a dose dependent
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manner (O'Neill et al., 1990). It has also been postulated that IL-1R function
may be regulated by guanine nucleotides via a higher affinity state for IL-1
binding, a mechanism different to that exhibited by conventional G-protein-
linked receptors. Evidence that IL-1 (3 induction of cGMP and nitric oxide is
blocked by the protein synthesis inhibitor cycloheximide, implicates both of
these in IL-1 effects (Corbett et al., 1992).
In the light of such contradictory data, a role for PKC/PKA in IL-1 signalling
remains controversial. Some kinase other than these two had been thought to be
involved in the signal transduction, and evidence for sphingomyelin signalling
pathway activation by IL-1 {3 in both dermal fibroblasts and EL4 thymoma cells
has recently been presented (Ballou et al., 1992; Mathias et al., 1993). This
signalling pathway, which is also utilised by TNFa, involves hydrolysis of
sphingomyelin to ceramide and stimulation of a ceramide-activated Ser/Thr
kinase. Another potential candidate is mitogen activated protein 1 (MAP-1), a
serine/threonine kinase (Bird et al., 1992).
1.12.3 Induction of Transcription Factors by IL-1
Changes in transcription are mediated by DNA binding proteins, many of which
are activated by phosphorylation. Of these, AP-1 and NF-kB are of particular
interest with regard to IL-1 and have been detected in a number of IL-1
responsive genes. AP-1 is the transcription factor with major involvement
following stimulation of the cell membrane and is the first IL-1 responsive
element. NF-kB serves to enhance transcription from cellular genes and also
mediates interactions between host cells and viruses.
IL-1 induces the active nuclear form of the DNA binding protein, NF-kB, in
both T and B cells but otherwise the activation pathways seem to be different in
the two cell types. In T cells and fibroblasts the activation is via AP-1 elements
whereas in B cells the NF-kB activation involves cAMP.
The proliferative response of T cells to mitogens or cytokines involves the
transcriptional induction of several cellular genes, prominent among these being
the immediate early nuclear proto-oncogenes c-fos and c-jun and the late c-myc,
c-myb and N-ras which encode transregulatory proteins important in the control
of gene expression (Cuiran and Franza, 1988). c-fos and c-jun form a stable
heteroduplex, the AP-1 transcription factor, which binds to the AP-1 binding site
present in the 5' upstream region of many cellular genes such as those of
metallothionine IIa, collagenase, IL-2, the cis-control region of SV40 virus and a
region of the HIV LTR. The affinity of the fos/jun heterodimer is much greater
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than that of a c-jun homodimer and c-fos, being unable to homodimerise, does
not bind DNA. (Munoz et al., 1992a). From mutational studies with IL-1J3, c-fos
and c-jun expression is not necessarily accompanied by increased transcription
of genes containing the AP-1 binding site and it seems probable that at least two
events are required for IL-1-mediated late gene induction in fibroblasts. Both IL-
1(3 and a mutated R/G127 form can stimulate transcription of c-fos, c-jun, and
the early IL-1 (3 and IL-6 genes, but the mutein can not induce transcription of
the late procollagenase and prostromelysin genes (Conca et al., 1991).
IL-1 has been shown to induce c-fos and c-jun genes in T helper type 2 (Th2)
cells via different signal transmission pathways (Munoz et al., 1990a). c-jun
gene transcription appears to depend entirely on a tyrosine kinase pathway
which is independent of PKC and cAMP production and which is linked to the
80K IL-1R. c-fos, on the other hand, seems to be absolutely dependent on, and
positively regulated by, the PKC pathway. In one particular T-cell line, LBRM,
which possesses a large number of IL-1 receptors, c-fos could be activated by
mitogens whereas c-jun was exclusively induced by IL-1 in the same cells 10 -
15 minutes later (Munoz et al., 1992). c-jun complexes with the glucocorticoid
receptor whereas c-fos can form complexes with other proteins and can act
through sequences other than AP-1 (Gurney et al., 1992). Phorbol esters and
calcium ionophores also induce c-jun, hence mimicking of IL-1 action
(Mantovani and Dejana, 1989).
Of the other proto-oncogenes, c-myc is significantly induced by IL-1 in
fibroblasts through positive regulation of NF-kB (Kessler et al., 1992).
The conventional view of NF-kB is that the unactivated form is held as an
extranuclear complex with an inhibitor IkB. Phosphorylation of IkB by protein
kinases including PKA and PKC, causes dissociation of the complex and the
liberated NF-kB translocates to the nucleus (Ghosh and Baltimore, 1990). This
pathway could operate in the IL-1 mediated activation of NF-kB in EL4, 70z/3
and YT cells (Chedid et al., 1990) but data from rat PC60 cells rather suggests
that IL-1 activates NF-kB molecules already present in the nucleus (Espel et al.,
1990).
Other IL-1-activated DNA-binding proteins exist, the best characterised so far
being NF-IL-6, which binds to a 14-bp sequence element in the IL-6 promoter,
which shares homology with a liver-enriched nuclear factor C/EBP and has been
shown to be essential for IL-1 inducibility (Akira et al., 1990). A motif within
the aracid glycoprotein promoter has been reported to respond to nuclear factors
produced by IL-1 in fibroblasts and hepatocytes (Prowse and Bauman, 1988).
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1.13 IL-1 inhibitors and binding proteins
1.13.1 IL-1 receptor antagonist (IL-lra or IL-1 receptor antagonist protein, IRAP)
Early studies described the presence of an inhibitor in the supernatant of human
monocytes cultured on adherent immune complexes which had potent effects on
IL-1 stimulation of thymocytes, chondrocytes, fibroblasts and synovial cells
(Arend et al., 1985, 1989). Now characterised, it is known as IL-1 receptor
antagonist (IL-lra), a specific antagonist produced predominantly by
monocyte/macrophages but also by polymorphonuclear leukocytes and
keratinocytes. What appears to be an identical inhibitor has been found in the
urine of patients with monocytic leukemia (Seckinger et al., 1987) and also in
supernatants from PMA induced U937 cells (Carter et al., 1990). Human IL-lra
has been mapped to chromosome 2, in the same location as other members of the
IL-1 family, but contrary to IL-1, the IL-lra mRNA does not contain the
AUUUA sequence implicated in regulating the IL-1 mRNA half-lives
(Eisenberg et al., 1990).
IL-lra is a 152-residue, 22-25K glycoprotein with a pi of 5.0 which, contrary to
IL-1, does have a signal peptide. The amino acid sequence shows 41%
homology with IL-1 (3 and 30% with IL-1 a. Although IL-lra is structurally
related to IL-1 (3, it specifically blocks both IL-1a and IL-1 (3 binding to the
receptors without itself activating the target cells (Eisenberg et al., 1990; Carter
et al., 1990; Arend et al., 1990). Murine IL-lra appears to exhibit IL-1R binding
competition only with IL-la (Matsushima et al., 1991). The IL-1 type I receptor
binds IL-lra selectively, but not exclusively and the unglycosylated 17K
recombinant IL-lra as expressed by E. coli is equally efficient at blocking IL-1
binding. The type II receptor has been shown to bind IL-lra but with a much
lesser affinity (Granowitz et al., 1991). IL-lra probably plays an extremely
important role in in controlling the immunoregulatory balance during immunity
and inflammatory processes. It follows that the type I IL-1 receptor represents
the predominant signaling pathway for many host responses attributable to IL-1.
Specific antagonists to IL-1RII, once found, will aid elucidation of the exact
function of this receptor.
The recently cloned human IL-lra promoter has been found to be selectively
active in cell lines in which the endogenous gene is active (Smith et al., 1993).
Experiments at both molecular and protein levels (Arend et al., 1991b; Poutsiaka
et al., 1991; Turner et al., 1991; Vannier et al., 1992) have established that EL-1
and IL-lra production by monocytes are differentially regulated by mediators
including LPS, TGFp and IL-4. Recent reports suggest that moncytes
constitutively produce IL-lra during maturation into macrophages, an effect
enhanced by GM-CSF (Roux-Lombard et al., 1989; Janson et al., 1991). Again
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it is suggested that the balance between the production of IL-1 and its antagonist
may be important for the regulation of the immune response and chronic
inflammation during pathological processes. As an example, the activity of IL-1
increases and of IL-lra decreases with respect to normal, in cells from healthy
smokers and patients with interstitial lung diseases (Takeuchi et al., 1992). Very
recently it was suggested that the induction of IL-lra by GM-CSF and IL-4
occur via different mechanisms as GM-CSF can induce IL-1 [3 co-ordinately in
U937 cells. In these cells IL-lra expression is not affected by EL-2, IL-3, EL-5,
EL-6, IFNy, M-SCF, G-CSF, TNFa, growth factors or IL-lra itself (Berger et al.,
1993).
IL-lra regulates IL-2-related functions by a suppressive action on the T
lymphocyte (Kashiwado et al., 1989). In this context, studies on AIDS patients,
which are at best confusing with regard to whether IL-1 production is normal or
impaired, suggest increased synthesis of EL-Ira with the balance of IL-1/IL-lra
production favouring receptor inhibition. As T cell function in these patients is
impaired together with a lessening of factors which augment IL-1 synthesis but
not IL-lra, it has been suggested that excessive production of IL-1 inhibitors
may contribute to immunodeficiency (Berman et al., 1987; Chensue et al.,
1992).
Keratinocytes have been found to produce constitutively large amounts of a
biologically active intracellular variant of IL-lra (icIL-lra) which is 20K in size,
unglycosylated, lacks a leader sequence and has an additional seven N-terminal
amino acids. Both forms of IL-lra are derived from the same gene through use
of an alternative transcriptional start site and internal splice-acceptor site
(Haskill et al., 1991). Epidermal IL-lra is found in both forms (Hammerberg et
al., 1992). With differentiation of the keratinocytes, the IL-lra/IL-1 ratio
increases, showing increased IL-lra mRNA (Bigler et al., 1992; Gruaz-
Chatellard et al., 1991). This is also true for both forms of IL-lra in psoriatic
skin (Hammerberg et al., 1992). Non-secreted IL-lra may therefore serve to
regulate autocrine IL-1-mediated pathways of growth/differentiation. In addition,
glucocorticoid treatment of epidermal cells abolishes IL-1 but not EL-Ira
production indicating that immunosuppressive effects of glucocorticoids, as well
as inflammatory effects of IL-1 a in human skin, are modified by EL-Ira (Stosic-
Grujicic and Lukic, 1993).
Examples of the beneficial effect of IL-1 blockade are that IL-lra protects
against IL-1 induced arthritis in rabbits (Henderson et al., 1991), has also been
shown to protect adrenalectomised rats against the lethal effect of IL-1
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(Mengozzi et al., 1991) and prevents death due to LPS administration in rabbits
(Ohlsson et al., 1990).
Reducing the pathogenic role of IL-1 by blocking its actions is a potential
strategy for treating patients with acute and chronic diseases. IL-lra has been
administered to normal subjects in a phase I trial, which showed that even at
plasma concentrations of 25-30fig/ml, no abnormal diagnostic indices were
detectable (Granowitz et al., 1992). This is consistent with non-involvement of
IL-1 in normal homeostasis. Clinical trials involving short term infusion of IL-
lra have shown potential benefit and trials involving patients with ulcerative
colitis have been initiated (Dinarello, 1993). Future trials will have to determine
to what extent blocking the action of IL-1 action may impair host defences
during prolonged treatment.
1.13.2 Other Inhibitors and IL-1 Binding Proteins
Uromodulin, an immunosuppressive glycoprotein found in the urine of pregnant
women, binds to IL-1a and IL-1 (3 but also to TNF and other cytokines and is
therefore non-specific (Hession et al., 1987; Brown et al., 1991).
Naturally occuring cytokine binding proteins include lipoproteins, lipids, acidic
polysaccharides and alpha-2 macroglobulin (oc2M). oc2M is a major plasma
binder whose native and activated forms bind different cytokines selectively. IL-
1(3 is bound preferentially by trypsin- or methylamine-reacted, ie. activated
forms of a2M through a thiol ester-dependent mechanism. a2M probably acts
by regulating the distribution, clearance and bioactivity of circulating IL-1
(Borth and Luger, 1989; LaMarre et al., 1991; Kaplan and Nielsen, 1979). Even
co-valently bound IL-1 (3 is biologically active and labelling experiments have
established that the binding is specific, via Cys-122, and can only be inhibited by
IL-1 (Borth et al., 1990; Teodorescu et al., 1991).
Several other IL-1 inhibitors have been described. A specific 52K IL-1 inhibitor
is produced by the human myelomonocytic M20 cell line and by the mouse
macrophage P388D cell line (Barak et al., 1991; Isono and Kumagai, 1989) and
virus infection can induce release of two additional inhibitors of 8K and 95K
from PMN and M<j) (Berman et al., 19; Roberts et al., 1986; Rodgers et al.,
1985). UV irradiated or hydrocortisone treated keratinocytes produce two basic
(pi 8.8) inhibitors of 40 and 50K (Schwarz et al., 1987; Kupper and McGuire,
1986). An IL-1 inhibitor, of 95K molecular weight is produced by virus-infected
monocytes in vivo and in vitro and contributes to the lack of detectable IL-1
activity (Rodgers et al., 1985; Roberts et al., 1986). None of the above appear to
be forms of the specific IL-1 receptor antagonist and the relationship, if any,
between these various inhibitors has not been established.
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IL-lR-related binding proteins have been detected. IL-1 is considered to be a
major link in the neuroimmune axis and shared saturable one way transport of
IL-1 a and IL-1 (3 from blood to brain has been demonstrated. The blood-brain
transporter appears to be similar, but not identical to, the T lymphocyte (Typel)
receptor and has greater affinity for DL-la than IL-1 (3 (Banks et al., 1991). The
soluble IL-1 (3 specific binding protein (see 1.11.2) is generated by proteolytic
cleavage of the extracellular portion of the type II receptor.
1.13.3 IL-1 Autoantibodies
Autoantibodies to IL-1a and IL-1 (3 have been detected by several groups in
normal human plasma as well as in patients in a number of disease states, some
of which are quoted as examples.
Data on the prevalence of IL-1 autoantibodies is inconsistent because of
differing methods of detection but trends are discernable from within individual
studies. From receptor binding studies, 25% of normal plasmas tested contained
anti-IL-la and 2% contained anti-IL-lf3 IgG antibodies (Gallay et al., 1991).
The binding capacity and affinity were found to be greater in male than female
sera (Svenson et al., 1990).
Patients with rheumatoid arthritis have been reported to have neutralising IgG
anti-EL-la autoantibodies; 16% of RA patients compared to 6% of normal
subjects and 5% of patients with systemic lupus erythematosis. Antibody titres,
as assessed by RIA, were shown to fluctuate with RA disease activity (Suzuki et
al., 1990, 1991). Anti-IL-la autoantibodies have also been seen at a higher
frequency in sera from patients with Schnitzler's syndrome (Urticaria, bone pain,
fever, macroglobulinemia). The predominant class was IgG but in some patients
IgA was also detected (Saurat et al., 1991).
These antibodies have potent neutralising capacity and a high receptor binding
capacity and are thus distinct from other cytokine autoantibodies. The presence
of these high affinity IL-1 a autoantibodies even in the sera of normal
individuals, has prompted the suggestion that they could act as specific
physiological carriers and regulators (Bendtzen et al., 1990). Receptor binding
and IL-1 a epitope studies are required to help elucidate their pathological
significance.
1.14 IL-ip as an adjuvant:
For quite some time, IL-1 (3 has been mooted as an effective adjuvant for poorly
immunogenic vaccines, for example IL-1 (3 and lipoxygenase metabolites have
been shown to mediate the lethal effect of Freund's adjuvant in adrenalectomised
rats (Peretti et al., 1991). IL-1 (3 with point mutations which yield proteins
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retaining immunostimulatory activity but with greatly reduced pyrogenicity are
all adjuvant candidates. The synthetic IL-1{3 163-171 peptide is extremely
effective as an adjuvant, being completely devoid of inflammatory or toxic
effects and has been recommended for human use (Tagliabue et al., 1991).
Hybrid proteins in which foreign sequences have been inserted into IL-1J3
without changing the overall structure have also proven useful for delivery of
therapeutic agents (Wolfson et al., 1991).
IL-la does not exhibit adjuvant properties but rather acts as a competitive
inhibitor of IL-1 (3 adjuvanticity (Boraschi et al., 1990).
1.15 IL-1 and Antigen Presentation
1.15.1 T Cells
Freshly derived human CD4+ T cells are divided into naive and memory T cells
based on the expression of the reciprocal CD45 isoforms, CD45RO and
CD45RA respectively (Swain et al., 1991). The requirements for IL-1 in the
activation of naive and memory T cells appear to be different. IL-1, including
membrane IL-la, plays a critical role in the early phases of a primary response
but it seems to have little effect on the later phases or on the responses of
memory T cells (Plebanski et al., 1992). Human prestimulated CD4+ T helper
cells, but not CD8+ cells, acquire the ability to stimulate monocytes to produce
IL-1. Cell to cell contact is a prerequisite for this stimulation in vitro (Dunlap
and Tilden, 1991). An earlier study showed that CD8+/CD4- cytotoxic T
lymphocytes have secrete IL-2 once the IL-1 R is triggered by IL-1 after antigen
stimulation (Klarnet et al., 1989).
Murine studies show IL-1 to be required for optimal clonal expansion of
memory cells in response to stimulus and differential expression of the IL-1
receptor mRNA correlates with their responsiveness to IL-1 (Luqman et al.,
1992). Accessory cells can significantly regulate T helper cell (Th) effector
function at the level of cytokine production (Bloom et al., 1992; Williams and
Unanue, 1991). The Thl subset, involved in delayed hypersensitivity, produces
IFNy and IL-2 and does not require IL-1 for proliferation. The Th2 murine
CD4+ subset activate B cells and produce IL-4. They express both forms of IL-1
receptor (80 and 60K) and whilst EL-1, especially IL-la in the membrane bound
form, is the requisite costimulator for the growth of Th2 murine T-cell clones
(eg. D10.G4.1 cells used for IL-1 bioassay), IL-4 production is not enhanced.
Antigen presentation reversibly upregulates both forms (80 and 60K) but
stimulation with Concanavalin A only upregulates the 60K form (Solari et al.,
1990b; Williams and Unanue, 1991).
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Human B cells, which are also involved in antigen presentation, only express a
few IL-1 receptors until stimulated with Staphylococcus aureus Cowan I (SAC)
ie. after stimulation the major low affinity class, increased from 320 to 1960 per
cell, Kd 3.8 x 10"10 and the minor high affinity class increased from 70 to 300
per cell, 4.4 x lO12 (Tanaka et al., 1989). Anti-class II antibodies also
inhibited the number of receptors on these cells indicating that class II may play
a part in the activation of these receptors.
1.15.2 Dendritic Cells
Dendritic cells are a system of antigen presenting cells which function to initiate
several immune responses such as the sensitisation of MHC-restricted T cells,
the rejection of organ transplants, the formation of T-dependent antibodies and
presentation of antigens in lymph nodes. DC, cells with a dendritic, veiled, cell
morphology which are rich in surface class II histocompatibility antigens (la
antigens) but lacking in other lymphocyte or monocyte markers, are found in
many non-lymphoid tissues but can migrate via the afferent lymph or the blood
to the T-dependent areas of lymphoid organs. They constitute a small proportion
(<1%) of circulating mononuclear cells. In inflammatory joint effusions they
constitute up to 7% (Tsai et al., 1989) and in peripheral afferent lymph, in which
the cells of dendritic morphology are derived mainly from Langerhans cells in
the local skin area, they constitute 5-10% of the monocyte population (Hopkins
et al., 1989). Follicular dendritic cells, although morphologically similar, are
thought to be functionally distinct and have not come under consideration in the
current study. Table 1.2 is a resume of DC distribution. Also included is the
potential for IL-1 production (+ indicates conflicting evidence).
TABLE 1.2
Tissue Distribution of Cells with Dendritic Characteristics
and Associated IL-1 Production


































DC occur in two states of differentiation. In the immature state they are highly
specialised to process foreign protein antigens and in the mature state they
efficiently stimulate resting antigen-specific T cells. DC can migrate from the
non-lymphoid tissues, where they reside in the immature state, via the afferent
lymphatics or the blood to the T cell dependent areas of the lymphoid organs
(lymph nodes, spleen), where they appear as mature cells.
Following exposure to sensitising chemicals, dendritic cells rapidly accumulate
in the draining lymph nodes. A proportion, at least, of the DC arriving at the
nodes bear significant amounts of antigen and are derived from LC. Although
LC are relatively inefficient antigen-presenting cells, the antigen-bearing DC
found within the draining node are potent accessory cells and induce immune
responses both in vivo and in vitro. As LC migrate from skin to lymph node they
are subject to a phenotypic maturation and as they develop into DC they acquire
active antigen-presenting function (Macatonia et al., 1987). It has been shown
that after skin painting mice on one flank, there is an increase in DC in the
collateral and distal lymph nodes in addition to the draining nodes but only DC
in the draining nodes carry antigen (Hill et al., 1992). Peripheral lymph node
DC, irrespective of whether they are derived from resting or draining lymph
nodes and irrespective of whether they are bearing antigen show elevated
membrane la antigen expression (Cumberbatch et al., 1991).
DC are generally thought to be of hemopoetic stem cell origin but if so, it is not
known at what stage of monocyte development the priming for development into
LC/DC occurs but autocrine stimulation may play a part (Reid et al., 1990; Rossi
et al., 1992a). There is histological evidence from heterologous skin graft
experiments that cutaneous regions can also serve as sources of LC (Demarchez
et al., 1993).
DC rapidly upregulate adhesion molecules in vitro (Teunissen et al., 1990)
which is important with respect to the immunogenicity of antigen containing
DC. Recent studies have shown that stratum corneum-derived human IL-1
injected into the skin will upregulate dermal dendritic cell expression of the
adhesion molecules ICAM-1 and VCAM-1 (Groves et al., 1992).
During two or three days of culture epidermal Langerhans cells (LC) develop
from immature into mature cells. GM-CSF is the major stimulus for maturation
of DC (Caux et al., 1992; Heufler et al., 1988) and IL-1 and TNFa have both
been strongly implicated as initiators of the migration of antigen-containing LC
to lymph nodes (Cumberbatch and Kimber, 1992, Vakkila et al., 1990). There is
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evidence that both interdigitating thymic reticulum cell and LC/DC function may
be dependent on IL-la but not IL-ip or TNF production (Ruco et al., 1990).
Veiled cells in afferent lymph were first described in 1978 (Kelly et al.) and
have become the subject of increasing interest as potent antigen presenting cells.
It is not known exactly how the cells take up antigen and although early reports
indicated a lack of phagocytic activity and antigen processing this now appears
to be incorrect. The presence or absence of Fc receptors on DC has been
variously reported. Murine lymph node and spleen (Nussenweig et al., 1981) and
human peripheral blood DC (van Voorhis et al., 1982) do not appear to express
Fc whereas rat lymph node (Schalke et al., 1985), murine pulmonary tissue
(Sertl et al., 1986) and Langerhans cells (Spry et al., 1980) and human afferent
lymph dendritic cells do (Witmer-Pack et al., 1988). Both Fc positive and
negative DC have been found in sheep afferent lymph (Bujdoso et al., 1990). It
is possible that varying states of differentiation are being seen. FcR negative
cells have been reported as having the greatest antigen presenting capacity
(Inaba et al., 1988). However, Harkiss et al (1989) have shown that
approximately two thirds of sheep afferent lymph DC bind antigen/antibody
complexes via Fc receptors.
Some in vitro studies indicate that DC process proteins for a short period of time
while the rate of synthesis of MHC products and content of acidic endocytic
vesicles are high (Pure et al., 1990). Flow cytometry evidence reveals that DC
are metabolically active and that traffic through the late endosome does occur in
a pattern of fluid-phase endocytosis similar to that described for other antigen
presenting cell types (Levine and Chain, 1992). Recently nitric oxide, which is
synthesised from arginine as part of a major route by which activated cells of the
macrophage lineage mediate cytostasis of the cells, has been demonstrated in rat
thoracic afferent lymph DC following IFNy exposure, although the NO detected
in lymph DC was markedly less than from macrophages (Denham and Barfoot,
1992).
Antigen presentation by dendritic cells requires antigen/la (class II) complex for
specific recognition of antigen. There is evidence that DC may direct local, as
opposed to systemic, immunity by controlling T cell cytokine production
(Spalding et al., 1983, 1986; Everson et al., 1992). Data on the interaction of
cytokines and DC from various sources is beginning to appear, much of it
contradictory and very little is yet known about IL-1 and the LC/afferent lymph
DC/Lymph node axis. Human tonsil DC do not produce IL-la or P and neither
is IL-1 essential for DC-stimulated allogeneic T lymphocyte responses (Calder et
al., 1992). The same authors have been unable to demonstrate IL-1R or TNFaR
44
mRNA by PCR, in peripheral blood DC. IL-1 mRNA or IL-1 activity has been
found in DC by some but not all groups (Koide et al., 1987b, 1988; Vakkila et
al., 1990; Waalen et al., 1986). DC from inflammatory sites have been found to
produce large amounts of IL-1 spontaneously whereas DC from peripheral blood
produce less IL-1 than autologous monocytes (Waalen et al., 1986).
DC maturing from LC in culture have been found to produce large amounts of
IL-1 (3 (Ruppert and Peters, 1991). However, SJ Hopkins et al (1990) have shown
that IL-1 production in vivo is a very early event and that levels of IL-1 in lymph
fluid after contact sensitisation are very low. Circumstantial evidence points to
IL-1 being produced by the DC in the lymph but this remains to be clarified.
An amplifying rather than an initiating role is currently being ascribed to IL-1.
From much of the published work on DC as antigen presenting cells, it appears
that IL-1 is not essential as a second signal for allogeneic T-cell responses, that
IL-1 a, IL-1 (3 and IL-6 are primarily monocyte derived and are neither required
nor produced during the activation of resting T cells by DC and that proliferation
is not blocked even by high concentrations of anti-IL-1 antibody (Bhardwaj et
al., 1989; McKenzie et al., 1989; Vakkila et al., 1990; Naito et al., 1989). GM-
CSF is a major macrophage activating factor which, apart from inducing
cytokines, also induces macrophage HLA-DR expression (Chantry et al., 1990).
There are a number of reports of direct augmentation of the DC/Tcell reaction by
GM-CSF and/or IL-1 (Koide et al., 1988; Wilson et al., 1988). Rabbit DC
activity is enhanced indirectly by IL-1 containing supernatants (Kapsenberg et
al., 1985) as is murine DC function, which has been shown to be enhanced if DC
are exposed to IL-1 prior to addition to an MLR assay (Koide et al., 1987a). The
enhancement is thought to be via direct action on the DC, not the T cell but the
mechanism whereby IL-1 enhances DC function has not yet been elucidated.
IL-1 seems to be produced during monocyte but not dendritic cell mediated T
cell proliferation (Koide et al., 1988). In primary antigen-dependent systems like
the MLR, IL-1 production is not detected in accessory (DC or M<j>) or T cells,
but monocytes can be induced to make IL-1 after interaction with sensitised
antigen specific T cells. Both alloreactive T cell clones and freshly prepared
lymphoblasts can induce IL-1 provided the monocytes carry the HLA-DR
antigens to which the T cells were initially sensitised. It seems that cell contact
rather than an IL-1 inducing factor leads to IL-1 production. Neither DC nor B
cells seem to make much IL-1 even under these conditions (Bhardwaj et al.,
1989).
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1.16 Ovine Afferent Lymph
Because of the ease of cannulation of its lymphatic ducts, the sheep is ideal for
the study of cells in afferent lymph. Using this system, fresh cells can be
continuously collected hence obviating cell culture, which could potentially
affect the characteristics displayed by the cells. Cannulation also allows
detection of early in vivo events following antigen challenge of the draining skin
area. Much work has been done in our department on the characterisation of
sheep afferent lymph dendritic cells (Bujdoso et al., 1989, 1990; Hopkins et al.,
1989; Harkiss et al., 1990). The majority of DC express surface immunoglobulin
(Ig) of IgM and IgGl types. At least four subpopulations of dendritic cell enter
the lymph node via the afferent lymph - CD1 positive and negative, Fc receptor
positive and negative. It is not yet clear whether these represent distinct cell
types or cells in a transitional state. Class II positive, Fc positive DC are known
to be efficient at presenting antigen to CD4+ T cells. Whether there is restriction
amongst the lymph DC subsets with respect to antigen presentation has not been
clarified, but the CD1 positive, Fc negative cell has been proposed as the
principal presenting cell for y5 T cells via a heat shock protein/CD 1 ligand
which would obviate the necessity for Fc. Sheep afferent DC constitutively
express ± 3 x 105 class II molecules per cell but cells entering the lymph node
from a site of secondary antigen challenge express a sixfold higher level. CD4,
LFA-3 and its ligand CD2, which are involved in signal transduction and
intermolecular binding, are all expressed as DC cell surface markers. Human
studies have shown that perturbation of LFA-3 causes IL-1 release (Le et al.,
1987) but it is not itself upregulated by IL-la or LPS (Swerlick et al., 1991).
The adhesion molecule ICAM-1 (CD54) is upregulated by IL-la (Swerlick et
al., 1991). A further adhesion molecule, ELAM-1 is only very transiently
expressed upon stimulation by IL-la (Beekhuizen et al., 1991). Interestingly,
although IL-1 does not affect adhesiveness of lymph node endothelial cells,
synergism of IL-1 with suboptimal doses of IL-4 and TNFa does increase then-
adhesiveness (Chin et al., 1991).
The proportions of various lymphocyte subpopulations in sheep blood differ
markedly from those in blood of other species. The CD4+ and CD8+ subsets are
sparse, being 20% and 12% respectively whereas in human blood these subsets
are 50-60% and 10-20%. slg+ cells are 30% in sheep compared to 10% in
human blood. CD3+, CD4~CD8~ cells comprise 3% of human PBL whereas in
sheep, the analogous population, T19+, is present at 15-20%. Because of the
different phenotypes in blood and lymph, cells in afferent lymph migrating from
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blood in peripheral tissues must presumably be selected at the blood vessel
endothelium and it appears that activated cells preferentially enter afferent
lymph (Mackay et al., 1990).
1.17 Summary of reasons for the study of ovine IL-1
Although a large amount of data on ovine and bovine leukocyte molecules has
been available for quite some time not much has been known about their
cytokine interactions. Partly because of the cloning of various bovine and ovine
interleukins, data on ruminant cytokine interactions is now accumulating at a
reasonably rate.
Two species with IL-1-like activity and characteristics were originally detected
from sheep peripheral blood mononuclear cells stimulated with Con A (Harkiss
et al., 1989). They induced both cartilage resorption and thymocyte activation
but not lysis of the murine L929 cell line which is responsive to TNF. Bovine
monocyte-derived IL-1 was first purified by Lederer in 1989.
It is clear that IL-1 plays pivotal a role in the regulation of normal tissue
function, the immune response and the pathogenesis of disease. In order to study
the involvement of IL-1 in disease states in sheep it is essential to acquire
knowledge of the normal reactions to immune stimulation on which subsequent
analysis can be based. When this study was initiated it was known that bovine
and ovine material were likely to be very similar. Bovine IL-1 c-DNA sequences
had just been published but no recombinant protein was available. Species
barriers do exist and other less closely related IL-ls might not be able to produce
data relevant in the sheep. The aims therefore were to clone and express ovine
IL-1 in order to be able to study it's involvement in the immune response.
Alveolar macrophages, rather than PBMCs, were used as a source of IL-1
mRNA because of the numbers of cells obtainable and ease of purification.
Cannulated of sheep lymph nodes provide a unique model of the in vivo immune
response. Afferent lymph drains from the surrounding skin area which can be
locally challenged with antigen. When this study was initiated, dendritic cells
were known to be extremely important antigen presenting cells but nothing was
known about the interaction of IL-1 and the Langerhans' cell derived afferent
lymph dendritic cells. Recombinant ovine IL-1, once available, could be used to
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determine whether these dendritic cells expressed IL-1 receptors and whether
this expression could be upregulated by antigen challenge. By determining the
type of IL-1 receptor, DC lineage could be established. The presence of IL-1
mRNA in these cells could be determined at a later stage by in situ hybridisation
with cDNA probes. This information is of potential importance with respect to
the processing of antigen and possible antibody targeting in future disease




Methods are detailed as they were most frequently used. Specific modifications
are noted in the main text where appropriate. Where considered relevant,
comments on the methods are included. The methods are ordered, as far as
possible, to relate chronologically to subsequent chapters. All tissue culture
media were purchased from Gibco and chemicals from Sigma Ltd. unless
otherwise stated.
2.1 Animals used in this study
2.1.1 Sheep
Finnish Landrace x Dorset, Grey Faced x Suffolk and Dorset x Suffolk sheep of
various ages were obtained from the Moredun Research Institute, Edinburgh.
2.1.2 Rabbits
Dutch albino rabbits from our own breeding colony.




a. Sterile RPMI 40, Iscoves serum free medium and Dulbecco's MEM,
were all supplemented with 5mM glutamine for use.
Benzylpenicillin and streptomycin were routinely added at 100
units/ml. Foetal calf serum was added to media as required.
b. Hanks balanced salt solution (HBSS).
c. Phosphate buffered saline (PBS): 137mM NaCl; 26.8mM KC1; 14.7mM
KH2P04; 81mM Na2HP04.
d. PBA: PBS containing 0.1% (w/v) bovine serum albumin fraction V and
0.1% Na azide.
2.2.1.2 Incubation conditions for tissue culture
All incubations were at 37°C in a humidified atmosphere of 5% C02/95% air.
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2.2.2 Nucleic acid manipulations
2.2.2.1 Commonly used reagents
a. 20 x SSC: 3M NaCl; 0.3M Na citrate; pH7.0.
b. TAE: 40mM Tris base; 0.114% glacial acetic acid; ImM EDTA.
c. TBE: 90mM Tris base; 90mM boric acid; ImM EDTA.
d. TE: lOmM TrisHCl; ImM EDTA.
e. TNE: lOmM TrisHCl; lOOmM NaCl; ImM EDTA; pH 8.0.
f. Salmon sperm DNA and yeast RNA: phenol extracted and
resuspended at lmg/ml in water.
g. Klenow fragment of E. coli polymerase I: referred to as 'Klenow'.
h. Tag polymerase: referred to as 'Taq'.
2.2.2.2 Purification of nucleic acids by phenol extraction and ethanol
precipitation
For RNA extraction, redistilled phenol was equilibrated with 0.3M Na acetate pH5.2.
For DNA extraction, redistilled phenol was equilibrated with lOmM TrisHCl pH8.0.
0.1% w/v hydroxyquinoline was added to scavenge oxidation products.
Redistilled phenol was stored at -20°C for up to a few months and buffered
phenol solutions at 4°C for 3-4 weeks.
a. Standard phenol extraction:
Nucleic acid samples were sequentially extracted by vigorous shaking with (i) an
equal volume of phenol; (ii) an equal volume of phenol:chloroform:isoamyl
alcohol (25:24:1 v/v/v), twice; (iii) an equal volume of chloroform:isoamyl
alcohol (24:1 v/v), twice. After each extraction step the solution was centrifuged
and the aqueous layer retained. RNA and DNA were finally precipitated by
addition of 0.25M Na acetate pH5.2 and 2.5 volumes nucleic acid grade ethanol,
either on dry ice for 1 hour or at -20°C for 16-20h. The precipitate was
microfuged at 4°C for 15min, washed with 70% ethanol and resuspended in
water. RNA samples were stored at -70°C and DNA samples at -20°C.
Unless otherwise indicated, use of the term 'phenol extraction' will encompass
the above procedure in full.
b. Hot phenol extraction:
Extraction of DNA from low gelling temperature (lgt) agarose gels included
additional initial extraction steps. Lgt was melted at 65°C, extracted first with
phenol/chloroform/isoamyl alcohol at 65°C then buffered phenol at 65°C.
Subsequent extraction steps followed the normal protocol.
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2.2.2.3 Purification of cDNA by absorption to silica
(Geneclean, Bio 101 Inc., La Jolla, California)
The manufacturers instructions for isolation of pure DNA by absorption to silica
powder were followed exactly.
2.2.2.4 Measurement of nucleic acid concentration
Nucleic acid concentrations were measured spectrophotometrically.
In solution, 50mg DNA = 1 unit OD260nm and 40mg RNA = 1 unit OD260nm.
The OD260/280 ratio at pH7.0 - pH8.0 should be 1.8 - 2.0. If outside this range, a
further chloroform extraction was performed.
2.2.2.5 Nucleic acid markers for agarose gels
a. RNA low molecular weight ladder (BRL Inc.): Fragment sizes are
1770, 1520, 1280, 780, 530, 400, 280 and 160 kilobases.
b. RNA high molecular weight ladder (BRL Inc.): Fragment sizes are
9500, 7500, 4400, 2400, 1400 and 240 kilobases.
c. DNA markers: Digestion of ADNA with EcoRI and Hindlll restriction
nucleases produces fragments of generally suitable sizes, ie.
21226, 5146, 4973, 4268, 3530, 2027, 1904, 1709, 1375, 947,
831, 564, 125 base pairs.
2.3 Preparation of RNA and cDNA
2.3.1 Preparation of alveolar macrophages
Ovine alveolar macrophages were obtained either by lung washout with 200ml
HBSS under anaesthetic or by bronchoalveolar lavage with 4 x 500ml HBSS at
postmortem. Cells were harvested by centrifugation at 1500 x g for 15min at
4°C, washed twice with 100ml HBSS and resuspended in 9ml HBSS. To lyse
any erythrocytes present, 13.5ml H20 was added, the tube inverted rapidly twice
and 1.5ml 10 x PBS added immediately to restore isotonicity. Macrophages were
washed and resuspended in 20ml Iscoves serum free medium. Cell
concentrations were adjusted as required.
2.3.2 LPS stimulation of alveolar macrophages
Macrophages were allowed to adhere to plastic culture bottles (Nunculon,
Denmark) at 37°C for 24h in a humidified atmosphere of 5% C02/95% air, prior
to stimulation with 10pg/ml or lOOjig/ml LPS in fresh medium. Cells were
stimulated for various time periods as required, with the 0 hour time point being
taken at the time of LPS addition. For experiments in which total RNA was
required, a T75 bottle containing 2 x 107 macrophages was used for each time
r /
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point. If polyA+ was to be prepared, 2 x 108 macrophages in T125 bottles were
used. Supernatants were stored in aliquots at -70°C and RNA was extracted from
the cells.
2.3.3 Preparation of Total RNA from alveolar macrophages
2.3.3.1 Isolation of RNA by centrifugation through CsCl
Culture medium was removed from the adherent macrophages. RNA was
extracted from the cells following the method of Chirgwin et al., 1979. Cells
were solubilised by addition of 8ml GTC buffer (5M Guanidine isothiocyanate;
25mM Na citrate; 0.5% Na lauryl sarcosinate; lOOmM [3-Mercaptoethanol; ImM
EDTA) with agitation of the bottle. Solubilised macrophages in GTC can be
stored at this stage, either at 4°C for a few days or at -20°C for longer periods.
Solubilised cells in a total volume of 11ml GTC were layered over 1.6ml 5.7M
CsCl and centrifuged at 76,000g at 20°C for 16h. The supernatant, including the
interface band which consists of DNA, was discarded and the tube drained
upside down. The sides of tube were dried without disturbing the pellet. The
pellet was resuspended in 300ml RNA uptake buffer (0.3M Na acetate pH5.2;
0.1% SDS; lOmM EDTA) by gentle pipetting. RNA was phenol extracted and
precipitated with 2.5 volumes cold analar ethanol. Precipitated RNA was
pelleted by microcentrifugation, washed with 70% ethanol, resuspended in H20
and the concentration measured (see Sect. 2.2.2.3).
2.3.3.2 Single-step RNA preparation (Chomczynski and Sacchi, 1987)
2.5ml of Solution D (4M GTC; 25mM Na citrate pH 7.0; 0.5% Sarcosyl) was
added to dissolve cells in 75ml culture flask then transferred to a polypropylene
tube. Sequentially, 0.1ml 2M Na acetate pH4, 1.0ml water saturated phenol and
0.2ml chloroform/isoamyl alcohol (49:1) were added and the mix shaken
vigorously for lOsec prior to cooling on ice for 15min. After centrifugation at
10,000g for 20min at 4°C the aqueous phase was mixed with 1ml isopropanol
and left at -20°C for at least lhr to precipitate the RNA. Proteins and DNA in the
interface and the phenol phase were discarded. The RNA was re-precipitated by
adding 0.3ml Solution D and 1 vol isoamyl alcohol. The resulting pellet was
washed with 75% ethanol, resuspended in 0.5% SDS (as an RNase inhibitor),
and stored at -20°C.
2.3.4 Preparation of PolyA+ RNA
PolyA+ enriched RNA was prepared by a modification of the method of
Manniatis (1982). All plastic was autoclaved, all glassware was siliconised and
baked and all solutions treated with 0.01% diethylpyrocarbonate (DEPC) at 4°C
to inactivate RNases. DEPC was removed either by autoclaving or by heating to
68°C for 4h in the case of solutions which could not be autoclaved.
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500mg (<2ml wet vol) oligo dT-cellulose Type7 (Pharmacia) was equilibrated in
Eppendorf tubes, by three washes in 0.1M NaOH; 5mM EDTA followed by
neutralisation with H20 and washing with 5 volumes of loading buffer (20mM
TrisHCl pH7.6; 0.5M NaCl; ImM EDTA; 0.1 %SDS). lmg RNA in as small a
volume as possible plus an equal volume of 2 x load buffer was heated to 65°C
for 5min, allowed to cool and added to the cellulose in the tube. After lOmin the
tube was centrifuged, the supernatant reheated, cooled and added to the
cellulose. After 5min the supernatant was removed and the cellulose washed
with four volumes of load buffer then four volumes of this solution plus an
additional 0.1M NaCl. RNA was eluted with 1.2ml buffer (lOmM TrisHCl pH
7.5; ImM EDTA; 0.05% SDS) for 2h at 4°C. Supernatants were concentrated
with isobutanol. The polyA+ RNA was precipitated with ethanol containing
0.3M Na acetate pH 5.2 and resuspended in 50pl H20.
2.4 cDNA and PCR
2.4.1 cDNA Synthesis
First strand cDNA was synthesised either from total RNA or from polyA4"
enriched RNA using Amersham cDNA synthesis kits and either oligo-dT12.18 or
random hexanucleotides as primer. PCR primer B5.1 (see Figure 3.4) was used
to prime the synthesis of cDNA for use in terminal transferase reactions (see
Sect. 2.3.5). Parallel labelled and unlabelled reactions were carried out, exactly
as per the manufacturers instructions, in order to assess the amount of cDNA
synthesised.
2.4.2 Preparation of oligo-dA tailed cDNA (Wensink et al. 1974)
B5.1 primed single strand cDNA was tailed with dATP using the terminal
transferase reaction. llOng cDNA (~2pM) was incubated at 37°C for 90min
with 20pM dATP and lOunits terminal transferase in cacodylate buffer (lOOmM
NaCacodylate pH 7.0; ImM CoCl2; 100|iM DTT; 50|ig/ml BSA) and the
reaction stopped by heating to 75°C for lOmin. Ideally 10 dA residues should be
added per 30min incubation with lOunits of enzyme and 4pM DNA hydroxyl
ends. Tail length was estimated from autoradiographic exposure of
electrophored samples (see Sect. 2.5). Tailed cDNA was used as a template for
anchored PCR.
2.4.3 XgtlO cDNA libraries
cDNA libraries were constructed using the Amersham ^gtlO cDNA cloning
system kit. The manufacturers directions for cloning, screening and isolating
cDNA clones were followed exactly.
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2.4.4 Polymerase chain reactions
lOOfil PCR reactions were carried out in 0.5ml Eppendorf tubes with overlaid
sterile mineral oil to prevent evaporation. In addition to the cDNA template,
reactions contained 10-20pM primers, lOOjig/ml BSA, 200pM each of dATP,
dCTP, dGTP and dTTP; 2.5units Taq polymerase and IOjllI buffer. Two buffers
were routinely used, Anglian (Anglian Biosystems Ltd) and Ohara (Ohara et al.,
1989) see below. Reactions were carried out in a Techne thermal cycler. 35
amplification cycles each consisting of denaturation 93°C/30sec, primer
annealing t°C/30sec, polymerisation 72°C/2.5min, were followed by 72°C/5min
to allow full extension of synthesised strands. The annealing temperature, t, was
determined for each primer pair. PCR products were analysed by agarose gel
electrophoresis (see 2.3.8.2),
Anglian PCR buffer: 6.7mM MgCl2; lOmM (3-Mercaptoethanol; 6.7pM EDTA;
16.6mM (NH4)2S04; 67mM TrisHCl pH8.8
Ohara PCR buffer: 1.5mM MgCl2; 3mM dithiothreitol; 50mM KC1; lOmM
TrisHCl pH8.8
2.5 Detection of Nucleic acids
2.5.1 Electrophoretic separation of nucleic acids on agarose gels
2.5.1.1 Denaturing RNA gel electrophoresis
3 volumes of denaturing solution (60% deionised formamide; 7.2%
formaldehyde; O.lmM EDTA; 20mM phosphate pH 7.0) was added to lOpg
RNA (at >lpg/fil in H20). After heating to 52°C for 15min, sample dye (30%
ficoll; 0.05% Bromophenol blue) and was added at l:5(v:v) and the sample
immediately loaded onto a 1.5% denaturing agarose gel (1.5% agarose; 20mM
phosphate pH 7.0; 6.7% Formaldehyde). Gels were run at 40V in 20mM
phosphate pH 7.0 for 16h at room temperature with buffer recirculation.
2.5.1.2 DNA gel electrophoresis
DNA samples in load buffer (0.25% bromophenol blue; 0.25% xylene cyanol;
40% sucrose) were electrophoresed through 0.8 - 1.5% agarose 6 x 8cm mini-
gels made with TAE/EtBr (0.04M Tris acetate; ImM EDTA; 0.5pg/ml ethidium
bromide). Gels were run in TAE and DNA bands visualised on a UV
transilluminator.
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2.5.2 Detection of immobilised nucleic acids by hybridisation with
radiolabeled cDNA probes
2.5.2.1 cDNA probe labelling (modified from Feinberg and Vogelstein, 1984)
Oligo labelling buffer (OLB) was prepared from the following components.
Solution O consisted of 1.25M TrisHCl; 0.125M MgCl2.
Solution A consisted of 1ml solution O; 18ml (3-mercaptoethanol; 5pi
dATP, 5pl dGTP, 5pl dTTP (each of which had been
previously dissolved in 3mM TrisHCl pH7.0; 0.2mM EDTA).
Solution B consisted of 2M Hepes titrated to pH6.6 with 4M NaOH.
Solution C consisted of Hexadeoxyribonucleotides (P-L No. 2166),
evenly suspended in TE at 90 OD units/ml.
Solutions A:B:C were mixed in a ratio of 100:250:150 and stored at -20°C. OLB
is not affected by repeated freezing and thawing cycles.
~30ng DNA was boiled for 3min with 6pl OLB in a total volume of 25pl then
allowed to cool to room temperature. 40pCi a32PdCTP (lOpCi/pl) and lpl (1
unit) 'Klenow' were added and incubated for 2h at 37°C. 32P incorporation was
monitored by precipitation of aliquots with 10% Tricarboxylic acid and
counting in LKB Optisafe scintillant in a (3 counter. Labelled probe was stored
at 4°C for no longer than 2 weeks. Probe specific activity typically was in the
range 0.5 - 1 x 109 cpm/pg. For use, aliquots of probe sufficient for >2 x
106cpm per filter were denatured by boiling for 5min prior to adding to the
hybridisation mix.
2.5.2.2 Northern blot analysis of RNA
Formaldehyde was removed from RNA gels by rinsing in 10 x SSC (1.5M NaCl;
0.5M Na citrate pH7.0) for <15min. RNA was transferred onto Hybond-C
nitrocellulose membrane (Amersham) by blotting for 20h with 10 x SSC, as
shown in Fig 2.1. The membrane was dried between Whatman 3MM filterpaper
sheets and baked for 2h at 80°C in a vacuum oven to fix the RNA.
Figure 2.1
Capillary transfer of nucleic acids from agarose gels onto membranes
glass plate
paper towel stack




Membranes were prehybridised, at 42°C for 16h with shaking, in RNA
hybridisation mix (5 x SSC; ImM EDTA; 0.5% non-fat driedmilk powder; 50%
formamide; 1.25% SDS; 125|ig/ml yeast RNA). Denatured 32P-c-DNA probe
was added to fresh hybridisation mix and the membrane hybridised at 42°C for
16h. Membranes were washed sequentially with vigorous shaking: three 15
minute low stringency washes in 2 x SSC; 0.1% SDS at RT and two 15 minute
high stringency washes in 0.2 x SSC; 0.1% SDS at 56°C. After air drying
membranes were exposed on Kodak XAR film.
2.5.2.3 Southern blot analysis of cDNA
Gels to be blotted were denatured for 15min in 1.5M NaCl; 0.5M NaOH then
neutralised with 1M TrisHCl pH7.0; 2M NaCl for 2 x 45min with gentle
shaking. DNA fragments were transferred from the rinsed gel onto nitrocellulose
membranes as shown in Fig. 2.1 and baked to fix.
Membranes were prehybridised and hybridised at 65°C in DNA hybridisation
mix (2.85 x SSC; 20mM phosphate pH7.0; ImM EDTA; 0.5% milk powder; 1%
SDS; lOOjig/ml salmon sperm DNA). Wash conditions were were the same as
for northern hybridisations except that the stringency wash was carried out at
65°C.
2.6 Cloning PCR products
2.6.1 Vectors used for cDNA cloning, sequencing and expression
pTZ18R and pTZ19R phagemid cloning vectors were purchased from
Pharmacia. These vectors contain overlapping enzyme restriction site
multilinkers derived from pUC18 and pUC19 plasmids which can be used for
specific cloning (see Chapter 3 Fig. 3.1).
pMA5620, pUGS41S and the E coli / yeast shuttle vector pOGS40 were gifts
from Dr. S.E. Adams, British Biotechnology Ltd, Oxford. pOGS40 plasmid
contains a unique BamHI restriction endonuclease site for insertion of
extraneous cDNA.
Schematic diagrams of these vectors are shown in Chapter 4 Fig. 4.1.
Vectors were digested with restriction enzymes as required and
dephosphorylated by addition of 10 units calf intestinal phosphatase for the last
30min of the digestion. Cut vectors were purified by electrophoresis on 1.0%
low gelling temperature (lgt) agarose gels. Bands were excised and the DNA
either purified by extraction (see Sect. 2.3) or stored in lgt at -20°C.
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2.6.2 Bacterial host strains (Messing, 1979; Yanisch-Perron, 1985)
pTZ18R and pTZ19R vectors were propagated in E.coli strain JM101 (supE, thi,
A(lac-proAB), [F\ traD36, proAB, laclQZ AM15]).
pOGS40, pMA5620 and pUG41S vectors were propagated in E.coli strain JM83
(ara, A(lac-proAB), rpsE(=strA), §80, lacZAM15).
2.6.3 Media for bacterial growth
Luria-Bertani broth (LB) consisted of 1% (w/v) Bacto-tryptone; 0.5% (w/v) Bacto-
yeast extract; 0.171M NaCl; pH7.5.
LB plates were made with the addition of 1.5% nutrient agar.
Selective medium was supplemented with 150fig/ml ampicillin (LB/Amp).
2.6.4 Preparation of competent E coli strains JM101 and JM83
A single colony selected from bacteria streaked on an agar plate was grown
overnight at 37°C in 10ml LB/Amp. 1ml was innoculated into 50ml psi broth
and grown to OD550m)I = 0.3. 5ml was innoculated into 100ml psi broth and
grown to OD550m^ = 0.48 then cooled briefly on ice, centrifuged at 3000g for
lOmin at 4°C and the cells resuspended in 33ml ice cold Transforming buffer I
(TfBI) on ice for 15min. Cells were again spun then resuspended in 4ml
Transforming buffer II (TfBII) on ice for 20min. 200|il aliquots were snap frozen
with liquid nitrogen and stored at -70°C.
psi Broth: tryptone 2% w/v; yeast extract 0.5%; 20mM Mg2S04; lOmM NaCl;
5mM KC1.
TfBI: 35mM NaOAc; lOmM CaCl2; 15% w/v glycerol; lOOmM RbCl;
200mM MnCl2; pH 5.9.
TfBII: lOmM morpholinopropane sulfonic acid; lOmM RbCl; 80mM CaC12;
15% glycerol; adjusted to pH6.8 with KOH.
2.6.5 Transformation of competent E. coli
50-200ng vector or vector construct was added to an aliquot of bacteria,
incubated on ice for 30min, heat shocked 90 seconds at 42°C then cooled briefly
on ice. 900(il filtered LB was added and the tubes incubated on their sides at
37°C for 60min without shaking. Bacteria were pelleted, resuspended in lOOjil
LB, plated onto LB/Amp plates and incubated at 37°C overnight. Plates for
growth of JM101 transfected with pTZ also contained 400mg/l X-Gal and
168mg/l IPTG (Northumbria Biologicals Ltd) for blue/white colour selection.
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2.6.6 DNA ligations
2.6.6.1 End-filling and phosphorylation of PCR products
cDNA (<lpg) was incubated with ImM TrisHCl pH7.5, 700pM (3-
Mercaptoethanol, 700pM MgCl2, lOOmM each dNTP and 4 units Klenow DNA
polymerase for 30min at room temperature to fill in any protruding ends present
after PCR. The reaction was stopped by heating at 70°C for lOmin then allowed
to cool to 37°C. To phosphorylate the 5' termini, ImM ATP and 20 units T4
polynucleotide kinase were added and the reaction incubated for 30min. After
addition of 20mM EDTA to stop the reaction, the cDNA was phenol extracted
and electrophoresed through low gelling temperature agarose. The required band
was excised and the DNA either stored at -20°C in lgt agarose or extracted by
absorption to silica (Sect. 2.2.2.3) prior to storage.
2.6.6.2 Ligations into pTZ18R and pTZ19R phagemid vectors
Phosphorylated PCR product was blunt-end ligated into Smal cut
dephosphorylated pTZ18R using a range of insert:vector ratios from 1:3 to 3:1
(w/w) in 'blunt-end ligation buffer' (50mM TrisHCl pH7.5; lOmM MgCl2; 5%
PEG6000; ImM ATP; ImM DTT). 4 units T4 DNA ligase were added and the
ligation incubated at 12°C for 16h. The reaction was stopped by heating to 70°C
for lOmin.
For placing inserts in the opposite orientation, selected pTZ18R clones were
digested with ECoRI and Hindlll restriction enzymes and the recovered purified
inserts ligated into pTZ19R as above but in 'cohesive-end ligation buffer', buffer
for use iwth T4 ligase, supplied by Amersham pic.
Ligation products were phenol extracted, resuspended in TCM (lOmM TrisHCl
pH7.0; lOmM CaCl2; lOmM MgCl2) and used to transform E. coli JM101
bacteria.
2.6.6.3 Ligation into pOGS40 expression vector
Varying ratios of dephosphorylated pOGS40 and phosphorylated PCR product,
both BamHI digested, were ligated in 'cohesive-end ligation buffer' When
ligating insert which had previously been excised from pTZ18R by digestion
with BamHI, the insert was gel purified twice and phenol extracted prior to
ligation into BamHI digested pOGS40. Ligation products were phenol extracted,
resuspended in 20(il TCM and used for transformation of E coli JM83 bacteria.
2.6.6.4 Ligations in low gelling temperature (lgt) agarose
Lgt samples containing the required DNAs were melted at 56°C and aliquots
transferred to 37°C (<25pi total vol.). Ligation buffer and enzyme were added
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and the samples incubated at 15°C for 16h. The reaction was stopped by heating
to 65°C for lOmin. Ligated products were hot phenol extracted, ethanol
precipitated and resuspended in 20|il TCM. Aliquots were used to transform E.
coli.
2.6.7 Selection of positive colonies
2.6.7.1 Plasmid miniprep
JM101 colonies positive for vector insert were detected on the basis of
chromatic selection on LB/Amp plates containing X-gal and IPTG (Sect. 2.4.5).
White colonies were grown to stationary phase in 10ml LB/Amp. Cells were
pelleted and resuspended in 200(_il TE pH8.0. An equal volume of phenol was
added and the DNA extracted and precipitated as normal. DNA was digested
with ECoRI and Hindlll restriction enzymes to yield vector and insert, which
were visualised on 1.2% agarose gels. Southern blot hybridisation with 32P-
dCTP labelled PCR product confirmed the presence of correct insert.
2.6.7.2 Colony hybridisation (Buluwela et al., 1989)
Colonies were replica plated onto three LB/Amp plates and incubated 24h. One
plate was kept sterile and colony lifts were taken off the other two by carefully
pressing a nylon hybridisation membrane on to the surface of the plate and
marking the orientation. After 3min the filter was lifted off and placed face up
on Whatman 3MM filter paper sheets soaked with 2 x SSC; 5% SDS as
lysis/denaturing solution, for 2min. The filter was then microwaved for 2.5min
at 650W ensuring that there was just enough liquid to prevent charring. Filters
were soaked in 5 x SSC; 0.1 %SDS and hybridised following the standard
method. Insert sizes in positive transformants were determined by restriction
enzyme digestion of plasmid minipreps as above.
2.6.8 Large scale plasmid preparation and CsCl purification of DNA
(Maniatis, 1987)
A single colony containing the required vector was grown to stationary phase in
10ml LB/Amp then subcultured in 500ml of the medium at 37°C for 16h with
vigorous shaking. Pelleted cells were resuspended in 10ml Solution I (50mM
glucose; lOmM EDTA; 25mM TrisHCl pH8.0; with lOmg/ml lysozyme added
immediately before use) for 5min at RT. 20ml fresh Solution II (0.2N NaOH;
1% SDS) was added and left on ice for lOmin. 15ml 5M potassium acetate
pH4.8 was added and the tubes incubated on ice for a further lOmin then
centrifuged at 5000g for at 4°C 20min. Isopropanol at 6:10 (v/v) was added to
precipitate the DNA. After 15min at room temperature the DNA was pelleted,
washed with 70% ethanol, dried and resuspended in TE pH8.0 in a total volume
of 30ml.
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The DNA was purified on a CsCl gradient as follows: 30g baked CsCl and
2.4ml of lOmg/ml Ethidium Bromide were added to the DNA and the
preparation centrifuged in a polypropylene tube at room temperature for 16h at
40,000rpm using a VTi50 vertical rotor. The DNA was visible as a bright orange
band when viewed under UV and could easily be removed by puncturing the
tube with a needle attached to a 5ml syringe and withdrawing the DNA. The
EtBr was removed from the DNA by repeated extractions with iso-amyl alcohol.
DNA was precipitated from the aqueous CsCl by addition of 2.5 volumes of
70% ethanol then resuspended in TE pH8.0, precipitated with ethanol and
0.25M Na acetate pH5.2, washed with 70% ethanol and finally resuspended in
water.
2.7 DNA Sequencing
2.7.1 Preparation of Single-stranded DNA
A 10ml culture of transformed E. coli JM101 or JM83 was grown overnight in
LB/Amp. 500[il was sub-cultured in 10ml 2 x YT (3.2% Tryptone; 2% yeast
extract; 86mM NaCl; pH7.4 with KH2P04) supplemented with 150pg/ml
ampicillin until reaching OD660m^ = 0.6. 400pl of this culture was infected with
2xl08 M13K07 helper phage (bacteria:M13 = 1:10) and shaken vigorously at
37°C for 1 hour. 10ml 2 x YT and 73mg Kanamycin were added and the culture
incubated overnight at 37°C with shaking. Cells were pelleted at 3000g for
lOmin. To isolate the phage, 2.5ml 20% PEG6000 in 3.5M NaCl was added to
the supernatant, incubated on ice >30min and the precipitated particles pelleted
at 11000 x g for 40min at 4°C. Care needs to be taken in removing all the PEG
supernatant as traces of PEG can be inhibitory to some enzymes. The pellet was
resuspended in 400pl NTE pH8.0 with vortexing, phenol extracted twice and
ethanol precipitated and finally resuspended in H20 at lpg/pl.
2.7.2 Sequencing Reactions
All sequencing reaction were based on the dideoxy chain termination method of
Sanger et al, 1977.
2.7.2.1 Sequencing using Sequenase T7 DNA Polymerase (USB)
Sequencing reactions were carried out using a Sequenase version 2.0 kit (USB
Corporation) and [a-35S]dATP but with slight modifications of the
recommended procedure, as detailed below. Either Ml3 reverse primer
(Pharmacia) or specific PCR primers were used. To anneal primer and template,
2-3\ig single-stranded Ml 3 cDNA, >5fig double-stranded pOGS40 or 600ng
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PCR product in 7|il was boiled for 2min with lpl primer (at a 1:1
template:primer stoichiometric ratio) and 2ji.l reaction buffer, then snap cooled
on ice. Chain elongation and dideoxy termination reactions were carried out as
per the protocol supplied with the kit except that terminations were incubated at
56°C. Reaction mixes could be stored at -20°C for short periods.
2.7.2.2 Sequencing using Taq Polymerase (modified from Innis et al., 1988)
6.5|il single-stranded cDNA (~3pg) was boiled for 3min with 30mM PCR
primer and 2pl 10 x Ohara buffer (Sect. 2.3.7) then snap cooled. 2jil labelling
mix, 7pi enzyme dilution buffer (lOmM TrisHCl pH8.0 containing 0.5% Tween
20 and 0,5% Nonidet) and lpl [a35S]-dATP were added on ice and the tube
warmed to 37°C. 2.5 units7a<? polymerase were added and incubated for 2min at
37°C. Termination mixes were overlaid with oil and prewarmed at 70°C.
Extension reactions were terminated by transferring 4pl of the extension reaction
to each 2pl termination mix and incubating at 70°C for 2min. 2pl stop solution
from the sequenase kit was added to stop the reaction.
Labelling mix: lOpM dGTP; 7.5pM dCTP; 7.5pM dTTP in lOmM TrisHCl pH8.0
Termination mixes: ddA: 30pM each dNTP; l.OmMddA; 1.12mMMgCl2
ddC: 30pM each dNTP; 0.5mMddC; 0.62mMMgCl2
ddG: 30pM each dNTP; 0.25mMddG; 0.37mMMgCl2
ddT: 30pM each dNTP; 1.5mMddT; 1.62mMMgCl2
2.7.3 Denaturing Polyacrylamide Sequencing Gels
6% acrylamide (19:1 acrylamide:bisacrylamide w/w) gels containing 7.67M urea
were run at 56°C in 0.5 x TBE using Bio-Rad Sequi-Gen apparatus. The glass
plates were sealed at the base with 35ml 6% acrylamide plus 210pl 25%
ammonium persulphate (AP) and 150pl TEMED (Tetramethylene-ethylene
diamine). Acrylamide solutions for the slab gel were degassed under vacuum
and filtered through a 0.45mM filter immediately prior to adding lOOpl each of
AP and TEMED and casting the gel. Gels were pre-run at 2700V for about
45min until the temperature reached 56°C. Samples were heated to 80°C for
5min. Urea was washed out of the wells using a syringe and up to 5pl of sample
loaded per well. Gels were run for 2-8h depending on the resolution required.
After drying under vacuum at 80°C for 2h, gels were exposed on Kodak XAR-5
film for a minimum of 12h at room temperature.
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2.8 Expression of Recombinant Proteins in Saccharomyces cerevisiae
2.8.1 Standard Media and Solutions (Kingsman et al., 1990)
a. YEPD: 2% (w/v) peptone; 1% (w/v) yeast extract; 2% (w/v) glucose.
b. Synthetic complete-glucose medium (Sc-glc): 0.67% (w/v) yeast nitrogen
base without amino acids; 1% (w/v) glucose. Appropriate amino acids
added after autoclaving.
c. Sc-glc/gal medium: 0.67% (w/v) yeast nitrogen base without amino
acids; 0.3% (w/v) glucose; 1% (w/v) galactose. Appropriate amino
acids were added after autoclaving.
d. Glycerol stocks: yeast strains were stored at -70°C in Scglc;20%
glycerol.
e. Amino acids: Tryptophan, uracil and leucine all used at 20mg/l.
f. Agar plates: 2% (w/v) nutrient agar was added to the medium prior to
autoclaving.
g. TEN buffer: lOmM TrisHCl pH7.4; 2mM EDTA; 140mM NaCl.
h. Acid washed glass beads: Glass beads, 40 mesh (BDH), washed in
concentrated sulphuric acid, rinsed 10 times in tap water and ten
times in distilled water, dried and baked at 150°C for 2h.
2.8.2 Yeast Strains
The protease deficient Saccharomyces cerevisiae strain BJ2168 (a, leu2=, trpl~,
ura3-52, prbl-1122, pep4-3, pcrl-407, gal2) (Jones, 1991) was transformed to
leucine and uracil independence with pOGS40 plasmid constructs in the
presence or absence of pUGS41S plasmid using the method of Hinnen et al.,
1978.
2.8.3 Yeast Transformation
All manipulations were carried out aseptically.
Untransformed yeast from glycerol stocks stored at -70°C was inoculated into
100ml YEPD, grown overnight at 30°C then subcultured to a density of
>1.5xl07 cells/ml (OD600nm -0.7). Cells were harvested at 3.500g for 5min at
room temperature, washed with 20ml 1M sorbitol and resuspended in 10ml 1M
sorbitol pH5.6. 200|ri glusulase (du Pont) was added and incubated at 30°C for
2h with occasional gentle shaking. The extent of spheroplasting was determined
by mixing lOOpl cell suspension with 1ml water and observing under a light
microscope. Spheroplasts remain intact in sorbitol but burst in water. The very
fragile spheroplasts were carefully washed twice with 10ml sorbitol and once
with 10ml STC solution (1M sorbitol; lOmM CaCl2; lOmM TrisHCl pH8.0)
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then resuspended in 1ml STC. 2-3pg DNA, (or 2-3(Jig of each DNA construct in
the case of double transformants with pUG41S vector), was added to lOOpl
competent cells, mixed by gentle flicking and incubated at room temperature for
15min. The total volume of DNA added must be less than 15pi in order to
maintain osmolality. 1ml 44% PEG4000 was added, mixed by inversion and
gently flicking and left at room temperature for lOmin. Cells were harvested
gently using the pulse button on a microfuge and resuspended in 1ml 1M
sorbitol then added to 20ml warm (not >48°C) regeneration agar (Sc-glc agar
with added 1M sorbitol and amino acids). After gentle mixing, the agar was
poured into petri dishes and incubated inverted at 30°C until colonies became
visible (5-10days). Individual transformants were streaked on selective Sc-glc
plates containing appropriate amino acids and re-incubated.
2.8.4 Storage of Yeast Transformants
50ml Sc-glc medium plus amino acids, was inoculated with a single colony and
incubated with vigorous shaking at 30°C until a concentration of 2-4 x 107
cells/ml was achieved. An equal volume of 40% glycerol was added and 1ml
aliquots frozen at -20°C for 2h before being transferred to -70°C for long term
storage.
2.8.5 Validation of Glycerol Stocks for PI or PI-Fusion Protein
2.8.5.1 Constitutive Expression of PI vlps (pMA5620 derived plasmid)
50ml Sc-glc plus 20mg/ml each tryptophan and uracil was inoculated with a
glycerol aliquot and shaken vigorously at 30°C for 2-3 days. 5 x 108 cells were
harvested at 3500 x g for 5min and resuspended in 1ml TEN buffer, lg acid
washed glass beads were added and the cells disrupted by vortexing 3x1
minute, cooling on ice for 1 minute in between. lOpl aliquots were analysed by
electrophoresis through 10% PAGE gels and blotting against anti-Pi antiserum
(Sect. 2.9).
2.8.5.2 Galactose Induced Expression of IL-1:P1 vlps (pOGS40
constructs ± pUG41S plasmid)
50ml Sc-glc plus 20mg/ml tryptophan was innoculated with a glycerol aliquot
and incubated at 30°C for 2-3 days. Cells were spun down, resuspended in 50ml
Sc-glc/gal with tryptophan and shaken a further 24h. 5 x 108 cells were
harvested and treated as above.
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2.8.6 Large Scale Culture of Recombinant Proteins
2.8.6.1 Constitutive Expression
100ml Sc-glc plus tryptophan and uracil was inoculated with the selected
transformant and shaken vigorously on a flat bed rotator at 30°C for 48h. 2 x 11
medium were inoculated with 50ml preculture and grown a further 24h to (~5 x
107cells/ml). Cells were harvested, washed four times with SDW and once with
TEN then either used immediately or stored as a pellet at -20°C in Falcon tubes.
2.8.6.2 Inducible Expression
100ml Sc-glc plus 20mg/ml tryptophan was innoculated with the selected
transformant and shaken vigorously at 30°C for 48h. The preculture was
inoculated into 11 medium and grown until cell numbers were about 4 x 107 per
ml. 250ml of the culture was innoculated into each of 4 x 11 Sc-glc/gal plus
tryptophan and shaken for 48-66h depending on the transformant. Cells were
harvested, washed four times with SDW and once with TEN, then either used
immediately or stored as a pellet at -20°C.
2.8.7 Purification of Recombinant Proteins
2.8.7.1 Preparation of vlps
Harvested cells were transferred to 30ml Corex tubes (5-7ml cells per tube) and
resuspended in 4ml ice cold TEN buffer. 5ml acid washed glass beads were
added and the tubes vortexed for 10 x 30sec periods interspersed with 30second
periods of cooling on ice. The suspension was centrifuged at 2000 x g for 5min
and the supernatant transferred to 30ml Oakridge tubes on ice. The pellet was
revortexed with 4ml fresh TEN buffer, respun and the supernatant added to the
Oakridge tubes. The cracking procedure was repeated with a further 3ml TEN
buffer. Pooled supernatants were centrifuged at 30,000 x g for 20min. The
resultant supernatant was layered over 60% (w/v) sucrose/TEN and centrifuged at
100,000 x g for 90min. The interface band and cushion were either collected
separately or pooled, depending on the protein, and dialysed overnight into fresh
TEN buffer. Any flocculant precipitate was removed from the dialysate by
centrifugation at 13,000 x g for 20min.
2.8.7.2 Purification of vlps by Sucrose Density Gradient Centrifugation
Sucrose gradients in TEN buffer were prepared by carefully layering sequential
8ml volumes of cold 45%, 35%, 25% and 15% sucrose into 40ml Beckman
ultraclear centrifuge tubes and allowing a linear gradient to develop by diffusion at
4°C overnight. Immediately before use, a 2ml 60% sucrose cushion was layered
under the gradient using a pasteur pipette. Gradients were loaded with up to 4ml of
vlp containing dialysate and centrifuged in an SW28 rotor for 3h at 25,000rpm..
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Sequential 2ml fractions were removed from the top of the gradients and stored at
4°C. The distribution of vlps across the gradient was assessed by running 5-10fil
samples from each fraction on 10% SDS/PAGE gels and staining with coomassie
blue (see Sect. 2.9.2). Protein concentrations in each fraction were determined by
Bio-Rad assay (see Sect. 2.9.4).
2.8.7.3 Cleavage of Fusion Proteins with Restriction Protease Factor Xa (FXa)
Selected gradient fractions were dialysed into Factor Xa buffer (lOmM CaCl2;
lOOmM TrisHCl pH7.6) at 4°C. Expressed protein was released from vlps by
digestion at 25°C with FXa (1:100 w/w) in the presence of added 0.02% DOC
(NaDeoxycholate) and 0.02% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulphonate). Cleaved vlps were removed by centrifugation at 40,000 x g
for 90min and the recombinant protein dialysed into PBS containing 0.1% Na azide
and stored at 4°C or -70°C.
2.8.7.4 Purification of Recombinant Proteins by Ion Exchange HPLC
Cleaved vlp preparations were dialysed into 20mM TrisHCl pH8.0. <5ml samples
at ~4fig/ml were purified by HPLC using an ion exchange column at a flow rate of
lml/min. Separation was achieved by use of a 0-300mM NaCl gradient in 20mM
TrisHCl pH8.0. 500pl fractions were collected. 50pl aliquots of these fractions
were precipitated overnight with 300pl cold acetone and analysed by 15%
SDS/PAGE gels (Sect. 2.9). Selected fractions were iodinated or biotinylated
(Sect. 2.14.1.2).
2.9 Analysis of Recombinant Proteins by SDS-PAGE
2.9.1 Sample Preparation
Samples and molecular weight markers (Pharmacia, used at 6pg per well), were
prepared by boiling for 3min in sample buffer (150mM P-mercaptoethanol; 15%
glycerol; 0.05% SDS; 0.005% (w/v) bromophenol blue; 50mM TrisHCl pH6.8).
2.9.2 Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Proteins were analysed by discontinuous polyacrylamide gel electrophoresis run
under reducing conditions (Laemmli, 1970) using Bio-Rad Mini-protean II
vertical slab gel apparatus.
A stock solution of 30% aerylamide:0.8% bisacrylamide was diluted as required
in 250mM TrisHCl pH8.7 containg 1.3mM EDTA and 0.1% SDS. Gels were
polymerised by addition of 0.5% ammonium persulphate and 0.05% Temed.
The stack gel solution consisting of stock acrylamide diluted to 3.5% with
0.145M TrisHCl pH6.8 containing 0.1% SDS, 0.05% ammonium persulphate
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and 0.1% TEMED was overlaid on the separating gel. After gel polymerisation,
samples were electrophoresed at 200V in 25mM TrisHCl containing 6mM
EDTA, 0.1% SDS and 156mM glycine.
2.9.3 Detection of Protiens within PAGE Gels
2.9.3.1 Staining PAGE Gels with Coomassie Blue
Gels were stained with coomassie brilliant blue G-250 or coomassie blue R
(0.25% (w/v) coomassie blue; 20% methanol; 5% acetic acid), destained with
20% methanol; 5% glacial acetic acid and dried onto Whatmans 3MM
filterpaper under vacuum at 80°C.
2.9.3.2 Staining PAGE Gels with Silver Nitrate
Gels were rinsed with de-ionised water then fixed sequentially with; (i) 50%
methanol; 10% acetic acid for 15min, (ii) 5% methanol; 7% acetic acid for
30min, (iii) 10% glutaraldehyde for 30min. Fixed gels were washed in several
changes of distilled water over a few hours. Gels were stained with 0.1% w/v
silver nitrate for 15min, rinsed briefly with water and developed with 2.6% w/v
sodium carbonate in 0.02% formaldehyde. The reaction was stopped by addition
of solid citric acid. Gels were washed well with water, fixed in 10% Ilfofix for
exactly 1 minute, rinsed briefly and dried under vacuum at 80°C.
2.9.4 Estimation of Protein Concentration
Vlp concentrations were determined using a dye-binding assay (Bradford, 1976)
obtained from Bio-Rad Laboratories.
Where recombinant protein concentrations were below the limits of detection of
the assay, sample dilutions were run alongside protein standards on SDS-PAGE
gels and the protein concentrations estimated from the relative staining
intensities on coomassie and silver stained gels.
2.9.5. Electroblotting PAGE Gels
After electrophoretic separation on SDS-PAGE gels, proteins were transferred to
Amersham Hybond C nitrocellulose membranes using a semi-dry electroblotter
(Ancos, Denmark) according to Khyse-Andersen (1984). Transfer was achieved
by electroblotting for 45min at 120mA between sheets of Whatman 3MM paper
soaked in 25mM TrisAc; 20% methanol. The molecular weight marker track
was cut off, stained with 5% amido black and destained with 50% methanol; 5%
acetic acid.
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2.9.6 Western Blot Analysis of Proteins
Membranes were 'blocked' with 5% non-fat dried milk in PBS for 4h at room
temperature then incubated with primary rabbit antibody diluted in 1%
milk/PBS for a further 20h at 4°C. Blots were washed with several changes of
1% milk/PBS over 30min at room temperature. The primary antibody was
detected by incubation with anti-rabbit IgG alkaline phosphatase conjugate
(Sigma) in 1% milk at room temperature for 60min. Excess reagents were
removed by washing with several changes of 1% milk/PBS then twice with
0.1M TrisHCl pH9.5. Immunoblots were developed in 0.1M TrisHCl pH9.5
containing 0.2mg/ml Nitroblue tetrazolium (NBT), O.lmg/ml Bromo-chloro-
imidolyl-phosphate toluidine salt (BCIP:- stock solution lOmg/ml in dimethyl
formamide, stored at -20°C) and 0.2mM MgCl2. The reaction was stopped with
water and blots were air dried.
2.10 Transmission Electron Microscopy (TEM)
2.10.1 Preparation of Yeast Cells for TEM
Fixation of yeast cells: 25ml of stationary phase yeast culture was centrifuged at
2500 x g for 5min at 4°C. The cell pellet was resuspended in 5ml
cacodylate/glutaraldehyde buffer (0.1M Na cacodylate pH6.8; 5mM CaCl2; 3%
glutaraldehyde), incubated 30min at room temperature, spun down, resuspended
in 10ml buffer and mixed on a rotator at 4°C for 20h. Cells were washed twice
with 10ml pretreatment buffer (0.2M TrisHCl pH8.1; 20mM EDTA; 0.1M
pmercaptoethanol, spun down and resuspended in 5ml 0.2M phosphate-citrate
buffer pH5.8 containing 250(il glusulase (du Pont). After 60min at 30°C cells
were checked for spheroplasting by resuspension in water. Spheroplasted yeast
cells were washed twice with 10ml phoshate-citrate buffer and resuspended in
5ml of this buffer. Post fixation, the cells were incubated in cacodylate buffer
containing 2% osmium tetroxide on ice for 60min, rinsed with water, incubated
in 2% aqueous uranyl acetate at 20°C for 60min. Samples were dehydrated
through graded acetone solutions and embedded in araldite resin. Ultrathin
sections were examined using a Phillips TEM 400 operating at lOOkV.
2.10.2 Negative Staining of Ty-vlps for TEM
A drop of vlp containing sample was placed on a plastic coated TEM grid and
allowed to dry partially for 15 seconds. It is important that the vlps be allowed
to adhere to the grid without the sample drying out. The grid was washed 3
times with 1 drop of water and partially dried. The sample was fixed with 1 drop
of 2% aq. uranyl acetate. Samples were examined directly by TEM.
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2.11 Assessment of Recombinant IL-1 Bioactivity
2.11.1 In vitro Thymocyte Co-mitogen Assay
Thymocytes were gently teased out of a fresh thymus into RPMI medium
supplemented with 10% foetal calf serum, 5mM L-glutamine, 100 U/ml
benzylpenicillin and 100 U/ml streptomycin. The suspension was depleted of cell
clumps by sedimentation under gravity for 5min. Cells were centrifuged at 1500
x g for 5min at 4°C, washed twice with RPMI;10%FCS medium plus 50mM (3-
mercaptoethanol (RPMI10ME) and resuspended in RPMI10 me at 4xl06 cells/ml.
IL-1 containing samples were diluted in PBS. Phythemagglutinin (PHA) as co-
mitogen was diluted in RPMI10 me. 200|il cultures containing 1 x 106 cells,
100pl sample and 9pg/ml PHA were established in triplicate in 96 well tissue
culture plates (Nunculon, Denmark). Negative controls were established by
substituting sample with PBS or PHA with medium. Proliferation assays were
incubated at 37°C in a humidified atmosphere of 5% C02/95% air. After 48h,
assays were pulsed with lfiCi 3H-thymidine (sp. activity 2Ci/mMole,
Amersham) for 20h. Cells were collected onto glass-fibre filter paper using a
semi-automated harvester and incorporated 3H-thymidine estimated by liquid
scintillation counting.
For neutralisation assays, rIL-1 was pre-incubated in the culture plates at 37°C
for lh (as recommended for comercial anti-EL-1 antisera), either with or without
heat inactivated polyclonal antiserum in a total volume of lOOjil. Thymocytes
and PHA were then added and the assay carried out as above. Negative controls
were established by pre-incubating antiserum with medium.
2.11.2 In vitro Cartilage Degradation Assay
1mm x 2mm discs, cut from fresh ovine xiphoid cartilage were washed with
DME medium supplemented with 5% foetal calf serum and 100 U/ml penicillin
and streptomycin (DME5). Discs were cultured individually in DME5 in 96 well
culture plates (Nunculon) at 37°C in a humidified atmosphere of 5% C02/95%
air. After 40h, the medium was replaced with lOOpl fresh medium and
quadruplicate cultures established by addition of 50p,l sample in PBS. Negative
controls were established by substitution of sample with PBS. Release of
glycosylaminoglycans (gags) was measured after 30h incubation. An aliquot of
culture supernatant was added to 0.0018% (v/v) dimethylmethylene blue dye in
formate buffer (0.21% (v/v) formic acid; 0.2% (w/v) Na formate; 0.5% ethanol)
and OD535m|X read within lOmin. The amount of gags present was read off a
standard curve constructed using fresh shark chondroitin sulphate solutions.
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2.12 Production of Polyclonal Rabbit anti-ovine-IL-1 Antiserum
Polyclonal antisera were raised in rabbits against recombinant ovine IL-1, yeast
PI and Factor Xa. Rabbits were injected with 10-20fig antigen in complete
Freund's adjuvant and boosted at intervals with 5-10|ig antigen in incomplete
Freund's adjuvant. Animals were exsanguinated by cardiac puncture. Sera were
heat inactivated by incubation at 56°C for lOmin and stored in aliquots at -20°C.
2.13 Ovine Afferent Lymph
2.13.1 Antigenic Stimulation of Sheep and Cannulation of the Afferent
Lymph Ducts
Pseudo-afferent lymphatic cannulations were performed by Dr. John Hopkins
(Department of Veterinary Pathology, University of Edinburgh) as described by
Hall, 1967. Prefemoral lymph nodes were excised at least eight weeks prior to
cannulation to allow the afferent and efferent lymphatic vessels to re-anastamose
after removal of the node. Sheep were simultaneously immunised with lmg
ovalbumin injected over two sites intramuscularly in a 1:1 mixture of PBS and
complete Freund's adjuvant or 9% Alum and subsequently boosted with 500|ig
ovalbumin, administrated intravenously in PBS after 4-6 weeks. Cannulated
sheep were kept in standard pattern metabolism cages and fed water and hay ad
libitum.
2.13.2 Establishing a Positive Response to Ovalbumin by in vitro
Proliferation of PBMC from Ovalbumin Primed Sheep
Peripheral blood from ovalbumin-primed sheep was obtained by venipuncture
and collected into preservative free heparin at a concentration of 10 units per ml
of blood. White blood cells, buffy coated by centrifugation at 1300 x g for
20min at 20°C were diluted 1:3 with sterile PBS and centrifuged over
lymphoprep (Nyegaard, Norway) at 850g for 20min at 20°C. Mononuclear cells
isolated from the interface were washed once with fresh PBS and twice in
RPMIio me- Cells were harvested by centrifugation at 250 x g for 4min at 4°C
between each wash step. 1 x 105 cells/well in RPMI10 me were cultured in 96-
well flat bottomed micro-culture plates (Nunclon, Denmark) with addition of
various concentrations of antigen in a total volume of 200ql. Cultures were
established in triplicate. Positive and negative controls were established by
substituting antigen with either Con A (20pg/ml; 6.7(ig/ml; 2.2|ig/ml) or
medium respectively. The proliferation assays were incubated at 37°C in a
humidified atmosphere of 5% C02/95% air for 5 days and pulsed with lpCi 3H-
thymidine (specific activity 2Ci/mMole, Amersham) over the final 7h. Cells
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were collected onto glassfibre filter paper using a semi-automated harvester and
3H-thymidine estimated by liquid scintillation counting.
2.13.3 Isolation of Afferent Lymph Cell Populations
Pseudoafferent lymph was collected into sterile 250ml plastic bottles containing
2.5xl03 units of heparin and 2.5X104 units each of penicillin and streptomycin.
Cells were washed and resuspended in cold Iscoves serum free medium. 2ml
medium containing <2 x 108 cells was layered over a discontinouus gradient of
2ml 20% metrizamide (Nycomed, Oslo, Norway) and 3ml 14.5% metrizamide in
Iscoves and centrifuged at 1500 x g for 20min at 4°C. The upper and lower
interface populations were collected separately, washed twice with 20ml cold
PBA (PBS; 0.1% BSA; 0.1% Na azide) and resuspended in PBA at 8 x 106 per
ml.
2.13.4 Analysis of Cell Populations by Cytochemical Staining
2.13.4.1 Preparation of Cytospins
Cells were applied to acid washed poly-L-lysine coated glass slides by
centrifugation at 350g for 6min at room temperature. Cells were fixed and the
slides either used immediately or stored in an airtight container at -20°C.
2.13.4.2 Giemsa Stain
Cytospun cells were fixed in cold acetone then stained for 5min in 2% (v/v)
Giemsa stain. Slides were destained in water.
2.13.4.3 Leishman's Stain
(Darmady and Davenport, 1963)
Cytospun cells were acetone fixed. A stock solution of Leishmans stain (1%
Grubler's methylene blue in H20; 0.5% Na carbonate; 0.1% Grubler's eosin extra
B in methyl alcohol) was diluted with 2 vols H20 for use. Slides were stained for
5min and destained with water.
2.13.4.4 Acetylcholinesterase Stain for Ovine Langerhans' Cells
(Adapted from Hollis and Lyne, 1972).
Cytospins were acetone fixed. Slides which had been stored at -20°C were
incubated in 0.22M sucrose at room temperaturefor a few minutes prior to
staining. Cytospins were incubated at 37°C for 70min in incubation medium (see
below), washed twice with distilled water then incubated for 5min at room
temperature in lOmM ammonium sulphide. Slides were washed twice with
distilled water, counterstained with methylene blue for 75sec, rinsed and
mounted.
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Incubation medium: (It is important that the ingredients are added in order)
50mg acetylthiocholine iodide
65ml sodium hydrogen maleate buffer pH7.2 (32mM NaOH; 5.3mg/ml maleic acid)
5ml sodium citrate (24.9mg/ml)
10ml CuS04 (7.47mg/ml)
10ml water
10ml potassium ferricyanide (1.65mg/ml)
7.5g sucrose
Methylene blue: 3ml saturated methyl blue in alcohol plus 10ml 0.01% KOH in water.
2.13.4.4 Non-specific Esterase Stain for Macrophages
(Hudson and Hay, 1989)
Cytospun cells were fixed at 4°C for 2min in 30mM Phosphate pH6.6
containing 9.25% formaldehyde and 45% acetone then washed with water.
Fixed cells were incubated at 37°C for 45min with activated hexazotised
pararosaniline (1.5% w/v pararosaniline; 75mM HC1; 0.12% w/v Na nitrite in
67mM phosphate pH5.8) containing 0.025% a-naphthyl acetate (2.5% w/v in
acetone) then counterstained for lOmin with 0.4% aqueous methylene green.
Excess stain was removed by washing with water.
2.13.5 Analysis of Ceil Populations by Immunofluorescence
Surface markers for macrophages and afferent lymph dendritic cells were
detected by incubation with mouse anti-sheep monoclonal antibodies which
were available in the department. These were used in order to be able to
distinguish between these two cells types within afferent lymph populations.
2.13.5.1 Immunofluorescence Analysis
Fluorescence analysis was carried out using a Becton Dickinson FACScan
which allowed measurements to be made on homogeneous populations of cells
by setting electronic gates in order to 'isolate' cells with particular forward and
side scatter profiles (FSC and SSC respectively). 104 cells were analysed per
sample. The fluorescence profile is displayed as a histogram representing
fluorescence intensity vs. relative cell number. Positive flourescence due to
binding of a monoclonal antibody to its specific ligands is indicated by a shift to
the right relative to background fluorescence intensity.
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2.13.5.2 Monoclonal Antibodies
Monoclonal antibodies used in this study are detailed in Table 2.1. Isotype and
specificity are included.
TABLE 2.1
Monoclonal antibodies used for assessing the surface phenotype
of alveolar macrophages and afferent lymph cell populations
Antibodv Specificity Isotvpe Reference
SBUT4 ovine CD4 !gG2a Maddox et al., 1985
SBU T8 ovine CD8 IgG2a Maddox et al., 1985
CC14 ovine CD1 IgGi MacHugh et al., 1988
VPM5 ovine CD1 IgM Bujdoso et al., 198
VPM13 ovine p-chain IgM unpublished
VPM32 ovine IgG2a Gonzales, 1991
VPM54 ovine DRa IgGi Dutia et al., 1993
VPM65 ovine CD14(?) IgGi V Gupta, personal
communication
1D10 EV1 p25 IgGi Reyburn et al., 1992
2.13.5.3 Immunofluorescence Staining
Cell surface phenotype was assessed using 2 x 105 cells. Washed cells were
resuspended in 25pl PBA and incubated with 25|il primary antibody at the
appropriate dilution for 30min on ice. Saturated supernatants were used neat and
ascites fluid at a dilution of 1 in 500. Unbound antibody was removed by
washing with 3 x 1ml PBA. Biotinylated antibodies were detected by incubating
with phycoerythrin conjugated to streptavidin (Serotec, Oxford). Non-
biotinylated antibodies were detected by incubation with 25|il of a 1 in 100
dilution of FITC conjugated F(ab)2 fragment of rabbit anti-mouse
immunoglobulin (Dakopatts, Denmark) for 30min on ice. Cells were washed,
resuspended in 600jil PBA and analysed by flow cytometry.
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2.14 IL-1 Receptor Studies
2.14.1 Labelling Recombinant Proteins
2.14.1.1 Iodination of rIL-1
IL-1 a and IL-1 (3 were iodinated following the Iodobead procedure of Markwell,
1982. lpg protein in either 1ml PBS or 1ml 20mM TrisHCl adjusted to pH7.0,
was incubated for 15min at room temperature with 1 activated Iodobead in a
1.8ml screwtop Eppendorf tube. Unincorporated isotope was removed by
extensive dialysis against PBS:0.1% azide at 4°C. 125I incorporation was
estimated from 10% TCA precipitable counts pre and post dialysis. l|il samples
were added to 500pl PBA on ice. 500|il ice cold 20% TCA was added and the
samples vortexed then left to precipitate on ice for 30min. Samples were filtered
through Whatman GF/C discs and washed with 50ml cold 10% TCA under
suction followed by 20ml absolute ethanol. The precipitated radioactivity on
dried filters was counted in a y-counter. Purity of the samples was visualised by
autoradiography of dried SDS/PAGE gels. Labelled protein was stored at 4°C.
Control pi preparations were similarly iodinated.
2.14.1.2 Biotinylation of rIL-1
IL-1 [3 samples at ~lpg/ml were dialysed into 0.1M NaHC03 pH8.0 at 4°C. To
this was added lOOng biotin in 50pl DMSO and the solution rotated for 4h at
room temperature. The biotinylated protein was dialysed extensively against
PBS then 0.1% Na azide added and the preparation stored in the dark at 4°C.
Because of the very small amounts of protein available for biotinylation, losses
could only be estimated from figures obtained during iodination parallel
iodination procedures.
The purity and extent of biotinylation of IL-1 (3 was assessed by enhanced
chemiluminescence using an Amersham kit. SDS-PAGE gels were
electroblotted and blocked then incubated with biotin:phycoerythrin:streptavidin
complex. The membrane was well washed with PBS containing 0.1% bovine
serum albumin then placed in a suitable container in a photographic darkroom.
To develop the blot, 1ml each of solutions A and B were mixed and placed on
the membrane for exactly lmin then rinsed off with water. The blot was
covered with clingfilm and exposed on Amersham ECL Hyperfilm for l-2min.
The Hyperfilm was developed as normal.
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2.14.2 Detection and Quantitation of IL-1 Receptors on Dendritic Cells and
Lymphocytes within Afferent Lymph and on Alveolar Macrophages
2.14.2.1 Use of 125I-rIL-l Binding to Estimate of IL-1 Receptor Density
2.14.2.1.1 Analysis of Total 125I-IL-1 Bound to Isolated Cell Populations
Isolated cell populations were resuspended in PBA and incubated with 125I-EL-1,
either with or without an excess of unlabelled IL-1, in a total volume of lOOpl in
1.8ml screw-cap Eppendorf tubes. Samples were incubated on a rotating mixer
for 2.5h at 4°C then washed with three 1.8ml volumes of ice-cold PBA,
resuspended in 1 OOfil PBA and layered over 300|il ice-cold phthalate oil (dibutyl
phthalate:bis(-ethylhexyl) phthalate 1.5:1 v/v) in 0.3ml microsedimentation tubes
(Sarstedt Ltd., Leicester). Sample tubes were microfuged at 13500rpm for
1 lOsec at 4°C then frozen in a dry ice/ethanol bath and the tip containing the cell
pellet cut off and counted in a y counter. IL-1 receptor characteristics were
determined by Scatchard analysis of bound 125I-IL-1 (Scatchard, 1949).
2.14.2.1.2 Analysis of Bound 125I-IL-1 at a Single Cell Level by
Radiographic Exposure of Cytospins
Samples were prepared and incubated as above then washed with five 1.8ml
volumes of ice-cold PBA and cytospun at 300g for 6min onto acid-washed glass
slides. Samples were fixed with cold acetone and the slides dipped in Amersham
LM-1 emulsion diluted 1:2 with water. Exposure times varied depending on the
expected signal. Samples were developed by successive dipping as follows:
3min in Kodak D19 developer (reconstituted as per the manufactures
instructions and diluted 1:1 (v/v) with water prior to use); 5 seconds in 1% glacial
acetic acid; rinse with water; 6min in Ilfofix (diluted 1:1 with water prior to
use). Slides were gently rinsed in water over 30min, dried and mounted.
Non-specific esterase staining of cytospins was done prior to dipping the slides
in emulsion whereas Giemsa staining was done after developing the exposed
slides.
2.14.2.2 Detection of IL-1 Receptors by FACScan Analysis of Bound
Biotinylated IL-1(3
All incubations were carried out on ice. 2 x 105 cells in PBA were incubated for
60min with up to 20ng biotinylated-IL-1 in a total volume of 50|il. Unbound
material was removed by washing three times with 1ml PBA. Cells were
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incubated with 25fil of a 1 in 400 dilution of streptavidin/phycoerythrin
conjugate (Serotec, Oxford) for 20min, washed three times and resuspended in
600pl PBA. Bound IL-1 was detected and analysed using a Becton Dickinson
FACScan with gates set as determined in Sect. 2.11.5.
2.15 Equations Utilised During this Thesis
1. Relative centrifugal force (g) = 1.12r(RPM/1000)2 where r is radius of the rotor.
2. Hexanucleotide frequency in random sequence DNA is 1 in 46 (4096) base pairs.
3. For estimating the melting temperature of oligonucleotide / cDNA annealing:
Tm = 3GC + 2AT
with a reduction of 1°C for each expected nucleotide mismatch.
4. For estimating growth of E. coli: 8 x 108 cells/ml =1.0 OD660nm
5. For estimating growth of S. cerevisiae : 5 x 107 cells/ml = 1.5 OD600nm
6. Scatchard analysis of membrane receptor expression (Scatchard, 1949);
Data from 125I-Ligand binding to cells was plotted as 'Bound/Free cpm' vs.
'pg Ligand Bound'.
Receptor sites/cell was calculated from the x intercept and the affinity
constant from the slope of the curve.
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CHAPTER 3
CLONING AND SEQUENCING OVINE
INTERLEI J KIN-lot AND INTERLEUKIN-lft cDNA
INTRODUCTION
At the time this study was initiated, human IL-la and IL-1 (3 and rabbit IL-la
genes had been cloned and fully sequenced (Furutani et al., 1986; Clark et al.,
1986; Bensi et al., 1987) showing that both genes consisted of seven exons with
six introns, spanning primary transcripts of roughly 10,206bp (IL-la) and
7,008bp (IL-1|3). Restriction mapping of human and bovine genomic DNA had
shown both genes to exist as single copies (Furutani et al., 1986; Maliszewski et
al., 1988). A number of IL-1 cDNA sequences had been determined and there
appeared to be a large measure of cross-species homology. Despite this
homology, preliminary work had shown that reagents developed from human
rIL-1 were fairly ineffectual for detecting ovine IL-1. This had also been shown
to be the case for bovine IL-1. The bovine IL-1 cDNA sequences, which had
only just been published (Maliszewski et al., 1988), might have been expected to
be much closer to the ovine but the reagents were not available. As my intention
was not only to generate probes for the study of ovine EL-la and (3 production at
a molecular level, but also to express the recombinant proteins, the most obvious
direction in which to proceed was to clone the ovine IL-1 cDNA sequences
which would subsequently be used for expression purposes.
Methods available for isolating and cloning specific nucleotide sequences
included screening of genomic or cDNA libraries with appropriate probes and
the comparatively new technique of polymerase chain reaction (PCR), which
utilised sequence specific primers and the heat stable Taq polymerase enzyme
to amplify DNA sequences (Mullis and Faloona, 1987). Library screening
methods were in general use and had been used for identifying all previous IL-1
sequences. In view of the immediate requirement for the IL-1 coding sequences
for expression purposes, genomic screening was not considered to be applicable
in the first instance. Screening genomic DNA for IL-1 sequences which would
yield information on the genomic organisation of the IL-1 genes, including
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intron/exon boundaries and specific IL-1 promoter and regulatory sequences,
could be done later but was not intended to be part of this thesis. The IL-1
mRNA sequences could be obtained by either by screening ovine cDNA
libraries with the human or murine cDNAs as probes or alternatively by PCR.
PCR seemed to provide the most direct method by which IL-1 sequences could
be efficiently and uniquely amplified. The fidelity of Taq polymerase had to be
taken into consideration. It had been estimated that around 10 errors per 15000
bases could be introduced during the polymerase step of the reaction (Saiki et
al., 1988). By obtaining a consensus sequence from a number of PCR-derived
clones this problem should, however, be obviated. The availability of suitable
sequences from which PCR primers could be chosen was also an important
consideration. A number of points had to be taken into account such as primer
length, total GC content, the requirement for the 3' end of the primer to be GC
rich if possible, potential for annealing between the two primers and potential
for cross-hybridisation to cDNAs not encoding IL-1. Published IL-1 sequences
showed regions of homology which were conserved across species and from
which suitable PCR primers could be chosen. It was therefore decided to
employ this technique for amplification of the ovine IL-1 cDNAs.
Alveolar macrophages were chosen as the source of RNA, from which cDNA
could synthesised, because they produce large amounts of IL-1 mRNA on
stimulation with LPS and an abundant and relatively pure cell population is
easily obtainable by bronchoalveolar lavage at postmortem. PCR products
amplified from first strand cDNA populations could be readily purified for
ligation into cloning vectors.
Of the numerous vectors available, the multifunctional phagemids pTZ18R and
pTZ19R (illustrated in Fig. 3.1), which can be replicated in E. coli JM101 host
cells (Mead, 1986), exhibit a number of features useful for cloning and
sequencing PCR products;
(i) The two vectors are identical apart from the presence of multiple cloning
sites derived from the lac Z' gene of the pUC plasmid (Yanisch-Perron et
al., 1985). This polylinker consists of a number of overlapping unique
restriction enzyme sites, which enables cDNA fragments with a range of
termini to be inserted into appropriately digested vector. pTZ18R and
pTZ19R contain this multiple cloning site in reverse orientations which
allows an inserted fragment to be specifically excised from the one vector
and oppositely orientated in the other;
(ii) IL-1 mRNA was expected to be <2kb, a size easily accepted by the vector;
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(iii) the small size of the vector, 2.9kb, should allow high transformation
efficiency;
(iv) the presence of an ampicillin resistance gene confers the ability to select for
specifically transfected bacteria on solid media containing ampicillin;
(v) the lac Z' gene flanking the multiple cloning site of the vector allows easy
identification of colonies positive for insert cDNA. The presence of an
intact lac Z' gene leads to blue colonies on plates containing the appropriate
chromogenic substrate, whereas disruption of the gene by inserted cDNA
leads to white colonies;
(vi) superinfection of JM101 transformants with the helper bacteriophage
M13K07 allows single stranded cDNA to be synthesised from the fl origin
of replication within the vector. Because of the reverse orientations of the
multiple cloning sites with respect to this origin of replication, each strand
of the insert DNA can be separately synthesised;
(vii) 'Universal' and 'Reverse' sequencing primers are available (Pharmacia)
which anneal to upstream oligonucleotide sequences on either side of the
multiple cloning site. These primers can be used to obtain sequence from
each strand of double stranded cDNA inserts. The 'Reverse' sequencing
primer can also be used to sequence single stranded cDNA preparations.
For expression purposes, the yeast Ty system was chosen. This system utilises
the pOGS40 expression vector (a gift from Dr. S. Adams, British Biotechnology
Ltd.) (Fig. 3.2.a) which is an E. coli / yeast shuttle vector containing modules
for selection by ampicillin resistance in E. coli and for leucine selection in
yeasts auxotrophic for leucine biosynthesis. Full details of this expression
system are given in Chapter 4. The pOGS40 vector contains a unique BamHI
restriction site for insert ligation within the 3' end of a sequence coding for the
yeast pi protein. A number of other restriction sites are present within the vector
which can be utilised for determining the orientation of the inserted IL-1 cDNA.
In this system, recombinant IL-1 would be produced as a pl:IL-l fusion protein
from which the rIL-1 would subsequently be cleaved by the action of activated
coagulation factor Xa (FXa). Sequences encoding the FXa recognition site have
therefore to be inserted between the pi and EL-1 sequences. Sequences encoding
BamHI restriction endonuclease sites are also required at either end of the
cDNA to be inserted into the vector. These sequences can be most efficiently
appended to the IL-1 coding sequences during PCR, by using tailored IL-1
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The pTZ18R and pTZ19R multifunctional phagemids (Mead et al., 1986) were purchased from Pharmacia.
These vectors permit DNA cloning, dideoxy sequencing, in vitro mutagenesis and in vitro transcription in
one system. The vectors contain both the fl and pBR322 origins of replication for generation of double-
stranded DNA or large amounts of single-stranded DNA. If the host cell containing the phagemid is
superinfected with the specially designed helper phage M13K07, replication will be initiated at the fl origin,
allowing single-stranded DNA to be produced.
The Multiple Cloning Site (MCS) from pUC18 and pUC19, respectively, has been introduced to facilitate
cloning. An ampicillin resistance gene for selection on LB/Amp plates and the lacZ' gene for blue/white
screening of recombinants on x-gal plates are also carried by the phagemids. The position of the reverse
sequencing primer site is indicated.
The phagemids also carry the highly specific bacteriophage T7 promoter immediately adjacent to the
multiple cloning site for in vitro synthesis of large amounts of specific RNA. This function was not utilised
during the study being reported here.
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FIGURE 3.2
pOGS40 Expression Vector Cloning




pOGS40 vector is an E. coli / yeast shuttle vector used for expressing recombinant protein as a fusion
product with the yeast pi protein. The fusion protein is cleaved by the action of Factor Xa restriction
protease to release the recombinant protein.
Only features of the pOGS40 vector which are important with respect to cloning are shown on this diagram.
Features which have been incorporated for expression purposes will be detailed in Chapter 4.
A BamHI restriction enzyme site within the 3' end of the pi gene is used for insertion of cDNA sequences.
Insert sequences are flanked at the 5' end by bases encoding a Factor Xa site. BamHI restriction enzyme sites
are appended at each end for insertion into the vector.
An ampicillin resistance gene for selection of E. coli recombinants on LB/Amp plates and a Leucine module
is carried for selection in yeast are also carried. The pOGS40 sequencing primer, derived from the pi protein
sequence (Mellor et al., 1985), binds 61 base pairs upstream of the BamHI insertion site.
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In vivo, IL-la and IL-1{3 are both initially produced as a proproteins which are
enzymatically cleaved to yield the mature proteins. Both proprotein and mature
protein coding sequences were to be inserted into pOGS40 and PCR primers
were designed accordingly. The start position of sequences encoding the mature
proteins was assumed by analogy with bovine and human sequences. Ligation of
the resultant PCR products into BamHI digested pOGS40 should yield
constructs in which the inserts are in frame for correct protein synthesis.
PCR techniques were employed for cloning both ovine IL-la and IL-ip
cDNAs, although the approaches were slightly different for each. Briefly, the
cloning strategy was as follows: Total RNA obtained from LPS stimulated
alveolar macrophages was enriched for polyA+ RNA. First strand cDNA
synthesised by reverse transcriptase was used as the template for IL-1 cDNA
amplification by PCR. Initial PCR primers were derived from published human
and/or bovine sequences and secondary primers were derived from the resultant
ovine sequences. All PCR products were cloned into pTZ18R and pTZ19R
vectors for sequencing and probe generation, ie. a number of overlapping IL-1 [3
sequences (together comprising 32bp 5' leader sequence, an 801bp coding
sequence and 145bp of 3' untranslated sequence), and a single IL-la sequence
(consisting of an 807bp coding sequence plus 19bp of the 3' untranslated
sequence). The proprotein and mature protein coding sequences for both ovine




Alveolar macrophages were obtained by bronchoalveolar lavage at postmortem
of gnotobiotic sheep. Careful excision of the lungs ensured minimal blood
contamination. Hypotonic lysis removed any red blood cells present. On average
>5x108 macrophages were obtained from a lung lavaged with 2 litres Hanks
balanced salt solution. The macrophages, washed and resuspended in Iscoves
serum free medium, were allowed to adhere to plastic culture dishes for 16h
prior to stimulation with 10|lg/ml LPS.
3.2 PolyA+ RNA and cDNA Synthesis
Total RNA extracted from these LPS stimulated macrophages was enriched for
polyA+ RNA. Samples from three different animals run on a denaturing agarose
gel display the characteristic total RNA pattern with prominent 18s (1.8kb) and
28s (4.4kb) RNA and numerous intermediate bands (Fig. 3.3.a). PolyA+ RNA
synthesised from one of these samples appears as a very faint smear on the same
gel. (See Sect. 2.3.7 for northern blot analyses of these preparations). On
average, 1 x 108 macrophages yielded 80pg total RNA of which <5% was
polyA+ RNA. cDNA was synthesised from polyA+ RNA as template, using an
Amersham cDNA synthesis kit with either oligo-dT121g or random hexamer
primers. The efficiency of first strand cDNA synthesis was 5-10% as estimated
by a32P-dATP incorporation and the labelled cDNAs both contained a
comprehensive range of sizes with greatest density between 500bp and 2000bp
as visualised on agarose gels. An autoradiograph of such a gel is shown in Fig.
3.3.b as an example.
3.3 Cloning Ovine IL-lp cDNA
As ovine IL-la cDNA was cloned subsequent to IL-lp and the methodology
was therefore more refined, ovine IL-ip cDNA cloning will be described first.
3.3.1 Cloning and Sequencing IL-ip cDNA in pTZ18R and pTZ19R Vectors
3.3.1.1 PCR Primers for Amplification of Ovine IL-1J3 cDNA
Figure 3.4 is a compilation of all the primers used for amplification of IL-ip
cDNA sequences. The derivation of individual primers will be detailed in the
following text where appropriate. A diagrammatic representation of the steps
involved in IL-lp cloning is shown in Fig 3.5.
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FIGURE 3.3
a. Electrophoretic Separation of Total RNA Extracted from
Alveolar Macrophages
Figure 3.3.a
RNA from ovine alveolar macrophages stimulated
with LPS for 4h was electrophoresed through
denaturing agarose gels as per Sections 2.3 and
2.5.1.1. Total RNA samples from three different
sheep show the characteristic pattern with prominent
28s and 18s bands as indicated. PolyA+ RNA
prepared from one of these samples appears as a faint
smear covering the size range 250 - 4400 bases.
Lanes 1 and 2, High and low molecular weight,
respectively, RNA markers (see 2.2.2.4 for sizes);
Lane 3, lOpg RNA - Sheep No.l;
Lane 4, lOpg RNA- Sheep No.2;
Lane 5, lOpg RNA - Sheep No.3;
Lane 6,4pg polyA+ enriched RNA - Sheep No.l.
b.
Figure 3.3.b
cDNA synthesised from Sheep No.l polyA+ RNA
(shown above) by reverse transcriptase using an
Amersham cDNA synthesis kit with added [a-32P]-
dCTP was electrophoresed through a 1.5% agarose
gel as per Section 2.5.1.2. The dried gel was exposed
on Amersham XAR film and shows a range of cDNA
sizes with greatest density between 500bp and
2000bp.
1 2 3 4 5 6






B5.1 and B3.1 are mixed primers chosen from consensus sequences in human and bovine IL-lp cDNAs
(March et al., 1985; Malisewski et al., 1988). In both bo = A and hu = G. This pair was used for amplifying
the central region of ovine IL-ip cDNA. Primers B5.2, B3.2 and B3.3 were chosen from the resultant ovine
sequence. Primer B5.3 was selected from the 3' untranslated region of the bovine sequence. Primer dT was used
for anchored PCR with polyA tailed cDNA. Clones pi - P3 were sequenced and used for probe generation.
Primers B3.4, B3.5 and B5.4 were designed for use in producing expression vector cassettes. The additional bases
at the 5' end of each primer are required for the expression vector constructs. BamHI digestion sites and bases
encoding the FXa recognition site are indicated. The amino acids forming the Factor Xa recognition site are
shown in small capital letters. PCR products were cloned into both pTZ18R/19R and pOGS40 expression
vectors. Clones P4 and P5 were excised from pTZ with BamHI and cloned into pOGS40 expression
vectors.
IL-1 nucleotide numbers are indicated at each end of IL-1 specific sequences within the primers.
Primers were used at concentrations of 10-20pM.
PCR products which resulted in clones pi - P5 in pTZ18R/19R are shown at the bottom of the diagram.
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FIGURE 3.4
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Single-stranded cDNA was synthesised from polyA+ RNA by reverse transcriptase (RT) and double-stranded
cDNA by the further action of Klenow T7 DNA polymerase. (Amersham cDNA synthesis kit).
The full IL-lp cDNA sequence was obtained via a number of PCR reactions and cloning steps which are
represented diagrammatically in this figure. Clone designations are also indicated.
(i) Amplification of a central section of the cDNA with primer pair B3.1/B5.1. This PCR product was
cloned into pTZ18R/pTZ19R and sequenced. This is Clone pi.
(ii) Tailing the 5' terminal with an oligo-dA sequence.
(iii) Anchored PCRs using specific sequence primers, B3.2 or B5.2, paired with oligo-dT to obtain sequences
flanking the central clone. Cloning and sequencing in pTZ18R/19R yielded the 5' flanking sequence,
Clone P2, but only partial 3' flanking sequence.
(iv) Amplification of the 3' flanking sequence using primer pair B3.1/B5.3. Cloning and sequencing
yielded Clone P3.
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3.3.1.2 PCR amplification of the IL-ip central region - Nucleotides 171-710
PCR primers B5.1 and B3.1, corresponding to nucleotides 171-190 and 710-690
respectively (Fig. 3.4), are mixed primers chosen from consensus sequences in
human and bovine IL-lp cDNAs (March et al., 1985, Maliszewski et al., 1988).
This primer pair, B3.1/B5.1, gave a PCR product of the expected size, 535bp, as
seen when run on agarose gels (Fig. 3.6.a). Magnesium concentration, which can
affect PCR efficiency (Bell, 1989), did not appear to be crucial for IL-ip
amplification but Ohara buffer (1.5mM MgCl2; 3mM DTT; 50mM KC1;
lOOpg/ml BSA; lOmM TrisHCl pH8.8) (Ohara et al., 1989) was marginally
better than a commercial Anglian buffer (6.7mM MgCl2; lOmM p-ME; 16.6mM
(NH4)2S04; 6.7mM EDTA; lOOpg/ml BSA; 67mM TrisHCl pH8.8). Standard
reaction parameters were; denaturation 93°C/30sec, primer annealing
50°C/30sec, polymerisation 72°C/2.5min; followed by 72°C/5min to allow full
extension of synthesised strands. The amplification was both specific and
efficient, giving good yields of IL-ip product, >2pg from lng first strand cDNA
after 35 cycles.
The PCR band was excised from an agarose gel, purified by adsorption to silica
(Geneclean) and ligated into pTZ18R vector. Transformation of E. coli JM101
cells with this ligated product yielded a number of recombinant colonies on
LB/Amp plates. An agarose gel of EcoRI and Hindlll restriction endonuclease
digested vector preparations from these colonies shows the presence of different
insert sizes. One insert, shown as lane 3 in Fig.3.6.a, appeared to be of the
correct size for a dimer. Both uncut and cut preparations of this clone hybridised
strongly with the original PCR product (Fig.3.6.b) but uncut pTZ18R and a
cDNA preparation from a negative colony which were run on the gel as controls
did not hybridise. This positively hybridising clone was called pi. All the IL-1
clones generated during this study are listed in Table 3.3 at the end of this
Results section. The insert excised from pTZ18R by EcoRI/Hindlll digestion
was ligated into pTZ19R to place it in the opposite orientation for single strand
preparation. Single stranded DNA in both orientations was sequenced using the
dideoxy chain termination method with T7 DNA polymerase (Sequenase II,
USB Ltd.). This central pi clone was 96.8% and 78.2% similar to the equivalent
bovine and human sequences respectively.
3.3.1.3 Amplification of sequences flanking pi
3.3.1.3.1 Anchored PCR
Comparison of the leader and 3' untranslated sequences of human, murine and
bovine IL-1 p showed no obvious region of homology on which PCR primers
could be based. Anchored PCR was therefore the next approach for obtaining
sequences flanking the pi sequence. This method utilises a fixed sequence for
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FIGURE 3.6
Cloning IL-lp Nucleotides 171 - 710 (Clone pi)
a. cDNA Amplification by PCR using Primer Pair B3.1/B5.1
Single-strand cDNA was amplified with mixed primers chosen
from consensus sequences in bovine and human IL-1|3 cDNAs
and the product electrophoresed through 1.5% agarose gels.
Lane 1, X markers; Lane 2, Ovine IL-ip PCR product at 535bp;
Lane 4, pTZ18R clone digested with EcoRI and Hindlll to give
pTZ18R at 2900bp and insert at 1 lOObp; Lane 5, X markers.
X EcoRI/Hincffll markers (21226, 5146,4973,4268, 3530,2027, 1904, 1709, 1375,947, 831, 564, 125 base pairs)
b. Selection of pTZ18R Clones by EcoRI/Hindlll Digestion




X 2 3 4 X 6 7 3 6
Vector preparations from selected JM101 colonies and the EcoRI/Hindlll digested preparation seen above
were electrophoresed through a 1.5% agarose gel together with the pTZ18R preparation used for the original
ligations (left half of the picture). The gel was blotted and hybridised with the original PCR product labelled
with 32P (right half of the picture). Undigested samples in lanes 2-4 and digested samples in Lanes 6-7 were
electrophoresed as two independent groups on the same gel, each with its own set of X markers.
Lane 1, X markers; Lane 2, original uncut pTZ18R; Lane 3, uncut pTZ18R from the positive colony with
1 lOObp insert; Lane 4, uncut pTZ18R from a negative colony; Lane 5, X markers; Lane 6, EcoRI/Hindlll
digest of positive sample with lOOObp insert; Lane 7, EcoRI/Hindlll digest of pTZ18R from the negative
colony.
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one primer together with a specific sequence for the second primer. The polyA
tail at the 3' end of the cDNA could be utilised as one such anchored primer site.
cDNA specifically primed with the PCR primer, B3.1, was tailed with a stretch
of 20 dA nucleotides, using the terminal transferase reaction, which provided a
similar fixed sequence at the 5' terminus. Primers B3.1 and B5.1 were paired
with oligo-dT as the anchored primer and should have yielded the outstanding
sequences at either end of the cDNA. The annealing temperature was lowered to
42°C because of the lower Tm of the oligo-dT primer but other PCR parameters
remained unchanged. Initial PCRs using either dTmg or dT1924 as the anchored
primer produced smears which hybridised fully with 32P labelled pi as shown by
a 3 hour exposure of dT1924 Southern blots (Fig. 3.7a). A simultaneous control
reaction with B3.1/B5.1 primers confirmed both the specificity of these two
primers and the intactness of the tailed cDNA. Although it seemed most likely
that the oligo-dT was mispriming, further PCRs were carried out using nested
primers, B5.2 and B3.2 selected from the pi clone sequence, in an attempt to
make the reaction more specific. Control PCRs using these primers yielded
products of the expected sizes but anchored PCRs again resulted in smears (Fig.
3.7b). Various buffers were tried, with or without the addition of DMSO to relax
secondary structure, the most successful of which was the low magnesium Ohara
buffer with no added DMSO. Three sequential reaction sets using nested primers
and increasing annealing temperatures (42°C, 50°C, 55°C), resulted in somewhat
tighter smears (Fig 3.7c).
The expected size of the 5' end product (primer pair dT/B5.2) was about 400bp,
ie. base pairs 1 to 315 of coding sequence plus <100bp leader sequence
(bovine=75bp; human=90bp). Smears covering 200-800bp for the 5' end were
therefore excised from agarose gels, purified and cloned into pTZ18R. The
largest 5' clones obtained, 694bp, were found to be dimers. These clones yielded
the outstanding 145 bases to the start codon plus 32 bases of leader sequence.
The cloned sequence -32 to 315 was called p2.1. A second 5' end smear, from a
different PCR reaction with the same primers, yielded clones which confirmed
the sequence apart from T/C differences at nucleotide positions 84 and 191. Four
clones were sequenced and found to be identical - clone P2.2.
The 3' end product (primer pair dT/B3.2) was expected to be about 1300bp, ie.
base pairs 438-801 of coding sequence, plus <900bp of 3' untranslated sequence
(bovine=876bp; human=616bp). Smears covering 800-2500bp were excised
from gels and cloned into pTZ18R. None of the 3' end clones contained full
length inserts, the largest size of positively hybridising insert being 600bp.
Sequencing of this clone revealed 223 bases of clear EL-1 sequence followed by
a 72 base region of compression, ie. bands in all four lanes, followed by a 17
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FIGURE 3.7
PCR Reactions using Oligo-dT as the Anchored Primer
a. Use of 01igo-dT12.18 vs 01igo-dT19.24 Primers
PolyA tailed cDNA was assessed by amplification with
theB3.1/B5.1 primer pair. cDNA and polyA-tailed
cDNA were used as templates for anchored PCR
reactions. Products from B3.1 and B5.1 primers paired
with either oligo-dT121g or oligo-dT1924 were
electrophoresed through 1.5% agarose gels. Southern
blots of oligo-dT19_26 products were hybridised with
32P-pl.
Lane 1, Tailed cDNA amplified with B3.1/B5.1
primers; Lane 2, B5.1/dT12 lg; Lane 3, B3.1/dT121g;
Lane 4, X markers; Lanes 5a and 5b, B3.1/dT19 24,
unhybridised and hybridised resp.; Lanes 6a and 6b,
B5.1/dT19_24, unhybridised and hybridised resp.
12 3 A. 5a 6a 5b 6b
b. Use of Nested IL-lp Primers Paired with Oligo-dT
Internal primers B3.2 and B5.2, chosen from the ovine
pi clone sequence, were paired with oligo-dT19 24.
Lane 1, X markers; Lane 2, B5.2/dT; Lane 3, B3.2/dT;
Lane 4, B5.2/B3.1; Lane 5, B3.2/B5.1.
A 2 3 4 5
c. Final PCR Products from Sequential Reaction Sets
Sequential reaction sets were carried out using B3.x
and B5.x nested primers paired with oligo-dT.
Annealing temperatures were increased with each set of
PCR cycles (42°C, 50°C, 55°C). Products
electrophoresed through 1.5% agarose gels are shown.
Lane 1, X markers; Lane 3, control B3.1/B5.1 product;
Lanes 5 and 6, 5' flanking region;
Lanes 7 and 8, 3' flanking region.
X 2 3456 7 8
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base sequence consisting of 14C and 3G residues. The final 17 bases before the
vector sequence showed 71% homology with the bovine 785-799 nucleotide
sequence. Secondary structure due to a fairly high GC rich sequence was
suspected as being the most likely cause of the compressions. Support was lent
to this idea by a computer model of the bovine sequence from nucleotides 600-
801, which showed a hairpin and potentially awkward secondary structure in this
region (Fig. 3.8).
Potential Secondary Structure of Bovine IL-ip from Nucleotides 600 to 801
Figure 3.8 The opitmal secondary structure of bovine IL-ip from bases 600 - 801
(Maliszewski et al., 1988) was determined using the method of Freier et al., 1986.
The stability of the structure is AGf = ~41.8kcal/mol.
3.3.1.3.2 Sequencing 3' cDNA clones
- Variations involving destabilisation of secondary structure
A number of sequencing variations designed to destabilise GC bonding and
hairpin loops were used in an attempt to sequence through the compression:
(i) using deaza dGTP or dITP in place of dGTP; (ii) adding DMSO up to 10%;
(iii) varying DNA:primer ratios; (iv) sequencing with Taq polymerase at 72°C
instead of T7 DNA polymerase at 37°C; (v) sequencing using primer B3.3 and 3
dNTPs only plus a 30 fold dilution of G mix, again to destabilise GC bonding;
(vi) adding the single strand DNA binding protein, T32, during the sequencing
reaction with deaza dGTP; (vii) running sequencing gels containing 8.3M urea
instead of the normal 7.67M urea. None of these methods yielded acceptable





3.3.1.3.3 A,gtlO cDNA library screening
In order to obtain the remaining nucleotides at the 3' end of the IL-lp cDNA
sequence the two alternatives considered were either to screen a cDNA library in
^gtlO vector or to chose another PCR primer. Screening of A.gtlO libraries
constructed from hexamer primed cDNA, provided a large number of positively
hybridising clones but many inserts were difficult to excise from the vector (Fig.
3.9.a). None of the 3' inserts which could be excised provided any additional
sequence (after having been subcloned into pTZ18R). The use of A.gtlO primers
to PCR across the insert from vector sites again produced some non-specific
priming presumably because the vector sequences flanking the insert site and
hence the primers, are very AT rich. Without amplification of the insert, direct
sequencing was not a viable alternative due to the relative sizes of vector and
insert ie. 43.3 and 1.5 kilobases respectively.
A library constructed from the B3.1 primed cDNA used for 5' anchored PCR
(see Sect. 3.3.1.3.1) was screened simultaneously but the inserts could not be
excised from positive constructs (Fig. 3.9.b). Clone J31 which was used for
probing the Southern blots of digested clones does not cross-hybridise with
A,gtlO. All positive signals therefore correspond to specific inserts.
3.3.1.4 PCR amplification of sequence extending into the 3'
untranslated region - Nucleotides 171-1011
The most important sequence to obtain, as far as I was concerned, was from
bases 1-801, the coding region of the IL-1J3 cDNA, because information on
regulatory sequences within the 3' untranslated sequence was not going to be
utilised in the subsequent expression work. One final primer, B5.3 (see Fig. 3.4),
was selected from the bovine 3' untranslated region. Even though this region is
not well conserved across other species, extremely close ovine:bovine homology
had been found in sequences already analysed and it was therefore hoped that
the 3' untranslated sequences might not be too divergent. The sequence closest to
the stop codon which fulfilled the requirements for a primer consisted of bases
995-1011, the region between 801 and 994 being too GC rich. PCR using
B3.1/B5.3 primers produced a product of the expected size, 841bp which
hybridised strongly with clone pi (Fig. 3.10). Sequencing of the cloned product,
P3, yielded the outstanding 78 bases between the central pi sequence and the
stop codon, plus 145 bases of 3' untranslated sequence. The latter did in fact
show 93% homology with the bovine IL-ip sequence. The sequence also shows
a region from bases 716 - 728 which could have accounted for misprinting by
the oligo dT primer and may have been the cause of the compression region.
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FIGURE 3.9
A,gtlO / IL-lp cDNA Clones
a. Positive Clones from a Hexamer Primed cDNA Library in A,gtlO Vector
The XgtlO library was screened with 32P-pl. Clones positive after tertiary screening were digested with
EcoRI. 1.5% agarose gels show the range of insert sizes obtained (Lanes 2-4 and 7 - 11). Hybridisation of
the Southern blotted gel, hybridised with clone pi, indicates the presence of IL-ip specific sequences.
A markers are shown as Lane 1. Lanes 5 and 6 contain no sample.
b. Positive Clones from the B3.1 Primed cDNA Library in A,gtlO Vector
DNA digested, electrophoresed and blotted as above but hybridisation shows that inserts did not excise
from the vector on EcoRI digestion.
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FIGURE 3.10
PCR Amplification of IL-lp Nucleotides 171 -1011
using Primer Pair B3.1/B5.3
X
Figure 3.10
cDNA amplification yielded a clean PCR product at the expected molecular weight
(841bp), which hybridised with clone pi.
Lane 1, X markers; Lane 2, PCR product on 1.5% agarose gel; Lane 3, Southern
blotted gel hybridised with pi.
At least 4 clones of each product were fully sequenced in both directions using
PCR primers as intermediate sequencing primers. The clones encoding the ovine
IL-1|3 sequence constituted 32bp of 5' leader sequence an 801 bp coding
sequence and 145bp of 3' untranslated sequence having two potential C/T
polymorphisms, at positions 84 and 193, the latter giving A/V on translation.
Further potential polymorphisms became apparent during the cloning of
expression constructs (see below) and the ovine IL-1{3 cDNA sequence and its
translation are therefore shown in Fig. 3.12 on pg.98.
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3.3.2 Production of IL-ip pOGS40 Expression Constructs
From the IL-ip coding sequence obtained above, PCR primers B3.4, B3.4 and
B5.4 (see Fig. 3.4) were designed which incorporated sequences required for
insertion into the yeast expression vector pOGS40 (see Fig. 3.2). The start
position of the mature IL-ip region was assumed from analogy with published
sequences of the human and bovine IL-1 proteins (March et al., 1985;
Maliszewski et al., 1988). Both the complete sequence coding for the IL-1 (3
proprotein (TY{3p), residues 1-801, and that coding for the IL-1 (3 processed
mature protein (TYPm), residues 340-801, were obtained (Fig. 3.11).
The outline of the protocol followed for production of expression constructs was
(i) PCR as above;
(ii) ligation of PCR product into pTZ18R/19R for confirmatory single stranded
sequencing;
(iii) excision of insert from pTZ18R with BamHI, gel purification of insert and
ligation into pOGS40 vector;
(vi) selection of expression constructs.
The clones in pTZ18R are (34, IL-lp proprotein sequence, and P5, mature IL-lp
sequence (all the IL-1 clones generated are collated in Table 3.3). All p4 clones
sequenced were identical, as were all P5 clones. However, the p4 sequence
revealed a further four potential polymorphisms with respect to the sequence
already obtained, ie. at positions 24, 41, 75, and 163. Differences at positions 41
and 163 lead to alterations on translation ie. C/Y and K/Q respectively. Table 3.1
summarises the sequence differences found, all of which are in the region
encoding the N terminal portion of the proprotein. The clone p4, which was
inserted into the expression vector, and the resultant amino acid incorporated
into the recombinant IL-ip proprotein are shown in bold print.
All cDNA preparations were derived from the same polyA+ RNA sample, pi,
P2 (ie. P2.1 and P2.1) and P4 clones were derived from three different cDNA
template preparations, pi and P4 were each derived from single PCR reactions.




PCR Amplification of IL-1J3 Nucleotides 1 - 801 and 340 - 801
with Primer Pairs B3.4/B5.4 and B3.5/B5.4 Respectively
X Pp Pm
Figure 3.11
cDNA sequences encoding ovine IL-ip proprotein and mature protein were amplified with primers designed
to include sequences required for subsequent insertion into expression vectors (see Fig. 3.4). The start of the
mature protein was assumed from human (March et al., 1985) and bovine (Maliszewski et al., 1988) IL-ip
cDNAs. PCR products on 1.5% agarose gels show bands at the expected sizes, 801 and 462 base pairs
respectively.
X = markers; Pp = cDNA for IL-1P proprotein; Pm = cDNA for IL-1P mature protein.
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TABLE 3.1
Potential IL-1(3 Polymorphisms Detected in PCR Derived cDNA Clones
Base No. Clone name Nucleic Acid Amino Acid
24 (32.1, (32.2 C (b) I
(34 T (o) I
41 (32.1, (32.2 G c
(34 A (b,h,o) Y
75 (32.1, (32.2 T (b,h,o) V
(34 C V
84 (32.1 T (h) p
(32.2, (34 C (b,o) p
163 (32.1, (32.2 A K
(34 C (b,h,o) Q
191 (31.1,(32.1 c (h) A
(32.2, (34 T (b,o) Y
Table 3.1
The clone P4, which was inserted into the expression vector, and the resultant amino acid incorporated into
the recombinant IL-ip proprotein are shown in bold print. Letters in brackets denote the nucleotide present in
human (h; March et al., 1985) and bovine (b; Maliszewski et al., 1988) IL-ip cDNA sequences and an ovine
sequence published subsequent to this work (o; Andrews et al., 1992).
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FIGURE 3.12




























EEKPVF LGRFRGGQD I TDFR 260
ATGGAAACCCTCTCTCCCTAAAGAAGCCATACGCAGGGGTCCACGTGGGCTGAATAACCCCGAG 84 4




cDNA and protein sequences are numbered starting with the initiator Met. The presumed start of
the mature protein, Ala-114, is designated V. Potentially polymorphic residues, detected from
sequencing a number of overlapping clones derived from various PCR amplifications (see Table
3.1), are shown in bold print. The sequence shown is that of Clone J}4 which was used in
expression studies.
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Although inserts cut out of pTZ18R with BamHI were gel purified twice on
1.2% agarose gels before being inserted into BamHI cut pOGS40 vector,
minimal amounts of pTZ18R were always carried over into the ligation mix.
Because the insert ligates more efficiently into pTZ18R than into pOGS40 and
transfection with the smaller vector is also more efficient, transfected E. coli
JM83 colonies positive for both IL-1(3 and pOGS40 were selected by colony
hybridisation on duplicate filters following the method of Buluwela et al., 1989.
pOGS40 was identified by probing with the Leu2 fragment (bp 6070-9390
excised from the vector with Hindlll), which does not cross-hybridise with pTZ.
The orientation of the insert in pOGS40 constructs was established by digestion
with Clal and Ball restriction enzymes, the latter providing a unique
assymmetric site in the insert. Expected fragment sizes are shown in Table 3.2.
Double stranded sequencing of selected clones, using a pi sequence specific
primer (see Fig. 3.2) situated 61 base pairs upstream of the BamHI insertion site,
confirmed that the cDNA insert was in frame for correct protein synthesis.
pOGS40 clones are designated TYPp for the proprotein coding region and
TYPm for the mature coding region.
TABLE 3.2
Orientation of IL-ip cDNA Inserts in pOGS40 Constructs


















pOGS40/IL-l cDNA preparations were digested with Clal and Ball restriction endonucleases. pOGS40
contains four Clal sites (see Fig. 3.2). The presence of a single asymmetrical Ball site in the IL-ip sequence
leads to the fragment sizes shown in bold print, as determined by the orientation of IL-1 cDNA in the vector.
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3.4 Cloning and Sequencing Ovine IL-la cDNA
From the experience gained in cloning IL-1{3, a much simpler strategy was
employed for cloning IL-la. Broadly, the entire ovine IL-la cDNA coding
sequence was amplified directly using primers with appended pOGS40 insertion
sequences. The resultant PCR product was inserted independently into
pTZ18R/19R and pOGS40 vectors.
3.4.1 PCR Amplification of IL-la cDNA - Nucleotides 1-826 and 358-826
In view of the high degree of homology exhibited by ovine and bovine IL-1|3
cDNAs, primers were chosen from the bovine sequence (Maliszewski et al.,
1988) which would cover the complete coding sequence for the IL-la proprotein
(TYap), residues 1-807. The 3' antisense primer of necessity extended into the
3' untranslated sequence because the sequence leading up to the stop codon
contains no stretches showing a GC content suitable for inclusion into a primer.
From the sequence of the resultant PCR product, a specific ovine PCR primer
was chosen for amplification of the IL-la mature protein (TYam), residues
358-807. The amino terminus of the mature protein was assumed from the
bovine sequence. Sequences for insertion into the pOGS40 expression vector,
plus additional bases to protect the BamHI restriction site, were also included in
the primers (Fig. 3.13).
PCR amplification parameters were 35 cycles of 93°C/30s denaturation;
56°C/2.5min annealing; 72°C/30sec polymerisation followed by a final strand
extension at 72°C for 5min. Addition of 5% DMSO to Ohara buffer (1.5mM
MgCl2) increased IL-lap yields but did not dramatically affect IL-lam yields
(Fig. 3.14). No product was obtained with Anglian buffer (6.7mM MgCl2) either
with or without added DMSO. The expected product sizes were 826bp and
479bp for pro- and mature IL-la respectively. Faint ghost bands of obviously
incorrect sizes were ignored. The PCR products were extracted with
phenol/chloroform, end-filled and phosphorylated, then purified on preparative
0.8% low gelling temperature agarose gels. The bands were excised and twice
re-extracted with phenol/chloroform. 600ng of each was sequenced directly by
double stranded sequencing using the PCR primers and confirmed as being IL-
la.
These PCR products were used for ligation into pTZ18R/19R vectors for




Primers Used for Ovine IL-la cDNA Cloning
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Primers A3.1, A3.2 and A5.1 were designed for use in expression vector cassettes. A3.1 and A5.1 sequences were
chosen from the bovine IL-la cDNA sequence (Maliszewski et al., 1988) and A3.2 was chosen from the resultant
ovine sequence. IL-1 nucleotide numbers are indicated for each primer. Nucleotides for insertion into pOGS40
expression vector were appended. BamHI restriction endonuclease sites and the Factor Xa recognition site are
indicated. Additional 5' bases were added to protect the BamHI digestion site. PCR products from primer pairs
A3.1/A5.1 and A3.2/A5.2 were cloned and sequenced in pTZ18R/19R. Clones al and a2 respectively.
Primer A5.2 was derived from the cloned ovine sequences and used as an internal sequencing primer.
Primers were used at 10-20pM.
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FIGURE 3.14
PCR Amplification of Ovine IL-Ia Proprotein and Mature Protein
Coding Sequences - Effects of Mg2+ Concentration and DMSO
IL-lap IL-lam
X — + X — +
DMSO DMSO
Figure 3.14
IL-la proprotein and mature protein coding sequences were amplified by PCR using primer pairs
A3.1/A5.1 and A3.2/A5.1 respectively. PCR products electrophoresed on 1.5% agarose gels show
the effect of adding 5% DMSO to the buffer. PCR products were obtained with Ohara buffer
(1.5mM MgCl2), but no product was obtained with Anglian buffer (6.7mM MgCl2) as shown in
Lane 4 on the IL-lap gel.
3.4.2 Cloning and Sequencing IL-la PCR Products in pTZ18R/19R Vectors
lOOng of filled in PCR product was blunt-end ligated into Smal cut pTZ18R
then pTZ19R vectors and single stranded DNA synthesised and sequenced. For
obtaining full sequence in both directions an antisense sequencing primer, A3.3,
was chosen from the ovine sequence as shown in Fig 3.13. No sequence
differences were seen either between individual IL-lal (proprotein) and IL-la2
(mature protein) clones or their primary PCR products. Fig. 3.15 shows the
ovine IL-la cDNA sequence and its amino acid translation.
3.4.3 Cloning IL-la into pOGS40 Expression Vector
Filled in PCR products were cut with BamHI restriction endonuclease and
phosphorylated prior to low gelling temperature (lgt) agarose gel purification
and ligation into CIP treated BamHI cut pOGS40 vector at a ratio of 300ng
insert to 500ng pOGS40. Numerous colonies of transformed E. coli JM83
bacteria were obtained, all of which contained positive inserts. BamHI digestion
confirmed insert size but as no suitable enzyme sites were available for
orientation digestion, vectors containing correct inserts were determined by
double stranded sequencing using the pi specific pOGS primer (see Fig. 3.2).
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FIGURE 3.15










LKKRRLS LNQF I TDDDLEAI 100
V
gccaatgataccgaagaagaaat catcaagcccagatcagcacattacagcttccagagt 360








PVTLR I SKTQLFVSAQNEDE 200
cccgtcttgcataaggagatgcctgagacacccaaaatcatcaaagatgagaccaatetc 660








DNA and protein sequences are numbered starting from the initiator Met. The presumed start of
the mature protein, Ser-120, is designated V.
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3.5 Summary of Ovine IL-1 Clones
The individual ovine IL-1 clones generated are summarised in Table 3.3.
TABLE 3.3
Ovine IL-1 Clone Nomenclature
Clone PCR primers IL-1 base Nos Insert size bp Vector
IL-lpl B3.1/B5.1 171-710 540 pTZ18R/19R
IL-1 (32.1 dT/B5.2 -32 -315 347 tt
IL-1 (32.2 dT/B5.2 -32 -315 347 tt
IL-1 (33 B3.1/B5.3 171 - 1011 841 tt
IL-1 (34 B3.4/B5.4 1 - 801 801
it
IL-1 (35 B3.5/B5.4 340 - 801 462 it
IL-l.TY(3p B3.4/B5.4 1-801 831 pOGS40
IL-l.TYJ3m B3.5/B5.4 340 - 801 492 it
IL-lcd A3.1/A5.1 1 - 826 864 pTZ18R/19R
IL-la2 A3.2/A5.1 358 - 826 504 n
IL-l.TYap A3.1/A5.1 1 - 826 851 pOGS40
IL-l.TYam A3.2/A5.1 358 - 826 491 it
Table 3.3
IL-1 fragment sizes differ from the vector insert sizes where the latter include pOGS40 insertion nucleotides.
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3.6 Interleukin-1 Sequence Comparisons
The ovine IL-la PCR product and all clones sequenced yielded identical
sequences for the cDNA which consisted of 807bp of coding sequence plus 19bp
3' untranslated sequence. IL-lf5 sequence consisted of 32bp leader, 801bp coding
sequence and 145bp of the 3' untranslated sequence. 6 nucleotide differences
were obtained from the various IL-ip clones sequenced. All clones from any one
PCR reaction yield consistent sequences. There is only 25% identity between
ovine IL-la and IL-1(3. Similar identities have been found between alpha and
beta forms of bovine, human and murine IL-ls. Table 3.4 shows the degree of
cross species homology exhibited by the ovine IL-ls. The IL-la and IL-1 (3
sequence comparisons from which these figures were derived are shown in Figs.
3.16 and 3.17 respectively. The start of the mature proteins are denoted v,
potential glycosylation sites are underlined and potentially polymorphic IL-lp
residues are indicated above the ovine sequence in Fig. 3.17.
TABLE 3.4
Relationship of Ovine IL-la and IL-1J3 cDNA Sequences to Other Species
Interleukin-1a Interleukin-18
Nucleotide Amino Acid Nucleotide Amino Acid
Species Coding Pro Mat 5' UTR Coding 3' UTR Pro Mat
Bovine 97 97 98 97 96 85 95 96
Porcine 88 83 80 na na na na na
Human 81 72 69 81 78 59 62 64
Rabbit 80 70 64 67 76 49 63 63
Rat 80 63 57 75 72 43 59 62
Murine 80 61 54 66 70 45 56 59
Table 3.4
Comparisons are listed as % identities with respect to the ovine sequences. Amino acid figures were obtained
from comparison of the cDNA translation products. Sequences were optimally aligned using the method of
Needleman and Wunsch, (1970). At the nucleic acid level, the ovine IL-la untranslated sequences were not
obtained. Only coding sequence comparisons are therefore given.
UTR - untranslated sequence; Pro - proprotein; Mat - mature protein; na - not available
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FIGURES 3.16 AND 3.17
IL-1 Sequence Comparisons
Published IL-1 sequences are aligned relative to the respective ovine sequences.
Dots indicate conserved residues. Potential glycosylation sites are underlined. The position of the start of the
mature proteins, Ser-120 in IL-la and Ala-114 in EL-ip, is indicated by V. Potentially polymorphic IL-lp
residues which were detected in this study are shown above the ovine sequence in Fig. 3.17.
References:
Bovine IL-la and IL-ip:
Porcine IL-la:
Rabbit IL-la and IL-1 p.-
Human IL-la and EL-IP:
Murine IL-la and IL-ip:
Rat IL-la and IL-ip:
Maliszewski et al., 1988; Leong et al., 1988
Maliszewski etal., 1990
Furutani et al., 1985,1986
March et al., 1985
Gray et al., 1986
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3.7 Northern Blot Analysis of IL-1 mRNA Production in LPS Stimulated
Alveolar Macrophages
IL-1 mRNA production by ovine alveolar macrophages on stimulation with
lOmg/ml LPS was analysed by northern blot using the cloned cDNAs as probes.
Ovine IL-1 (3 m-RNA seems to be produced earlier than IL-la m-RNA as seen in
Fig. 3.18, the beta form showing a maximum at around 4h post induction as
opposed to 6h for the alpha. IL-1 (3 m-RNA has all but disappeared by 24h and
IL-la message is still detectable at 19h. This is similar to the profile of m-RNA
production of human (Bemaudin et al., 1988) and murine (Chensue et al., 1991)
IL-ls. Ovine IL-1 m-RNA molecular weights are approximately 2.0Kb (alpha)
and 1.6Kb (beta), smaller than their bovine and human counterparts at approx.
2.2Kb and 2.0Kb respectively (Maliszewski et al., 1988). Blots of alpha and beta
m-RNAs both also show faint bands hybridising at higher molecular weight,
which may be partially spliced or unspliced RNAs.
Fig. 3.19 shows a northern blot of polyA+ RNA and in the total RNA from
which it was derived (4h LPS stimulation) probed with (31 cDNA. The polyA+
RNA shows a band at roughly the same position as in total RNA ie. at ~1.5Kb.
A parallel blot probed simultaneously for IL-1 (3 and TNFa showed no detectable
2.0Kb TNFa mRNA. This is in agreement with other studies in our laboratory
which show that TNFa message is detectable at a maximum level l-2h post LPS
induction and thereafter rapidly disappears (Green et al., 1991). The sequence of
production of these cytokine mRNAs by LPS stimulated ovine alveolar
macrophages appears to be TNFa, IL-1 [3, IL-la.
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FIGURE 3.18
Northern Blots of IL-1 mRNA Production from
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a. and b. 10(ig Total RNA extracted from alveolar macrophages after stimulation with 10(ig/ml LPS for the
times shown, was electrophoresed through denaturing agarose gels.
Northern blotted gels were hybridised with 32P-labelled IL-la (a) or IL-1 (3 (b) cDNA probes.
c. 4pg polyA+ RNA and 10|Xg total RNA from which the polyA+ RNA had been selected, were
electrophoresed as above and hybridised with 32P-IL-1(3 cDNA
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DISCUSSION
Although PCR has now become an extremely widely used and useful technique
for isolating and amplifying DNA sequences, some of the problems which can
be encountered, especially with respect to misprinting, became apparent during
the amplification of ovine IL-1(3. As a result, the cloning of ovine IL-la by PCR
was approached in such a way as to circumvent these problems.
The initial amplification attempted, of a central region within the IL-1{3 cDNA
using mixed primers derived from consensus sequences in the human and bovine
cDNAs, produced a product which appeared as a single strong band on
electrophoresis. This band when cloned into pTZ18R revealed sequence with no
clonal variations which was 96.8% and 78.2% homologous to the corresponding
bovine and human sequences. Attempts to clone the outer ends of the molecule
via anchored PCR were fraught with difficulty. Use was made of the IL-1(3
polyA tail in order to obtain the 3' sequence flanking the central clone and at the
other end of the cDNA, the 5' leader sequence was extended by addition of an
oligo-dA sequence using the terminal transferase reaction. Instead of the oligo-
dT primer annealing to these polyA sequences in a specific 'anchored' fashion as
anticipated, it appeared that the primer could also anneal to internal A-rich
sequences.
The problems induced by this were two-fold. Firstly, PCR produced a large
range of product sizes. It appears that concatamers can be formed, as these large
products hybridise strongly with the pi central clone. Sequencing showed that
both the 3' and 5' end cloned inserts obtained from such products were
multimers. In addition, high molecular weight areas excised from smears on gels
and used as templates for PCR with the intention of amplifying a large sized
product, invariably produced a smear with a bias towards the lower molecular
weight products. A concatamer containing primer binding sites along its length,
would result in a range of product sizes, the smaller products effectively being
preferentially amplified.
This phenomenon of oversize PCR products which produce smaller products on
re-amplification, was also observed in our laboratory by Ian Green (personal
communication) when using the technique of inverse PCR (Ochman et al.,
1988). Inverse PCR involves circularising the cDNA and using outwardly
pointing primers, complimentary to the ends of a known sequence within the
cDNA. The resultant PCR, across the rest of the cDNA circle, should produce
both 3' and 5' ends of the molecule in a single product. Green also obtained
larger products than anticipated, which he postulated were the result of a "rolling
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circle" type of mechanism operating during strand extension. The potential for
concatamerisation, which may be greater when a monobasic primer is used,
means that under these circumstances, products for cloning can not be selected
on the basis of size.
Secondly, chimeric products could be formed as was detected during the
attempted cloning of the 3' end of the cDNA, apparently as a direct result of
using the homopolymeric oligo-dT as a primer. Clones obtained from the 3'
region PCR smears yielded readable sequence followed by apparent compression
over 78 bases then further sequence. This type of compression shows extension
products present in all four lanes which did not mimic true compressions.
Secondary structure was ruled out as being the cause of the compressions and on
close inspection of the 3' sequence of the bovine IL-1(3 cDNA, it became
apparent that there were a number of A-rich stretches which could potentially
cause misprinting. As even the shorter oligo-dT was a 12-18bp mix (this being
minimal for PCR primers), one can visualise the primer being able to anneal
across these regions. One such section occurs at bases 482-506;
AAGGAGAGGAAAGAGACAACAAGA which lies between and partially
superimposed on the ovine nested primer sites B3.2 (bases 457-474) and B3.3
(bases 498-516). Oligo-dT misprinting in this region could potentially cause
hindrance to the annealing of either or both B3.2 and B3.3 primers. Of probably
greater significance, however, is the stretch of bases 715-727, which in the
bovine sequence is AAATCGAAGAAAG. The ovine sequence was eventually
found to contain A, not G, at base 727 which gives a 69% A content. (G=T base
pairing is also stable which would increase this figure to 84% a + g content). The
readable sequence from the 3' clones finished at base no. 721 which is in the
middle of this proposed area of mispriming. Sequence 3' of this is only partially
homologous with the subsequently determined ovine sequence and its origin is
not obvious. This phenomenon of chimeric PCR products has been reported by
other workers (Brakenhoff et al., 1991).
In retrospect, ligation of an oligonucleotide of known sequence to the cDNA
termini, as suggested by Ohara et al, would be a more reliable basis for anchored
PCR as the oligonucleotide could be tailored to ensure specific priming.
The final IL-lp cDNA sequence was obtained by choosing a bovine sequence
primer from within the 3' untranslated region, which it was hoped would be
reasonably specific. Although the untranslated sequences are not well conserved
across other species, the bovine and ovine sequences are fortunately very similar
(Table 3.4).
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The original objective had been to obtain cDNA sequences by a PCR related
cloning route, with the thought that library screening could be used to provide
confirmatory sequence data. A A.gtlO cDNA library was prepared and
subsequent PCR reactions using positive A.gtlO clones as templates and the
B3.1/B5.3 primer pair, produced single bands on gels, which were the correct
size and hybridised with |33 (data not shown). These clones therefore probably
contain complete 3' untranslated sequences and may contain full length cDNAs.
These clones have not been pursued further.
PCR of IL-la posed no problems even though the 3' primer site extended into
the untranslated region. No problems were incurred as a result of having
appended nucleotides at the 5' end of each primer which were required for
cloning the product into the expression vector. The last four 'protective' bases
were sufficient to allow efficient cutting by BamHI and subsequent direct
ligation into BamHI cut pOGS40 vector. The PCR product cloned into
pTZ18R/19R showed no sequence differences between any of the clones
sequenced or the original PCR product.
The final accumulated ovine IL-1(3 cDNA sequence consisted of 32 bases of 5'
leader, 801 coding bases and 145 bases of 3' untranslated sequence. The IL-la
cDNA consisted of 807 coding bases and 19 bases of the 3' untranslated
sequence.
Comparison with other species, shows ovine and bovine IL-1 cDNA sequences
to be very close, as expected. Porcine, human, rabbit, murine and rat IL-ls show
decreasing degrees of homology with the ovine IL-ls. Homologies with respect
to the three distinct cDNA regions, ie. 5' leader, coding and 3' untranslated
sequences, are compared in Table 3.4 in the Results section. It can be seen that
the 3' UTR is the most variable region although only 145 ovine nucleotides were
available for inclusion in this analysis. Regions of translated sequences which
are conserved across all other species are also generally conserved in the sheep
although there are some notable differences. Chapter 6 will address conservation
across specific regions within these sequences. The 25% identity between ovine
IL-la and IL-ip is similar to the human (26%), bovine (23%) and murine (22%)
IL-ls (March et al., 1985; Maliszewsi et al., 1988; Gray et al., 1986).
Although ovine IL-la and IL-1 (3 sequences both display potential
polymorphisms, IL-1 (3 appears to be more variable than IL-la. Three ovine IL-
ip and two IL-la ovine cDNA sequences have now been published. The IL-la
and IL-ip sequences published by Andrews et al. (1991) were derived by
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screening a XgtlO cDNA library. The Seow et al. (1991) IL-ip coding sequence
was PCR derived using one set of bovine sequence primers. Differences between
these sequences and those presented here, give rise to one potential IL-la and
four potential IL-ip amino acid polymorphisms. It is of interest that all but one
of the IL-1(3 differences are within the proprotein and not the mature protein
coding sequences, which may be of significance considering that the IL-ip
proprotein is supposedly not functionally active in vivo. The few sequence
differences present are discussed below in relation to polymorphisms.
Potential ovine IL-la polymorphisms
No differences within the IL-la coding sequence were apparent from any of the
clones sequenced here. There are, however, four nucleotide differences between
this sequence and the ovine IL-la sequence of Andrews et al. which represent
potential polymorphisms. These differences are shown in Fig. 3.5 in comparison
with the equivalent bovine bases, the two published bovine sequences being
identical (Maliszewsky et al., 1988; Leong et al., 1988a). The resultant amino
acid obtained on translation is given in brackets.
TABLE 3.5
Potential Ovine IL-la Polymorphisms
Nucleo- Amino Ovine Ovine Bovine


















Nucleotides and amino acids are numbered from the beginning of the ovine IL-la pre-
protein. Nucleotides in the Fiskerstrand sequences were PCR derived. Nucleotides in the
Andrews' ovine sequence and the two bovine sequences were derived by LgtlO library
screeing. Amino acids obtained on translation are given in brackets.
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It can be seen that only one of these base changes gives rise to an amino acid
alteration. Val-74 is conserved across all other species except porcine which has
Ala-74. Fig. 3.5. The Andrews sequence was derived by library screening, which
has a low rate of error incorporation. An ovine polymorphism is therefore likely
at this point. Restriction digestion of genomic DNA with Maelll and
hybridisation with labelled LL-la would confirm the presence of a G/A220
polymorphism. Given that none of the other base alterations result in amino acid
changes, they may also represent polymorphisms. No enzymes are available for
assessing these by digestion.
Polymorphisms have been reported for human IL-la (Auron et al., 1984; March
et al., 1986) giving rise to amino acid differences at positions 110 (Lys/Asn) and
114 (Ala/Ser), the latter of which is in the predicted mature protein. As both the
human and the ovine amino acid substitutions are within regions showing high
rates of evolutionary variation, the alterations probably carry no functional
significance.
Potential ovine IL-ip polymorphisms
Polymorphisms seen in my PCR-derived LL-lp sequences are detailed in Table
3.1. Only three of the six nucleic acid differences give rise to amino acid
differences. To assess the significance of these potential polymorphisms one
must look at PCR error rates. The generally accepted average figure for PCR
error is one change per 1500 bases, (similar rates have been measured in our
own laboratory), which would mean an expected ten bases in a 15000 base pair
sequence, ie. if all the nucleotide differences detected in IL-ip cDNA had been
PCR induced, the rate of PCR error would be about that seen here. However, if
some of the nucleotide differences detected in the IL-ip cDNA were due to PCR
error rather than genuine polymorphism, one would expect a more random
distribution, especially towards the 3' end of the coding sequence which was
amplified via numerous independent but overlapping PCR reactions. No
differences were however detected in this region although a few differences
between the two published ovine IL-lp sequences were seen in the 3'
untranslated region. From Table 3.1 it can be seen that each of the nucleotides
detected, apart from C-74, was either found in clones derived from at least two
independent PCR reactions, or appears to have a counterpart in the sequences
from other species. Nucleotide C-74 is only present in clones derived from one
particular PCR reaction. This nucleotide may therefore have been inserted as a
result of PCR error. The other five alterations could represent genuine
polymorphisms.
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Even assuming a lesser error rate, one would also anticipate at least some PCR-
induced error in the IL-la cDNA clones. Not one difference was however
detected.
Comparison the IL-1 (3 sequences which I obtained with other published ovine
sequences shows three amino acid differences with respect to the Andrews
sequence and a further one with respect to the Seow sequence, as shown in Table
3.6. The Seow sequence also shows a TAA to TAG change. Apart from amino
acid L/P145, the only differences between these sequences are at positions in
which polymorphisms within my own clones were detected. The amino acid
present in clone |34, which was used in expression studies, is indicated in bold
print. Amino acids present at the same positions in other IL-1 sequences are
appended at the bottom of the table for reference.
TABLE 3.6
Potential Amino Acid Polymorphisms Within Ovine IL-ip
Study Nucleic acid / Amino acid
Fiskerstrand A41/Y14 C163/Q55 Tl93/^64 T434/L145 A.801/*
G41/C14 A163/K55 C193/A64
Andrews et al. A41/Y14 C163/Q55 T193/V64 T434/L145 A80l/*
Seowetal. A41/Y14 C163/Q55 T193/V64 C434/P145 G80l/*
bo/h/rab lL-ip = Y14 bo/mu/rat/rab bo/rab = V64 bo = L145
mu/rat = F14 = Q55 h/mu/rat = A64 mu/rat/rab = N145
all species IL-la = C14 h = H55 h = Q145
Table 3.6
Sequences from all PCR derived ovine IL-1 (3 clones obtained in the study being reported here, were
compared with the two other published ovine IL-1 (3 sequences. Differences are shown as the nucleotide and
its position / amino acid obtained on translation. 'PCR polymorphisms' are shown separately under the
Fiskerstrand study and the clone used for expression of the IL-1 (3 protein is given in bold print. Amino acids
present at these positions in other EL-1 sequences are indicated below the double line for reference. The stop
codon is indicated by *.
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One method of assessing potential polymorphisms is by sequence comparison
across species. By this criterion, differences at three of these residues could
represent true polymorphisms (see Table 3.1). There is no precedent for residue
K55 but the nucleotides coding for this amino acid were present in clones
derived from separate PCR reaction sets. PCR induced error therefore seems
highly improbable. This amino acid change would also represent a moderately
conservative substitution.
Restriction digests of genomic DNA could confirm the presence of
polymorphisms by yielding different patterns of digestion products.
Unfortunately, however, there are no restriction enzyme sites which encompass
the suspected polymorphic sites in ovine IL-1 (3 cDNA.
IL-1 mRNA production by macrophages
Northern blot analysis of the production of IL-1 by LPS stimulated ovine
alveolar macrophages over 24h suggests that IL-1 [3 mRNA is produced no later
than IL-la mRNA. IL-1 (3 mRNA appears to peak at about 4h and IL-la mRNA
around 6h. The exact sequence of events can not be deduced as this data was
derived from separate experiments. Andrews et al. have suggested that ovine IL-
1 alpha is produced earlier than beta. The main differences between the two
ovine studies are the length of time for which alveolar macrophages were
allowed to adhere to culture dishes prior to LPS stimulation and the culture
medium used, both of which could affect the mRNA levels detected. The LPS
dosage, lOpg/ml, was the same in both studies. Nash stimulated the
macrophages in RPMI medium containing 10% foetal calf serum (RPMI10) after
allowing the cells to adhere for 1 hour. In my experiments, the macrophages
were allowed to adhere and stabilise in Iscoves serum free medium for 16h prior
to stimulation, the reasons being that the process of macrophage adhesion is
known to stimulate IL-1 mRNA synthesis even though translation is not induced.
It is also known that adhesion and LPS can induce IL-1 mRNA simultaneously
via independent mechanisms (Labadia et al., 1990), so that in effect, more IL-1
mRNA would be detected from cells not allowed to recover from the adhesion
process before prior to LPS stimulation. In addition, heat inactivated serum has
also been shown to induce greater amounts of IL-la than IL-1 [3 from human
macrophages (Lonneman et al., 1989 and data not shown). In support of the
effect of serum on IL-1 mRNA induction in sheep, I initially found that
macrophages incubated overnight in RPMI10 contained readily detectable
amounts of IL-1 mRNA, prior to LPS stimulation. In contrast, after 16h
incubation in Iscoves serum free medium, only traces of the mRNAs were
detectable by northern blotting. It could be, therefore, that the effects of both
adherence and foetal calf serum are leading to the different induction patterns
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seen in the two laboratories. Northern blot data from unstimulated samples in the
Nash study, in which both IL-1 mRNAs are seen to be present at 5h but have
disappeared by 20h, may substantiate this idea.
In conclusion, the ovine IL-1 cDNAs have been cloned into both sequencing and
expression vectors, and the methodology by which these sequences were
obtained has been appraised. Potential nucleic acid polymorphisms have been
detected in ovine sequences, 1 in the mature IL-1 {3, 6 in the IL-1 (3 proprotein and
4 in the IL-1 a proprotein. Of these, 1 in IL-1 (3m, 3 in IL-l(3p and 1 in IL-lap
lead to amino acid differences. There is only 25% identity between ovine IL-1 a
and IL-1 (3, the same as is seen in other species. The coding regions of both
sequences show high levels of homology with their bovine counterparts and on
translation show retention of motifs conserved across all other species. Initial
comments have been made on the significance of some regions within the
sequence. The importance of conserved regions with respect to structure,
receptor binding and biological activity, will be addressed in chapter 6.
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CHAPTER 4
EXPRESSION AND CHARACTERISATION OF RECOMBINANT
OVINE
INTERLEIJKIN-lrc AND INTERLEIJ KIN -1 ft
INTRODUCTION
Human, murine and bovine IL-ls have all been expressed as recombinant
proteins and both prokaryotic and eukaryotic expression systems have been
successfully used for this purpose. E. coli has been the most frequently used
host but rIL-1 has also been expressed in transfected monkey COS cells, murine
L cells and yeast, as well as by in vitro translation in rabbit reticulocytes and
Xenopus laevis oocytes (see Chapter 1, Sect 1.7.2). In some cases the rIL-1 has
been synthesised fused to hybrid secretory sequences for the study of its
secretion and activity (Rosenwasser et al., 1986; Casagli et al., 1989; Pecceu et
al., 1991). The choice of expression vector and host cell depends on various
factors including expected yields of protein, ease of purification and possible
posttranslational modification of the protein.
At the time when ovine IL-1 was to be expressed as recombinant protein, the
yeast Ty-vlp expression system was a comparatively new system, produced by
British Biotechnology Ltd., which had only been used for the production of viral
proteins. In this system, Saccharomyces cerevisiae, strain BJ2168, transformed
with vectors based on the yeast retrotransposon Ty, yields fusion proteins which
self-assemble into virus like particles (vlps) from which the recombinant protein
can be enzymatically cleaved. Studies on recombinant HIV proteins and
Interferon (Adams et al., 1987a; Malim et al., 1987; Kingsman et al., 1987;
Griffiths et al., 1991) had shown the following attractive features of the Ty
expression system;
(i) the ability to produce a range recombinant proteins from 3-42 kD
(ii) high yields of biologically active recombinant protein
(iii) ease of purification of the recombinant protein
(iv) increased immunogenicity of the recombinant protein when presented in the
arrayed, multivalent form of the vlp




Growth of Transformed Saccharomyces cerevisiae Strain BJ2168
a. pMA5620 transformant for constitutive pi protein production
b. pOGS40/IL-l transformant pre-induction
c. pOGS40/IL-l transformant post galactose induction
Samples from growing cultures were viewed under a light microscope and photographs were taken at x50
magnification.
These features fulfilled the requirements for recombinant ovine IL-1 and in
addition, the system was currently being successfully used in our own laboratory
for production of maedi-visna virus p25 core protein (Reybum et al., 1992).
A brief description of the essential components of this expression system
follows. Yeast Ty is a member of a class of eukaryotic DNA retrotransposons.
The haploid genome of laboratory strains of yeast contains 30-35 copies of Ty
which are found at variable chromosome locations (Kingsman and Kingsman,
1988). The major Ty RNA, which is also the intermediate in Ty transposition, is
5.7kb in length and consists of two open reading frames, TYA and TYB. TYA
is expressed by simple translation to produce pi, a 50kD protein (Mellor et al.,
1985a; Adams et al., 1987b). TYB is expressed as a fusion with the TYA gene
resulting in a 190kD TYA:TYB fusion protein, p3. TYA is further processed to
smaller proteins, p2, p4, p5 and p6. The transposition cycle of Ty involves the
packaging of Ty RNA into pre-Ty-vlps comprised of pi and p3, followed by
proteolytic maturation due in part to the action of the TYB-encoded protease.
The vlps also contain reverse transcriptase, a tRNA primer and probably
integrase which enable the vlps to carry out an endogenous reverse transcription
to produce a double stranded copy which integrates into the genome (Mellor et
al., 1985b). Although p2 is the major protein in mature vlps, the pi to p2
proteolysis is not necessary for particle formation. It is therefore possible to
construct hybrid Ty-vlps from pi fusion proteins, which are polyvalent
derivatives of the added protein. The specialised expression vectors pMA5620
and pOGS40, illustrated diagramatically in Fig. 4.1a,b, have been designed to
include elements required for recombinant protein:pl vlp expression (Adams et
al., 1991).
Plasmid pMA5620 consists of an expression cassette inserted into an E. coli
yeast shuttle vector. The expression cassette consists of the yeast
phosphoglycerate kinase (PGK) promoter flanking the TYA gene, TYA(d),
which has been truncated at codon 381 by addition of a BamHI site, for insertion
of additional cDNA. Termination codons in all three reading frames and a
transcription terminator follow the BamHI site. The shuttle vector contains
origins of replication for growth in both E. coli and yeast, the gene for
ampicillin resistance for selection in E. coli, and a LEU2 gene for selection in
yeast strains which are auxotrophic for leucine production. The plasmid copy
number is maintained at 100-200 copies per cell. In the current study, this vector
was only used for constitutive production of pi protein as a control preparation.
Plasmid pOGS40 is derived from pMA5620 and contains a hybrid PGK-GAL
promoter (PAL). pOGS40 is used for production of the fusion protein by
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insertion of the required cDNA sequence within the 3' end of the TYA(d)
sequence. A Factor Xa (FXa) restriction protease recognition sequence is
appended at the 5' terminus of the inserted cDNA. pi or pl-fusion genes are
only expressed from the PAL promoter following induction by galactose. The
resultant fusion proteins self-assemble into vlps consisiting of a yeast pi protein
core fused to recombinant protein on the outside with the FXa recognition site as
a bridge (Fig. 4.2). Inducible expression is advantageous because in general,
induction by galactose results in greater yields of fusion proteins than obtained
by constitutive production. In addition, allowing the yeast to grow to a high
density prior to switching on fusion protein production is important if the
recombinant protein is liable to be toxic to the cells.
The yeast host strain, S. cerevisiae BJ2168, is a protease deficient strain which
minimises degradation of the vlps by intracellular proteases. The strain carries a
mutation in the GAL2 gene, (a gene normally encoding a permease which allows
galactose to enter the cell), but as some galactose can enter the cell via a
constitutive pathway, the strain is useful when galactose induction of expression
is required.
In the presence of galactose, GAL4 protein is released, binds to the upstream
galactose activation sequence of the PAL promoter and activates transcription of
the TYA gene. One of the main constraints of the galactose induction system is
the low level of GAL4 gene expression especially if the cell contains multiple
copies of the plasmid. The plasmid pUG41S contains the structural gene for
GAL4 under the control of the GAL1 promoter and which is over expressed in
the presence of galactose. Co-transformation of pUG41S as a helper plasmid can
therefore act to increase fusion protein yields. pUG41S also contains a uracil
selection module. The BJ2168 yeast strain can therefore be transformed to
leucine independence with either pMA5620 or pOGS40 plasmids and to both
leucine and uracil independence if both pOGS40 and pUG 41S plasmids are
present.
The production and processing of IL-1 has been described in detail in Chapter 1
Sect 1.4. In vivo, the IL-1 proteins are produced as precursor molecules of Mr
~31kDa which are processed to yield the Mr ~17.5kDa mature proteins. IL-lcx is
active as both precursor and mature protein. Although IL-1 (3 is generally
considered to be biologically active only in its mature form, recombinant human
proIL-1 (3, either expressed in COS monkey cells or synthesised by in vitro
translation, has been reported to be biologically active in D10.G4.1 assays and
on fresh thymocytes (Rosenwasser et al., 1986; Andrews et al, 1992; Jobling et
al., 1988) although to a much lesser degree than the mature protein.
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FIGURE 4.1
Vectors used for Transforming S. cerevissiae Strain BJ2168
in the Yeast Ty-vlp Expression System
A. pMA5620 expresses yeast pi protein constitutively from the TYA(d) gene under the
control of the phosphoglycerate kinase (PGK) promoter.
B. pOGS40 is a derivative of pMA5620 which requires galactose induction for protein
expression. cDNA sequences are inserted into the vector via the BamHI restriction
enzyme site within the TYAfdl gene. Fusion proteins are expressed under the control of
a hybrid PGK/GAL (PAL) promoter.
pMA5620 and pOGS40 plasmids are E. coli / yeast shuttle vectors each of which contains an Ampicillin
resistance gene (AMP) for selection in E. coli and a Leucine selection module (LEU) for growth in yeasts
auxotrophic for Leu biosynthesis.
C. pUG41S expresses the GAL4 gene in the presence of galactose and under control of the
GAL1 promoter. The plasmid contains a Uracil selection module.









































(i) Galactose inducible fusion protein is expressed from pOGS40 constructs under the control of the hybrid-
PGK/GAL (PAL) promoter. Each construct contains, 5' to 3', the TYA(d) gene for expression of yeast pi
protein (shown in red), a Factor Xa restriction protease coding sequence (shown in green) and cDNA
sequence coding for the recombinant protein (shown in blue). The primary expression product is a fusion
protein pi : FXa : rProtein. (ii) Fusion proteins assemble into packed spherical virus-like particles (vlps)—
which when cleaved with Factor Xa, (iii), release the recombinant protein while retaining their pi vlp
structure.
125
For the purpose of determining the biological activity of ovine IL-1, pOGS40
expression constructs for precursor and mature forms of both IL-1 a and IL-1 (3
have been produced as detailed in chapter 3. Briefly, PCR derived cDNA was
inserted into the vector via linkers containing BamHI restriction enzyme sites.
The 5' end linkers included a sequence encoding the Factor Xa recognition site.
CsCl purified DNA was prepared from 500ml cultures of selected E. coli JM83
colonies transformed with these constructs. Sequencing of the double stranded
pOGS40/IL-l-cDNA constructs confirmed that each of the inserts was in frame
for correct protein synthesis and that the BamHI insert site had not been
corrupted on ligation. Constructs were transfected into S. cerevisiae strain
BJ2168 either with or without pUG41S as co-transformant.
A number of assay systems are available for determining IL-1 bioactivity. Of
these, the two most specific and frequently used assays employ the murine cell
lines EL4.NOB1 and D10.G4.1 or derivatives thereof. In view of suspected
species barriers there was a possibility that these cell lines would not be of use
in determining ovine IL-1 activity. Bioassays for IL-1 which are less specific
because of being responsive to more than one cytokine, can however be
effectively used for determining recombinant IL-1 activity ie. where there is no
interference from cytokines such as TNFa. These assays involve either
measuring thymocyte proliferation stimulated by IL-1 with Phytohemagglutinin
(lectin extracted from Phaseolus vulgaris) as co-mitogen or measuring
glycosylaminoglycans released from cartilage as a result of the degradative
action of IL-1. The basis of these assays has been detailed under 'actions of IL-1'
in Chapter 1, Sect. 1.5. Because fresh tissue has to be employed for each assay,
the reproducibility may not be as great as that obtained with cell lines, but the
advantage of these assays is that homologous tissue can be used thus obviating
any problems with respect to species specificity.
This chapter describes the successful expression of biologically active
recombinant ovine IL-1a and IL-1 [3 in the yeast Ty-vlp system. S. cerevisiae,
strain BJ2168, transformed with pOGS40 / IL-1 vector constructs yielded rIL-1




The expression of IL-la and EL-1(3 as fusion proteins are detailed separately,
Sections 4.1 and 4.2 respectively. Subsequent data is combined.
4.1 Expression of ovine IL-1J3 : yeast pi fusion proteins
4.1.1 Transformation of S. cerevisiae BJ2168 with p()GS40/TY[3 constructs
Five IL-1(3 preprotein (TY(3p) and two mature protein (TY(3m) constructs were
transfected, into yeast. Transfectants and control transfectants were plated on Sc-
glc (leu") plates in regeneration agar with additions as shown in Table 4.1.
Table 4.1
Growth of Saccharomyces cerevisiae Strain BJ2168
Transformed with IL-lp Expression Vectors
Vector Insert fig Construct pg pUG41S Additions Transformant
+/-1 T.-/+U lBm - 6BmpOGS40 TY(3ml,2 7
pOGS40 TYppl-5 7-14
pOGS40 - 4













BJ2168 yeast was transformed various constructs: pOGS40/IL-l(3 + pUG41S for galactose induced
expression of fusion proteins or pMA5620 for constitutive production of pi protein for use as a control
preparation Amino acids were added as appropriate. Uracil and tryptophan were added for growth of single
transformants. Double transformants only required added tryptophan. Untransformed cells only grew in the
presence of added tryptophan, uracil and leucine.
U - Uracil; T - Tryptophan; L - Leucine; all at 2[ig/ml
TYPm - cDNA coding for IL-ip mature protein, 2 different preparations transfected
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TYfJp - cDNA coding for IL-ip preprotein, 5 different preparations transfected
Transformation efficiencies of IL-ip constructs were all very low. Six
pOGS40/TYpm transformants (named lBm -> 6Bm) were obtained, all of which
were much slower growing than pMA.pl. The Bm colonies were re-plated and
incubated a further four days at 30°C then innoculated into Sc glc + T for small
scale test culture. Phase contrast microscopy of transfected cultures showed the
cells to be healthy and budding well at this stage. They are greenish grey, of
diverse sizes and some contain large vacuoles, (see Fig. 4.6). Very few dead
cells are seen. After subculture in galactose/minimal glucose medium, Sc-gal, to
induce recombinant protein synthesis, the yeast cells were generally larger with a
slight increase in the number of dead cells. Increased induction times resulted in
marginally lower rather than higher yields of cells, which may be indicative of a
slight toxicity of the vlps.
Only one IL-1(3 proprotein transformant, a double transformant called lBp, was
obtained from five attempts at inserting the construct into yeast using three
separate preparations of pOGS40/TYpp. lBp was initially even more slow
growing than Bm transformants but the rate of growth increased after 4-5 days.
Small scale liquid cultures were shaken in Sc-glc for seven days before the
optical density was high enough to ensure sufficient growth under galactose
induction conditions. By light microscopy the yeast cells looked healthy and
were budding well. Most of the pOGS40/TY(3p transformations were performed
at the same time as successful transformations using other constructs. All
pOGS40/TYpp construct preparations were CsCl purified and undegraded and
the reasons for lack of transformant colonies are not obvious, although extremely
slow growth may be a contributing factor. Under the microscope numerous small
clusters of dividing cells were seen within the regeneration agar, but these did
not develop into colonies of any useful size.
4.1.2 Selection of pOGS40/TYp transformants for large scale culture
Crude protein preparations from non-induced and induced Bm and Bp
transformants, pMA.pl and untransformed BJ2168 were run on 10% reducing
PAGE gels. Representative coomassie blue stained gels, show the appearance of
a protein band at about 80kDa in the pOGS40/TY(3p sample (Fig 4.3 a) and
68kDa in pOGS40/TY(3m transformed samples. These bands are consistent with
predicted sizes for fusion proteins consisting of pi (Mr = 50kDa) plus IL-l(3m
(Mr = 17.5kDa) or IL-iPp (Mr = 31kDa) respectively. pMA5620 produces the
expected 50kDa pi band and no vlp bands are seen in the untransformed sample.
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Electroblotted gels incubated with an anti-pl polyclonal antiserum (Fig 4.3 b),
show the presence of pi or pi fusion proteins in pMA5620 and pOGS40 vlp
preparations respectively. Double transformants produced higher yields of
[3m:pl vlps and lBm, was selected for large scale culture.
4.1.3 Preparative culture of IL-lp transformants and purification of vlps
Large scale cultures of lBm reached OD600m^ of about 1.3 after 20h pre-induction
and OD600m|X =1.2 after 48h induction in 41 Sc-gal. lBp only reached an OD of
0.88 even after 66h induction. Light microscope pictures of IL-1(3 transformants
pre- and post induction of BJ2168 are shown in Fig 4.6 combined with pictures
of IL-la transformants on pg *. Transmission electron microscopy reveals cells
of diverse morphology and size. Induced cells contain variable numbers of vlps.
Examples of IB and 1A transformants are shown in micrographs Fig. 4.7. Data
on growth of IL-1 and pi transformants and resultant vlp yields are combined in
Table 4.2 on pg 134.
Centrifugation of crude cracked yeast supernatant onto a 60% sucrose cushion
yielded a thick, particulate, ochre coloured interface consisting mainly of vlps
but also some yeast protein. Samples from the supernatant, interface and cushion
fractions were run on SDS-PAGE gels and showed that the vlps are in fact
distributed throughout. Fig 4.4 (lanes 1-4) compares the relative amounts of vlps
and yeast proteins in untransformed samples, crude extracts of transformed
samples and the interface and cushion fractions of partially purified preparations.
Up to 4ml of pooled interface and cushion layers was centrifuged through 34ml
15 - 45% linear sucrose gradients over a 60% sucrose cushion at 50,000g for 3
hours at 4°C and sequential 2ml fractions collected from the top of the gradient.
Coomassie stained 10% SDS-PAGE gels show the distribution of (3m:pl and
(3p:pl vlps within these gradients (Fig 4.4 lanes 6-19). The bulk of the
contaminating yeast proteins remain in the upper fractions of the gradient, with
the remainder being distributed fairly evenly throughout the vlp containing
fractions. Sedimentation velocities of (3m:pl vlps were 30s to 300s, and of the
larger J3p:pl vlps were 200s to 500s. Transmission electron microscopy revealed
a large range in size of the vlps, many of which are very irregularly shaped. Fig.
4.7 shows examples of (3m vlps both within transformed yeast cells and after
purification. PI vlps in contrast are regular and are seen at a greater density
within yeast cells (the latter is not shown).
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FIGURE 4.3
Fusion Protein Expression from BJ2168 Transformed with TY|3 Constructs
(a) Coomassie stained 10% SDS-PAGE gel of crude extracts from BJ2168 yeast preparations showing the
appearance of pi at 50kDa, (3p:pl fusion proteins at 81kDa and pm:pl fusion proteins at 68kDa.
Lane 1, untransformed; Lane 2, transformed with PMA5620; Lane 3, transformed with
pOGS40/TY(3m; Lane 4, transformed with pOGS40/TY(3p.
(b) Electroblotted 10% SDS-PAGE gel reacted with anti-pl polyclonal antiserum showing the presence of
pi in all transformed samples.
Lane 1, untransformed; Lane 2, pi vlp; Lane 3, pm:pl vlp; Lane 4, (3p:pl vlp.
FIGURE 4.4
Purification of IL-ipm IL-l(3p Fusion Proteins
(a) (3m:pl; (b) Pp:pl.
Coomassie stained 10% SDS-PAGE gels of crude extracts from pOGS/TYPm and pOGS/TY/pp transformed
BJ2168 and sucrose gradient purification profiles of the vlps. Lane numbers apply to both fusion proteins.
Lane 1, untransformed BJ2168; Lane 2, transformed BJ2168; Lane 3, interface vlps; Lane 4, cushion vlps.
Lane 5, molecular weight markers; Lanes 6-19, vlps in successive fractions after sucrose gradient purification
of pooled interface and cushion samples. Gels of 20pi aliquots from Pm:pl gradient fractions and 5pi
aliquots from Pp:pl fractions are shown. Sucrose concentration across the gradient is indicated.
Two aspects of vlp recovery had to be taken into consideration, purity and
concentration. Processing the the interface and cushion vlps separately did not
result in a greater degree of vlp purity. Neither did longer or faster
centriguagtion during the cushioning step which rather resulted in pelleting of
the vlps with subsequent reduction in recombinant protein yields. Gradient
purified samples can be diluted up to fifteen-fold which is not ideal for
preparation already at a relatively low concentration. In an attempt to increase
both concentration and purity of the vlps, various 15ml 15-60% discontinuous
sucrose step gradients were run in place of the 43ml linear gradient. These
gradients did not however appear to confer substantial benefit and were not
routinely used in vlp purifications. The purity problem was judged to be the
result of the comparatively low yield of (3m:pl vlps. Gradient fractions
containing the highest concentration of vlps were therefore retained as optimal,
and individual fractions were pooled or not, as required.
4.2 Expression of ovine IL-la : yeast pi Fusion proteins
4.2.1 Transformation of S. cerevisiae BJ2168 with pOGS40/TYa Constructs
Constructs for both forms of the IL-la protein were transfected into yeast
BJ2168 either with or without pUG 41S as co-transfectant. A number of
transformants were obtained for each IL-la construct, all of which grew well, as
opposed to those containing IL-ip constructs. A coomassie stained 10% PAGE
gel of crude extracts (Fig 4.5 a) shows that IL-lap vlps (ap:pl) appear to be
produced in greater amounts than IL-lam vlps (am:pl). Co-transfection with
pUG 41S enhanced production of am:pl slightly, as is also shown by a western
blot against polyclonal anti-pl antiserum (Fig 4.5 b).
4.2.2 Preparative Culture of IL-la Transformants and Purification of vlps
Selected colonies, lAp and lAm, were grown in large scale culture. lAm
growth was comparable to lBm and lAp was much faster growing than lBp. By
light microscopy there are no obvious differences between pOGS40/TYa and
pOGS40/TYP transformed yeasts either before or after induction. Fig. 4.6 shows
the relative sizes of uninduced transformants (b) and transformants under
conditions of vlp production (a, c). Electron micrographs of 1 A, IB and pMA.pl
transformants are similar, both showing great morphological diversity (Fig. 4.7).
IL-la vlps were cushioned onto 60% sucrose but because yields of both IL-lap
and IL-lam vlps were greater than IL-ipm vlps, it was found to be not
necessary to run the cushioned extracts on sucrose gradients in order to obtain
vlp preparations of equal purity (85-95%). The advantage of this was that the
vlps were retained at higher concentrations. The concentration of cushion vlps is
typically 10 times that of sucrose gradient purified material.
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FIGURE 4.5
Fusion Protein Expression from BJ2168 Transformed with TYa Constructs
a.
12 3 12 3
Figure 4.5
a. Coomassie stained 10% SDS-PAGE gel of 5pi aliquots of crude extracts from single or double
transformants, showing the appearance of ap:pl fusion proteins at ~81kDa and am:pl fusion proteins at
~68kDa. By way of comparison, pi runs at 50kDa on 10% SDS-PAGE gels.
Lane 1, ap:pl vlp, pOGS40 single transformant; Lane 2, ocm:pl vlp, pOGS40/pUG41S double
transformant; Lane 3, am:pl vlp, pOGS40 single transformant.
b. The presence of pi in con:pl vlps blotted against polyclonal anti-pl antiserum at 1/2000 dilution shows
that co-transformation with pUG41S increases am:pl yields slightly.





Electron Microscopy of Yeast Transformants
and Purified Fusion Proteins (Vlps)
Purified Pm:pl vlps ( x 330000)
Figure 4.7
pOGS40/IL-ipm yeast cells under conditions of vlp production and preparations of purified IL-ipm:pl
fusion proteins were treated as described in Chapter 2.10 and viewed by Transmission Electron Microscopy.
A pi vlp is shown as an inset for comparison with the Pm:pl vlps. Magnifications are shown on the
individual components of the composite figure.
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4.3 Comparison of IL-la and IL-ip Fusion Protein Expression
The essential details of the production of the IL-la and IL-ip fusion proteins are
compared in Table 4.2. Prior to induction, all pOGS40/IL-l transformants grew
equally well, although more slowly than pMA.pl. Galactose induction reduced
the growth rates, especially those of the proprotein transformants. This is in
agreement with earlier observations on transformant growth rates on solid
medium. Vlp production was independent of cell growth, ie. vlp production by
lAm, lAp and lBp were all comparable, ~0.2pg/cell, about half the amount of
constitutive pi vlp production, ~0.4pg/cell. In contrast, lBm vlp production,
~90fg/cell, was less than half that of the other IL-1 transformants despite good
growth of the yeast, indicating a possible Pm:pl stability problem within the
yeast. The amount of IL-1 within each of these vlp preparations is indicated in
the column headed "Crude [IL-1]" where [IL-1] designates IL-1 concentration.
Although vlp losses occurred at all stages of purification, the greatest am:pl and
pm:pl losses were during the 60% sucrose cushioning step, >40% of the vlps
remaining in the 60% sucrose supernatant. <15% of the more dense ap:pl and
Pp:pl vlps were retained in this supernatant. Dialysis accounted for a ~10%
reduction in yield.
TABLE 4.2
Growth of Transformed BL2168 in Large Scale Preparative Liquid
Culture.
Fusion Protein Yields and Recovery of Recombinant Protein
OD
vlp Crudev Total IL-1
Trans¬ 600m(i cells/ml Hrs. yield [IL-1] recovered
Construct formant Glc Gal Gal Gal mg/1 mg/1 |ig/l %
pOGS/TYap lAp 1.30 0.80 2.7x107 48 5.3 2.0 600# 53*
pOGS/TYam 1 Am 1.30 1.20 4.0x107 48 8.9 2.5 1000 45
pOGS/TYpp lBp 1.30 0.88 2.9xl07 66 6.2 2.4 800 33
pOGS/TYPm lBm 1.20 1.20 4.0x107 48 3.7 1.0 300 30
pMA5620 *pMA.pl 1.50 na na na 20.0 na na na
Table 42
ODboom^, = 1-5 represents 5xl07cells/ml; Cells were cultured in Sc-glc for 48 hours. Growth in Sc-glc
inducing medium was as indicated. 20% glycerol stocks of all preparations were made prior to induction.
[IL-1] represents the IL-1 concentration within unpurified vlps. Total IL-1 recovered represents the amount
of IL-1 recovered after removal of cleaved vlps.
v - theoretical yield; * - see below with respect to FXa cleavage, yield calculated on the basis of the
size of the cleaved product actually recovered; * - constitutive production; na - not applicable.
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4.4 Factor Xa (FXa) Cleavage of rIL-1 from Fusion Proteins
Vlps preparations dialysed into FXa buffer were cleaved for 24 hours at 22°C.
From test cuts, a ratio of 1:100 FXa:vlp (w:w) and CHAPS and DOC at 0.05%
(w/v) were established as the lowest concentrations required for efficient cleavage
of all vlps. A western blot probed with anti-pl polyclonal antiserum, shows the
presence of pi in the fusion protein, cleaved fusion protein and pi only
preparations, Fig. 4.8. pi in the cleaved sample is slightly truncated with respect
to native pi because of the IL-1 coding sequence being inserted 5' of the pi stop
codon within the pOGS40/EL-l vector construct.
FIGURE 4.8
Demonstration of the Presence of pi Protein in Vlps
Figure 4.8
Western blot of fusion protein, cleaved fusion protein and native pi vlps probed with
anti-pl antiserum at a dilution of 1/1000.
Lane 1, fusion protein; Lane 2, FXa digested fusion protein; Lane 3, p 1.
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FXa cleavage of ap:pl and Pm:pl fusion proteins gave rise to unexpected
products. The predicted molecular weight of the IL-la proprotein, ap, is 31kDa.
However, digestion of ap:pl gave a main band running at about 21kDa on SDS-
PAGE gels, just above that for the mature IL-la protein. On digesting the Pm:pl
vlp, two bands were consistently seen, but in varying proportions, running at
about 20kDa and 18kDa, instead of the expected one band at less than 20kDa.
(These cleavage products can be seen in Fig. 4.9). On inspection of the amino
acid sequences it appeared that cleavage by the enzyme might have been
occurring at "relaxed" sites. Table 4.3 shows motifs which have been found to be
FXa cleavage recognition sites, the essential amino acid features being: pi basic,
p2 variable, p3 charged and p4 lieu.
TABLE 4.3
Recognition Sites for Proteolytic Cleavage by Factor Xa
Substrate Peptide recognition sequence Refererence
Prothrombin (bo)
p4 P3 p2 pi
EEGR- Magnusson et al., 1975
Prothrombin (h) IDGR- Butkowski et al., 1977
(3-globin IEGR- Nagai and Thorgersen, 1984
HIV p24 vlp ISPR- Gilmouret al., 1989
ovine IL-la IKPR- (position 110-113) putative - current study
ovine IL-1{3 IEEK- (position 240-243) putative - current study
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To test the possibility that the fusion proteins were being cleaved at internal IL-1
sites, the appearance of cleaved IL-1 was followed over 24 hours. Aliquots were
removed from the digestions at time intervals and the reaction stopped by adding
SDS/PAGE load buffer and boiling for 5min. The results, as shown by SDS-
PAGE gels (Fig. 4.9), are consistent with the enzyme cutting at the supposed
relaxed sites. Digestion of ap:pl initially yields the expected 31kDa band with
subsequent appearance of the 20kDa band and eventual loss of the larger band.
Pm:pl digestion shows the initial appearance of the 20kDa band followed by the
18kDa band. On longer incubation the 20kDa band eventually disappears. The
appearance of these bands was not affected by altering concentrations of CHAPS
or DOC.
The apparent molecular weights of the recombinant ovine IL-1 proteins were
larger than expected from the calculated sizes, i.e. ~20kDa as opposed to
17.5kDa for the mature proteins, in good agreement with data on IL-1 from other
species which exhibit the same phenomenon (Maliszewski et. al., 1988). N-
glycosidase treatment confirmed that this effect was not due to glycosylation of
the recombinant proteins.
pi vlps were removed from the digested samples by centrifugation at 100,000g
for 90 minutes which unfortunately also removes a quantity of recombinant
protein, possibly by adherence to the sticky vlps. The recombinant proteins at
this stage were judged to be 80-95% pure and were used for activity studies and
antiserum production. Examples from EL-la preparations are shown in Figure
4.10. Recombinant IL-1 products, after spinning out the pi vlp, are shown in
Figure 4.11.
Final yields of rIL-1 at this stage are detailed in Table 4.2. For receptor binding
studies the am and J3m preparations were further purified by HPLC (see below)
which resulted in further losses of recombinant protein at each dialysis step.
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FIGURE 4.9
Cleavage of IL-1 Fusion Proteins with Factor Xa Protease
Vlps were digested with 1:100 (w/w) FXa in the presence of 0.02% CHAPS and 0.02% DOC. Aliquots were
removed at intervals and the reaction stopped by boiling in SDS-PAGE gel loading mix. Samples were run on
15% SDS-PAGE gels.
(a) IL-lap:pl vlp cleavage products stained with Coomassie blue.
(b) IL-l(3m:pl vlp cleavage products stained with silver.
The positions of fusion proteins, pi, initial EL-1 cleavage product and final IL-1 cleavage product are
indicated by arrows. Lane 9(b), vlps incubated without FXa, shows that the band appearing at >20kDa under























IL-la preparations at various stages electrophoresed through 15% SDS-PAGE gels and stained with
coomassie blue. Lanes 3 (not labelled) and 6 are two different loadings of the same sample.
FIGURE 4.11




Pp Pm am ap
Figure 4.11
Coomassie blue stained 15% SDS-PAGE gel of recombinant IL-1 protein samples after removal of pi vlps
by centrifugation.
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4.5 Biological Activity of Recombinant IL-ls
4.5.1 In vitro Stimulation of Thymocyte Proliferation by Ovine rIL-1
Figure 4.12.a shows the proliferative response of fresh ovine thymocytes to
mature rIL-la (am), mature rIL-ip (Pm), and rIL-ip preprotein (pp) in the
presence of 9pg/ml PHA as co-mitogen in the standard IL-1 assay. Using the
accepted unit of activity, (one unit being that amount of protein which yields
half maximal counts per minute of incorporated 3H-Thymidine), one unit of
ovine am is <0.04ng (>2.5 x 107 U/mg), one unit of Pm is <0.8ng (>1.25 x 106
U/mg). The proportion of upper and lower bands in pm sample preparations did
not affect the activity units obtained. One unit of Pp is ~3.5ng (2.9 x 105 U/mg)
but the level of incorporated counts is 35-40% of the incorporation induced by
Pm. Neither uncut IL-1 :pl vlps nor a 'FXa cut' pi protein control (treated exactly
as the IL-1 :pl vlps and added to the assay at concentrations up to a hundred-fold
greater than those estimated to be in the IL-1 samples) induce thymocyte
proliferation. There is some variation in proliferative response from thymus to
thymus with respect to both total cpm incorporated and background cpm but the
concentrations yielding 1 unit of ovine or porcine IL-1 activity did not vary to
any great extent across these assays. The activity of purified natural porcine IL-
lp (a gift from Dr. J. Saklatvala, Strangeways Research Laboratory, Cambridge)
was assayed for comparison. Using the unit definition of activity, porcine IL-lp,
at lunit = 0.2-0.5ng, is slightly more active than ovine pm and less active than
ovine am. The proliferative response as measured by total incorporation of 3H-T
in a number of assays was however about half that induced by either ovine rIL-1
preparation.
About 50 fold higher amounts of am and 2.5 fold higher pm were required to
stimulate murine thymocytes to proliferate under the same assay conditions as
used for ovine thymocytes (Fig 4.12.b).
The activity of a preparations containing the truncated form of IL-lap was
compared to IL-1 am activity in an assay shown in Fig.4.13. The unit activities
and initial slopes of the curves are similar, but IL-lap appears to yield a
pronounced biphasic curve.
Ovine rEL-1 samples assayed up to 5 weeks after cutting the vlps showed no
decrease in their unit activity if stored at 4°C. Aliquots of samples stored at -
20°C showed some loss of activity on freezing. Pre-incubation at 37°C for as
little as 1 hour caused a large loss of pm activity. (Figure 4.14). EL-la activity
was similarly reduced by freezing (data not shown).
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Figure 4.12
Thymocyte Proliferation as a Measure of rIL-1 Activity
a. Stimulation of Ovine Thymocyte Proliferation by IL-1
1 x 106 freshly isolated thymocytes were cultured with IL-1 in RPMI;10%FCS;50mM P-ME containing
9mg/ml PHA as a co-mitogen, for 48 hours at 37°C, then pulsed with l|i.Ci 3H-Thymidine for 24 hours.
Cells were harvested onto fibre discs and incorporated radioactivity measured.
Proliferation profiles of ovine thymocytes stimulated by purified recombinant ovine IL-1 am, IL-lpp and
IL-lpm expressed in the Ty system are shown. Purified natural porcine IL-ip is included as a contol.
A pi vlp preparation mock-digested with FXa and treated in exactly the same way as the rIL-1
preparations was included as a negative control, pi concentrations were matched to those in the EL-1
samples.
b. Stimulation of Murine Thymocyte Proliferation by Ovine IL-1
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Thymocyte proliferation was assayed as described for Figure 4.12.
The activity of a freshly purified IL-lap preparation which contained the truncated FXa digested form was
compared with a fresh IL-lam preparation. Mock-digested pi was included in the assay as a control.
In the assay shown, the background counts with medium alone were unusually high (~25000cpm).
Figure 4.14
Thymocyte proliferation was assayed as described for Figure 4.12.
The stimulating activity of aliquots of purified IL-1 Pm stored either at 4°C in PBS or at -70°C in PBS
containing 0.1% bovine serum albumin were compared. The effect of incubating IL-lpm for 1 hour at 37°C
prior to adding to the cells was also tested.
FIGURE 4.13
Comparison of rIL-lam and FXa truncated rIL-lap Stimulation
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4.5.2 In vitro Induction of Cartilage Degradation by Ovine rIL-1
The rIL-ls were assayed for their action in triggering metalloprotease activity
with resultant release of glycosylaminoglycans from ovine xiphoid cartilage
(Figure 4.15). The activities of both mature proteins were about 10 fold less in
this assay than in the ovine thymocyte assay, one unit of am being ~200pg (5 x
106 units/mg) and of (3m being ~10ng (1 x 105 units/mg). Storage at -20°C also
reduced IL-1 activity in this assay, as shown by the curve obtained with IL-la.
IL-1(3 activity was similarly affected (data not shown). As in the thymocyte
assay, none of the controls showed any positive effect in this assay. Porcine IL-
1(3 activity was not compared in this assay due to shortage of material.
FIGURE 4.15
Ovine rIL-1 Induced Degradation of Ovine Xiphoid Cartilage
1 x 2mm discs cut from fresh ovine xiphoid cartilage were pre-incubated for at 37°C for 40 hours in DME
medium plus 5% fetal calf serum. IL-1 in fresh medium was added and the discs cultured a further 30 horn's.
Release of glycosylaminoglycans was measured by adding dimethylene blue dye in formate buffer to aliquots
of supernatant. The amount of gags present was determined by comparing OD535nm readings with a standard
curve constructed with fresh chondroitin sulphate solutions.
Release of gags by the action of IL-la and IL-ip stored at 4°C as well as by IL-la stored at -20°C is shown.
IL-ip activity is similarly reduced by -20°C storage (not shown).
Endotoxin levels in all samples were low and did not affect any of the assays
descibed above.
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4.6 Storage of Fusion Proteins
The fusion proteins are stable for months if stored at 4°C in at least 25% sucrose.
If stored in buffer or low sucrose concentrations, the fusion proteins start to
degrade within 3-4 weeks even in the presence of 0.1% azide. Samples were
therefore dialysed into Factor Xa buffer only when required for cleavage. No loss
of IL-1 activity occurred under these conditions. Freezing of vlps at either -20°C
or -70°C tends to cause clumping with subsequent reduction in both IL-1 yield
and activity and is best avoided.
4.7 Polyclonal Antisera to rOvIL-1
Monoclonal antibodies to IL-1 a and IL-1 (3 are currently under production. Only
polyclonal antisera are dealt with here.
4.7.1 Rabbit Anti-IL-l(3m
Rabbits were injected with either uncut (3m:pl vlps or purified IL-1 (3m samples
in which pi protein concentrations were below the limits of detection by either
by coomassie blue or silver staining of SDS-PAGE gels. In both cases anti-IL-1
responses were overshadowed by a strong response to the pi protein, as
demonstrated by a Coomassie stained gel and Western blot of FXa cleaved IL-
1(3 samples from which vlps have not been removed (Fig. 4.16). The polyclonal
rabbit antiserum raised against (3m, and used at a dilution of 1/50, also cross-
reacted with the proprotein, as indicated by arrows. There is no cross-reactivity
of the anti-(3m antiserum with am (data not shown). Polyclonal rabbit anti-pl
antiserum, raised against a pi vlp preparation, does not cross-react with any of
the IL-1 proteins on Western blots (see Fig. 4.9 for an example of a cut (3m:pl
vlp preparation blotted against anti-pl, in which only the pi band is positive).
The anti-(3m antiserum shows weak neutralisation of IL-1 (3m activity in
thymocyte assays (Fig 4.17). IL-1 a activity was not affected by this antiserum.
Polyclonal rabbit anti-pl antiserum used at dilutions of 1/10, 1/100 and 1/1000,
did not inhibit IL-1 activity in the assay.
4.7.2 Rabbit Anti-IL-lam
An initial bolus of lOpg am in complete Freunds' adjuvant had no adverse effect
on the two rabbits injected but a secondary boost of 4pg am in incomplete
Freunds' adjuvant resulted in death after 24-36 hours. I have, to date, no
available anti-ovine rIL-la polyclonal antiserum.
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Figure 4.16
Reactivity of Polyclonal Rabbit anti-IL-lBm Antiserum
as Visualised on Western Blots
A Coomassie blue stained 15% SDS-PAGE gel shows the positions of uncut IL-ip vlps and IL-ip proteins in
cleaved samples from which pi has not been removed. A companion gel blotted with polyclonal rabbit anti-
pm at a 1/50 dilution shows positively reacting bands. The positions of Pm and Pp on both gels are indicated.
Lane 1, markers which apply to both coomassie stained gel and blot; Lanes 2-5, Coomassie stained gel,
Lanes 6-9, Western blot with anti-Pm. Bands containing pi protein are overexposed in order to visualise the
specific IL-ip bands.
Lane 2, uncut Pp:pl vlps; Lane 3, FXa cut Pp:pl; Lane 4, uncut Pm:pl vlps; Lane 5, FXa cut Pm:pl with
pi removed by centrifugation.
Lane 6, uncut Pm:pl vlps; Lane 7, Fxa cut Pm:pl (with pi still present); Lane 8, FXa cut pp:pl;
Lane 9, uncut Pp:pl vlps.
Figure 4.17
Neutralisation of IL-ipm Induced Thymocyte Proliferation
by a Rabbit Polyclonal anti-pm Antiserum
EL-l samples were pre-incubated for 1 hour at 37°C with (i) no antiserum; (ii) normal rabbit serum; (iii)
polyclonal rabbit anti-Pm at 1/10, 1/20 and 1/50 dilutions; (iv) polyclonal rabbit anti-pl at 1/10 dilution. As
controls, medium was incubated with or without the antisera. Pre-incubated samples were assayed with fresh
thymocytes as described for Fig. 4.12.
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4.8 HPLC Purification of IL-la and IL-1J3 Mature Proteins
It has been demonstrated in Section 4.5 that the small amounts of contaminating
proteins in the rIL-1 preparations do not interfere with the biological activity of
the proteins. However, receptor binding studies with either iodinated or
biotinylated material require rIL-1 samples which are as pure as possible. In
addition, because of the antiserum data obtained thus far, it seemed advisable to
use HPLC purified material for the generation of both monclonal antibodies and
reasonable titre polyclonal anti-IL-1 antisera.
Samples of am and (3m from which pi had been removed, were further purified
by HPLC using a DEAE column with a 40ml 0-500mM NaCl gradient in either
20mM Tris pH8.0. The (3m sample chosen for HPLC purification contained
minimal detectable amounts of the truncated form. Because of decreased protein
concentrations due to spinning out pi vlps from cleaved preparations, samples
were subsequently purified without first removing the pi and this modification
proved to be successful.
0.5ml fractions were collected and 50-100(_il aliquots of selected fractions were
acetone precipitated and visualised on SDS-PAGE gels. Fig. 4.18 shows pre and
post purification material, am eluted from 200-250mM NaCl and (3m from 63-
125mM NaCl.
Assay by thymocyte proliferation showed that the fractions containing bands of
the correct size were also active at the expected level (Fig. 4.19).
The concentration of pooled am fractions after HPLC was ~20p.g/ml, and of
pooled (3m was ~lpg/ml. These samples were used for biotinylation and
iodination (see Chapter 5).
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FIGURE 4.18
HPLC Purification of IL-lam and IL-ipm
a. Coomassie blue stained 15% SDS-PAGE gel of FXa cut EL-lam vlps.
Lane 1, Pre-HPLC;
Lane 2, Post purification by ion-exchange HPLC. Acetone precipitated aliquot of a column fraction
containing IL-lam.
b. Silver stained 15% SDS-PAGE gel of IL-lpm.
Lane 1, Pre-HPLC;
Lane 2, Acetone precipitated aliquots from sequential HPLC fractions containing purified IL-ipm.
The mark across the gel at ~50Kd is a staining artefact which appears on all silver stained SDS-PAGE
gels.
c. Pooled purified HPLC preparations were dialysed into PBS. Aliquots of these were acetone precipitated,
electrophoresed through 15% SDS-PAGE gels and stained with Coomassie blue. These samples were used




Biological Activity of HPLC Purified IL-lam and IL-l|3m
The activity of pre-HPLC and post HPLC purified IL-1 (samples shown in Fig. 4.18.C above) was determined
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DISCUSSION
Although the Ty-vlp system had not previously been used for cytokine
expression, the advantageous features displayed on expression of viral proteins
appeared to fulfil the requirements for recombinant ovine IL-1. From the
experience of expressing IL-1 in the Ty-vlp system it has become apparent that
these features do not hold universally. Biologically active ovine IL-1 a and IL-1 (3
were produced but the protein yields were lower than expected, Factor Xa
cleavage of the vlps yielded unexpected products and the immunogenicity of the
fusion proteins was not satisfactory. The reasons for this and the consequences
are discussed below.
Of the four IL-1 fusion proteins, the IL-1 (3m vlp yields (3.7mg/l) were lowest
and IL-1 am vlp yields highest (8.9mg/l). Yields of the two proprotein vlps were
intermediate (5.3-6.2mg/l). In addition, although the initial protocol
recommended 24 hours induction, continued induction for longer than 36 hours
increased IL-1 a vlp yields, ap:pl more so than am:pl. 66 hours induction was
required to produce equivalent yields of (3p:pl vlps but decreased (3m:pl vlp
yields. By comparison, yields of constitutively expressed pi vlps were 20mg/l
after 24 hour culture. As all these vlps were synthesised from the same promoter
and the numbers of cells in the lAm and lBm cultures were roughly equivalent,
these differences could be indicative of IL-1 vlp stability differences within the
yeasts. Evidence of some in vitro |3m:pl instability is seen during 4°C storage of
vlps, |3m vlps tending to start degrading in advance of the others if stored in
buffer as opposed to sucrose. Incubation at 25°C can also cause non-specific
degradation of (3m vlps.
In our department, the Ty system has now been used for the production of a
number of recombinant proteins including TNFa, IL-2, IL-2R, IL-6 and maedi-
visna retroviral (MVV) proteins. Data is emerging that not all proteins can be
expressed efficiently as vlps but not enough data is yet available to evaluate the
reasons for these differences.
Vlps form in a range of sizes, as evidenced by sucrose gradient purification and
electron microscopy. Individual vlp structures appear to vary, pi vlps show
regular morphology whereas a large proportion of the IL-l:pl vlps (both IL-1a
and IL-1 (3) show irregularities which are independent of vlp size. These
irregularities presumably result from three-dimensional restraints induced by the
recombinant protein. Distorted morphology has been similarly reported for HIV-
1 p24 and MVV p25 vlps (Gilmour et al., 1989; Reyburn et al., 1992).
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Ovine IL-lam was synthesised with N-terminal Ser-120 following bovine IL-la
data (Maliszewski et al., 1988). This protein was active in the expected range
(see below). Ser-113 is most often cited as the N-terminal of human or murine
IL-lam. Active proteins or subpeptides with other N-termini are however
routinely detected in biological fluids (Cannon and Dinarello, 1985). A number
of enzymes have been implicated in the processing of the IL-la preprotein. A
calcium activated neutral protease, calpain, digests the protein at Ser-113
(Kobayashi et al., 1990). Trypsin and chymotrypsin (cut sites Arg vSer and Phe
vLeu respectively) as well as serine proteases have all been proposed as IL-la
processors (Lomedico et al., 1984, Cameron et al., 1986, Cannon and Dinarello,
1985). Of interest is that the putative sequence at which Factor Xa is cutting the
ap:pl vlps is IleuLysProArgvSer, Gin replaces Lys in the mouse but otherwise
this sequence is conserved across all other species so far sequenced (see Chapter
6 for full sequence comparisons). Jones and Geczy (1990) found that Factor Xa
and thrombin greatly increased IL-1 activity in macrophages stimulated by
suboptimal concentrations of LPS. It was proposed that this was via FXa
conversion of prothrombin to thrombin. The Factor Xa cleavage pattern of
purified ap:pl vlps has raised the interesting possibility that FXa could be acting
directly on IL-la.
IL-1 moves anomalously in SDS-PAGE gels which may be due to the highly
charged nature of the proteins. This phenomenon has been reported for various
polypeptides (Marnell and Summers, 1984). Bovine and human rIL-1
(Maliszewski et al., 1988; March et al., 1985), as well as ovine IL-1 expressed in
an E. coli system (P. Wood, personal communication, 1993), behave in a similar
fashion.
It is difficult to quantify differences in IL-1 activity as measured in biological
assays. From the thymocyte proliferation curves obtained, it is obvious that both
total 3H-T incorporation and unit activity values have a bearing. For example,
the initial slopes of ovine and porcine IL-1 [3 induced proliferation curves are
superimposable but the extent of proliferation, as measured by maximum cpm
incorporated, is about 1.5 times greater with the ovine material. The unit
activities of these two proteins, however, indicate that porcine IL-1 {3 is slightly
more active in this system than ovine. Similarly the proliferation curve obtained
from rIL-1 which had been stored at -70°C showed the same initial slope but
with reduced maximum incorporation. In the following discussion, stated IL-1
activities are based on the generally accepted definition of IL-1 unit activity
which is:- that amount of IL-1 which will induce half-maximal proliferation.
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The activities of ovine rIL-ls in thymoctes assays, ~2.5xl07 units/mg IL-la and
>1.25xl06 units/mg IL-1{3, compare favourably with reported thymocyte
activities of human and murine rIL-ls (Lomedico et al., 1984; Gubler and
Hoffman, 1983; Huang et al., 1988; Tocci et al., 1987) and purified natural
bovine IL-1 (Lederer and Czuprynski, 1989b), ie. Ranging from 1 x 106 to 5 x
107 units/mg for IL-la and 1 x 106 to 5 x 106 units/mg for IL-ip. The reported
activities of human rIL-1 expressed in E. coli are only very slightly lower than
those of murine rIL-1 from E. coli, when assayed on fresh mouse thymocytes or
on murine cell lines, a reflection of the close homology of the human and murine
proteins. Results obtained from ovine rIL-1 stimulation of ovine and murine
thymocytes show a preference for the homologous cells, a phenomenon already
described with respect to the activity of natural purified bovine IL-1 (Lederer
and Czuprynski, 1989b), recombinant bovine IL-1 (Maliszewski et al., 1988)
and recombinant human IL-1 (Thieme et al., 1987). The human rIL-1 did not
stimulate ovine or bovine thymocytes to proliferate. From preliminary work for
the study being reported here, there was little evidence of commercially
produced anti-hIL-1 antisera having much neutralising activity against ovine
macrophage supernatants in the thymocyte assay (data not shown). This
preference for homologous cells needs to be taken into account when addressing
the biological activity of IL-1, especially as the species specificity appears to
depend on which IL-1-mediated activity is being examined. For example, human
endothelial cells can be induced by both human and murine IL-la to produce
platelet-activating factor whereas only the human IL-la induces secretion of
PGI2 in these cells (Dejana et al., 1987).
Just prior to submitting this thesis it was reported that the activity of ovine IL-
lfJm expressed in E. coli and assayed with ovine thymocytes was >106 units/mg
(P. Wood, personal communication, 1993), similar to the activity of the Ty-
expressed ovine IL-lpm reported here.
The activities of both IL-la and IL-lp are about ten times lower in the cartilage
assay than in the thymocyte assay. Freezing rIL-1 at -20°C has also been shown
to result in a loss of ovine rIL-1 activity, thymocyte proliferation being less
affected than cartilage degradation.
None of the IL-l:pl vlps show any biological activity. Presumably residues
required for receptor binding are not accessible.
Despite the use of fresh tissue, the reproducibility of the thymocyte assay was
good. IL-lam activity ranged from 2.5xl07 to 5xl07 units/mg and IL-lfJm
activity from 1.25xl06 to 3xl06 units/mg. IL-la and IL-ip stimulation of
thymocytes did however produce different proliferation profiles. When assayed
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concurrently, the amount of IL-lam required to induce half-maximal
proliferation was about 20 times less than IL-1 (3m but the maximum cpm of
incorporated 3H-thymidine (3H-T) induced by IL-lp was greater. The initial
slopes of the proliferation curves were similar for all the recombinant ovine IL-
ls and as well as for natural purified porcine IL-1 (3 (see Fig. 4.12.a). Ovine IL-
l|3p and IL-1 (3m induced ^H-T incorporation both reached maximal levels at 20-
30ng then decreased dramatically with increasing IL-1 concentration. Porcine
IL-1(3 produced a similar profile but with a much lower amplitude of
incorporated counts. In contrast, IL-1 a induced incorporation seemed to plateau
at >lng IL-1.
The data obtained for IL-1 (3m activity suggests that truncated 18kDa form is
active because the activity detected in thymocyte and cartilage assays seemed to
be independent of the proportions of 20kDa and 18kDa forms in the
preparations. Antibody studies and mutational analyses reported in the literature
are conflicting as to the essential requirements for IL-1 [3 activity and there is
little data on the importance of C-terminal amino acids. One study suggests that
amino acids 163-171 and 187-204 are the essential domains for IL-1 (3 activity
(Boraschi and Tagliabue, 1990), each being important for different functions, but
another study has suggested that amino acids up to 259 are essential for activity
(Mosley et al., 1987a). Yet others have reported a core peptide which retains
biological activity (Schmidt and Bomford, 1991). It seems to be clear that even
point mutations at distinct locations can uncouple IL-1 activities (see Chapter 1
Sect. 1.11.1.6). Whether the loss of amino acids 244-266 from IL-1 (3 has any
biological relevance has yet to be determined. Residue 245 is fully conserved
across IL-1 a, IL-1 (3 and the IL-1 receptor antagonist which may indicate a
structural or receptor binding rather than signal transducing function. From the
data obtained with ovine IL-1 (3, it appears that loss of this residue does not
adversely affect IL-1 (3 activity, at least with respect to ovine thymocyte
proliferation or cartilage degradation. Both these cell types possess the type IIL-
1 receptor which has a greater preference for IL-1 a than IL-1 (3 (see Chapter 1
Sect. 1.11.1.3). It may be that the truncated form would not be as active on cells
possessing the type II receptor which have a greater preference for IL-1 (3 than
IL-1 a. IL-1 structure/function relationships will be discussed in Chapter 6.
Human IL-1 [3 possesses a glycosylation site at residues 123-125 in the mature
protein. Glycosylated rhIL-l|3 mature protein has been produced in yeast and
CHO cells but only by use of fused hybrid secretory sequences (Casagli et al.,
1989; Pecceu et al., 1991). This protein is inactive until deglycosylated. It is
possible that human IL-1 {3 could be glycosylated in vivo although there is no
evidence for this. Glycosylation may inhibit receptor binding as three residues
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(Arg-120, Leu-122, Glu-128) of the seven implicated in receptor binding
(Labriola-Tompkins et al., 1991) are in very close proximity to this site. The
ovine rIL-ls are not expressed as glycosylated proteins in the yeast Ty system.
The choice of vector, (including promoter and enhancer) and expression system
affect the production and activities of recombinant proteins. This is the case with
glycosylated mature hIL-1 (3 as mentioned above and is also clearly seen with
respect to IL-1 [3 proprotein, IL-l(3p, which until recently has been thought to be
biologically inactive in vivo. Ovine IL-l(3p, synthesised from the PAL promoter
in yeast, was bioactive although the unit activity was about five times less than
IL-1 (3m and the amplitude of 3H-T incorporated in the thymocyte assay was
about 30% of that after induction by IL-1 (3m. E. coli has been reported not to
produce active IL-l(3p but there are three reports of the recombinant protein
having some activity when expressed in other systems. Two studies using
mammalian COS-7 cells and one using in vitro translation have produced
recombinant IL-l(3p which is active on the murine D10.G4.1 cell line and on
fresh thymocytes.
The one COS-7 cell study produced active human IL-l(3p under full control of
SV40 sequences (Rosenwasser et al., 1986). The relative activities of the hlL-
l(3p and hIL-1 (3m proteins from this system were similar to those found for the
ovine proteins in the thymocyte assay.
Interestingly, the other COS-7 cell study, by Andrews et al, (1992), concerned
ovine IL-l(3p expressed from a vector containing the SV40 origin of replication,
enhancer and polyA signal, and under control of a human metallothionine
promoter. In this system, deletion of the 3' untranslated sequence which is
supposed to confer instability on the mRNA, resulted in greatly increased yields
of active IL-1 a and IL-1 (3 preproteins. Figures are not quoted for protein yields
or purities and the activities are quoted as raw counts not units. It is therefore
impossible to relate these quantitatively to the ovine IL-1 activities which I
found.
In the third report, Jobling et al. (1988), synthesised biologically active hIL-l(3p
in the rabbit reticulocyte translation system using bacteriophage SP6 polymerase
(Melton et al., 1984; Krieg and Melton, 1984). The protein yield was
significantly increased by replacing the cognate IL-1 (3 leader sequence with the
37 nucleotide plant viral leader, alfalfa mosaic virus RNA 4. Only by enhancing
mRNA translational efficiency, using the chimeric mRNA, was sufficient
protein produced to stimulate thymidine incorporation. The specific activity of
IL-1 (3 proprotein was 6.8 x 105 units/mg in the D10.G4.1 assay and the specific
activity of IL-1 (3 mature protein, synthesised and assayed in an identical way,
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was 1.7 x 108 units/mg, similar to that reported for IL-1 (3m synthesised in E. coli
and assayed with D10.G4.1 cells. (March et al., 1985). Generally, human and
murine IL-1 (3 D10.G4.1 activities seem to be 50 - 200 times greater than
thymocyte activities (Auron et al., 1984; March et al., 1985; Jobling et al.,
1988). On this basis, ovine IL-1 [3m and IL-1 [3p activities in the ovine thymocyte
assay (>1.25 x 106 units/mg and -2.9 x 105 units/mg respectively) were both
roughly comparable to the above.
From the above, transcriptional and translational control of rIL-1 production
both seem to be important with respect to its activity. Posttranslational
modification may also be of importance. The importance, therefore, of
producing recombinant proteins with characteristics as close as possible to the
natural protein, is obvious.
Immunisation of rabbits with IL-ipm vlps produced a minor anti-IL-ip and
major anti-pl response which may have been a consequence of the irregular
shape of the vlp. pi has been found to be extremely immunogenic (Kingsman
and Kingsman, 1988) and it may be that presentation of a recombinant protein in
the form of a vlp is only advantageous if the vlps are completely regular and the
pi protein presumably not accessible. Purified rIL-l(3m from which the cleaved
pi had been spun out and was not detectable by coomassie staining was
subsequently used for immunisation. Again a strong anti-pl response was
obtained. There is no amino acid homology between pi (Mellor et al., 1985) and
IL-1 and neither does anti-pl antiserum react with either IL-1 protein on
Western blots. IL-1 has been advocated for use as an adjuvant (Tagliabue et al.,
1991) and it is possible that IL-1 (3 could be acting as an adjuvant for the pi
response in this case. In view of the 76% similarity between the rabbit and sheep
mature IL-1 (3 proteins, there may also be limited 'foreign' IL-1 sequence for the
rabbit to recognise, resulting in a low-grade response to the ovine DL-1.
It has been presumed in the literature that a conformational change, resulting
from the enzymatic removal of the N-terminal portion of IL-l(3p is required for
the generation of biologically active IL-1 (3m in vivo (Mosley et al., 1987a). The
rabbit anti-ovine-IL-1 (3m polyclonal antiserum cross-reacted with ovine IL-l(3p
on Western blots indicating that at least some of the epitopes are similarly
exposed in both proteins. There is a possibility that the folding pattern of
recombinant IL-l(3p protein may not be identical to that of the natural molecule.
If so, this may also have some bearing on the activity detected although the
antiserum was not tested for neutralisation of (3p activity. There are no reports in
the literature of antisera to IL-1 (3 cross-reacting with IL-1 a andvv. Polyclonal
anti-ovine-IL-1 (3m also did not cross-react with ovine IL-1 am on Western blots.
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In conclusion, biologically active preprotein and mature forms of ovine IL-la
and IL-lp have been expressed in as recombinant proteins in Saccharomyces
cerevisiae strain BJ2168 using Ty-vlp expression vectors. Yields of the purified
proteins range from 0.3 to lmg/1 and purities have been estimated at 80-95%
prior to HPLC purification.
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CHAPTER 5
II -1 RECEPTOR EXPRESSION BY OVINE AFFERENT LYMPH
DENDRITIC CELLS
INTRODUCTION
There is currently much interest in the mechanism whereby T cells become
sensitised to antigen and on the induction of cytotoxic T cell responses by
specialised antigen presenting cells (APC), dendritic cells, macrophages and B
cells being considered to be the most potent of these. Accessory cells perform at
least two important functions with respect to T cell responses to antigen, (i) to
present antigen, usually in association with major histocompatibility (MHC)
Class I or Class II glycoproteins, for recognition by clonotypic antigen receptors
on T cells; (ii) to activate and induce subsequent proliferation of antigen specific
T cells. Generally, antigens taken up by APC, are processed within these cells to
small peptides, 8-12 amino acids, which are presented to T cells in association
with specialised glycoproteins, the most common being MHC Class I and Class
II molecules (Monaco, 1992; Neefjes and Ploegh, 1992). Endogenously derived
peptides are presented by Class I molecules and exogenously derived peptides
by Class II molecules. A wide variety of MHC Class II-positive cells induce
proliferation of previously activated T cells but only dendritic cells have the
capacity to cluster with and stimulate proliferation of normal resting T cells
(Inaba et al., 1984). Knowledge about the sphere of influence of cytokines on
both antigen processing and presentation is assuming increasing importance and
it is becoming clear that data from one type of APC can not necessarily be
extrapolated to another.
Dendritic Cells
Dendritic cells (DC) form a system of antigen presenting cells which function to
initiate several immune responses such as the sensitisation of MHC-restricted T
cells, the rejection of organ transplants and the formation of T-dependent
antibodies. Immature DC, which are highly specialised to process foreign
antigens, reside in non-lymphoid tissues. They migrate via the afferent
lymphatics or the blood to the T-dependent areas of lymphoid organs where, as
mature interdigitating dendritic cells, they can efficiently stimulate resting
antigen-specific T cells. DC do not migrate further and are not found in efferent
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lymphatics (Pugh et al., 1983; Knight, 1984; Kraal et al., 1986; Bujdoso et al.,
1989; Fossum 1989; Larsen et al., 1990). Follicular dendritic cells which are
involved in the regulation of B cell function are derived from a different lineage
and are not under consideration here.
Cells with a dendritic, veiled, cell morphology were first descibed in afferent
lymph in 1978 by Kelly et al. and have become the subject of increasing interest
as potent antigen presenting cells. Following exposure to sensitising chemicals,
dendritic cells rapidly accumulate in the draining lymph nodes. A proportion of
the DC arriving at the nodes bear significant amounts of antigen and are derived
from epidermal Langerhans' cells (LC). LC, immature DC, are relatively
inefficient antigen-presenting cells but as they migrate from skin to lymph node
they are subject to a phenotypic maturation and the antigen-bearing DC found
within the draining node are potent accessory cells which can induce immune
responses both in vivo and in vitro (Steinman, 1991; Fossum, 1991; Romani and
Schuler, 1992). 5-10% of the afferent lymph mononuclear cell population
consists of DC. Not all of these DC are skin derived, as indicated by the absence,
in a small percentage of cells, of CDla-i- and CDlc+ expression, specific
markers for LC (Caux et al., 1992).
Earlier controversy as to whether DC are metabolically active and whether they
phagocytose and process antigen is now beginning to be resolved. Recent data
indicates that LC are initially endocytic but as their antigen presentation
potential increases, the cells no longer process antigen. Endocytosis through late
endosomes has been shown to be as active in DC as in other antigen presenting
cells and chloroquine inhibition of antigen processing has confirmed a central
role for acidified endocytotic processing to form peptide-class II MHC
complexes for presentation to CD4+ T cells (Stossel et al., 1990; Cohen and
Katz, 1992; Hoyne et al., 1993; Levine and Chain, 1992). This is not, however,
the complete picture. Membrane peptidase mechanisms are expressed by DC and
there is evidence that initial processing may release peptides which are
subsequently internalised and processed (Chain et al., 1989; De Bruijn et al.,
1992). Immune complexes may also be retained on the surface of some DC for
the purposes of antigen transport (Szakal et al., 1989). The expression of Fc
receptors, which enhance antigen uptake by B cells and macrophages, does not
seem to be a uniform characteristic of DC and may be related to the above.
Murine lymph node and spleen (Nussenweig et al., 1981) and human peripheral
blood DC (van Voorhis et al., 1982) do not appear to express FcR whereas rat
lymph node (Schalke et al., 1985), murine pulmonary tissue (Sertl et al., 1986)
and Langerhans cells (Spry et al., 1980) and human afferent lymph do (Witmer-
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Pack et al., 1988). FcR" DC have been implicated as the major antigen
presenting cell in the murine thymus (Inaba et al., 1988).
IL-1, Dendritic Cells and the Immune Response
Antigen presentation by dendritic cells requires antigen/la (Class II) complex for
specific recognition of antigen. Until comparatively recently, not a great deal has
been known about the interactions of DC and cytokines but information is
accumulating increasingly rapidly. Much of the data currently in the literature
has been derived from tissue culture studies using cells derived from skin,
thymus, spleen, tonsil and lymph nodes. Some differing DC characteristics have
been detected which may be a consequence of localised and specific functional
requirements of the DC in the different tissues.
IL-1 mRNA has not been consistently detected in DC populations from
lymphoid tissue or peripheral blood (Calder et al., 1992; Hopkins et al., 1990;
Koide et al., 1987b, 1988; Vakkila et al., 1990; Waalen et al., 1986) and IL-1
production may depend on the state of differentiation or activation of the cells.
DC from inflammatory sites appear to produce large amounts of IL-1
spontaneously while associated peripheral blood DC produce minimal amounts
(Waalen et al., 1986). Maturing DC in culture have been found to produce large
amounts of IL-1 (3 (Ruppert and Peters, 1991; Heufler et al., 1992).
From much of the published work on DC as antigen presenting cells, an
amplifying rather than an initiating role is currently being ascribed to IL-1. It
appears that IL-1 is not essential as a second signal for allogeneic T-cell
responses, but rather enhances the function of the accessory dendritic cells
(Bhardwaj et al., 1989; McKenzie et al., 1989; Vakkila et al., 1990; NaitoK et
al., 1989). Rabbit and murine DC function can be amplified by pre-exposure to
IL-1 (Kapsenberg et al., 1985; Koide et al., 1987a) and this enhanced function is
not blocked by anti-IL-1 (Inaba et al., 1988), suggesting direct action of IL-1 on
the DC not the T cell.
GM-CSF is a major macrophage activating factor which, apart from inducing
cytokines, also induces macrophage HLA-DR expression (Chantry et al., 1990).
It is currently thought that GM-CSF is the most important mediator of the
maturation of LC into DC (Heufler et al., 1992). GM-CSF and TNF have now
been shown to co-operate in the generation of dendritic Langerhans cells from
hematopoetic stem cells (Caux et al., 1992). In vivo, IL-1 may synergise with
GM-CSF and TNF to initiate mobilisation of Langerhans cells from the
epidermis and maturation into lymph borne dendritic cells (Cumberbach and
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Kimber, 1992). Whether IL-1 is a requirement for this process is not certain,
although there is experimental evidence that injection of human IL-1 a into pigs
induces transient dose-dependent lymphocyte traffic into the draining lymph
nodes which peaks at 4h, earlier than that induced by bovine or human TNFa
which peaks at 9-12h (Binns et al., 1992). There are a number of reports of
direct augmentation of the DC/Tcell reaction by GM-CSF or GM-CSF plus IL-1
(Heufler et al., 1988; Koide et al., 1988; Wilson et al., 1988). Some authors
suggest that IL-1, in contrast to TNF, has no effect on DC viability. TNFa on
the other hand does not appear to be involved in either maturation of DC or
antigen presentation (Koch et al., 1990; Hosoi et al., 1993).
DC rapidly upregulate adhesion molecules in vitro (Teunissen et al., 1990)
which is important with respect to the immunogenicity of DC associated with
antigen. Recent studies have shown that stratum corneum-derived human IL-1
injected into the skin will upregulate dermal dendritic cell expression of the
adhesion molecules ICAM-1 and VCAM-1 (Groves et al., 1992).
Much remains to be learnt about IL-1 involvement both in antigen uptake by DC
and in antigen presentation.
Sheep Afferent Lymph Dendritic Cells
Because of the importance of afferent lymph dendritic cells in antigen
presentation and their pivotal role in the immune response, the relationship
between these cells and IL-1 needs to be established. Any influence of IL-1 on
DC could be via either direct or indirect mechanisms. From the data available at
the start of this study, it seemed highly likely that DC could possess IL-1
receptors. One of the main reasons for the lack of data on fresh DC is the
problem of obtaining sufficient numbers of DC ex vivo, especially if working
with small animals. Because of the ease of cannulation of its lymphatic ducts,
the sheep is ideal for the study of cells in afferent lymph. Using this system,
fresh cells can be continuously collected hence obviating cell culture, which
could potentially affect the characteristics displayed by the cells. Cannulation
also allows detection of early in vivo events following antigen challenge of the
draining skin area.
DC numbers in normal sheep afferent lymph are ±1x105 DC/ml, comprising 5-
8% of the cell population and sufficient for isolation provided the lymph flow
rate is reasonable. Study of DC freshly isolated from sheep afferent lymph
would be expected to give information on DC characteristics expressed in vivo,
both in a resting state and after antigen challenge.
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Macrophages (M<j>) are also potent antigen presenting cells but to a much lesser
degree than DC. Various differences between cell surface markers expressed by
macrophages and DC have been noted on human and murine cells. Very few
markers, however, have so far been proposed for specific identification of DC
and, because of lack of species cross-reactivity, none of these can be used for
definitive identification of sheep DC. As opposed to macrophages, DC are only
transiently adherent to glass or plastic, a fact which is utilised for separation of
the two populations.
Much work has been done in our department on the characterisation of sheep
afferent lymph dendritic cells (Bujdoso et al., 1989, 1990; Hopkins et al., 1989;
Harkiss et al., 1990). Sheep afferent DC constitutively express ± 3 x 105 MHC
Class II molecules per cell but cells entering the lymph node from a site of
secondary antigen challenge express a sixfold higher level than this. The
majority of DC express surface immunoglobulin (Ig) of IgM and IgGl types. At
least four subpopulations of dendritic cell enter the lymph node via the afferent
lymph; CD1+, CD1", FcR+, and FcR". It is not yet clear whether these represent
distinct cell types or cells in transitional states. Evidence for the latter comes
from cultured murine LC which lose expressed FcR as they develop into DC
(Witmer-Pack et al., 1988; Romani et al., 1989). Approximately two thirds of
sheep afferent lymph DC bind antigen/antibody complexes via Fc receptors. Of
these cells, about 43% were shown to be CD1+ and are likely to be LC derived.
The complexes may be internalised and processed, or the DC may be acting as
carriers presenting antigen in an undegraded form. Class II positive, FcR+ DC
are known to be efficient at presenting antigen to CD4+ T cells and the CD1+,
FcR" dendritic cell has been proposed as the principal presenting cell for ovine
y5 T cells via a heat shock protein/CD 1 ligand which would obviate the
necessity for FcR (Harkiss et al., 1990). Whether there is restriction amongst the
lymph DC subsets with respect to antigen presentation has still to be clarified.
Morphologically different DC subpopulations are found in sheep afferent lymph
but little is known about their origin and surface antigen expression. In culture,
murine DC developing from LC become veiled cells, showing highly
characteristic sheet-like cytoplasmic processes and being typically devoid of
organelles (Romani et al., 1989). These cultured cells are not necessarily
identical to freshly isolated DC. Interdigitating dendritic cells while they are
resident in tissues display dendritic processes and contain cell organelles
whereas, once isolated, they display veiled cell characteristics. In culture, the
dendritic processes seem to be constantly extended and retracted. The sequence
of events during in vivo differentiation is not known and veiled morphology can
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not therefore be assumed to be the final stage of differentiation. LC are
generally identified by the presence of Birbeck granules which can be seen in
ultrathin sections viewed in the electron microscope (Birbeck et al., 1961), or by
membrane ATPase (Juhlin and Shelley, 1977). Maturing murine and human LC
in culture may lose these LC specific Birbeck granules but this does not seem to
be the case for all LC/DC and can not be used as a reliable indicator of
maturation stage (Schuler et al., 1985; Romani et al., 1989; Bucana et al., 1992).
Ovine LC do not stain for ATPase but epidermal dendritic cells which contain
acetylcholinesterase (AChe) have been identified specifically as being LC
(Hollis et al., 1972). Changes in AChe staining with maturation of ovine LC has
not been determined but AChe activity might be expected to diminish with
decreasing processing potential.
Antigen presentation to T cells by sheep afferent lymph DC is much more
efficient during secondary responses to antigen. From data showing increased
proliferative responses due to increased uptake of antigen in the presence of
specific antibodies, it has been proposed that FcR mediated uptake could
represent a mechanism whereby antigen can be concentrated during secondary
responses (Harkiss et al., 1990).
The mechanism whereby EL-1 influences the DC has yet to be elucidated. One of
the methods by which the response of DC to IL-1 could be studied, is by
determining IL-1 receptor expression by DC.
IL-1 Receptors
Two types of cellular IL-1 receptor have so far been characterised and have been
described in detail in Chapter 1. Although IL-la and EL-1(3 differ markedly in
amino acid sequence, the two proteins bind to the same receptors and induce
similar biological responses (reviewed in Chapter 1, Sect. 1.11.1.3). The binding
is specific and saturable but the relative affinities differ depending on cell type.
The two receptors represent different gene products whose extracellular
structures are similar but whose intracellular portions are very different and
induce different signal transduction pathways (see Sect. 1.11). EL-1 can
upregulate both IL-1RI and EL-1RII (Akahoshi et al., 1988b; Chin et al., 1988;
Sheih et al., 1990; McMahan et al., 1991; Takii et al., 1992) but has also been
reported to downregulate its own receptor on fibroblasts, large granular
lymphocytes and some T cell lines (Mizel et al., 1987; Matsushima et al., 1986b;
Lacey and Erdmann, 1990), these two different effects possibly being EL-1
concentration dependent (Takii et al., 1992).
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Having expressed biologically active recombinant ovine EL-la and IL-1{3, I was
in a position to attempt to define more clearly the relationship between afferent
lymph DC and EL-1. The study reported below was designed to answer some of
the basic questions and has involved demonstrating the presence of IL-1
receptors on afferent lymph DC and determining the effect of localised antigen
challenge on the surface expression of these receptors.
Summary of Experimental Strategy:
Sheep prefemoral lymph nodes were excised and the animals primed with 500pg
ovalbumin (in complete Freund's adjuvant), injected intradermally at three sites
round the lymph node area. After at least eight weeks, the sheep were boosted
with 50|ig ovalbumin (in PBS) and 6 weeks later the anastamosed
pseudoafferent lymph ducts were cannulated. Cannulations were allowed at least
three days to stabilise before afferent lymph was collected into heparinised
bottles. For studying the effects of secondary antigen challenge, the animals
were injected with 50pg ovalbumin a few days after cannulation.
DC enriched and lymphocyte fractions of lymph cells were separately incubated
with ovine rIL-1. For determination by Scatchard analysis of numbers of
receptors expressed and their dissociation constants, 125I-rIL-l specifically bound
to the cells was counted. The binding of 125I-rIL-l at an individual cell level was
visualised on cytospins exposed with Amersham LM-1 emulsion. Binding of
biotinylated rIL-1 was visualised by FACS (Fluorescence Activated Cell Sort)
analysis. Ovine alveolar macrophages were used as positive control cells for rlL-
1 binding.
The following progression of experiments was employed;
1. Iodination and biotinylation of rIL-1
2. Assessment of biological activity of labelled proteins
3. Identification of macrophages (M<|>) vs afferent lymph dendritic cells (DC)
4. Detection of IL-1 receptors on alveolar macrophages
5. Detection of IL-1 receptors on resting DC
6. Establishing a binding assay
7. Quantitation of IL-1 receptors on DC and Mcj)
8. Expression of EL-1 receptors on DC and lymphocytes during primary and
secondary responses to ovalbumin challenge
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RESULTS
5.1 Iodination and Biotinlyation of Recombinant Proteins
Protein iodination and biotinylation occur via different amino acid residues.
Iodination involves tyrosine and histidine (Tyr preferentially). Biotinylation
involves lysine, asparagine, glutamine and arginine. Table 5.1 shows rIL-1 and
pi residues available for labelling.
TABLE 5.1
Amino Acid Residues Available for Labelling IL-1 and pi Proteins
a. Residues available for iodination:
Residues per molecule Y per pg Y + H per p.g
am 4Y + 4H 1.42 xlO14 2.85 x 1014
(3m 5Y + 1H 1.78 x 1014 2.14 xlO14
pi 15Y + 11H 1.81 xlO14 3.13 xlO14
b. Residues available for biotinylation:
Residues per molecule Total residues per pg
am 12K + 8N + 7Q + 3R 1.03 x 1015
(3m 14K + 5N + 8Q + 9R 1.24 x 1015
pi 23K + 36N + 29Q + 15R 1.24 xlO15
5.1.1 Iodination
0.4 -l(ig of HPLC purified IL-1 am (am) and IL-1 [3m (|3m) were iodinated for
15min using the Iodobead method (Markwell). Mock-digested pi vlps,
Irrelevant protein (discard fractions off the HPLC gradient which contain various
yeast proteins and only trace amounts of IL-1) and 0.1% BSA were also
iodinated as control preparations. Protein concentrations were estimated by
comparison with standards on coomassie and silver stained gels, (as in Ch4).
Unincorporated isotope was removed by extensive dialysis into PBS:0.1% azide.
If the protein to be labelled was at <500ng/ml, the solution was allowed to sit for
at least 2h after removal of the iodobead in order to allow the active labelling
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reactants to disappear. 0.1% BSA was then added prior to dialysis in an attempt
to minimise loses due to protein adhering to the dialysis membrane. Specific
activities obtained were routinely in the range 0.7-1 x 106 cpm/pM for 125!-am,
125I-|3m and 125I-pl, similar to IL-1 iodination figures reported in the literature.
The specific activity of the irrelevant protein sample was difficult to calculate
but was estimated to be in roughly the same range as the other proteins.
5.1.2 Biotinylation
Samples of IL-1 (3m, 2jig (pre HPLC ) and 0.4jig (HPLC purified), were labelled
with biotin at a ratio of 10:1 (w/w). Biotinlyated protein in PBA was visualised
on electroblotted 15% PAGE gels, using enhanced chemiluminescence. Some
remaining pi in the pre-HPLC preparation appears in the sample. During FACS
analysis of receptor binding, addition of unlabelled pi protein to the incubation
buffer should minimise any non-specific binding caused by the biotinylated pi.
Fig. 5.1 shows representative 15% SDS-PAGE gels of unlabelled and labelled
proteins.
FIGURE 5.1
Purity of Labelled Proteins as Visualised on 15 % SDS-PAGE Gels
a.
Figure 5.1
(a) 1-^-labelled detected by autoradiography of dried gels; pi (lane 1); irrelevant yeast proteins (Lane 2);
IL-loun (lane 3); IL-l-(3m (lane 4);
(b) biotin-labelled IL-lpm detected by enhanced chemiluminescence.
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5.2 Bioactivity of labelled rIL-1
All the cells which were available to me for assaying IL-1 activity, possess the
type I receptor. The effect of labelling on IL-1 binding to the type II receptor, as
found on macrophages, could not therefore be determined by these assays.
Iodination did not significantly reduce the bioactivity of either IL-1 a or IL-113 as
assayed by cartilage degradation and activity profiles were similar to those
shown in Fig. 4.15. Biotinylation did however greatly reduce the bioactivity of
IL-ip in the thymocyte assay although mock-biotinylation did not (Fig. 5.2) and
it may be that biotin is partially masking the IL-1 (3 binding site.
FIGURE 5.2






The bioactivity of biotinylated EL-1(3 was determined in the standard ovine thymocyte proliferation assay.
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5.3 Identification of Macrophages, Dendritic Cells and Lymphocytes
within Afferent Lymph Cell Populations
Afferent lymph may contain some blood or tissue derived macrophages. It is
therefore important to be able to establish that any IL-1 binding detected is not
due to the presence of contaminating macrophages. Although there is no
absolute method by which to distinguish macrophages and dendritic cells, cell
surface markers and cytochemical staining can be used as indicators.
5.3.1 Cell Collections
5.3.1.1 Macrophages
Ovine alveolar macrophages were obtained either under anaesthetic by lung
washout with 200ml HBSS at the time of cannulation, when possible, or from
unrelated sheep by bronchoalveolar lavage with 2 x 500ml HBSS at post
mortem. Cells were purified by Lymphoprep cushioning and resuspended in
PBA.
5.3.1.2 Afferent Lymph Dendritic Cells and Lymphocytes
Pseudoafferent lymph from cannulated prefemoral ducts was collected into
sterile, heparinised bottles. Polymorphonuclear leucocyte and red blood cell
counts had returned to minimal levels by 3-6 days post cannulation and lymph
was normally not utilised prior to this. On average, 24h lymph collections
produced 80-150ml lymph containing 2 x 106 cells/ml of which 5-10% were DC.
Centrifugation over a discontinuous (14.5% over 20% w/v) metrizamide gradient
in Iscoves serum free medium enriched the DC fraction. The upper interface
population consisted of >80% DC, the remainder being lymphocytes. The lower
interface consisted of lymphocytes and some dendritic cells. Washed DC and
lymphocytes were resuspended in PBA;0.1% Na azide.
5.3.2 Analysis of Surface Phenotype by Immunofluorescence
A number of anti-ovine monoclonal antibodies were available in the department,
some of which proved useful for differentiating between M<|) and afferent lymph
DC by FACS analysis. Table 5.2 shows the results of FACS analysis of 105 cells
from gated populations, the gates used being shown in Fig. 5.3.A. Fluorescence
is graded from undetectable (-) or faintly positive (+), to strongly positive
(++++). Normal mouse serum and an antiviral antiserum, 1D10, which does not
bind to M(|), were used as negative controls. Some antisera produced both
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negatively and positively reacting populations, in which case each population is
graded separately (eg. +/-). The percentage of positive cells in each case is
indicated in parentheses. Fig. 5.3.B shows examples of FACS profiles obtained
with VPM5 and VPM32, the antisera which can best be used to distinguish
between M(J) and DC. Analyses carried out on total and gated populations show
minimal macrophage contamination of DC preparations. Lymphocyte
contamination in different preparations ranged from 15 - 20%.
TABLE 5.2
Determination of Surface Phenotype of Alveolar Macrophage and Afferent
Lymph Cell Populations by Immunofluorescence
Ab Ag Isotvpe Macrophage Dendritic Lvmphocvte
CC14 CD1 IgGj ++ ++++ ++++
VPM5 CD1 IgM - +++ —
SBUT4 CD4 hA, ++ — +++
SBUT8 CD8 +/—(<10% +ve) — +++
VPM13 |j.-chain IgM — +/—(<10% +ve) ++
VPM32 CD14(?) IgG2a +++ + —
VPM65 CD14(?) iA +++ + —
VPM54 DRa IgGj ++ ++++ —
Class II
1D10 EV1 p25 IgG, — — —
NMS — — — — —
Table 5.2
Surface phenotype was determined by FACScan analysis. Isolated cell populations were incubated either
with FITC conjugated primary antibody or non-biotinylated antibodies which were detected with FTTC-
conjugated F(ab)2 fragment of rabbit anti-mouse immunoglobulin. Washed cells were analysed by flow
cytometry of 104 cells within gated populations). VPM32 and VPM65 display the characteristics expected of
and-CD 14 monoclonal antibodies but N-terminal analysis is still required for confirmadon.
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FIGURE 5.3
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Cell populations were isolated on the basis of their forward scatter (FSQ and side scatter (SSC) profiles when
analysed by FACScan using the Consort 30 Data management system. The gate settings shown were used for
all analyses of individual cell populations.
1. Alveolar macrophages (Mt}>) and Dendritic cell (DC) gate
2. Lymphocyte (L) gates
B. FACScan Profiles of Macrophages and Afferent Lymph Dendritic Cells
Reacted with VPM5 and VPM32
400 350
Positive fluorescence is indicated by a shift to the right on the FSC axis.
a. Positive fluorescence of DC and negative fluorescence of macrophages reacted with VPM5;
b. Positive fluorescence of macrophages and minimal fluorescence of DC reacted with VPM32.
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5.3.3 Distinguishing M<)> from DC by Cytochemical Staining
5.3.3.1 Leishman's Stain
Cytospins stained with Leishman's stain show the comparative distribution of the
various cell populations in unfractionated afferent lymph and whole blood (Fig.
5.4.a).
5.3.3.2 Giemsa Stain
Giemsa staining shows DC to be lightly staining, veiled cells or cells with
pseudopodia (Fig.5.4.b). Many of the nuclei appear kidney shaped. The stain is
not very useful for DC/M(j) differentiation purposes but is useful for
counterstaining cells which have been exposed with radiographic emulsion (see
Sect. 5.4)
5.3.3.3 Non-specific Esterase Stain (NSE)
M(|) stain very darkly for non-specific esterase whereas DC stain much less
strongly, as seen in Figs. 5.5. Whereas M(j) stain fairly uniformly, a number of
different patterns of DC staining were seen, the most obvious being indicated as
follows:
Large cells showing;
(a) dark cytoplasmic staining of various distributions
(b) light cytoplasmic staining
(c) extremely faintly staining veiled cells with no visible granules
Vacuoles can be seen in some cells and all of the above, apart from type (e),
can display dendritic processes as can be clearly seen in Fig. 5.5.B
Smaller cells with dendritic morphology showing;
(d) mainly intermediate reticular type staining.
Lymphocytes all stain pale green and are esterase negative.




Unfractionated Afferent Lymph and Top Fraction Metrizamide
Cell Populations
Figure 5.4
Cells were stained by standard staining techniques detailed in Chapter 2.11.4
a. Leismans' stained preparation of unfractionated lymph. DC - dendritic cell; L - lymphocyte;
E - erythrocyte, (x 320)
b. Giemsa stained preparation of isolated afferent lymph dendritic cells, (x 780)
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FIGURE 5.5
Staining Macrophages and Dendritic Cells for Non-specific Esterases
Figure 5.5
Cytospun cells were stained for non-specific esterase and counterstained with methyl green as per Chapter
2.11.4.5. Cells were viewed under a light microscope at x500 or x780 magnifications.
A. Alveolar macrophages stain dark red and are strongly positive (x 500).
B. Various dendritic cell staining patterns, indicated as a - d (x 500), are detailed in the main text, Sect
5.3.3.3. Cells at x 780 magnification show dendritic processes.
Lymphocytes stain pale green.
 
5.3.3.2 Acetylcholinesterase Stain (AChe)
Within the sheep epidermis, AChe activity is detected specifically in
Langerhans' cells (Hollis and Lyne, 1972) and it is the cell membrane and not
the cytoplasm which stains positively for AChe. Macrophages and lymphocytes
do not contain AChe and only take up the counterstain, methylene blue. This
stain is of use for positive identification of Langerhans' or Langerhans'-derived
cells but it can be seen from Fig. 5.6 that only a very small proportion (~2%) of
isolated afferent lymph DC show positive staining for AChe. The number of
non-staining DC means that AChe content can not be used to distinguish
between macrophages and DC within these populations.
Three apparently distinct patterns of AChe staining are seen;
(a) large cells with rounded or kidney-shaped nuclei and short dendritic
processes, which show overall strong staining
(b) cells similar to the above but which show more diffuse and fainter staining
(c) cells, many with irregularly shaped nuclei, which show granular staining
which may be either round the circumference of the cell or in the form
of distinct punctate staining. The latter sometimes appears to be
associated with longer processes.
These staining patterns are highlighted on counterstained samples in Fig 5.6.A.
Isolated DC which have been stained for AChe, but not yet counterstained, show
the presence of long dendritic processes on many of the cells when viewed under
phase contrast conditions (Fig. 5.6.B). It is extremely difficult to distinguish
these processes after counterstaining. Only very few of these latter cells show




Staining Afferent Lymph Dendritic Cells for Acetylcholinesterase
Figure 5.6
Cytospins of isolated afferent lymph DC populations were stained for AChe as per Sect. 2.11.4.4, and
viewed under a light microscope. Magnifications at which photographs were taken are given.
A. DC stained for AChe and counterstained with Methylene blue. Staining patterns a - c, as described in
Sect. 5.3.3.4 in the text, are indicated (x 320).
B. DC stained for AChe, but not counterstained, viewed under phase contrast conditions. AChe positive
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5.4 Detection of IL-1R on Alveolar Macrophages
Alveolar macrophages are known to possess IL-1 receptors and as such are a
good positive control for the detection of specific binding by the labelled
proteins. Both biotinylated and iodinated IL-1 preparations were used for
detecting IL-1R on M(j). Binding of the biotinylated protein was detected by
FACS analysis. Bound 125I-IL-1 was detected either on cytospins as above or by
counting the radioactive samples.
5.4.1 Detection with Fluorescent Ligand
1 x 105 M(j) in PBA were incubated with up to lOOng biotinylated IL-1 (3 and the
bound ligand detected with phycoerythrin-conjugated streptavidin. Fluorescence
analysis of the gated macrophage population showed minimal positive signal
even at the highest IL-1 (3 concentration (Fig. 5.7). The biotinylation method
used had been adapted from the standard method for antibody labelling (Pierce
Ltd.). Molar ratios of the reactants were maintained and the protein labelled
successfully (see Sect. 5.1.2). However, in view of the comparatively minute
amounts of protein being labelled here (<l|ig IL-1 vs. mg amounts of antibody),
there was a possibility that these conditions might not be ideal for maintaining
acitivty. Three different preparations were made with titrated amounts of biotin
(10 x more; 10 x less and 100 x less) were all similar to the initial preparation
and none gave a stronger fluorescence signal. These results corroborate the low
biological activity found for biotinylated IL-1 (3.
FIGURE 5.7
Detection of IL-1R on Alveolar Macrophages using Biotinylated IL-1 [3
Figure 5.7
1 x 105 macrophages were incubated with lOOng biotinylated IL-ip in PBA. Bound ligand was
deteced with Streptavidin-PE and the macrophage gated population analysed by FACScan.
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5.4.2 Radiographic Detection
In order to establish that the 125I-IL-1 would bind to its receptor, 2 x 106 M(j)
which had been incubated for 2h at 4°C with 5ng 125I-IL-1 in PBA were washed
with cold PBA and cytospun at 500rpm for 5min. Bound 125I-IL-1 was detected
by exposing the slides with Amersham LM-1 emulsion. Sodium azide was
included in all solutions to prevent intemalisation of bound ligand. Developed
cytospins were counterstained with Giemsa.
Representative pictures of iodinated protein binding to M<j) are seen in Fig. 5.8.
No bound radioactivity was detectable on cells which had been incubated with
any of the control preparations (125I-pl shown). 125I-am binding is detectable on
14% of cells and 125I-(3m on 24% of cells. On an individual cell basis, the
amount of material bound varies greatly but IL-la binding (Fig. 5.8.a), at <200
grains per cell, appears to be less concentrated than IL-lp (Fig. 5.8.b), at up to
>500 grains per cell. Specific competition with >lpg unlabelled material greatly
reduced 125I-IL-1 binding to M(J>. In addition, IL-1 {3 competed with 125I-am
binding but IL-la was very inefficient at competing with 125I-(3m binding. The
125I-IL-1 binding was not inhibited by the presence of unlabelled pi.
Having been able to detect specific IL-1 receptors on macrophages, the
iodinated reagents could now be used for establishing whether afferent lymph
dendritic cells express IL-1R.
5.5 Detection of IL-1R on Afferent Lymph Dendritic Cells
Iodinated IL-1 preparations were used for detecting IL-1R on afferent lymph
DC. It had been hoped that biotinylated protein could be used for fluorescence
analysis but in view of the lack of positive signal on macrophages this was not
however feasible. Bound 125I-IL-1 was detected either on cytospins as above or
by counting the radioactive samples.
5.5.1 Cytospins
Incubation of DC with 125I-am or 125I-f3m as above revealed a low level of
binding to the cells (Fig. 5.9). Cytospins show <0.5% of DC with grains and
125I-am and 125I-(3m binding patterns appear to be slightly different. More cells
were 125I-am positive but with fewer grains per individual cell; <80 on average.
Positive 125I-J3m cells had 94 ± 43 grains, divisible into two groups; <90 grains
(54.2 ± 14.6), and >90 grains (130.9 ± 29), over individual cells. None of the
positive cells appear to display the classical veiled dendritic morphology and
they are mainly faintly staining, 'non-granular' cells. There is little evidence of
macrophage contamination. Photographs of dendritic cells to which 125I-IL1 has
bound are shown in Fig. 5.16 on pg 200.
181
FIGURE 5.8
Binding of 125I-Labelled Proteins to Alveolar Macrophages
Figure 5.8
Isolated alveolar macrophages were incubated with 5ng 12SI-IL-1 for 2h at 4°C and unbound material
removed by washing with cold PBA. Cells were cytospun and dipped in LM-1 emulsion. Slides were
developed after 4 weeks exposure and counterstained with Giemsa, Magnifications are those at which the
photographs were taken
a. EL-la (x500); b. IL-Ip (x500); c. IL-lp (x780); d, pi (x500).
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5.6 Establishing an Assay for the Binding of 125I-IL-1 to M<|> and DC
A reproducible assay procedure for quantitation of bound 125I-IL-1 had to be
established, from which the number of binding sites per cell and the binding
affinity could be calculated (Scatchard). Cytospins would further define the
binding on an individual cell basis.
5.6.1 Binding Assay
All binding experiments were done in the presence of 0.1% Na azide to prevent
internalisation of the bound ligand. Initial experiments involved incubation of
M(j), DC or lymphocytes with 125I-IL-1. Unbound radioactivity was removed by
sequential washing of the samples with ice cold PBA in either 1.5ml Eppendorf
tubes or FACS tubes. Half of the sample was counted and the rest cytospun and
exposed with LM-1 emulsion. It became apparent that unbound 125I-IL-1 was
adhereing to the plastic tubes hence giving falsely high cpm figures. Unbound
material was subsequently removed by centrifugation through an oil gradient
(see below).
For Scatchard analysis all incubations were carried out in final volumes of lOOp.1
in 1.8ml screw cap Eppendorf tubes using a rotating mixer for 2.5h at 4°C. Fig.
5.9 shows that binding has reached equilibrium by this time. Cells to be counted
and those to be cytospun were incubated independently, the former with 0.01,
0.05, 0.1, 0.5, 1,5, 10 and 50ng 125I-Protein and the latter with 5ng 125I-Protein.
Cells for counting were washed three times with 1.8ml ice cold PBA,
resuspended in lOOjil PBA and spun through 300|il phthalate oil (dibutyl
phthalate:bis(2-ethylhexyl) phthalate 1.5:1 v/v), in Sarstedt 0.3ml
microsedimentation tubes, to remove the remaining unbound labelled protein,
modifying the method of (Bomsztyk et al., 1989b) slightly. The tube was frozen
in a dry ice/ethanol bath and the tip containing the cell pellet cut off and counted.
Tests with varying concentrations of labelled protein established that provided
the oil was frozen prior to loading the sample, microfuging for llOsec at
13500rpm would pellet the cells efficiently without contamination by unbound
material. (Surface tension effects cause warm oil to enclose the sample as a




Determining the Time Required to Establish Binding Equilibrium
Hours
Figure 5.9
Samples containing 2 x 106 dendritic cells were incubated at 4°C for 2.5h with 5ng 12SI-IL-ip.
Bound radioactivity was determined at intervals, as shown. 100% binding represents 1500cpm.
Binding of IL-la to DC and of IL-la and IL-ip to M<|) all reached equilibrium in less than 2h.
5.6.2 Cytospin analysis
Cells for cytospinning could not be centrifuged through oil and were given two
additional washes with PBA prior to spinning. Most of the remaining free
labelled protein could be washed off the slide. Residual unbound radioactivity
would be visualised as background. Cytospins were fixed with cold acetone and
dipped in Amersham LM-1 emulsion diluted 1:2 with water. Grains seen after
short term exposure were very small and slides were left for 4-8 weeks,
depending on the expected signal, before developing.
Staining of cytospins: Non-specific esterase staining was done prior to dipping
the slides and Giemsa staining after developing the exposed slides.
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5.7 Quantitation of IL-1 Receptors on Alveolar Macrophages and
Afferent Lymph Dendritic Cells and Lymphocytes
5.7.1 Specificity of Binding
Cells were incubated with 125I-IL-1 in the presence or absence of an excess of
cold competitor. Representative binding curves, of 125I-IL-lp binding to M<|)
(Fig. 5.10), demonstrate the specificity of binding, the presence of the unlabelled
material dramatically reducing the binding of 125I-IL-1. Binding of 125IL-la and
125IL-ip to M<J> and DC could all be specifically inhibited by cold competition.
FIGURE 5.10
Demonstration of the Specificity of 125I-IL-1 Binding
Figure 5.10
Macrophages were incubated with increasing concentrations of 125I-IL-1 in the presence or
absence of 250ng unlabelled IL-1.
a. IL-la; b. IL-ip
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5.7.3 Scatchard Analysis of IL-1 Receptor Binding
Both M(|) and DC Scatchard plots are biphasic curves, indicating the presence of
high and low affinity IL-1 binding sites. Far more IL-1 sites are detected on Mc|)
than on DC. M(() appear to have a significantly greater affinity for 125I-(3m than
125I-IL-lam and bind 5-6 times more 125I-pm. Resting DC, on the other hand,
bind 125I-am and 125I-Pm to a similar degree. 125I-pl, 125I-Irrelevant-protein and
125I-FXa do bind to M(f> and DC, but non-specifically and only at high
concentrations (>500ng/ml). Afferent lymphocytes, at 2 x 106 cells per
incubation, showed some binding of 125I-am and minimal binding of 125I-pm.
Representative Scatchard plots of 125I-IL-1 binding are shown in Fig. 5.11 and
Table 5.3 summarises the individual cell and Scatchard analysis data obtained.
TABLE 5.3
Quantitation of IL-1 Binding Sites on Ovine Alveolar Macrophages and
Afferent Lymph Dendritic Cells and Lymphocytes
IL-lam:
IL-lfhn:
Cell Grains/cell % -i-ve Sites/cell Kd-PM
M<f) 30 - 200 14 2600 ±98 56 ± 11
DC 41 ±25 <0.5 510 ± 36 30 ± 4
L 50 ±30 <1.0 417 ±147 181 ± 61
M([) 30 - »500 24 16500 ±707 4.6 ±1
DC 94 ±43 <0.5 350 ±145 160 ±58
L «< <« <50 not calc.
Table 5.3
Grains/cell indicates the number of grains detected over individual cells for incubation of 5ng 125I-IL-1




Representative Scatchard Plots of 125I-IL-1 Binding to Alveolar
Macrophages and Resting Afferent Lymph Dendritic Cells
Figure 5.11
Cells were incubated with 125I-IL-1 and bound radioactivity detected as described in Sect. 5.7.1. Scatchard
analyses were carried out as per Scatchard (1949).
a. 125EL-la binding to macrophages; b. 125IL-ip binding to macrophages
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5.7.4 Limits of detection
Calculations based on the specific activity of labelled IL1 suggest that the
lowest numbers of receptors detectable by Scatchard analysis would be
150sites/cell and 50sites/cell for incubations with 2 x 105 cells and 2 x 106 cells
respectively.
5.7.5 Reproducibility of the Assay
Due to the small numbers of DC obtainable, especially over short time periods if
the lymph flow rate was low, it frequently proved difficult to have enough cells
for duplicate or triplicate incubations. It was imperative, therefore, to establish
that standard deviations obtained with this binding assay were low.
Quintuplicate samples of 2 x 105 DC were incubated with varying concentrations
of 125I-IL-1. Because of the number of cells involved, the assays had to be
carried out with different DC collections. Standard errors were of the order of
9% and judged to be acceptable.
5.7.2 Dissociation Kinetics of IL-1 Binding to Dendritic Cells
Full dissociation kinetics were not calculated but DC samples which had been
washed were split and half spun through oil immediately. The other half was
incubated overnight at 4°C prior to separating the unbound material. About 9%
bound IL-1a and 25% bound IL-1{3 had dissociated, indicating a higher affinity
of the receptors for IL-1 a.
5.8 Effect of Ovalbumin Challenge on IL-1R Expression by Afferent
Lymph Dendritic Cells and Lymphocytes
5.8.1 Resting State Prior to Secondary Challenge
6 sheep were boosted with 50|ig ovalbumin and the pseudoafferent ducts
cannulated 6 weeks later. Cell output and IL-1 binding was monitored over 2-3
weeks. Total cell output showed little variation and averaged 1.9(±0.08) x 106
cells/ml over this period. The binding assay results were similar to those shown
in Fig. 5.11 and were included in the data in Table 3.1 above. Although there
was some variation between animals with respect to 125I-(3m binding, sequential
samples from any one animal showed no significant variation. Variations in 125I-
am binding were less.
189
5.8.2 Responsiveness of Sheep to Ovalbumin Challenge
Blood monocytes were separated from jugular vein samples. Their ability to
proliferate when incubated with ovalbumin was measured by incorporation of
3H-Thymidine. A typical response curve is shown in Fig. 5.12. All sheep used
were found to be adequate responders to ovalbumin challenge.
FIGURE 5.12
in vitro Proliferative Response to Ovalbumin by Mononuclear Cells
from Ovalbumin Primed Sheep
(Ig/ml Ovalbumin
Figure 5.12
Peripheral blood mononuclear cells and unfractionated afferent lymph were incubated with ovalbumin
for 5d. Cultures were pulsed with l|iCi 3H-T over the final 7h. Incorporated radioactivity on harvested cells
was measured by scintillation counting. The proliferative response of PBMC to ConA, used as a positive
control, was typically ten-fold greater than the ovalbumin response.
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5.8.3 Secondary Ovalbumin Challenge
3 sheep were injected intradermally with 50pg ovalbumin in PBS at sites round
the cannula. Afferent lymph was to have been collected at four hourly intervals
for the first 24h and thereafter at 24h intervals. In practice, one cannulation,
(SHI), stopped flowing by 6h and a second, (SH2), by 25h. From the
information gained from these two sheep, collections from the third sheep were
taken at 4h and 18h and then at 24h intervals for 10 days (SH3-1), by which time
total cell counts and IL-1 receptor expression had returned to resting levels. This
sheep was re-challenged with ovalbumin on day 10 (SH3-2), and lymph
collected at 24, 48 and 72h. A couple of episodes of lymph clotting within the
cannula occurred during this repeat challenge, after each of which the canula
was manually cleared and heparin administered. Lymph collection was only
restarted after excess heparin had been allowed to flow out of the tubing.
Heparin concentrations thus remained unaltered throughout collections. It will be
seen from the results that the single heparin injection did not induce detectable
IL-1R. The cannula blocked irreversibly overnight between 58h and 72h after
challenge. As a result of these clotting episodes, only small volumes of lymph
were obtained from SH3-2.
5.8.3.1 Cell Output in Afferent Lymph
Resting state cell output averaged 1.9 x 106 cells/ml. In response to secondary
challenge, total cell numbers in the three sheep studied had risen by 4h, (only
slightly in two sheep but nearly two-fold in one, SH2), followed by a fall to less
than baseline by 8h and a return to normal by 12h. Only one animal, SH3, could
be followed for longer than 24h. From 18h the SH3-1 cell numbers again
increased to reach a maximum of 4 times baseline by 66h, after which the counts
decreased slowly and had returned to normal by day 8. During the repeat
ovalbumin response, the SH3-2 cell count reached a maximum by 48h. SH2,
which had a nearly two-fold increase in total cells by 4h also showed a two-fold
increase in the proportion of DC in this sample. Otherwise the only other distinct
variation in %DC was in SH3-2 at 24h and 48h. These low numbers may be a
result of clots forming within the lymph. Table 5.4 details the afferent lymph cell
output. The proportion of AChe positive cells (~0.05%) showed no obvious
increase at any point during the cannulation.
The resting rate of DC influx into the node if flow is good is 5 x 105 DC/h. This
increases to >1.3 x 106 DC/h over the first 4h and >3.8 x 106 DC/h between 24h
and 72h after secondary challenge.
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TABLE 5.4
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ml/h Total %DC ml/h Total %DC DC AChe
x 106/ml x 106/ml X lftVml +ve/ml
1.3 2.0 4 7.1 1.8 4 7.2 90
5.8 3.6 8 10.0 2.1 6 12.6 105
3.8 1.7 4
5.3 2.0 4
10.4 1.9 5 9.5 95
1.6 2.2 5
10.8 4.0 5 20.0 200
* 10.6 7.2 5 36.0 360
10.4 5.2 5.5 28.6 260
7.5 4.4 5 22.0 220
10.0 2.8 5 14.0 140
6.5 2.5 5.5 13.8 125
6.2 2.0 6 12.0 100
6.2 1.3 5 6.5 nd
#1 2.8 0.9 2.5 2.2 nd
#2 1.7 6.4 3 19.2 nd
1.3 5.0 4 20.0 nd
Table 5.4
The ovalbumin primed sheep was challenged with 50(ig ovalbumin injected locally round the cannulation
site.Psuedoafferent lymph was collected into sterile 250ml plastic bottles containing 2.5 x 103 units of
heparin and 2.5 x 104 units each of penicillin and streptomycin. The dendritic cell fraction was isolated by
centrifugation onto a 14.5% metrizamide cushion, washed and resuspended in PBA for counting. The
percentage of AChe positive cells was established from stained cytospins of isolated DC.
2° = secondary;
#! = heparinisation of cannula;
#2 = heparin injection.
* = sample clotted on metrizamide;
nd = not determined because of limited cell numbers
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5.8.3.2 Binding Assays and Cytospins
When there were enough cells to do so, 2 x 105 DC and 2 x 106 lymphocytes
were incubated for Scatchard analysis with 125I-Protein covering the range 0.05 -
50ng. Otherwise, DC for counting were incubated with 1, 2, 5 and lOng 125I-
Protein and DC for cytospinning were incubated with lOng 125I-Protein. After
secondary challenge, 4, 8 and 12h lymph collections contained very few DC and
were only incubated for cytospins. To minimise any bias, incubation tubes were
always washed and spun in random order.
5.8.3.2.1 Binding Assays
Throughout the cannulation IL-1(3 binding to lymphocytes was virtually
undetectable. The ~420 IL-la binding sites detected in resting animals
decreased to fewer than 200 throughout the first 4 days of secondary challenge.
The small number of contaminating lymphocytes in the DC enriched fraction (<
20%) did not therefore contribute significantly to any bound counts detected in
the DC population. In addition, non-specific esterase and acetylcholinesterase
staining excluded the possibility that this binding detected in this population was
due to contaminating macrophages.
Fig. 5.13 shows the results of incubating SH3 DC with a fixed concentration of
125I-Protein. The number of receptors, (R), were calculated from 125I-IL-1
specific activities. The pattern of receptor binding after SH3-1 challenge was
reproduced during the repeat SH3-2 challenge. Both 125I-am and 125I-(3m
binding are seen to increase from 18h post challenge. Increased 125I-Pm binding
appears to be transient, 24-48h, whereas 125I-am increases rapidly to peak over
days 2-3. The binding then slowly decreases over the next 6-7 days. This pattern
of IL-la receptor expression correlates with the cell output. Unfortunately the
SH3-1 66h sample, which might have been expected to show peak 125I-IL-la
binding, clotted while being centrifuged through metrizamide and no DC could
be salvaged.
Scatchard data on DC during the secondary response is not complete because of
the dependence on cell numbers. Curves can be fitted to the data, as seen on the
representative plots in Fig. 5.14, but more points are required to be accurate.
Plots of data from other time points are not shown but follow a similar pattern.
Estimated figures for numbers of receptors and Kd values can nevertheless give
an indication of trends (see Table 5.5).
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FIGURE 5.13
Sheep No.3: IL-1 Receptors Detected on Afferent Lymph Dendritic Cells
in Response to Secondary Ovalbumin Challenge
Incubation of 2 x 105 cells with lng 125I-IL-1
Figure 5.13
Sequential samples from the cannulated sheep SH3 were collected after challenge with 50|ig OVA and
isolated DC assayed for IL-1R expression. Graphs show IL-1R detected by incubating 2 x 105 DC with a
fixed concentration of 125I-IL-1. Total bound radioactivity was counted and the number of binding sites
calculated from the specific activities of the labelled proteins. A control pi preparation did not bind
detectably to the DC at any stage throughout the cannulation.. The sheep was challenged twice with OVA
(Ova 1 and Ova 2) and the two series of results have been superimposed. Total cell and DC output over the
two cannulation periods is shown on the overlaid transparent film in order to demonstrate the co-incidence of
cell courts and receptor expression. Binding sites could not be determined at 63h post Ova.l
a. Receptor expression detected by incubation with 125IL-1 a
b. Receptor expression detected by incubation with 125IL-l3
FIGURE 5.13
IL-1 Receptor Binding Sites on Afferent Lymph Dendritic (Jells
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None of the Scatchard plots post ovalbumin are obviously bi-phasic, which may
just be a consequence of the small number of IL-1 concentrations used. More
importantly, all samples showing increased 125I-ccm binding also show reduced
affinities. Of interest is that the Kd for 125I-am, which has returned to normal by
day 10, increases again with increased binding at 48h and 72h after the repeat
challenge. The specificity of the enhanced 125I-am binding was confirmed by
cold competition using the SH3-1 114h sample, IL-la and IL-lp being equally
efficient at competing with 125I-am (>72%). Scatchard plots of IL-la binding
after OVA challenge are shown in Fig. 5.14. Plots from both challenges show
similar profiles.
125I-(3m binding data is difficult to interpret. After secondary challenge the
Scatchard plots for all samples showing resting levels of 125I-(3m binding are all
similar, as expected. However, Scatchard plots could not be constructed for the
2d samples of either SH3-1 or SH3-2, both of which do show increased 125I-IL-
1{3 binding, indicating that the increased binding may not just represent
upregulation of receptors specific for IL-1 p. SH3-1 and SH3-2 also both show
less than baseline binding immediately following the peak. SH3-1 binding then
returned to baseline by 114h and remained at this level until re-challenged. The
specificity of IL-lp binding was tested on day 4 (114h) and at this time point,
125I-IL-lp was competed off efficiently by IL-ip (85%) and less so by IL-la
(53%). This information may not however be of any value with respect to the
specificity of the 2 day peak binding because the 114h Scatchard plot is
acceptable and shows the expected parameters.
The few results on the early response to OVA challenge which were obtained
from SHI and SH2 indicate similar trends to those detailed for SH3. An increase
in bound IL-1 was detected at 4h and IL-1 binding had returned to normal by 8h
(SH2), confirming a very transient early increase in receptor expression.
At no time did the irrelevant protein bind to any significant degree.
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FIGURE 5.14
Scatchard Analysis of 125I-IL-la Binding to Dendritic Cells
after Secondary Ovalbumin Challenge
Figure 5.14
12^I-IL-1 binding to 2 x 10s DC was determined using the standard assay.
a. 12^I-IL-la binding by SH-3 afferent lymph dendritic cells immediately prior to OVA challenge
b. Data from Fig. 5.14.a. compared with 12SI-IL-la binding at Oh, 90h after Ova.l challenge and 48h and
72h after the repeat, (Ova.2) challenge. Hatched lines have been used for determination of receptor
numbers and Kd values because of the minimal numbers of points on these plots.
FIGURE 5.14
125I-IL-loc Binding to SH3 Afferent Lymph Dendritic Cells
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5.8.3.2.2 Cytospin analysis
Between 800 and 1000 cells in consecutive fields were analysed for the presence
of silver grains. Cells were only counted in areas of low background, (ie. not
exceeding 20 grains over cell equivalent areas). To be positive, cells had to have
more than three times the background grain count. Only a small percentage of
cells displayed grains and the results are therefore quoted in two different ways
in Table 5.5; (column 4) the average number of grains/+ve cell, ie. including only
those cells which were positive; (column 5) grains/cell, being the total number of
grains with respect to the total number of cells counted. This latter figure should
relate to the Scatchard 'sites/cell' figure, ie. an overall figure not subdivided into
IL-1R expression on individual cells.
By 4h after secondary challenge, a large but transient increase in the number of
125I-am positive cells was seen on cytospins but with a concommitant decrease
in the number of grains on each cell. By 90h, the number of sites/cell had
increased nearly twenty times, which correlated with increases in the number of
positive cells and grains/cell. However, the number of grains/+ve cell was still
less than at 4h. By day 10, ie. just before re-challenging with ova, grain counts
and Scatchard data both showed a return to normal. Due to limited numbers of
cells, no cytospin data was obtained after re-challenge.
Odd cells, have extremely heavy graining which appears to emanate from a focal
point (Fig. 5.15.B.f). The pattern of grains seems to be specific and not
artefactual because (i) all such heavy graining is cell associated, as demonstrated
by giemsa and NSE staining, (ii) all these cells display similar patterns of grains,
and (iii) no random 'hot spots' were seen on these slides. No similar patterns of
binding to macrophages have been seen. These cells are seen in all IL-la-DC
samples but more are apparent at times of increased binding eg. 0.002% pre ova;
0.85% at 4h post ova; 0.1% at 43h and 0.25% at 90h. For reference, grains/cell
(column 5 Table 5.5) are given both excluding and including these cells. The latter
is impossible to assess accurately and can only be an underestimate, as will be
understood from the photograph. Additional evidence for these cells not being
artefactual comes from comparisons of the EL-la grains/cell and sites/cell
figures. For example, the figure of 9116 sites/DC at 90h post ovalbumin can be




Demonstration of 125I-IL-la Binding by Individual DC
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Figure 5.15
2 x 10s DC were incubated with 5ng 125I-IL-la under standard assay conditions.
A. Giemsa stained cells:
Cytospins were exposed with Amersham LM-1 emulsion, developed and stained.
Individual cells are shown to give an indication of variations in grain density which can be
obtained.
Photographs were taken the following magnifications:
a,b (xlOOO); c(xl500).
B. Non-specific esterase stained cells:
Cytospins were stained for NSE prior to exposure.
Photographs demonstrate how individual cells within a cluster are selectively labelled.
Comparative magnifications are as follows:
a, b (x500); c(xlOOO); d (x780); e (x600); f (x500).
 
Cytospin analysis of IL-1(3 binding at 43h (ova-i) and 48h (ova-2) post challenge
shows no evidence of specific increased binding at these times, either in terms of
the proportion of positive cells or of cell-associated grains. If anything, the
number of positive cells appears to be reduced. This data confirms the lack of
specific binding detected by Scatchard analysis.
5.8.3.2.3 Compilation of Scatchard and Cytospin Data
Table 5.5 shows combined cytospin and Scatchard data for IL-1 binding before
and after secondary ovalbumin challenge. Macrophage binding data is included
for comparison. The figures for resting lymph (1°) are those from Table. 5.3 and
were derived from a number of samples from different sheep. Data for secondary
challenge (2°) is from sheep SH3.
Scatchard analysis calculations:
Results were plotted in the accepted format of Bound/free cpm 125I-IL-1 vs. pg
125I-IL-1 bound. The number of receptors/cell was calculated from the x
intercept and the Kd value from 1/slope (Scatchard, 1949).
IL-1 P data is included but grain counts after challenge were difficult to establish











Mo - alveolar macrophage; DC -afferent lymph dendritic cell.
1° - resting state; 2° - secondary challenge; Sample times are quoted as hours post ova
challenge; (1) - first secondary challenge; (2) - repeat secondary challenge.
% cells on cytospins with associated grains. 5000 cells in consecutive fields were counted.
Average number of grains counted over individual cells on cytospins.
The total number of grains counted over 5000 cells expressed as grains/percell. Figures are
given both excluding and including the extremely heavily grained cells. The latter are given in
brackets.
Sites/cell calculated from Scatchard plots such as shown in Figs. 5.12 and 5.15.
Kd calculated from Scatchard plots such as shown in Figs. 5.12 and 5.15.
Data in Columns 4 and 5 was derived from cytospins of 2 x 105 cells incubated with 5ng 125I-IL-1.
Data in Columns 5 and 6 apply to total cell populations and do not take account of any individual cell data.
na - not available;
ns - potential non-specific binding, therefore unable to obtain Scatchard plot or reliable grain counts
TABLE 5.5
IL-la Receptor Expression by Ovine Afferent Lymph Dendritic Cells
Detected Before and After Ovalbumin Challenge.
Comparison with Resting Dendritic Cells and Alveolar Macrophages
Column No: 1 2 3 4 5 6 7
% +ve grains/+ve cell grains/cell sites/cell Kd pM
Cells Sample cells (single cells) (over total cells) (ex Scatchard analyses)
n.-lam:
M<(> 14 30-200 -25 2600 ±198 56 ± 11
DC 1° <0.5 41 ±25 <0.1 510 ± 56 30 ±4
2° ' °(i) <0.5 <40 <0.1 568 29
4 2.4 64 ±36 0.96(>7) na na
43 1.2 26 ±19 0.23(>1) 4300 168
90 5.6 42 ±12 2.25(>100) 9116 181
168 <0.5 <50 <0.1 490 31
2° ~ °(2) na na na 435 29
48 na na na 21700 181
72 na na na 13180 180
IL-lftm:
M<j) 24 30 to >500 -100 16500 ±707 4.6 ±0.5
DC 1° <0.5 94 ±43 <0.05 350 ±145 160 ±58
2°"0(i) <0.5 <120 <0.05 344 185
18 <0.5 <130 <0.05 360 na
43 <0.1 <150 ns ns ns
90 <0.5 <80 <0.05 74 39
114 <0.5 <100 <0.05 385 172
2°-48(2) na na ns ns ns
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DISCUSSION
IL-1 is known to enhance dendritic cell function but the mechanism has not yet
been elucidated. The aim of this study was to determine whether ovine afferent
lymph dendritic cells express receptors for IL-1 and if so, how this expression is
affected during a secondary response to ovalbumin challenge. The study was
approached in such a way as to be able to determine both surface expression of
IL-1R (using 125I-IL-1) and co-expression of IL-1R with surface antigens known
to be expressed by dendritic cells (using biotinylated IL-1 and FACS analysis).
Ovine alveolar macrophages were used as control cells for two reasons; (i) M<|)
express high levels of IL-1 receptors and would therefore be a positive control
for specific IL-1 binding; (ii) The presence of contaminating Mc)) in afferent
lymph would have to be determined as these could bias DC binding figures.
Quantitation of IL-1R expression by binding 125I-EL-1 to its cellular receptor has
been successfully applied to numerous human and murine cell types (Appendix).
Two studies, on bovine neutrophils and skin fibroblasts, provide the only data on
IL-1R expression in ruminants (Lederer and Czuprynski, 1992, 1993).
To determine receptor expression using labelled ligand, it is essential to have
purified protein which retains biological activity after labelling. Chloramine T
and Bolton and Hunter methods have been successfully used for iodinating
human rIL-1 (Dower et al., 1985, Fuhlbrigge et al., 1988) and very recently
lactoperoxidase iodination of bovine rIL-1 was reported (Lederer and
Czuprynski, 1993). The more gentle Iodobead method used for labelling ovine
rIL-1 was equally efficient and reproducible, yielding specific activities in the
range 0.7-1 x 106 cpm/pmol without any significant reduction in bioactivity.
Biotinylation of IL-1 on the other hand yielded material which could not be used
for receptor studies. The proteins labelled efficiently but only retained minimal
assayable activity. In addition, biotinylated IL-1 (3 did not compete with 125I-IL-
1(3 binding to macrophages whereas unlabelled material did. From the data
available on residues involved in human and murine IL-1 (3 activity and receptor
binding (see Chapter 1, Sect. 1.11.1.6), some of the equivalent ovine residues,
Gln-4, Gln-24, Lys-93 and Lys-102, could potentially be biotinylated with
resultant inhibition of IL-1 (3 receptor interaction. Recently biotinylation has also
been shown to reduce the activity of recombinant ovine TNFa to unacceptable
levels (B. Lund, personal communication). Because of the DC subpopulations
present in afferent lymph, fluorescently labelled IL-1 would be useful for
determining co-expression of EL-1R with various other markers using two colour
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FACS analysis. Use of FITC, which binds to the same residues but is much
smaller than biotin, could cause less interference with IL-1R binding and may be
worth future investigation.
FACS analysis of macrophage, DC and lymphocyte populations confirmed
previous data (Bujdoso et al., 1989) that resting afferent lymph DC express
minimal CD4+, intermediate levels of CD1 (VPM5) and strong MHC Class II
(VPM54) surface antigens. In comparison, ovine M(j) do not express VPM5 and
Class II expression is two orders of magnitude less than on DC. The purity of
DC preparations was estimated at >80% by FACS, the remaining 20% of cells
being lymphocytes. Cytochemical staining for non-specific esterases confirmed
that contaminating macrophages were present only in very low numbers.
Peripheral blood DC express similar markers to afferent lymph DC (Caux et al.,
1992; Thomas et al., 1993) and the presence of PB DC could not therefore be
ruled out. Staining for acetylcholinesterase which, in sheep, is specific for LC or
LC derived cells, also could give no reliable indication of the presence of PB DC
because it is not known to what extent AChe activity varies with maturation of
LC to DC. The presence of few erythrocytes was therefore taken as an indication
of minimal blood contamination.
The resting rate of DC influx into the sheep node was about 5 x 105/h,
comparable to rat mesenteric and rabbit popliteal lymph nodes at 1 x 105 and 2 x
105 DC/h respectively (Pugh et al., 1983; Kelly et al., 1970). This increased to
>1.3 x 106/h over the first 4h and to >3.8 x 106/h between 24h and 72h after
secondary challenge but without any significant alteration in the proportion of
NSE or AChe positive DC.
For IL-1 binding assays precautions were taken with respect to incubation
conditions. Because IL-1/IL-1R complexes can be rapidly internalised and IL-1
can also affect expression of its own receptor (Matsushima et al., 1986b;
Akahoshi et al., 1988; Takii et al., 1992; Lacey et al., 1990; Shieh et al., 1990;
Arend et al., 1991; McMahan et al., 1991), Na azide was always added to inhibit
this internalisation and signal transduction (Uhl et al., 1989; Horuk et al., 1987).
In addition, all incubations were done at 4°C because thymocyte proliferation
assays had indicated that incubation at 37°C could reduce the biological activity
of ovine IL-1 (See sect. 4.5.1).
The majority of published ligand binding studies using cell lines have relied on
the use of >106 cells per sample, which allows work well above the limits
detection, hence increasing accuracy. Despite having to use low cell numbers
(2xl05) in the current study, the intra-assay variability for IL-1 binding to ex
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vivo afferent lymph cells was low, although some differences between animals
were seen.
In considering IL-1R expression on afferent lymph DC, two different but
complementary representations have been taken into account; (i) overall
expression with respect to the whole DC population, ie. Scatchard and sites/cell
data; (ii) expression by individual cells as visualised on cytospins. Scatchard
sites/cell exhibit a positive correlation with cytospin grains/cell but the
efficiency of autoradiographic detection is low and long exposure times are
required.
Using the 125I-IL-1 binding assay, resting ovine afferent lymph DC, ex vivo,
have been show to express ~500 receptors (Kd 30pM) for IL-la and ~350
receptors (Kd 160pM) for IL-lp. IL-1R expression has also been shown to be
upregulated during the inflammatory response following secondary ovalbumin
challenge. Kampgen et al., (1992) recently presented data on cultured murine LC
and DC which expressed >500 and >100 IL-1R per cell respectively
(KdclOOpM), but I am not aware of any other studies of IL-1 binding by
dendritic cells in the peripheral immune system.
The response of IL-1R expression by DC after secondary ovalbumin challenge
to sheep SH3 was greater for IL-la than for IL-1 (3 (Fig. 5.14 and Table 5.5). A
transient but significant increase in IL-la but not IL-ip binding is seen on
cytospins at 4h post ovalbumin challenge. Unfortunately there were not enough
cells for multiple assays and Scatchard binding data was not obtained at this
time. IL-la and IL-lp binding both increase from about 24h post challenge and
maximal expression occurs between 43h and 72h post challenge. Cytospin data
correlate positively with this, showing increases in the precentage of positive
cells and in grains/cell. Figures for binding of lng 125I-IL-1 to 2 x 105 DC show
that IL-la binding has been enhanced nearly eighteen-fold and IL-ip at least
ten-fold at 43-72h. Equilibrium binding data for this time point reveals a forty-
fold increase to <21700 IL-la receptors/cell but this figure is based on an
incomplete Scatchard plot (Fig. 5.15.b) and may well be an overestimate.
Resting level IL-ip binding appears to be specific but Scatchard data on the
increased IL-lp binding is difficult to interpret and may represent some non¬
specific binding, a conclusion supported by cytospin data. In addition, the repeat
Ova.2 challenge would be expected to produce a greater response to ovalbumin
than after the first Ova.l challenge. This was clearly seen with IL-la binding to
DC but IL-ip binding was no greater after the re-challenge. There is therefore
no clear evidence that receptors for IL-lp are specifically upregulated during a
secondary response to antigen.
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These results support published evidence indicating that both interdigitating
thymic reticulum cell and Langerhans' cell function may be dependent on EL-la
but not IL-ip (Ruco et al., 1990). Upregulation of the number of receptors for
EL-la appears to correlate inversely with their affinity. The Kd value increases
from 29 ± lpM on resting cells to 173 ± llpM at high IL-1R expression and
returns to the lower figure as receptor expression decreases. Similar data on IL-
1R upregulation and affinity (but for IL-1{3 in this case), has been obtained from
in vitro treatment of two human B cell lines, STS25 and H7, with
dexamethasone (Stoppacciaro et al., 1991). It is not clear from my data whether
DC IL-1R upregulation involves high or low affinity sites but this may be a
reflection of the non-homogeneous nature of the DC population. Individual cell
data suggests that the few extremely heavily grained cells could be the main
contributors to the altered Kd values.
Dissociation kinetics were not calculated but the higher affinity of the receptor
for IL-la is corroborated by the finding that only 9% of bound 125I-EL-la but
25% of bound 125I-IL-lp dissociated from DC during overnight incubation at
4°C. There should be no internalisation of the ligand at this temperature in the
presence of 0.1% Na azide. Dissociation of bound 125I-IL-1{3 from bovine and
porcine fibroblasts is in the same range, irrespective of the presence or absence
of cold IL-lp. Rapid initial dissociation becomes gradual dissociation and has
more or less reached equilibrium at 30% dissociated material by 6h. Greater
dissociation is seen at 37°C (Bird et al., 1987, Lederer and Czuprynski, 1993).
Analysis of IL-1R expression at a single cell level shows that 125I-EL-la binding
is heterogeneous. Only a very small proportion of resting DC bind IL-la and
OVA challenge causes an increase both in the number of positive cells and in the
grains detected on each cell. There is also an increase in the number of cells
showing extremely large numbers of grains. It is possible that the latter are
displaying non-specific binding of 125I-EL-la but the sites/cell figures and the
consistent patterning of grains, in the form of a halo around the cells which
appears to emanate from a focal point (Fig. 5.18), would argue against this.
In view of the diversity of DC subtypes within afferent lymph, it is possible that
if the action of IL-la is transitory, IL-1R expression will only be detectable at
certain stages of differentiation or activation of the cells. On a morphological
basis, the only cells with associated grains are either dendritic in nature, as
opposed to veiled, non-granular DC which stain weakly for non-specific esterase
or the occasional smaller DC with reticular staining (types c and d respectively,
Sect 5.3.3.3). The type of staining exhibited by cells with an extremely high
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density of grains is very difficult to determine, but seems to be stronger than that
of cells with fewer grains and more like the types b or f staining described in
Sect. 5.3.3.3 (Fig. 5.6). Whether these cells represent either discrete stages in
DC maturation or distinct phenotypic subgroups within the population would
have to be determined by dual staining with fluorescent markers. Too few cells
were available to be able to compare these cells with those positive for AChe.
IL-1RI bound IL-la (Grenfell et al., 1989) and IL-lp (Qwarnstrom et al., 1988;
Falk et al., 1989; Grenfell et al., 1991) can be internalised, although this may not
be essential for activity. The internalised IL-1 is undegraded, retains biological
activity and accumulates both on nuclei and in lysosomes. Late endosomes
within DC are now known to be involved in antigen processing (Levine and
Chain, 1992) and Arkema et al (1991) have shown clustering of Class II positive
vesicles and lysosomes in the juxtanuclear area of human DC. This is also the
region which specifically reacts with the human anti-CD68 (EBM11) and murine
EDI myeloid markers (Betjes et al., 1991; Beelen et al., 1992). Although 125I-
IL-1 should not have been internalised to any extent under the conditions used, it
is interesting to speculate on whether this could also be the area from which the
higher intensity graining emanates hence indicating concentration of IL-1
receptors in specific areas. The type of concentration of receptors seen in the
study being reported here has not, to my knowledge, been described for other
cells, although clustering of IL-1 receptors into focal adhesions on human
fibroblasts has been described (Dower et al., 1990). This latter study visualised
grains by electron microscopy and therefore represent a different order of
detection. In view of the highly specialised nature of the DC it is possible that
specialised expression of membrane proteins has developed.
Comparison with IL-1 receptor/cell expression on alveolar macrophages (IL-la
±2600; IL-ip ±17000) shows that resting DC express minimal numbers of
receptors (IL-la ±500; IL-1 {3 ±350). Activated DC can express nearly ten-fold
more receptors than Mcj) for IL-la but fewer receptors than M<j) for IL-1 p. These
figures are assessed with the proviso that Mcj) activation, either by anaesthetic or
by manipulation at the time of cell collection, could potentially increase IL-1R
expression in which case the figures obtained are not those of resting M(J). IL-1 (3
binding to ovine alveolar macrophages is comparable to IL-1 (3 binding to human
RAJI/H7 B cells, ie. 24% ovine M(j) expressing 16500 EL-lR/cell and 15%
resting RAJI cells expressing 15524 IL-lR/cell which is upregulated to 28%
expressing 45000 IL-lR/cell when stimulated (Stoppacciaro et al., 1991).
Irrespective of the state of activation of the macrophages, it is obvious that
activated DC bind IL-la preferentially whereas Mcj) bind IL-1 (3 preferentially. In
addition, both IL-la and IL-1 {3 could compete for binding to DC but, although
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IL-lp competed with IL-la binding to Me), IL-la did not effectively compete
with IL-1 (3 binding.
Because of the small numbers of lymph DC which express detectable IL-1R,
cross-linking or ligand blotting techniques were not sensitive enough to allow
determination of the size of the receptor. Pulse labelling experiments could be
used to determine the kinetics of internalisation of bound ligand, IL-1/IL-1RI
complexes being rapidly internalised and IL-1/IL-1RII not being internalised to
any great extent (Horuk et al., 1987). Alternatively PCR or in situ PCR with
primers derived from human IL-1R sequences might be useful, depending on
sequence homologies. A number of pieces of circumstantial evidence do
however point to the receptor type being IL-1RI rather than the IL-1RII which is
expressed by macrophages. IL-1RI and IL-1RII differ in their IL-1 binding
potential in a number of ways. Cells expressing IL-1RI reach binding
equilibrium rapidly, l-2h as opposed to 2-4h for IL-1RII. IL-1RI binds IL-la
better than IL-1 (5. IL-1RII on the other hand binds IL-1 (3 to a much greater
extent than IL-la and certain B lymphoma lines show exclusive IL-ip binding
(Dower et al., 1986). IL-la and IL-1 [3 can compete with each other for IL-1RI
whereas IL-la does not compete off IL-1|3 from IL-1RII. All of the above
criteria for IL-1RI binding are exhibited by ovine afferent lymph DC and point
to expression of the type I receptor.
Preliminary cross-linking results from cultured murine LC/DC have shown the
IL-1R to be +80kD and it has been suggested that this, together with a Kd of
<100pM, is indicative of IL-1RI expression (Kampgen et al., 1992). The sizes of
both receptors can vary with cell source ie. IL-1RI 80-100kD and IL-1RII 60-
80kD, and Kd values are equally variable, so that it is in no way certain that the
murine data does in fact represent a type I receptor. Ovine alveolar macrophage
IL-1 binding data, in contrast to the DC data, shows IL-1RII receptor binding
characteristics, as would be expected. If DC do indeed express the type I
receptor, this would indicate a lineage distinct from that of macrophages. DC
express markers indicating a myeloid origin (eg. CD13, CD33, CD34) and it has
been suggested that LC derived DC, peripheral blood DC and are all
ultimately bone marrow derived, possibly from a common progenitor, but it is
not known at what point separate development would be initiated (Caux et al.,
1992; Romani et al., 1989b; Thomas et al., 1993). That other bone marrow
derived cells, B cells and PMN, also express the type II receptor makes
expression of the type I receptor by DC seem unlikely. In addition, there is
evidence of rapid binding of rhIL-la to a PMN receptor of about 70kD, with
subsequent rapid internalisation at 37°C (Rhyne et al., 1988) demonstrating that
bone marrow derived cells can express IL-1 receptors with type I characteristics.
210
The cytokines IL-4 and IFNy can each elicit different responses from DC and
Mcj) (Chin et al., 1990,1991). If different signal transduction pathways can be
operative in the two cell types, this could also be the case for IL-1. It is
conceivable that myeloid precursors could have the potential for expressing both
types of IL-1R and that functional selection determines which is ultimately
expressed.
In conclusion, afferent lymphocytes express no detectable receptors for IL-lp
and only low levels of receptors for IL-1 a, which may even decrease after
secondary antigen challenge. Dendritic cells have been shown to express IL-1
receptors which are specifically upregulated with respect to IL-1a following
secondary ovalbumin challenge. This upregulation appears to occur slightly in
advance of increased MHC class II expression and to co-incide with increased
CD1 expression. No specific upregulation of receptors for IL-1 (5 was apparent.
As large quantities of IL-1 a are produced constitutively from keratinocytes, it
was initially thought that IL-1 a rather than IL-lp might be the more important
for LC/DC function. The IL-1 receptor data confirms that this is the case after
secondary antigen challenge but resting LC/DC display only a slight preference
for IL-1 a. The implications of the dendritic cell IL-1 binding data will be




6.1 General Considerations and
Sequence Conservation within the IL-1 Family
This project was initiated because of the central role of IL-1 in the pathology of
immunity, inflammation and infection. Little was known about any of the ovine
cytokines and it was considered important to be able to monitor alterations in
IL-1 production and activity caused by various disease states in the sheep. If the
involvement of ovine IL-1, or certain aspects of it's actions, could be
understood, the potential for therapeutic intervention could become a subsequent
consideration.
No useful reagents were available with which to study ovine IL-1. Human and
murine IL-ls had been cloned and there were antibodies to the expressed
proteins but these were of little use in ovine systems because of low species
cross-reactivity. The prerequisites were therefore twofold; (i) cloned IL-1a and
IL-1 (3 cDNAs for use as molecular probes and (ii) expressed recombinant IL-1
proteins for use in IL-1 receptor studies, antiserum production and the
development of specific ovine IL-1 assays. The project was not intended to
encompass assay development.
In the process of successfully cloning and expressing ovine IL-1 a number of
interesting factors became apparent. Amplification of cDNA sequences by PCR
although allowing rapid cloning, did introduce errors, either as a result of
infidelity due to the Taq polymerase enzyme or misprinting during anchored
PCR reactions or via chimeric products, all of which reduce the efficiency of the
system. Three potential IL1(3 polymorphisms but no IL-1 a polymorphisms were
detected. The ovine IL-1 a and IL-1 (3 proprotein/mature protein sequences were
found to be 97/98% and 95/96% similar respectively to their bovine
counterparts. The comparatively low homology found between the mature ovine
IL-ls and the human (IL-1 a, 69%; IL-1 J3, 64%) or murine (IL-1 a, 54%; IL-1J3,
59%) mature proteins, substantiated the low species cross-reactivities mentioned
above. In confirmation, the expressed ovine IL-1 proteins also exhibited species
specificity in assays on murine tissue. A similar species barrier has been
observed for the ovine cytokines TNFa and GM-CSF (Green et al., 1993;
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Mclnnes and Haig, 1991) and Lederer and Czyprynski (1989b) have reported a
species preference of bovine thymocytes and fibroblasts for bovine IL-1. This
specificity is of interest because there is little evidence of other IL-1 species
specificity using a variety of mammals and even reptiles and fish. It has however
been suggested that species specificity can play a role in some biological
responses. One report on IL-1 triggered release of ACTH from rats shows that
rat and human IL-1 (3 are equally efficient whereas rat IL-1a is 10 times more
potent than human IL-1 a (NaitoY et al., 1989) and it has been postulated that
cells which express primarily the type II receptor may be more species restricted
than cells bearing the type I receptor (Dinarello, 1991). The ovine data indicates
a clear species specificity for IL-1 biological activity ellicited through the type I
receptor. The apparently more distinct species preference exhibited by
ovine/bovine IL-1 as compared to other species will be analysed in relation to
sequence alignments in Sect. 6.1.1.3.
6.1.1 Assessment of Conserved Motifs at the Primary Structure Level
All known IL-1 cDNA sequence translations are aligned in Table 6.1. The
human IL-lra sequence is included for reference and has been related to human
IL-lp with respect to conserved residues. Protein sizes and species identities
relative to the respective ovine proteins have also been included. Dots in the
ovine IL-lp sequence indicate conserved residues with reference to ovine IL-1 a.
For all other species, dots indicate conserved residues with referecnce to the
equivalent ovine IL-1 sequence. Twelve common motifs within p-strands of the
three tertiary structures (Eisenberg et al., 1991) are indicated by horizontal bars
and the three potentially polymorphic ovine IL-1 p residues which were detected
in the current study are shown. 33 residues are conserved across IL-1 a and IL-
ip and 12 are conserved across all members of the IL-1 family. Potential
glycosylation sites are present in all sequences.
Patterns emerging from these alignments will be discussed first and individual
residues addressed subsequently with reference to the tertiary structure of the
proteins. The N-terminal region of IL-1 a shows minimal variation. The EL-ip
N-terminal sequence is far more variable but the C-terminal sequences of both
proteins are similarly variable. Both IL-1 a and IL-ip exihibit stretches of low
conservation at the N-termini of their mature protein sequences which has been
thought to be of relevance with respect to the different activities attributable to
these two proteins. The importance of conserved motifs has been extensively
reviewed and the most important features have been described in Chapter 1.
Only features relevant to ovine IL-1 activity will therefore be discussed here.
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Figure 6.1
All known IL-1 amino acid sequences are aligned compared to the respective ovine sequences. Ovine IL-ip
has also been related to ovine IL-la with respect to conserved residues. The human IL-lra sequence has been
related to human IL-ip with respect to conserved residues. Twelve common motifs within P-strands of the
three tertiary structures are indicated by horizontal bars over the sequences and potential glycosylation sites
are shaded. The IL-lra secretory sequence is shown in small size capital letters.
V - start position of mature proteins
(X) - potentially polymorphic IL-ip residues
X - residues conserved across all IL-1 sequences
A - residues conserved across all IL-1 and IL-lra
* - residues conserved between ovine IL-lp and human IL-lra
A - residues forming putative discontinuous IL-ip binding site for IL-1RI
xxxx„
- Putative Factor Xa recognition site
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6.1.1.1 Processing of IL-la
The IL-la nucleotide sequence GKILKKRRLS (ovine residues 78-87) is
conserved across all species, except for a human Val for Leu-81 substitution.
The tetrabasic KKRR, a trypsin digestion site, was originally proposed as a
potential primary processing site with the resultant molecule being further
digested by other enzymes to yield the mature IL-la (Lomedico et al., 1984). It
was subsequently shown, however, that the murine IL-la proprotein, which is
phosphorylated at the adjacent Ser, is trypsin insensitive and that this
phosphorylation may inhibit digestion by trypsin. Phosphorylation may be used
as a control mechanism because there is evidence that unstimulated macrophages
do not phosphorylate human IL-la and this proprotein can be trypsin digested,
hence leading to a disposal pathway, whereas the proprotein from stimulated
Mcj)s is phosphorylated and appears to be protected (Beuscher et al., 1988). This
Ser is conserved in all species and is the only phosphorylated amino acid to have
been detected in the IL-1 proteins. Assuming that ovine IL-la would be subject
to the same proteolytic restriction, a-Ser-87 is likely to be phosphorylated.
By analogy with other species the amino terminus of the bovine IL-la mature
protein has been presumed to be either a-Ser-120 (Maliszewski et al., 1988) or
a-Ser-113 (Leong et al., 1988). Amino acids a-105-114 are highly conserved,
which might indicate a protease recognition site including Ser-113. Although
various means for processing IL-la to its mature form have been postulated (see
Chapter 1, Sect. 1.4), it is of interest that during this study, activated Coagulation
Factor Xa appeared to cleave ovine IL-la between Arg-112 and Ser-113.
Although this has not yet been confirmed by N-terminal analysis, no other FXa
recognition sites are present in IL-la and non-specific cleavage has been ruled
out. From work in our laboratory, the minimal sequence requirement for a FXa
recognition site has been found to be IxxR and FXa would therefore be expected
to recognise murine IQPR as well as the IKPR motif found in all other species.
Jones and Geczy (1990) have demonstrated FXa-like activity on the surface of
LPS stimulated guinea-pig macrophages and found that FXa and thrombin
greatly induce IL-1 activity in macrophages stimulated by suboptimal
concentrations of LPS. It was proposed that this could be either via direct action
on IL-1 or via the action of FXa converting prothrombin to thrombin. It appears
from the ovine results that FXa can act directly on IL-la and may therefore be
one of the natural processing enzymes. Sequencing of murine and human IL-la
has in fact revealed a heterogeneous population of amino termini for mature IL-
la all of which exhibit equivalent activities (Lomedico et al., 1984; March et al.,
1986; Van Damme et al., 1985; DeChiara et al., 1986). The activities of ovine
rIL-la possessing either amino terminus, ie. either specifically expressed to start
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at a-Ser-120 or cleaved by FXa, presumably at a-Ser-113, were both found to
be comparable to other species. Because FXa had to be used to cleave IL-1 from
the expressed IL-lap:pl fusion protein, the complete IL-1a proprotein was not
available for comparison.
6.1.1.2 Processing of IL-113
In common with human and murine IL-1 [3, ovine IL-1 (3 contains the Asp-
113:Hydrophobic-114 motif and is therefore probably also processed to its
mature form by the specific ICE enzyme (Sleath et al., 1990). The importance of
this processing has been emphasised by the finding that cowpox virus encodes a
highly specific ICE inhibitor which is necessary for the virus to suppress the host
inflammatory response (RayCA et al., 1992). Substrate inhibitors specific for
ICE are thought to regulate macrophage output of mature DL-1|3 (Thornberry et
al., 1992). Like IL-1 a, IL-1 (3 can be processed by any one of several proteases,
such as elastase and cathepsin G, to yield mature proteins with different amino
termini (Hazuda et al., 1991) but unlike IL-la, most of these EL-1{3 proteins
have been found to have reduced biological activity (Black et al., 1988; Mituzani
et al., 1991b). Human mast cell chymase which is prevalent in the skin,
generates biologically active IL-1 [3 with N-terminal h(3-Val-l 14 rather than h(3-
Ala-117 (Mizutani et al., 1991b). Neither ovine nor bovine IL-1(3 contain an
equivalent site which might be susceptible to chymotryptic cleavage and it
would be interesting to determine whether the granule-specific sheep mast cell
proteinase (Huntley et al., 1992) can process IL-l(3p produced by ovine
keratinocytes.
6.1.1.3 Sequence Conservation and Species Specificity
IL-la has been calculated to be diverging at a greater rate than IL-1 (3 (Clark et
al., 1986; Eisenberg et al., 1991), and this certainly seems to be the case for
human, rabbit, rat and murine IL-1 (see Table 3.4 and Fig. 6.1). If, however, one
compares identities with reference to the ovine sequences, ovine/bovine IL-1J3
seems to have diverged from the rest to a greater extent than ovine/bovine IL-
la. On an individual residue basis, the IL-1 (3 alignment shows a striking pattern
of conservation, residues frequently being seen to be conserved across human,
murine, rabbit and rat but not ovine and bovine IL-1 (3 sequences. This
phenomenon is most marked within the mature IL-1 {3 sequence but is also
apparent to a lesser extent in the N-terminal proprotein sequence. Most of the
differences between the 'human group' and 'ovine group' sequences represent
conservative substitutions but may nevertheless contribute to the marked
differences in species specificity exhibited by the two groups which were
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mentioned at the beginning of this chapter. Interestingly, at four of these
positions, (3-Glu-152, (3-Gly-188, |3-Arg-206 and (3-Thr-222, it is the ovine
residue which appears in the human IL-lra. This pattern of conservation relative
to the ovine/bovine sequences is also apparent in IL-la although it is not as
obvious because of the higher mutation rate within the human, rat, rabbit and
murine IL-la sequences.
6.1.1.4 Conservation and the Receptor Antagonist
The IL-1 receptor antagonist does not contain sequences present at the presumed
start positions of either of the IL-1 mature proteins, ie. DA in IL-1 (3 and IKPRS
in IL-la, further evidence for the specificity of these sites.
IL-lra competes with both IL-la and IL-ip for binding to both IL-1RI and IL-
1RII. Because IL-lra binds to the IL-1 receptors without eliciting a biological
response, analysis of residues conserved across the mature IL-1 proteins and the
antagonist could be expected to yield information on which amino acids might
be important for receptor binding and/or activity. Twelve residues are conserved
across all members of the IL-1 family but otherwise residues conserved between
hIL-lp and hlL-lra are different to those conserved between hIL-la and hlL-
lra. A few IL-lra residues are equivalent to ovine rather than human IL-1 (3 and
are indicated on Fig. 6.1 (*). The potential importance of these will be discussed
in Sect. 6.1.2. At only one IL-la residue, a-Val-170, is the IL-ra residue
equivalent to ovine rather than human IL-la, which may implicate this residue
in the observed IL-la species specificity.
Examination of the residues emphasises how cautious one must be in drawing
conclusions from primary structure data. For example, one third of the IL-
lra/hlL-lp conserved residues are within the (3-173-204 region thought to be
involved in activity not binding. In addition, far more residues are conserved
than would be expected to be necessary for receptor binding. By comparison,
only ~5% of total residues are required for C5a or human growth hormone
binding to their respective receptors (Mollison et al., 1989; Cunningham et al.,
1990). Some of the residues are required to conserve the general shape/structure
of the protein although not in actual receptor contact themselves. It also has to
be borne in mind that there is likely to be some chance conservation of the
sequence of the primitive gene prior to gene duplication.
A more appropriate analysis might be of residues conserved across IL-1 but not
the antagonist. Of the twentytwo amino acids conserved across the mature IL-ls,
eleven are not present in the antagonist. These latter residues are distributed
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throughout the tertiary structure (see Fig. 6.2.b). Only one of these eleven IL-la
residues has so far been mutated, ha-Met-168 to Leu which resulted in some
loss of LAF and 50% loss of A375 proliferative activities. This loss of activity
may be due to structural alterations (see Sect. 6.1.2.5). Seven of the eleven IL-1 (3
residues are within regions supposedly important for activity but not binding.
Preliminary evidence has been presented that IL-lra binding to IL-1RI may not
be identical to either IL-la or IL-1 {3 binding (Arend et al., 1992) but the actual
importance of any of these residues has yet to be established.
6.1.2 Assessment of IL-1 Conservation at the Tertiary Structure Level -
Possible Contribution of Individual Residues to Species Specificity
Although there is only 25% homology between IL-la and IL-1 (3 amino acid
sequences, and 41% homology between EL-1(3 and IL-lra, crystallographic and
nuclear magnetic resonance studies have shown their folding patterns and
tertiary structures to be very similar, each being in the form of a trigonal
pyramid made up of 12 antiparallel strands (Graves et al., 1990; Clore et al.,
1990; 1991a; 1991b; Labriola-Tompkins et al., 1991; Eriksson et al., 1991; Zhu
et al., 1991; Eisenberg et al., 1991; Arend et al., 1991; Stockman et al., 1992;
Veerapandian et al., 1992).
Figure 6.2 has been assembled using crystallographic co-ordinates of the hIL-lp
mature protein as determined by Veerapandian et al., 1992. IL-la co-ordinates
were not available and this structure will therefore be used to illustrate the
positions of residues of interest with respect to both proteins, with the proviso
that IL-la and IL-ip folding patterns may not be identical. Although sequence
alignments show exterior residues to be much less conserved than interior
residues (Priestle et al., 1989 and Fig. 6.2.b), certain exterior residues proposed
as being important for the generation of human or murine biological responses
do appear to be well conserved. These residues have been highlighted in Fig.
6.2.a in order to assess their potential importance with respect to ovine IL-1
activity and will be referred to as appropriate. Residues which are not conserved
in the ovine sequences are identified with an asterisk. Throughout this thesis,
amino acids have been numbered from the start of the IL-1 proproteins, ie. Met-
1. Because of the enumeration of the X-ray co-ordinates, residues in Fig. 6.2 are
numbered as from Ala-1, the start of the IL-1 (3 mature protein. In the discussion
that follows, the equivalent ovine proprotein residue numbers will therefore be
given in brackets in order to relate these residues to the alignments shown in




Tertiary Structure of Human IL-lp
These figures have been compiled from the crystallographic co-ordinates of the hrEL-ip mature protein
determined by Veerapandian et al., (1992). The ribbons represent the backbone of the molecule and white
arrows indicate the N and C termini of the molecule. Highlighted residues within these representations of the
IL-lp monomer are numbered as from Ala-1, the start of mature IL-ip. These residues need to be assessed in
conjunction with the sequence alignments in Fig. 6.1. For this purpose, equivalent residue numbers with
respect to the ovine EL-1 proproteins are given in the main text. It is not certain exactly how this structure
interacts spatially with either IL-1 receptor although in the orientation shown in Fig. 6.2.a, the majority of
highlighted residues are pointing away from the reader, ie. the face of the molecule which interacts with the
receptor is facing into the page. In Fig. 6.2.c the molecule has been rotated round all three axes in such a
way as to show that the majority of residues supposedly involved in receptor contact (for binding or initiation
of signal) are facing out of the protein surface and that the three groups. (The colour coding of groups of
residues in figures 6.2.a and 6.2.c are not the same)
Different orientations of the monomer are shown in Fig. 6.2.a (opposite), and Figs. 6.2.b and 6.2.c on the






Group 1: residues forming a discontinuous IL-ip/IL-lRI binding site (Lys-93 is
common to groups 1 and 2)
Group 2: residues involved in nuclear localisation of IL-1 P (because of crowding,
only 4 of the 7 residues within this cluster have been labelled)
Group 3: residues involved in IL-1 a or IL-1 P activity rather than receptor binding.
(Arg-11 and Asp-12[paie yellow], represent actual IL-ip residues and the
rest, are the IL-1 P equivalents of IL-1 a residues for which no co¬
ordinates were available).
Residues marked with a white asterisk are different in the human and ovine sequences as shown below.
The equivalent ovine residue numbers with respect to Figure 6.1 are given in brackets (see text for details).
Residue No. Human/Murine Ovine
Group No. on Figure IL-lp IL-1B
1 (Red) 4 Arg Gin (117)
6 Leu Val (119)
2 (Yellow) 93 Lys Arg (206)
1,2 (Red) 94 Lys Asn (207)






Assuming the axes of rotation to be through the centre of the molecule, this figure has been rotated, with
respect to Fig. 6.2.a, through about 180° round the x-axis and clockwise a few degrees round the y-axis.
Groups 1-3 residues have not been highlighted but their relative positions are indicated for orientation
purposes.
Green - residues conserved across IL-la and EL-ip.
Gold - residues conserved across human IL- Ira and ovine/bovine IL-1P but no other EL-1P
sequences. Equivalent ovine proprotein numbers for these 4 residues are given below:
Residue No. on Figure Human IL-ip Ovine IL-ip/Human IL-lra
39 Gin Glu (152)
75 Asp Gly (188)
93 Lys Arg (206)
109 Lys Tyr (222)
Figure 62.c
Similar orientation to Fig. 6.2.b but with some further rotation round all axes. Individual residues have not
been named but the three main receptor-contact groups are indicated and residues which are different in
ovine IL-ip are again indicated with an asterisk.
Green Group 1: red in Fig. 6.2.a
Orange/dark yellow Group 2: yellow in Fig. 6.2.a
pink/pale yellow Group 3: green/pale yellow in Fig. 6.2.a
 
6.1.2.1 Group 1: IL-1 Residues Important for Binding to Type IIL-1R
It has been proposed that seven residues within human IL-ip form a
discontinuous IL-1 type I receptor binding site (Labriola-Tompkins et al., 1991).
These residues, which are shown in red on Fig. 6.2.a (and green in Fig. 6.2.c),
and are indicated by A in Fig. 6.1, are clustered in one area of the molecule. Of
these seven residues, four are fully conserved across all IL-1 (3 sequences, ie.
Phe-46(P-i59), Ile-56(P-i69), Lys-103(3-216) and Glu-105((3-218). Human residues
Leu-6(ovine 3-Vai-ii9) and Lys-93(ovine p-Arg-206) both show conservative
substitutions in the ovine sequence. The seventh residue, Arg-4(P-i 17), is
conserved across all but the ovine and bovine sequences which both contain Gln-
117. In addition to structural differences, the pis of these two amino acids are
very different, Arg being pl=10.76 as opposed to Gin, pl=5.65. This amino acid
difference could explain in part the reduced biological activity of ovine and
bovine IL-1 (3 when assayed on murine cells. In support of this contention,
Labriola-Tompkins et al., (1991) showed that mutation of this residue to Asp
abrogated binding to both type I and type II receptors indicating that an acidic
side chain may not be tolerated at this position. In addition, they showed that
even the conservative Lys/Arg-4(i 17) substitution abrogated receptor binding,
which could have implications with respect to other basic/basic amino acid
substitutions. Substitution of (3-Lys-93 with amino acids containing aromatic,
polar or negatively charged side chains all abrogate receptor binding. This
residue is conserved across all species except ovine and bovine IL-lp which
both have the related p-Arg-206. In this context it may be of interest that the
human IL-1 receptor antagonist also has Arg at the equivalent position. Taken as
a group therefore, the ovine/human differences at positions P-4(ii7), P-6(ii9) and
p-93(206) which are in close proximity spatially, as seen in Fig. 6.2, could be a
major factor contributing to the species specificity observed in this study.
Only three of these seven IL-lp residues have conserved IL-1 a counterparts, p-
Arg-4(ov. a-Arg-i28), which has been shown to be important for IL-la/IL-lRI and
IL-1RII interactions (Nanduri et al., 1991; Labriola-Tompkins et al., 1991) and
P-Leu-6(ov. a-iie-i30) and P-Ile-56(ov. a-Leu-180) both of which are only partially
conserved. For IL-ip binding, an aromatic residue at position P-46(i59) is
essential for receptor binding but all IL-1a sequences have Ala at this position.
These residues demonstrate potentially different type I receptor binding
requirements for IL-1 a and IL-ip.
6.1.2.2 Residues Important for Binding to Type IIIL-1R
Few residues have yet been implicated in IL-lp binding to the type II IL-1R. P-
Asp-145(P-258) which is important for IL-1RII binding is conserved in the ovine
sequence as is Phe-46(P-i59). This latter residue and Arg-4(ii7) are the only two
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residues within the proposed IL-1RI discontinuous binding site which have any
great effect on IL-IRII binding (Labriola-Tompkins et al., 1991). For both
receptor types an aromatic ring is essential at position (3-46 and acidic side
chains at (3-4 reduce binding. Unlike type I requirements, however, type II
binding will tolerate mutations to (3-Ala-4 or (3-Lys-4. Antibody studies have
indicated that two sequences, equivalent to ovine residues (3-162-165 and (3-
174-183, are important for human or murine IL-1RII binding but without being
directly involved (Boraschi et al., 1991b). These sequences are not highlighted
on Fig. 6.2, but can be seen from Fig. 6.1. Amino acids (3-162-165 are only
partially conserved across species and their importance in this context is unclear,
although they are centred within the nona-peptide ((3-160-168) which has been
advocated for adjuvant use. This latter function, however, involves type I rather
than type II receptor generated responses. The second peptide sequence, residues
(3-174-183, is reasonably well conserved and seven of the amino acids are
present in the ovine sequence with the other three being conservative
substitutions. Ovine IL-1 binding to macrophages (IL-1RII), from other species
was not examined in the study being reported here and the importance of any of
these residues with respect to ovine IL-1RII generated bioactivity is unknown.
Residues essential for type II receptor mediated IL-1 a activity are not known.
6.1.2.3 Group 2: Residues Involved in Nuclear Localisation of IL-1(3
IL-1 (3 bound to the type I receptor is thought to be internalised and translocated
to the nuclear membrane either on its own or attached to the receptor. In EL4
cells which possess the type I receptor, the kinetics of nuclear membrane and
plasma membrane binding have been shown to be similar (Grenfell et al., 1989).
There is nevertheless still controversy as to the significance of IL-1 (3 nuclear
binding in the generation of biological responses, as has been detailed in Chapter
1.11.1.4.
Residues within the putatitive IL-1(3 nuclear localisation sequence, 91-97(3-204-
210) are shown in dark yellow on Fig. 6.2.a (orange/dark yellow in Fig. 6.2.b)
and form a group distinct from the surface receptor binding group. The putative
nuclear localisation sequence present in human, murine, rat and rabbit IL-1 (3,
91PKKKMEK97, is altered to 204PKRNMEK210 in both ovine and bovine IL-1 (3.
These alterations appear to be relatively minor, apart from a charge change due
to the K/N substitution, and may not restrict nuclear membrane binding. Lys-
93(3-206), the only one of these residues common to both plasma membrane and
nuclear binding, is situated at the junction between the two groups. The level of
conservation of these Group 2 residues strongly suggests functional importance
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and Lys-93(206) appears to be a key residue. It may be significant with respect to
both human/murine IL-ip activity that hlL-lra, which binds to the receptor but
would not be expected to be internalised, has residues equivalent to P-206 and P-
207 but does not contain the full nuclear localisation sequence. That the
antagonist has the equivalent of ovine p-Arg-206, not Lys as in the human
sequence, may also be relevant in the context of low ovine IL-ip activity on
murine cells. IL-la, which is not thought to be localised to the nucleus, appears
to have deletions within this region but does have an LKKRRL motif, bases a-
82-87, which might represent a nuclear localisation signal (Grenfell et al.,
1988).
Of the residues supposedly involved in surface receptor and nuclear IL-ip
binding, all except Arg-4(ovine (3-Gln-117), Leu-6(ovine |3-Val-119), LyS-93(ovine 3-Arg-
206) and Lys-94(ovine p-Asn-207) are conserved across all species. From the above
analyses, three points in particular are interesting: (i) ovine IL-lp and hEL-lra
both have Arg rather than Lys at position P-206; (ii) there is charge difference in
the ovine protein at position P-207; (iii) residues p-4(ii7) and P-93(206) are in
close proximity regardless of orientation of the molecule; all of which may
indicate a significant contribution to species specificity by these residues.
6.1.2.4 Group 3: Residues Involved in IL-1 Activity
Mutational studies and chemical modification have so far implicated numerous
residues in IL-1 activity but many of the alterations have produced relatively
minor effects. The most important residues, as demonstrated by point mutations
(Poindexter et al., 1991; Kawashima et al., 1992; Yanofsky et al., 1990; Nanduri
et al., 1991; Nakii et al., 1990; Gehrke et al., 1990; Conca et al., 1991), are
highlighted on Fig. 6.2.a. All are situated within the common p-sheet motifs. IL-
ip residues are pale yellow and IL-la-equivalent residues are green with
numbers being those of the corresponding IL-ip residues (pink and yellow
respectively in Fig.6.2.b). IL-la numbers will therefore be given in brackets to
identify the specific residues. It can be seen that these amino acids are spatially
separated from those involved in receptor binding and except for Lys-88(a-2i2, p-
201) form a distinct, though somewhat more disperse, grouping. This latter
residue is conserved across IL-la and IL-ip sequences, except for the rabbit
which has conservative substitutions, and the equivalent IL-lra residue is the
non-basic Asp, observations which suggest an important role for Lys-88(a-2i2).
Mutational studies have in fact shown that the requirement at this position, for
IL-la at least, is a basic amino acid. Mutation of a-Lys-88 to Arg had no effect
on stimulation of A375 cell proliferation whereas mutation to lie resulted in a
40-60% loss of this activity (Kawashima et al., 1992).
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Of the other important IL-la residues, all are conserved in ovine IL-la. Only
two are not also conserved in ovine IL-1 (3, Lys-16(a-Gin-i42; 0-Lys-i29) and Val-
41(a-Lysi66; 0-Vai-i54) and in each case the equivalent IL-lra residue is Lys. Asp-
26(a-i38) and Leu-41(a-i53) residues are also conserved in IL-lra. This degree of
conservation and the inwardly facing position of Leu-18(a-i44) suggests a
structural role for these latter three residues. Asp-151(a-262) is conserved in IL-
la and IL-1 (3 but not IL-lra. Mutation of a-Asp-151 to Tyr resulted in no
change in IL-1RI binding affinity but some activities were reduced (Yamaoshi et
al., 1990). Its equivalent (3-Asp-145(0-258) has been shown to be essential for IL-
1(3 activity generated from the type II receptor but its importance with respect to
the type I receptor has not been established.
The remaining amino acid in this group, (3-Arg-11(0-124), is (3-Gln-124 in both
ovine and bovine sequences but is not conserved in IL-la. Mutation of human
Arg-11(0-124) and Arg-4(0-ii7) reduces T cell activation by lowering receptor
binding affinity (Nakai et al., 1990; Gehrke et al., 1990; Conca et al., 1991;
Labriola-Tompkins et al., 1991; Chang et al., 1992), and the substitution of (3-
Gln-124 for Arg at this position could therefore be expected to contribute to the
comparatively low ovine IL-1(3 (this study) and bovine (Maliszewski et al.,
1988) activities detected with murine cells. Ovine IL-la was also less active on
murine cells but none of the above residues are obviously involved in this
species specificity.
Three residues, Arg-4(a-i28; 0-ii7), Asp-12(a-i38; 0-125) and Asp-145(a-262; 0-258)
have been shown to be important for selected activities of both IL-la and EL-1(3.
Within the Group 3 residues, a-Gln-142 and a-Lys-166 appear to be important
for IL-la activity exclusively and Arg-11(0-124) for IL-1(3 activity exclusively.
Otherwise the conservation within this group might predict that IL-la and IL-1(3
illicit signal transduction from IL-1RI via similar residues. Within the human IL-
1(3 C-terminal regions 148-162 and 173-204, which have been shown to be
involved in activity but not receptor binding (Boraschi et al., 1991a; Herzberg et
al., 1989), eleven residues are conserved across EL-la and IL-1(3 in all species.
Taken together, these observations could indicate that it is the receptor binding
requirements which determine IL-1 activity and that once bound, the IL-1
residues required for initiating signal transduction pathways may not be all that
different for IL-la and IL-1 (3. Cross-species data however contradicts this view
to some extent. Much more data on IL-1/IL-1RI interactions is required before
the precise involvement of particular residues can be stated with any certainty.
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One further consideration which has to be borne in mind when assessing these
residues is that mutation may not necessarily show which residues are being
implicated in any particular function. For example, it appears that different
residues may be essential for generation of selected activities. Mutation of a-
Glu-94 to Val reduces LAF activity by 46% without affecting either A375 cell
proliferation or prostaglandin synthesis whereas mutation to Gly does not inhibit
any of these functions (Kawashima et al., 1992). However, a-Glu-94 is also
conserved in the antagonist. It is equally possible that conformational change
induced by mutation of a-Glu-94 alters receptor contact by other residues and
that a-Glu-94 is not intrinsically important for initiation of signal transduction.
In the current study, FXa unexpectedly truncated the C-terminal of IL-1 (3m.
Unlike IL-la, a FXa site is only present in the ovine and bovine sequences. IL-
l(3m and its truncated form exhibited similar biological activities therefore, if the
assumption that IL-1 (3m is cleaved at (3-244 is correct, this would indicate that
amino acids [3-244-266 may not be absolutely essential for ovine IL-1(3 activity
via the type I receptor and that loss of these amino acids may not adversely
affect IL-1 (3 tertiary structure with respect to the ovine receptor requirements.
This is in contrast to data showing that deletion of (3-253-266 results in loss of
activity and that mutation of Lys to Asp in the IL-lra at the position equivalent
to p-Asp-258 results in the antagonist displaying minimal agonist activity (Ju et
al., 1991). (3-Asp-145(258) is supposedly essential for human IL-1(3 binding to the
type II receptor (Kawashima et al., 1992). In this study, binding of an 125I-IL-1(3
preparation which contained 50% FXa truncated IL-1(3 to macrophages, was not
significantly different to that of preparations containing only the full length
protein (data not shown). This is the only indication that IL-1/IL-1RII
interactions may also be different in the sheep.
6.1.2.5 Residues Essential for Maintaining the Structural Integrity of IL-1
Labriola-Tompkins et al., (1991) have shown that [3-Met-157 and (3-Val-171 are
essential for maintaining the structural integrity of IL-1 with respect to binding
to either receptor type. These two residues are fully conserved across IL-la and
IL-1 (3 sequences but it is of interest that the equivalent residues in IL-lra are the
related Val and Ala respectively which may mean that the receptor antagonist is
slightly more flexible, allowing for less restricted receptor binding.
6.1.2.6 Thoughts on the Requirements for Ovine IL-l/IL-1 Interactions
Two obvious factors are important for ligand/receptor interactions. Firstly that
the ligand structure assumes optimal configuration for binding and secondly that
within this configuration, individual residues can make appropriate contact for
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initiation of the signal transduction cascade. Receptor binding requirements are
difficult to assess because so much of the data available in the literature is based
on mutational studies which, by definition, must induce some conformational
change in the molecule. It is by no means certain that altered activities can be
attributed purely to the amino acid(s) mutated. Equally, data derived from
antibody studies is dependent on specific epitopes being recognised and results
from different studies are not always in agreement. Without more knowledge
about potentially important residues, it is difficult to predict exact requirements
for activity. That having been said, it appears from the above analyses, that the
binding requirements for the sheep IL-1 receptors may be slightly different to
those of the human or murine IL-1 receptors. EL-ip residues Gin-117, Gin-124,
Arg-206 and Asn-207 all seem to be important with respect to generation of
different levels of biological responses from the ovine vs. murine IL-1 type I
receptor. No conclusions could be drawn about residues contributing to the
similar species specificity exhibited by ovine rIL-la but a-Val-170 may be a
candidate. Residues thought to be required for activity via the IL-1 type II
receptor are partially conserved in the ovine protein and this receptor would also
be expected to exhibit species specificity although this has not been tested.
All those residues which the above data would suggest are functionally
important, are identical in all published ovine and bovine IL-1 sequences with
the exception of bovine (3-Ile-l 19 which represents a conservative Val/Ile
substitution (Fiskerstrand et al., 1990, 1992; Seow et al., 1991; Andrews et al.,
1991; Leong et al., 1988; Maliszewski et al., 1988). In view of the comparatively
low level of conservation between human/murine and ovine IL-1 it is likely that
the respective tertiary structures might assume slightly different configurations
which could implicate different residues in receptor contact and generation of
biological responses.
6.2 Biological Activity of the IL-ip Proprotein
Ovine rIL-lp proprotein was found to be 5 times less active than the mature
protein in thymocyte assays. By comparison, the human recombinant proprotein
is 120 times less active than the mature protein in the D10.G4.1 assay (Jobling et
al., 1988). Both these cell types display the type I receptor. Human IL-ipp and
IL-lpm separated by chromatofocusing (isoelectric points 5 vs 7 respectively),
could also both be bound to EL4 cells (IL-1RI), the binding affinity of the
proprotein being 3.5% that of the mature protein (Kd IL-ipm=lxl09M). In
contrast, the soluble IL-1R, a proteolytically cleaved portion of the IL-1 type II
receptor, binds the IL-ip proprotein efficiently (Symons et al., 1991b), which
may indicate that human and murine IL-1 Pp function at least, is largely directed
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through IL-1RII or an IL-lRII-like receptor. If this were the case, it could
explain, in part, the low EL-1(3 proprotein activities generally reported from T
cell or chondrocyte assays. Different folding patterns of IL-l(3p and IL-1 (3m
could determine the relative binding affinities for the two cellular receptors or
alternatively, the structure of the proprotein may limit its activity and it may be
more active if membrane bound.
Whether the activity of pro-{3 is of any importance remains to be determined but
it is interesting to speculate on its possible function. The idea that the EL-1(3
proprotein may have some restricted function(s) in vivo, is attractive from a
number of points of view:
(i) Membrane bound forms of IL-1 have been described which are involved in
direct cell-cell communication between macrophages and T cells (Nagelkerken
and van Breda Vriesman, 1986; Bhardwaj et al., 1989). The main constituent of
membrane bound IL-1 seems to be proIL-la, but the presence of IL-1 (3 has been
suggested (Jobling et al., 1988). Platelets express active IL-1 a and EL-ip which
are entirely membrane bound and rapid delivery of EL-1 to vascular endothelial
cells following injury has implicated platelets as providers of an initiating signal
for the inflammatory response (Hawrylowicz et al., 1989a, 1991). These
membrane IL-ls have not been characterised but may prove to be the
proproteins. Membrane bound IL-1 and soluble IL-1 may act via different
mechanisms or receptors (Kurt-Jones et al., 1986; Hurme, 1987).
(ii) Keratinocytes constitutively produce large amounts of proIL-l(3, only some
of which is processed. Cultured keratinocytes do not process the IL-1 (3 at all
(Bigler et al., 1992). The specific monocyte IL-1 (3 processing enzyme, ICE, has
not been detected in keratinocytes although serine proteases are known to
process the proIL-l(3 to unusual peptides (Cooper et al., 1990a; Hammerberg et
al., 1990). It is likely that there could be some as yet unknown, but specific,
function for the IL-ip proprotein in these cells. Involvement in localised
inflammatory reactions is possible. As I was in the process of writing this
chapter, two papers were published, one showing that LPS or IL-ip stimulated
human foetal microglial cells produce abundant levels of potent IL-ip which
remains primarily cell associated (Lee et al., 1993) and the other that there is
reduced secretion of IL-lp by peritoneal cells during continuous ambulatory
peritoneal dialysis (Hart et al., 1993). Both suggest a pro-inflammatory role for
the cell-associated IL-ip proprotein. That this form of IL-ip may be involved in
antigen presentation has also been suggested.
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(iii) As many as thirty residues in the N-terminal region of the proproteins are
conserved across the IL-lp and a further eleven across both IL-la and IL-ip.
which suggests some functional significance. It is possible that this region
contains recognition sites for chaperonin proteins responsible for transport of IL-
ip across the cell membrane.
6.3 Genomic Organisation of Ovine IL-1
Human, murine, rabbit and bovine IL-1 genes appear to exist as single copies.
Although I did not investigate ovine IL-1 at a genomic level, recently published
data from Andrews et al. (1992) suggests that the same is true for the ovine
genes. For future study of IL-1 it would be useful to have knowledge of the
promoter and regulatory regions within the ovine IL-1 genes. All that is
currently known is that the 3' regions of IL-la and IL-lp cDNAs in the sheep
are both AU rich and, in common with other species, contain a number of copies
of AUUA motifs thought to be responsible for the short, <30min, mRNA half-
lives (Turner et al., 1989; Andrews et al., 1991).
6.4 Production of Ovine IL-1 by LPS Stimulated Alveolar Macrophages
Northern blot analysis of LPS stimulated ovine alveolar macrophages showed
production of IL-la and IL-ip mRNAs to peak around 4-6h (Fig. 3.18) but no
data is yet available on the synthesis and secretion of the IL-1 proteins. In other
species synthesis of IL-la is delayed and it appears to exert its influence in a
predominantly cell associated form. IL-lp is more rapidly translated and has
been thought to require secretion and processing for optimal biological activity
(see Chapter 1, Sect. 1.4). It would be of interest to assess the translation rates
and export of ovine IL-1, not only by macrophages but also other cell types such
as fibroblasts, dendritic cells and platelets. Secretion of IL-1 into the
macrophage supematants could not be determined in this study because TNF,
and to a lesser extent IL-6, also act as proliferative agents in the thymocyte and
cartilage degradation assays which were used for estimating recombinant IL-1
activities. Routinely employed biological assays specific for human and murine
IL-1, such as induction of proliferation of D10.G4.1 or EL4.NOB1 cells, are of
no use for measurement of ovine IL-1 activity because of the low species cross-
reactivity.
Preliminary work involving non-reducing PAGE gel electrophoresis of LPS
stimulated macrophage supernatants has shown that the polyclonal rabbit
antiserum raised against ovine-IL-lpm detects a single band on Western blots
(data not shown). This band is not detected in unstimulated macrophages but
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increases in intensity over the first four hours of LPS stimulation. The band is
seen at an apparent molecular weight much higher than expected for either form
of IL-13, ie. at >68kDa, which may mean that the IL-13 is either aggregated or
bound to a chaperonin. Elucidation of the patterns of ovine IL-1 production
awaits the development monoclonal antibodies and specific ovine IL-1 assays.
6.5 IL-1 and Afferent Lymph Dendritic Cells
That numerous cytokines are involved in the induction of antigenic or
inflammatory responses is very clear and the extremely complex response to
antigen is obviously under very tight cytokine control.
The mechanism whereby IL-1 enhances DC function has not yet been
elucidated, neither is it known to what extent IL-1 is involved in the early
response to antigen. It is now known that even in non-inflamed skin, LC adhere
strongly to keratinocytes via E-cadherin, the expression of which decreases as
the LC differentiate into DC (Tang et al., 1993). Cell-associated or membrane-
bound keratinocyte IL-1 could therefore potentially act on LC by celkcell
contact.
IL-1R expressed by ovine LC have yet to be assessed but in the current study
300-400 IL-1 receptors were detected on resting DC found in peripheral afferent
lymph. Secondary ovalbumin (OVA) skin-challenge, dramatically increased both
the number of IL-1a receptors and the proportion of DC expressing IL-1R.
Changes in IL-1a binding were much larger than IL-13 and were co-incident
with cell numbers; a transient increase by 4h, followed by a second increase to
maximum cell output on days 2 and 3 after which the count gradually returned to
baseline by day 8. IL-13 binding, in contrast, was increased on days 2-3 but then
dropped dramatically.
Antigen uptake by sheep cells after secondary challenge is known to be rapid.
Following the injection of 200p.g OVA, <40% of DC arriving at the lymph node
by 40min were positive for FITC-labelled antigen and the response had
disappeared by 2h (Harkiss et al., 1990). A larger OVA dose (2mg) resulted in a
greater response (70% DC positive for antigen) of longer duration (4h). Having
only injected 50jig OVA in the current experiments, a lesser response would be
expected but it is conceivable that the individual DC from the 4h lymph
collection which bind IL-1a could also be antigen-associated. If IL-1 action is
transient, receptors may be internalised rapidly, in which case only a small
proportion would be detected. Even after secondary challenge only very few DC
showed extremely high IL-1 a binding and no more than 10% of DC expressed
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detectable IL-1R. IL-1 (3 at all times was bound to a much lesser extent than IL-
la.
Only a very small proportion of non-specific esterase (NSE) positive dendritic
cells in afferent lymph were also positive for acetylcholinesterase (AChe).
Veiled afferent lymph DC were not strongly positive with either of these stains
which, if these veiled cells are most mature form of DC found in afferent lymph,
may indicate diminishing lysosomal activity with maturation of the DC. Veiled
DC also do not seem to be the cells expressing IL-1 receptors although this can
not be stated with absolute certainty from the data obtained. NSE/125IL-1
positive cells appear to be dendritic as do the AChe positive cells. Staining
labelled cells with AChe prior to exposure would clarify whether the AChe
positive subpopulation of cells are also expressing IL-1R.
The size of the IL-1 receptor operative on ovine DC has not been determined but
it seems to exhibit IL-1R type I rather than type II characteristics. This is also
claimed to be the case for cultured murine LC/DC (Kampgen et al., 1992). B cell
lines exhibit a heterogeneous population of receptors, expressing 68kDa and
80kDa receptors, the latter of which bind IL-1a with a greater affinity than IL-
1(3 (Benjamin et al., 1990). IL-1 can enhance PMN and monocyte FcR mediated
phagocytosis (Simms et al., 1991) and the action of IL-1 on PMN could possibly
be via the same 80kDa receptor, in which case a parallel might be active in
LC/DC. Amplification of receptor cDNA by in situ PCR using primers
appropriate for each IL-1 receptor type would establish which is expressed by
LC/DC lineage cells.
Earlier studies on sheep have shown that MHC class II expression by afferent
lymph dendritic cells increased uniformly to almost sixfold by days 4 and 5
following secondary antigen challenge and had returned to resting levels by day
8 (Hopkins et al., 1988). Maximal IL-1R expression precedes increased MHC
class II expression by 1-2 days, which may indicate either no correlation or else
an indirect association between IL-1 action and class II-restricted antigen
presentation. IL-1 does not upregulate la on the mature DC surface (Koide et al.,
1987a) but a trace population of murine thymic la- DC precursors can be
induced to form fully functional Ia+ DC by the action of IL-1 (Inaba et al.,
1988). More direct evidence in favour of a connection between IL-1 and class II
expression comes from data showing that intracutaneous injection of IL-1 (3 into
mice resulted in decreased density of Ia+ DC over 2-7days with the remaining
DC showing increased Ia+ expression over days 1-4 (Lundqvist and Back,
1990).
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Resting DC express the sheep analogue of human CD1 uniformly. Increased
expression of CD1 is also seen from days 2-7 after challenge but only on about
35% of the cells (Bujdoso et al., 1990; Hopkins et al., 1989). CD1 restriction has
recently been demonstrated as being potentially important in antigen
presentation by peripheral blood DC suggesting a functional parallel between
CD1 and MHC class II-restricted responses (Porcelli et al., 1992). CDla, which
is the first marker to appear which distinguishes cultured monocytes from
developing macrophages, is specifically expressed by Langerhans cells and
thymocytes (van de Rijn et al., 1984). GM-CSF is involved in the generation of
DC from LC and has been shown, together with EL-4, to induce CDla,-b,-c
expression on blood monocytes (Porcelli et al., 1992). CDla+, CDlb+ and
CDlc+ afferent lymph DC have all been detected in sheep. The role of CD1 in
the antigen presentation by lymph DC is as yet not understood, and the spectrum
of cytokine influence is unknown. The involvement of IL-4 in a secondary
response may prove to be closely linked to that of IL-1. In addition to its ability
to upregulate CD1, IL-4 has also been shown to decrease human FcyR
expression (Chin et al., 1990; te Velde et al., 1992; Bieber, 1993) which would
correlate with the observed FcR involvement in antigen uptake followed by
decreased FcR expression prior to antigen presentation in sheep (Harkiss et al.,
1990). More importantly, IL-4 can upregulate IL-1RI expression (Koch et al.,
1992).
In view of the temporal co-incidence of the very early IL-1R expression and
antigen uptake, and the later IL-1R and CD1 expression, it would interesting to
determine the relationship between IL-1R expressing DC, OVA-associated DC
and DC expressing CD1 subclasses. If a clear relationship does exist and if the
IL-1 receptors are concentrated over the region of juxtanuclear vesicles, as might
be indicated by the pattern of 125I-IL1 grains on the exceptionally hot cells, this
data, together with evidence that IL-1 enhances antigen presentation through its
action on the DC, could point to a role for IL-1 a with respect to antigen uptake
or processing. In support of an early role for IL-1 a, intravenous injection of rlL-
la into mice has shown a concommitant rapid cell depletion of spleen and
thymus which may represent mobilisation of immunocompetent cells during the
development of the immune inflammatory response. Very few DC are required
to present antigen and a ratio of 1:200 DC:TC is sufficient to induce a strong
response in in vitro assays (Klinkert and Steffen, 1988). In culture, IL-ip
mRNA transcription is upregulated during DC maturation (Heufler et al., 1992)
and during in vitro antigen presentation to T cells, DC/T cell clusters form
which induce IL-1a mRNA synthesis but no IL-1 has yet been detected in cell
supernatants. Cell-associated IL-1a and/or IL-ip could have a role in antigen
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presentation, the DC IL-1 acting on T cells via cellxell contact. Evidence for
this was suggested as early as 1986 by the finding that DC from rat thoracic duct
lymph possess membrane-associated structures identical to or mimicing IL-1
which are involved in T cell activation (Nagelkerken and van Breda Vriesman,
1986) and more recently evidence has been put forward that membrane
associated IL-1 a may play a role in activating antigen-presenting cells, albeit
peripheral blood monocytes and B-lymphocytes, in the initiation of immune
responses (Eugui and Almquist, 1990).
Keratinocytes constitutively produce mRNAs for a number of cytokines without
actively secreting the cytokine, IL-1 being a prime example. Of the other
cytokines, IL-10 is secreted in response to contact allergens reaching peak
activity by 12h (Enk and Katz, 1992) and although IL-10 has been implicated
along with secretion of TNFa and IL-lra in the suppression of DTH responses
after UV irradiation, a differential mechanism of release may exist whereby
positive and negative effects of the cytokines are regulated (Rivas). IL-10 is also
capable of inducing FcR expression while suppressing MHC class II expression
in macrophages (Chin et al., 1991; te Velde et al., 1992).
6.5.1 Speculation about the Role of IL-1 in Secondary Responses to
Localised Ovalbumin Challenge
From what is currently known in the sheep, a sequence of events following
secondary ovalbumin challenge could be envisaged which include putative DL-1
actions: i) antigen is taken up by DC, possibly via FcR; ii) keratinocyte derived
IL-1 a and possibly keratinocyte and/or LC derived IL-1 (3 could be involved in
initiating mobilisation of LC and maturation into DC; iii) CD1 and IL-1R
expression are increased while FcR expression is down regulated; iv) IL-1 a
might indirectly influence antigen processing in the late endocytic vesicles; v)
MHC class II becomes upregulated; vi) processed antigen is presented to
specific T cell subsets via MHC class II and/or CD1 ligands.
The importance of supplementary cytokines including IL-4, IL-6, IL-8, IL-10,
TGFp, IFNy and GM-CSF with respect to positive and negative regulation of
intermediate stages between antigen administration and antigen presentation to T
cells has yet to be determined in the sheep.
An enhancing role in antigen presentation has previously been ascribed to IL-1.
The results of this study do not dispute this and it has been confirmed that IL-1,
and in particular IL-la, does act directly on dendritic cells. LC/DC IL-1 [3
mRNA is massively upregulated in culture where DC:T cell contact is not an
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issue (Heufler et al., 1992). It is tempting to speculate that IL-la or some other
cytokine might induce transcription of IL-1|3 mRNA but that the signal for
translation comes from DC:T cell contact and IL-1 [3 acts in an entirely cell
associated form during clustering. IL-la may also be induced and would also act
in a membrane associated form. Such a scheme could explain why the enhancing
effects of IL-1 appear to be directed purely at DC not T cells and why anti-IL-1
can not inhibit this enhancement. There are precedents for disconnected actions
of IL-la and IL-1 (3. For example, Boraschi et al. (1990) demonstrated that IL-
la and IL-1 (3 might perform different functions with respect to immune
responses to sheep red blood cells. Both forms were involved equally in
inflammatory reactions but only IL-1 (3 was immunostimulatory and it appeared
that IL-la could act as a negative regulator of this immunostimulation.
6.5.2 Projections
LC/DC derived IL-1 (3 has been shown to be involved in T cell priming responses
after initial antigen challenge (Enk et al., 1993) but it appears to play a lesser
role in secondary responses (Ruco et al., 1990). Could the view that during
secondary responses IL-la is involved in LC/DC mobilisation and antigen
processing whereas IL-1 (3 is primarily involved in antigen presentation and T
cell reactions, be correct? Much still needs to be established, such as; (i)
exactly at which stage IL-1 is exerting its effect; (ii) whether IL-la and IL-1 (3
are serving different functions in the early response to secondary antigen
challenge; (iii) whether IL-1 synthesis is induced during the response and if so,
at what point and is EL-1 or some other stimulus responsible; (iv) whether IL-la
could induce IL-1 (3 mRNA transcription and the signal for translation be
supplied by T cell contact; (v) whether the enhancing effect of IL-1 on antigen
presentation may purely be due to upregulation of adhesion molecules.
Information on the regulation of DC function could also become of interest in
wider contexts eg. in various cancers, in which infiltrates of DC have been found
which are thought to participate in anti-tumour reactions (Peng, 1991, Tsujitani
et al., 1992) and in the development of autoimmune diseases such as diabetes
(Tafuri et al., 1993).
Future work may need to take into account the regulatory effects of both IL-lra
and sIL-lR. Keratinocyte IL-lra remains intracellular which would support a
role for localised control of keratinocyte IL-1. With differentiation of the
keratinocytes, the IL-lra/IL-1 ratio increases, showing increased IL-lra mRNA
transcription (Bigler et al., 1992; Gruaz-Chatellard et al., 1991). This is also true
for both monocyte and keratinocyte types of IL-lra in psoriatic skin
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(Hammerberg et al., 1992). Non-secreted IL-lra may therefore serve to regulate
autocrine IL-1-mediated pathways of growth/differentiation. In addition,
although dexamethasone does not affect LC production of IL-1, glucocorticoid
treatment of epidermal cells abolishes IL-1 but not IL-lra production (Stosic-
Grujicic and Lukic, 1992) indicating that immunosuppressive effects of
glucocorticoids as well as inflammatory effects of IL-1a in human skin can be
modified by IL-lra. sIL-lR, on the other hand, appears to be predominantly
immunosuppressive, indicating a major role for IL-1 (3 in the induction of
immune responses.
The expression of IL-1 by LC or DC in the sheep either in response to cytokines
including IL-1, or as a result of antigen challenge, has not yet been determined.
Probes available as a result of this project could be used for detection of IL-1
mRNA by in situ hybridisation or in situ PCR and EL-1 mRNA transcription
could be followed throughout a secondary response. Standard PCR detection
methods would not be a viable alternative in this instance because of the
sensitivity of PCR and the extreme difficulty in obtaining pure cell preparations.
Although IL-1 production by ovine keratinocytes has also not yet been studied,
these cells would be expected to produce cell-associated IL-1 a and IL-1 (3, thus
providing an abundant source of IL-1 in the skin.
6.6 Conclusions
In conclusion, the main aims of this project have been met. The ovine IL-1
cDNAs have been cloned and biologically active recombinant ovine IL-1
proteins have been expressed. The latter are being used to raise monoclonal and
polyclonal antibodies.
Experiments using radiolabelled recombinant ovine IL-1 a and IL-1 (3 have
established that ovine afferent lymph dendritic cells express IL-1 receptors
which are upregulated during a secondary immune response to ovalbumin
challenge.
The cloned cDNAs, recombinant proteins and antisera will all be of use in




Summary of IL-1 Receptor Expression on Various Cell Types
This table has been compiled from published data in order to give an idea of the variations in receptor
characteristics which have been detected by different groups. The species from which the cells or tissue have
been derived is indicated and the IL-1 species used for receptor detection is given if different. Cells
possessing the type I EL-1R are listed first. The size of the receptor and percentage of cells expressing
detectable receptors has been inserted if known, as has data on the effect of upregulating or inhibitory agents
on IL-1 receptor expression. In some cases only the size of the receptor has been determined. Data on both
high and low affinity sites is included and related figures are bracketed }. Although this list is reasonably
comprehensive, it by no means covers all reported studies.











a 80/120 - 4000 - 55 Savage et al., 1989
a nd - 400 - 5 Lowenthal et al., 1986
19600 500 "
"h 87 nt 6700-14200 - 1000 Bomsztyk et al., 1989a,b
PMA 6200 - 1000 "
«h 80 - 2800 - 625 Dower et al., 1986a
P„ 80 - 2400 - 560
ii
a 80 nt 22656 - 1000 Scapigliati et al., 1989
DEX •i - H ••
P 80 nt 2988 - 360
ii
DEX it - " "
Pp 80/100 - nd - nd Bird et al., 1987
a/3 nd - 241 - 400 Horuk et al., 1987
a/p nd - 1565 - 200-360 Bird et al., 1988a,b
a/p 100 - 850-1857 - 20-87 Chizzonite et al., 1989a
D10.G4.1
m a/p nd 1256 - 107 Chizzonite et al., 1989a
D10Sm a 73/46 - 3300-23800 - 227 Savage et al., 1989




a nd nt 9 - 2-4 Lowenthal et al., 1987
230-800 175-430
PMA 27 - 2-4 •i
850 175-430
YT-C3h a 80 - 600 - 40 Bensimon et al., 1989
7000 7000 •i
LBRM-33-IA5m 0^ 80 - 3430 - 217 Dower et al., 1986
Ph 80 - 3200 - 3333 ii
Pn 80 - 2800 - 74
ii
P nd - - 300-1400 ii
NK 70 - nd - nd Bensimon et al., 1989
T lympho 78 - nd - nd Thieme et al., 1989
PBTh cx/p nd nt 40 - 300 Shirakawa et al., 1987
ConA 350 - 300 "
Eoithelial:
NMuLi
m Ot/p nd - 790 - 70 Chizzonite et al., 1989a
238








h cc/p nd nt 300-600 - 200-400 Blantonet al.,1989
PMA 3400 - II
h a/p 72 - nd - nd Kupper et al., 1988
PAM-212
m
72 - 1900 - 52 Chizzonite et al., 1989a
Chondrocyte:
P a nd - 7000 - 250 Saklatvala et al., 1986
r P nd nt 1620 - 0.1 Chandrasekhar et al., 1989
FGF 2960 - 0.1 •i
h oc/p nd - 3000-5000 - nd McCollum et al., 1991
IL-1 1000 - nd M
h Ot/p nd - 2315 - 30 Martel-Pelletier et al., 1992
OAh oc/p nd - 4069 - 30
"
Fibroblast:
Synovial,, OC/p 97 - 3-5000 - 160 Birdetal., 1986P
80 - nd - nd Dower etal., 1985
Synov-Rheum^ a nd - 3000-14000 90-100 66 Chin et al., 1988
P nd - 3000-14000 - 4
ii
MLg-2908m ^Ph^, nd - 2900 - 32 Chizzonite et al., 1989a
lun8m ^Ph™ nd - 2.1fmol/mg - 23
ii
lungh P 80/200 - 3000 10-15 8.4 Chin et al., 1987
TIG-lh a 80 nt 26000 - 510 Takii et al., 1992
pge2 38000 - 360
"
nd IL-1 - 770 Pronost et al., 1993
h a 78 - nd - nd Thieme et al., 1989
dermalh a nd nt 1600 - Akahoshi et al., 1988b
pge2 5400 -
ii
a 80 - 2800 - 625 Dower et al., 1986a
Pn 80 - 2400 - 560
•i
dermal
m oc/p 80 - 3-5000 - 100 Bird and Saklatvala, 1986
dermalb P 72 - 130 - 49 Lederer and Czuprynski 1993
2500 3700
diploidh OC/p nd - 5000-15000 - 63 Qwarnstrom et al., 1988
diploidm oc/p nd - 2900-5673 - 32-57 Chizzonite et al., 1989a
oc/p nd PDGF up 4-5x - Bonin and Singh, 1988
oc/p 74 - nd - nd Bird et al., 1985
BALB-c/3T3m Oh 78 - 5500 - 333 Dower et al., 1986a
Pn 78 - 4800 - 476
•i
Pp 80/100 - nd - nd Bird et al., 1987
3T3JLL,m O'Ph.m nd - 220-570 - 10-60 Chizzonite et al., 1989a
3T3.Swissmm O^Ph^ nd - 5673 - 57
••
Osteoblast:
m a/Pp nd - 3000-5000 - 100 Bird and Saklatvala, 1986
MC3T3.E1 a/P 100 - 6500 - 102 Shelly and Laborde, 1992
Endothelial:
h a 78 - 100-500 - -90 Thieme et al., 1989
s.END.l
m
a 80 - 1273 - 95 Boraschi et al., 1991c
t.END.l
m
a 80 - 771 - 85
Smooth muscle:
vascularh a 78 - nd - nd Boraschi et al., 1991c
Cell Type IL-1 IL-1R Treatment R/cell % +ve K^CpM)
M kDa ("if anvl cells
Reference
Brain:
hypothal- P ?I - 75fmo!/mg - 1300
cortex P ?I - 17fmol/mg - 1300
pituitary P ?I - « - nd
pit- AtT-20m a nd - 1500 - 150
Kidnev:
cortex„m a nd nt 34.7fmol/mg - 6.6
LPS 11.3fmol/mg - 6.6
medulla^ a nd nt 52.7fmol/mg - 6.6
LPS 26.0fmol/mg - 6.6
Cells possessing il-1r type ii:
Bone marrow:
m a/Ph,m nd - 233-549 - 244-294
Macrophage:
J774A.1
m a/Ph,m 80 - 387-1196 - 133-347
P388D1
m «/Ph^ 80 - 604 - 59
AJM9.C11Z m 80 - 1755 - 348
Monocyte:
h p 80 - 100 - 600
THP-1 a 64 nt 0 - -
ii dex 2000 - 300
P 64 nt 0 - -
•• PMA 0 - -
•i
pge2 0 - -
ii
dex 0 - -
ii
PMA +PGE2 1000 - 2000
ii
PMA + DEX 4000 - "
ii
PMA + pge2 +DEX 32000 -
••
PMN:
h a nd - 700 - 2800
h a/p nd - 900 - 300
m a/P nd - 1700 - 300
b P 71 - - - -
B cell:
Bh a nd nt 100 - 260
GC 2000 - 260
a 68/80 - 14-866 - 100-300
• •
- 238-15817 - 5200-16000
P ii - 253-8171 - 1500-7700
MCI 16 a ii - 67 - 120
P •i - 43 - 430
Bh a/p
ii
nt 70 3-5 4
320 3-5 380
SAC 30 20 4
1960 20 380
RAJIh a 68 nt 316 - 2400
DEX incr. - 2400
P nd nt 2400 - 130
DEX incr. - 130
P nd PMA deer. - nd
Katsuuraet al., 1988
Bristulf et al., 1991
Takao et al., 1991
• i
m
Chizzonite et al., 1989a
Chizzonite et al., 1989a
Uhl et al., 1989
Spiggs etal., 1990
Rhyne et al.,1988
Parker et al., 1989
Lederer and Czuprynski, 1992
Akahoshi et al., 1988a
m
Benjamin et al., 1990
•i
Tanaka et al., 1989











RAJI^Ccont.) P 68 nt 1941 5-16 2100 Stoppacciaro et al., 1991
DEX 9205 14-30 1100 "
P nd - nd - 2200 Symons et al., 1991
cc/p 68 - 7709 - 2100 Horuk et al., 1989
lH7h P 67 - 15524 15 700 Stoppaciaro et al., 1991
DEX 48000 28 1100 "
PMA <10 0.5 nd ii
STS 25h P 71 nt 3174 16 800
ii
DEX 13467 29 1300 "
Daudi ot/p ? nt <10 0 nd Horuk et al., 1989 /
DEX <10 0 nd Stoppaciarro et al., 1991 /
Benjamin et al., 1990
3B6h a 70 - 300 - 60 Bensimon et al., 1989
6000 5000
ARH77h a ? - « - nd Dower et al., 1986
P nd - 11000 - 480 •i
P nd - 1100 - 2000
"
Pn nd - 11300 - 2273
ii
PreB:
70Z/3m 66 nt 100 - 60 Bomsztyk et al., 1989a,b
900 140
PMA 76 - 53 "
166 1400
60 - nd - nd Matsushima et al., 1989a
a^Ph^, 82 - 616-930 - 244-522 Chizzonite et al., 1989a
Langerhans' cell:
BALB-cm ot/p 80 - >500 - <100 Kampgen et al., 1992
C3H/Hem Ot/p 80 - >500 - <100
ii
Cultured Dendritic cell:
BALB-cm Ot/p 80 - 100 - <100 Kampgen et al., 1992
C3H/Hem a/p 80 - 100 - <100
ii
Pancreas:
P-cells a ? - 0 - nd Hammonds et al., 1990
P nd - - 200
1400 •i
Carcinoma:
MDA-MB-415 P nd - 700 - 880 Gaffney et al., 1988
HBL-KXL ot/p m - « - nd ii
colon SW48h ot/p
••
- 700 - 900 ii
melanomah P
•i
- 100-1000 - 160 Bauman et al., 1993
" A375-CC a ii nt 701 - 19 Usui et al., 1991
" A375-C5 a ii nt 58 - 17 ii
IL-la ? - 19
ii
EL-la ? - 17
ii
RAJI: P 47 (sIL-lR) na 2700 Symons etal., 1991
h - human; m - mouse; p - pig; r - rabbit; n - purified natural IL-1
GC - glucocorticoids; synov-RA - rheumatoid synoviocytes; PB - peripheral blood; OA - osteoarthritic
sIL-lR - soluble IL-1R.
For other abbreviations see pp. xv-xvii
nt - no treatment; nd - not determined; na - not applicable; ? - not known or not stated
} - high and low affinity sites from Scatchard plots
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APPENDIX 2
Examples of Cytokine Networking
The effects of cytokines on cytokine expression can vary depending on the target cell (see Chapter 1, Sect. 1.5),
for example, LL-4 stimulates IL-1 expression in B cells but inhibits IL-1, IL-6 and TNFa expression in
macrophages. The cytokine (Cyto.) effects listed below apply principally to monocytes and macrophages,
being the prime controllers of cytokine networking.
Cytokine effects on MHC class II expression by macrophages have been included because of potential









































For abbreviations see pp. xv-xvii
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The interleukins have been the subject of intense research interest
because of their central role in the coordination of the processes
of immune cell growth and differentiation, inflammation and
responses to antigenic stimulation. Central to an understanding
of these processes has been the cloning of the genes encoding
these mediators. We have used PCR to obtain 3 overlapping
clones which together constitute the ovine IL-1/3 c-DNA.
When ovine alveolar macrophages were stimulated with 100
ng/ml lipopolysaccharide from Salmonella abortus equi for 4
hours they produced IL-1 like activity as measured by a
thymocyte co-proliferation assay. Total RNA was extracted from
these cells and enriched for polyA+ RNA by oligo dT-cellulose
chromatography. cDNA synthesised from this RNA by the
method of Gubler and Hoffman (1) was hybridised to primers
chosen from sequences conserved in bovine (2) and human (3)
IL-1/3 genes (nucleotide numbers 171 — 190 and antisense of
690—710 of the bovine gene). The cDNA was amplified by PCR
to produce a central segment of the ovine gene. This segment
was sequenced and from this sequence further primers were
chosen for amplifying 5' and 3' regions of the gene. A similar
cDNA population was tailed with dATP using terminal
transferase, (so that both sense and antisense strands ends would
have polyA tracts) and IL-1/3 molecules in it amplified using
anchored PCR with a new primer (antisense of nucleotide
numbers 297 — 314 of the ovine sequence) and oligo dT to
generate the 5' end. PCR with a further pair of primers
(nucleotides 457—474 of the ovine sequence, and antisense of
995 — 1011 from the bovine 3' untranslated region) was used to
generate the 3' end. (Anchored PCR using oligo dT did not give
a full length product at the 3' end). The 3 PCR products were
cloned into pTZ18R expression vectors and several clones of each
type sequenced using the dideoxy chain termination method with
T7 DNA polymerase (Sequenase II, USB Ltd). The clones
obtained encode an ovine IL-1/3 sequence consisting of 32 bp
of 5' leader sequence, an 801 bp coding sequence and 145 bp
of 3' untranslated sequence. Comparison of this sequence with
bovine and human IL-1/3 shows similarities of 95.3% and 76.1%
respectively at the nucleic acid level, or 84.9% and 57.5% at
the protein level.
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Tamarillo mosaic virus (TaMV), a member of the potyvirus
group, causes yield loss and fruit blemishing in tamarillo
(Cyphomandra betacea Sendt.) (1). Potyvirus genomes contain
approximately 10 kb of a single stranded RNA and are translated
as a polyprotein that is subsequently proteolytically cleaved.
A cDNA clone covering the 3' terminus of TaMV (strain R)
has been isolated and sequenced; part of this sequence is shown
in the figure below. N-terminal sequencing of the first 10 amino
acids of purified virus coat protein identified the beginning of
the coat protein gene in the cDNA sequence (sequenced amino
acids are underlined). The amino acid residues immediately
upstream of the coat protein gene are homologous to proteolytic
cleavage sites preceding the coat protein genes of other
potyviruses (2, 3). T7 RNA transcripts were synthesized from
a cDNA clone containing an in-frame AUG initiation codon
immediately 5' of the coat protein gene. An in vitro translation
product synthesized from this RNA comigrated with the native
coat protein and was immunoprecipitated by antibodies raised
against purified virus (data not shown).
The TaMV coat protein shows 55 — 66% amino acid identity
to the coat proteins of eleven distinct members of the potyvirus
group. This level of homology suggests that TaMV is an
independent member of the potyvirus group rather than a strain
of an existing member (4). The TaMV 3' untranslated sequence
shows less than 50% homology with other potyviruses, providing
further support for this conclusion (5).
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INTERLEUKINS la AND 0
C.E. Fiskerstrand,* D.J. Roy, I. Green, D.R. Sargan
Ovine interleukin la (IL-la) c-DNA, obtained by polymerase chain reaction, has been cloned
into pTZ18R and pTZ19R. The resulting DNA sequence shows close homology with the
bovine sequence. The derived amino-acid sequence shows conserved motifs similar to those
observed in all species studied so far. No signal peptide is seen. Northern blots of RNA from
lipopolysaccharide (LPS)-stimulated ovine alveolar macrophages show IL-ip m-RNA to be
produced earlier than and to be more transient than IL-la m-RNA. c-DNAs coding for the
IL-la proprotein and IL-la and IL-ip mature proteins have been cloned and expressed in
the yeast Ty-VLP system as fusion proteins. The resultant IL-1 protein preparations, cleaved
from their fusion partners by the action of activated coagulation Factor Xa, are 80-95% pure
and show biological activity in standard thymocyte co-mitogen and cartilage degradation
assays for IL-1. Some species specificity is observed in that sheep thymoctyes are more
responsive to ovine rIL-1 than are mouse thymocytes. The presence of a Factor Xa cleavage
site in the IL-la proprotein suggests that Factor Xa may be involved in the processing of ovine
IL-la to its mature form.
The cytokine interleukin 1 (IL-1) is an important
endogenous mediator involved in regulation of immu¬
nological and inflammatory reactions, cellular activa¬
tions and pathways of cellular maturation and differ¬
entiation. Either on its own or in conjunction with
other mediators, IL-1 regulates the synthesis of other
cytokines and is a potent activator of T cells and a
lymphocyte promitogen. IL-1 has been reported to
have actions on most cell types, either directly or
by upregulating the expression of cellular receptors
for other growth factors. It is involved in the matu¬
ration and activation of macrophages, bone marrow
cell differentiation and cartilage and bone proces-
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sing.1-5 Epithelial cell growth has been reported to be
inhibited but smooth muscle cell growth to be stimu¬
lated by IL-1.6 Clinically IL-1 is involved in the pro¬
gression of various disease states such as rheumatoid
arthritis, inflammatory bowel disease, septic shock,
tumourgenesis and in the pathogenesis of retroviral
disease.7-10 Many of the effects of IL-1 appear to
oppose each other, not least because of concomi¬
tant production of specific inhibitors in many situa¬
tions.1112 Recombinant IL-1 proteins are therefore
very important in the elucidation and understanding
of these actions and have possible therapeutic value.
Two distinct forms of IL-1 have been identified,
a and (3, having minimal sequence identity but each
being well conserved across species.13 The range of
functions of the two proteins is similar. They also
bind to different components of the same receptor(s)
in a mutually exclusive manner.12 Both proteins are
initially produced as a proprotein of about 31 kDa
which is subsequently cleaved to a mature 17-18 kDa
form.14"19 IL-la is predominantly cell associated,20
with small quantities only of the mature form being
secreted. The proprotein and mature form are equally
418 CYTOKINE, Vol. 4, No. 6 (November), 1992: pp 418-428
and Control, South Mimms, Herts, EN6 3QG, UK.
Reference reagents for mouse TNF-a and human TNF-
(3 are similarly available. Requests should be addressed
to the Director.
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active. On the other hand IL-1(3 in all species so far
studied is secreted as the proprotein, which appears
to require cleavage and consequent conformational
change for both its activity and receptor bind¬
ing. 1 !.1204—is Monocytes and polymorphonuclear
leucocytes are capable of producing active IL-1(3.19-21
Fibroblasts and cultured human keratinocytes produce
the inactive beta proprotein which is not processed.18
c-DNAs encoding the IL-ls have been sequenced
from human, murine, bovine, porcine, rabbit and
rat sources.13-22-29 Recombinant human, murine and
bovine mature IL-1 proteins expressed in bacterial
and mammalian systems 13,20,22-27,30-31 have been
reported to be active in a variety of in vitro assays
such as the murine thymocyte co-mitogen, D10.G4.1
and EL4.NOB1.CTLL cell line assays.32-33 The ovine
IL-1 (3 c-DNA sequence has been published.34 We
report here the cloning of ovine IL-la c-DNA from
alveolar macrophage RNA and the expression and
characterization of ovine IL-la and IL-1(3 in the yeast
TY system. The recombinant proteins are 80-95%
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RESULTS
PCR, Sequencing and Cloning
c-DNA synthesized from polyA+ RNA from LPS-
stimulated ovine alveolar macrophages was the sub¬
strate for all PCR reactions. From the ovine IL-
Ip sequence,34 PCR primers were chosen as shown
in Fig. 1, incorporating sequences required for the
insertion into the yeast expression vector pOGS40
expression vector (Fig. IB) of the c-DNA coding for
the mature protein, IL-ip (mat).
To obtain the complete ovine IL-la proprotein
coding sequence, IL-la(pro), primers were initially
chosen from positions in the bovine RNA sequence
which cover the whole coding region13 and used in
amplification of the same c-DNA populations. The
resulting PCR product was cloned and sequenced.
The ovine IL-la c-DNA sequence is shown in Fig.
2. There is one potential A-Iinked glycosylation site,
in the putative mature protein region. From the
sequence a primer was chosen for the mature pro¬
tein coding region IL-la(mat). The amino terminus
of the mature protein was assumed on the basis of
human and bovine data.13-22 All PCR products were
sequenced, cloned into pTZ18R and pTZ19R and
resequenced in both directions using single stranded
DNA preparations. At least five independent clones
for each form of IL-1 were sequenced. No sequence
differences between individual clones or between the
clones and the primary PCR products were seen.
Figure 1. (A) PCR Primers. 5' proprotein (p5') and mature protein
(m5'). (B) Map of expression vector pOGS40.
(A) PCR primers contain two enzyme sites, a Factor Xa site and
the IL-1 sequence. 3' primers (3') have no Factor Xa site. IL-la
proprotein primers are from the bovine sequence.13 IL-la mature
protein primers and s, which is an internal sequencing primer, were
chosen from the resulting ovine PCR sequence. IL-ip primers are
from our already published ovine sequence. (B) Map of cloning
vector pOGS40 (42) which carries an AMP resistance gene for
selection purposes. IL-1 c-DNA, containing its own terminator
codon, is ligated into the vector using the unique BamHl site.
IL-1 fused to the yeast PI protein is synthesised under control of
the hybrid PGK/GALp promoter in galactose medium.
Homologies between IL-1 sequences of different spe¬
cies are shown in Table 1. There is only 25% iden¬
tity between ovine IL-la and (3. Similar identities
have been found between the IL-la and IL-1(3 of
bovine, human and murine IL-ls.13-22-25 Subsequent
to cloning the inserts into the pOGS40 vector, re-








































720 Figure 2. Nucleotide and predicted amino acid sequence
240 of ovine interleukin-la.
ttgttcattgccacaaagcaagaaaaactggtgcacatggcaagcgggccgccctcgatc
LF I ATKQEKLVHMASGPP S I
actgactttctgatattggaaaaatagccttgactgtgcactctac
TDFLILEK*
DNA and protein sequences are numbered starting with
the initiator Met. The presumed start of the mature protein
82 6 is designated V. There is one potential /V-glycosylation site,
2 80 shown in bold print, in the mature protein.
sequencing confirmed the orientation and reading
frame of the inserts.
m-RNA Production From Alveolar Macrophages
Stimulated With LPS
Northern blot data (Fig. 3A,B) from LPS-
stimulated ovine alveolar macrophages, suggest that
ovine IL-1(3 m-RNA is produced earlier than IL-la
m-RNA, the (3 form showing a maximum at 4 h
post-induction as opposed to 6 h for the a form. By
8 h the IL-lp mRNA is already declining and has
all but disappeared by 24 h whereas the a message
is still detectable. This is a similar profile of m-RNA
production to that of human19 and murine10 IL-ls.
Mixed IL-la and IL-1(3 probe experiments suggest
that more IL-1[3 than IL-la m-RNA is produced (data
not shown). This is in accordance with published data
for bovine, murine and human IL-ls showing the 3
message to be produced in a 10 times greater abun¬
dance than the alpha. Ovine IL-1 m-RNAs MWs are
c. 2.0 kb (a) and 1.6 kb ((3), smaller than their bovine
and human counterparts at c. 2.2 kb (a) and 2.0 kb
O)-13
Protein Expression
pOGS40 is a galactose-inducible yeast expression
vector which produces yeast PI protein fused to the
protein of interest. These fusion proteins assemble
into virus-like particles (vlp) from which the inserted
protein can be cleaved away by proteolysis with acti¬
vated coagulation Factor Xa (FXa). PI is released as
vlp which can be removed by centrifugation. Selected
colonies of yeast strain BJ2168 transfected with pOGS
expression constructs were grown in liquid culture.
Under induction conditions, 7xl08 cells/ml were
obtained for IL- la(pro), 8 x 108 cells/ml for IL-la(mat)
and 7xl08 cells/ml for IL-1 p. Colonies constitutively
expressing PI (i.e. transfected with PMA5620) yielded
c.109 cells/ml. Vlps were prepared as described
in Materials and Methods. Electron micrographs of
vlps show them to be somewhat irregular though basi¬
cally circular and of varying sizes (data not shown).
TABLE 1. IL-la and IL-1(3 - species comparisons. Figures
show percentage similarities between ovine IL-ls and those
from other species.
Nucleic acid Amino acid
a P a P
Bovine 97 95 97 96
Human 81 76 72 77
Murine 80 70 72 56
Porcine 88 - 89 -
Rabbit 80 - 79 -
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Figure 3. IL-1 gene expression in ovine alveolar macrophages. (A) IL-la mRNA. (B) IL-ip mRNA.
10 (ig total RNA extracted from ovine alveolar macrophages after stimulation with LPS for the times shown,
was run on denaturing agarose gels and probed with 32P-labelled full length IL-la (A) or IL-1(3 (B) c-DNAs
as probes (The 10 h time point. Fig. 3A, was slightly >10 pg as seen on the ethidium bromide stained gel prior
to blotting). The positions of 18s and 28s RNA are shown for reference.
Figure 4 shows stages in the purification of the fusion
proteins. Bands corresponding to the fusion proteins
are clearly visible in extracts from yeast cells of
the mature rIL-1 fusion proteins (Fig. 4A). Purified
rIL-l(3 vlp preparations before and after cleavage with
Factor Xa and the preparation of the rIL-l(3 mature
protein ((3m) after spinning out the vlps are shown
in Fig. 4B. Also shown are the final preparations
of rIL-la pro- and mature proteins (ap, am). The
mobility of these proteins through the gels is consist¬
ent with the sizes expected for the fusion proteins (PI
protein travels at 50 kDa and when fused to the IL-1 (3
mature protein should appear at about 68 kD). A
western blot (Fig. 4C) probed with anti-Pi polyclonal
antisera shows the presence of PI in both the fusion
protein and the PI only preparations. Also shown is
a FXa cleaved sample in which PI (lane 2) is slightly
truncated with respect to native PI (lane 3). Yields
of the purified recombinant proteins are: am >150
Mg/1 of culture, ap >120 pg/1 and [3m >50 pg/1. These
preparations are estimated to be 80-95% pure.
FXa cleavage of ap:Pl and (3m:Pl fusion proteins
gave rise to unexpected products. The predicted
molecular weight of ap protein is about 31 kDa.
However digestion of ap:Pl gave a main band running
at about 21 kDa, just above that for the mature IL-la
protein. On digesting the (3m vlp, two bands were
consistently seen, but in varying proportions, running
at about 20 kDa and 18 kDa, rather than just the
one expected band at less than 20 kDa. On closer
inspection of the amino acid sequences it appears that
cleavage by the enzyme may occur at 'relaxed' sites
(listed in Table 2). If the enzyme were to be cutting
at these sites, proteins of the observed sizes would
be produced. To test this possibility, time courses of
digestion of the proteins were done with the results
being shown in Fig. 5. It appears that the enzyme could
indeed be cutting at the relaxed sites as the ap shows
the expected 31 kDa band initially, with subsequent
appearance of the 21 kDa band and eventual loss of the
larger band (Fig. 5; see also Fig. 4B, lane 3). |3m shows
the initial appearance of the 20 kDa band followed by
the 18 kDa band. On longer incubation the 20 kDa
band disappears. The apparent molecular weight of
the recombinant ovine IL-1 [3 is larger than expected
from the calculated size i.e. 20 kDa as opposed to 17.5
kDa. This is in good agreement with published data on
other IL-l[3s which exhibit the same phenomenon.13
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Figure 4. Purification of recombinant IL-1 from yeast.
Denaturing PAGE gels of: (A) Crude extracts of yeast cells
containing fusion proteins run on a 10% gel and stained with
Coomassie brilliant blue. Lane 2 shows proIL-la:Pl (ap), lane 3
matIL-la:Pl (am) and lane 4, matIL-ip:Pl (Pm). The positions
of the fusion proteins and PI vlps are denoted by arrows. (B)
Purification of rIL-ls shown on 15% gels. Purified pm vlps (lane 1).
FXa cut pm vlps (lane 2). FXa cleavage of ap and am vlps, follow
the same pattern and are not shown. Final matlL-ip product (lane
3). Final proIL-la product (lane 4). Final matlL-la product (lane
5). (C) Blotted 10% gel of purified mature IL-ip fusion protein
(lane 1), Factor Xa cut fusion protein (lane 2) and yeast PI protein
(lane 3) hybridized with anti-Pi polyclonal antiserum showing the
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Figure 5. Cleavage of vlps by Factor Xa. (A) IL-la proprotein, (B)
IL-ip mature protein.
Time courses of the cleavage of IL-1 fusion proteins with 1:100 FXa
(w/w). Products are shown run on 15% gels. (A) IL-la proprotein
on a 15% Coomassie blue stained gel. Bands of 81 kDa (fusion
protein), 50 kDa (PI), 31 kDa (intact ap) and 20 kDa (ap final
cleavage product) are labelled with arrows. (B) IL-1 (1 mature
protein on a 15% silver stained gel. Bands of 70 kDa (fusion
protein), 50 kDa (PI), 20 kDa (Pm) and 18 kDa (pm final cleavage
product) are labelled with arrows (see also Fig. 4B, lane 4). The
band at c. 25 kDa is a degradation product of PI which appears
after incubation 24 h at 25°C without enzyme.
TABLE 2. Factor Xa cleavage recognition sites. Motifs
show peptide sequences required for cleavage by Factor Xa.
Putative sites in ovine rIL-ls are shown in bold type.
Substrate Peptide recognition sequence Ref.
prothrombin IDGR 43
P-globin IEGR 44
HIV p24 vIp ISPR 42
IL-la IKPR (position 110-113)
IL-ip IEEK (position 240-243)
Biological Activity ofRecombinant IL-ls
Induction of Thymocyte Proliferation
Figure 6A,B shows the results of incubating ovine
thymocytes with mature rIL-la or rIL-l(3 using
9 pg/ml PHA as co-mitogen. Using the accepted




















Figure 6. Biological assays for rIL-1 activity.
(A), (B) Sheep and (C) mouse thymocyte proliferation induced by rIL-1 with 9 pg/'ml PHA as co-mitogen
was measured by incorporation of 3H-thymidine. (D) Degradation of sheep xiphoid cartilage by the action
of rIL-1. Resultant glycosylaminoglycans (gags) were added to methylene blue dye and measured by the
increase in absorbance at 540 pm as compared with a chondroitin sulphate standard curve. No release of
gags by PI was detected. In all assays, the PI control is a preparation of constitutively expressed PI vlps
incubated with Factor Xa and containing yeast contaminants which could be present in the rIL-1 preparations.
Concentrations were matched to the rIL-1 samples.
definition of activity (one unit being that amount of
protein which yields half maximal counts per minute
of incorporated 3H-thymidine) one unit of ovine am is
40pg and one unit of ovine (3m is 800 pg in this assay.
Samples assayed up to 5 weeks after cutting the vlps
showed no decrease in their unit activity over this time
if stored at 4°C. Aliquots of the same sample stored
at —20°C show some loss of activity on freezing and
incubation at 37°C for as little as 1 h caused a large loss
of activity (data not shown). Purified porcine IL-ip
was used as a comparison for activity. It is slightly
more active than the ovine pm and less active than
the ovine am. Neither uncut IL-1 vlps nor a cut PI
protein control induce any thymocyte proliferation.
There is considerable variation in activity from thymus
to thymus which accounts for the differing levels of
counts incorporated in the assays shown. About 50-
fold higher amounts of IL-la and 2.5-fold higher of
IL-ip were required to stimulate murine thymocytes
to proliferate (Fig. 6C).
Cartilage Degradation Assay
The rIL-ls were assayed for their action in
triggering metalloprotease activity in ovine Xiphoid
cartilage (Fig. 6C). The activities of both were about
10-fold less in this assay than in the ovine thymocyte
assay, one unit of am being 400 pg and of pm being
10 ng. As in the thymocyte assay, none of the controls
affected the assay in any way.
DISCUSSION
An alignment between derived IL-la amino-acid
sequences of different species is shown (Fig. 7). As
for all IL-ls described so far, no hydrophobic signal
peptide is seen. Our IL-la sequence is identical to
that published very recently by Andrews et al.35
except for one amino acid difference; Val compared
to Met at position 73. Expression of IL-1 c-DNAs in
the yeast TY system yielded recombinant proteins
of 80-95% purity. The specificity of Factor Xa in
cleaving these fusion proteins is relaxed, leading to
the rIL-la proprotein being truncated probably by
loss of 113 amino acids from the amino terminal.
By the same token the rIL-ip mature protein
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on cleavage produces both the expected protein
of 136 amino acids and a slightly smaller one
probably of 113 amino acids, missing 23 amino
acids from the carboxyl end. This cleavage is shown
clearly by the time course of FXa cutting. In-vivo
cleavage of the IL-1(3 from proprotein to active
mature protein is thought to occur via the action
of serine proteases. Potential processors include
Proteinase K which has been shown by Hazuda
et al.17 to transform IL-lp to the active mature
form which is Proteinase K insensitive, as is IL-
la. An endoproteinase, IL-1 converting enzyme36-37
which appears to be found only in monocytes,
has been shown to be able to cleave human and
murine IL-13 specifically at Asp:Basic motifs (at
positions 27 and 116) to yield an active protein. The
ovine sequence contains this same motif and could
potentially be processed similarly. Trypsin and chymo-
trypsin (cutting sites ArgSer and PheLeu respectively)
have been proposed as IL-la processors.27-38 Of
interest is that the putative sequence at which Factor
Xa is cutting our IL-la proprotein is IleuLysProArgSer
(Fig. 7). Gin replaces Lys in the mouse but otherwise
this sequence is present in all other species sequenced.
Jones & Geczy39 found that Factor Xa and thrombin
greatly induced IL-1 activity in macrophages stimu¬
lated by suboptimal concentrations of LPS. It was
proposed that this was via the action of FXa on
prothrombin —» thrombin because the effect of
thrombin alone was greater than that of either FXa
or prothrombin alone. From our results it appears
that FXa at least, can act directly on ovine IL-la.
A-terminal analysis of purified natural IL-la is needed
to clarify the actual start of this protein. It remains
to be seen whether the cut site in the mature IL-1 (3
has any functional significance. Our data suggest that
Qyine IL~1« Sequence comparisons
Ovine 1 MAKVPDLFEDLKNCYSENEDYSSEIDHLSLNQKSFYDASYEPLREDHMDK
Bovine Q.N.
Human M ED . . S HV. . G . . H . GC . . Q
Murine A GS.H.TCT.Q
Porcine E...D PG.G...
Rabbit F....E...A H . .C.N.
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Bovine K A. S
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Figure 7. IL-la amino acid alignments.
Amino acid translation products of published
IL-la sequences from various species are aligned
to show conserved residues. The proposed start
of the mature protein is designated V and a
potential glycosylation site is in bold print. The
proposed Factor Xa recognition site in ovine
IL-la is underlined.
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both forms of IL-1 (3 are active because preparations
containing mainly 20 kDa or 18 kDa IL-ip are equally
active in thymocyte and cartilage degradation assays
(data not shown). This is not unexpected as amino
acids 163-171 and 187-204 have been cited, from
peptide studies, as being essential domains for activity
in the mouse, each being important with respect to
different functions of IL-1.15 Deletion mutants have
also been described,40 requiring up to amino acid 259
for activity. Others have reported a core peptide which
has retained biological activity.41 Relaxed cutting sites
of FXa are as in Table 2. It appears that in vitro the
specificity for Factor Xa is not as rigid as has been
reported.43'44
Both rIL-la and (3 have been shown to be
biologically active in a variety of assay systems
(Fig. 6). The activity of am on ovine thymocytes
is x 10 greater than on ovine cartilage whereas (3m
is equally active on both cell types. Much data is
currently emerging on the IL-1 receptors from which it
is becoming clear that although the receptor will bind
both forms of IL-1, it has at least two components,
80 and 100 kDa, with differing affinities for a and p.
Differential expression of these on different cell types
are probably implicated in the differing activities seen
on assay, ap is active in all assays but this preparation
is of course partially cleaved at a site close to the
putative start of the mature protein. We are currently
expressing ap in a mammalian system which should
yield data on the activity of the intact proprotein.
We have observed reduced activity of ovine rIL-ls
on murine thymocytes. Similar species barriers have
previously been seen between murine and human in
various assays.26-31
In conclusion, therefore, we have cloned ovine
IL-1a and IL-1(3 c-DNAs from alveolar macrophages.
The encoded proteins expressed in yeast show bio¬
logical activity in ovine assays as well as cross species
activity in murine assays. The recombinant proteins
can be produced fairly easily and in large quantities




Macrophages obtained by lung lavage of gnotobiotic
sheep were allowed to adhere to plastic culture bottles
in Iscoves serum free medium at a density of 2 X 107
cells per bottle for 24 h prior to stimulation with 10 pg/ml
lipopolysaccharide in fresh medium. At each of various time
intervals up to 24 h post stimulation, total RNA was isolated
from one bottle following the guanidine isothiocyanate
method of Chirgwin et al.45
RNA Analysis
10 pg samples of total RNA were run on denaturing gels
for northern blot analysis46 of the time course of production
of IL-la and (3 m-RNAs. Blots were prehybridized for 4 h
then hybridized with the appropriate 32P-labelled probes for
20 h at 42°C in 5 x SSC, 0.5% low-fat dried milk, 1 mM
EDTA, 0.5% SDS, 50% formamide and 125 pg/ml yeast
RNA. Filters were washed with 2 X SSC, 0.1% SDS for
2 x 10 min at 22°C then 0.2 x SSC, 0.1% SDS for 3 x 10
min at 50°C.
PCR and Cloning ofc-DNAs
First strand c-DNA synthesized from PolyA-l- enriched
RNA47 was used as the template for PCR reactions as fol¬
lows; denature 95°C, 30 s; anneal 52°C, 30 s; extend 72°C,
1.5 min; final extension 72°C, 5 min. The reaction buffer
contained 100 pM dNTPs, 1.5 mM MgCl2, 100 pg/ml BSA,
50 mM KC1, 3 mM DTT, 10 mM Tris pH8.8, 0.3 units Taq
polymerase. PCR primers were as shown in Fig. 1. Initial
IL-la primers, to amplify the complete ovine IL-la coding
sequence were chosen from the bovine IL-la sequence.13
After sequencing the ovine IL-la cDNA, we derived
the primer sequence for the start of the mature protein
as well as a primer, s in Fig. 1, for use as an internal
sequencing primer. IL-13 primers for the mature coding
region were from the previously published ovine IL-1 [3
sequence.34 A number of protective bases and a BamH I
site for ligation into the POGS40 vector were included in the
primers. In addition, the sense primers contained a coding
site for coagulation Factor Xa (FXa) recognition, to allow
for cleavage of the expressed protein. PCR products were
sequenced by the dideoxy chain termination method using
Sequenase II.48 For ligation into pTZ, the PCR products
were made blunt ended by 'fill in' using Klenow fragment
of DNA polymerse, phosphorylated, purified on 1.2% low
gelling temperature agarose, the appropriate bands excised
and ligated into pTZ18R and pTZ19R.49 For sequencing,
single-stranded DNA was synthesized from these constructs
by the method of Messing.50 For expression, inserts were
excised from pTZ using BamH I, gel purified and ligated
into BamH I digested pOGS4042 expression vector (Fig.
2B). Blunt-ended PCR products were also digested with
BamH I, gel purified and ligated directly into pOGS40.
Recombinant colonies were selected by colony hybridization
using appropriate a32P-dCTP-labelled PCR products.51 CsCl
gradient52 purified plasmid was used for double-stranded
sequencing of the recombinant pOGS vector and for
transfection into yeast for protein expression.
Expression and purification of IL-1 proteins from
yeast:
This method is essentially that of Gilmour et al.42
with minor variations as detailed. pOGS40 constructs for
inducible cytokine expression or pMA5620 for constitutive
PI expression, were transfected into yeast BJ2168 by
spheroplasting, plating in regeneration agar (0.67% yeast
nitrogen base; 1 M sorbitol; 1% glucose; 30% Difco agar)
and incubating at 30°C. Colonies obtained, usually after
3-4 days, were restreaked onto 0.67% yeast nitrogen base
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(YNB) plates and subsequently grown up in liquid culture.
Yeast cultures for inducible expression were grown for
48 h at 30°C in YNB containing 1% glucose and 0.002%
tryptophan then induced for 24 h with 1% galactose plus
0.3% glucose and tryptophan. Yeast cultures for consti¬
tutive expression were grown in YNB glucose medium,
supplemented with 0.002% uracil. Cells were harvested,
suspended in 10 mM Tris-HCl pH 7.4, 2 mM EDTA,
140 mM NaCl containing protease inhibitors and lysed
by vortexing with acid washed glass beads. Supernatants
were spun at 10 000 g, the yeast debris discarded and
the vlp containing suspension partially purified and con¬
centrated by spinning at 30 000 g for 90 min onto a 60%
sucrose cushion. The interface and cushion material were
dialysed into 100 mM Tris pH7.4, 10 mM CaCl2 containing
0.02% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulphonate) and 0.02% DOC (NaDeoxycholate).
Expressed protein was released from the vlps by digestion
with Factor Xa (FXa) at a concentration of 1:100 w/w and
further purified by spinning at 40 000 g to remove the PI vlps
present post cleavage as well as any remaining yeast proteins.
Samples dialysed into PBS were stored at 4°C or -70°C.
Anti-Pi andAnti-FXa Antibodies
Rabbits were immunised with a PI vlp preparation or
FXa using standard techniques to obtain polyclonal antisera




Vlps, cut vlps and isolated protein were analysed on
polyacrylamide/SDS denaturing gels53 stained with either
0.25% Coomassie brilliant blue or silver.54 Blots of gels
were incubated with 1/1600 anti-Pi first antibody, 1/8000
anti rabbit second antibody and developed with 0.2 mg/ml
NBT (Nitrobluetetrazolium); 0.1 mg/ml BCIP (Bromo-
chloro-imidolyl-phosphate toluidine salt); 0.2 mM MgCl2 in
0.1 M Tris pH 9.5. Concentrations of recombinant proteins
were estimated by comparing dilutions of each sample with
protein standards on PAGE gels.
Thymocyte Co-stimulation Assay
Recombinant proteins were assayed using either mouse
or sheep thymocytes at 1 x 106/ml with 9 |ig/ml
phytohaemagglutinin as co-mitogen. Samples were pre-
incubated for 48 h at 37°C in 100 pi RPMI; 100 pi phosphate
buffered saline; 5% fetal calf serum, then a further 16 h
with 20 pCi 3H-thymidine added. Cells were harvested and
counted as a measure of de-novo DNA synthesis.
Cartilage Degradation Assay
This assay was performed as per Dingle et al.55 with
minor variations. Discs (2 mm x 1 mm) of fresh sheep
xiphoid cartilage were incubated for 48 h in DME medium
with 5% FCS prior to incubation for 24 h in fresh medium
with the recombinant protein sample. Glycosaminoglycans
released from the cartilage were measured by treating
with methylene blue dye and comparing the absorbance
at 540 mp with a chondroitin sulphate standard curve.
EMBL Accession numbers are as follows: ovine IL-1
alpha X60167; ovine IL-1 beta X54796.
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